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ABSTRACT 
 
 
In the current dissertation, we focused on the development and application of 
multiple mass spectrometry-based bioanalytical platforms for phosphoproteomic 
characterization in cell culture and clinical specimens of prostate cancer; and on the 
application of optimized methods to analysis of differential protein expression to reveal 
molecular mechanism of drug action in animal model of prostate cancer.  
 
Characterization of the phosphoproteome in prostate cancer 
 
Our study in phosphoprotein signatures on a large scale in prostate cancer focused 
on the LNCaP human prostate cancer cell line, and on human prostate cancer tissue.  
 
For the LNCaP prostate cancer cell line, we applied a combination of analytical 
platforms: (1) a novel in-gel isoelectric focusing (IEF) LC-MS/MS analytical platform; (2) 
a 2-DE based platform combined with phospho-specific staining.  
 
The in-gel IEF LC-MS/MS analytical methodology used in the study included 
separation of the LNCaP proteins by in-gel isoelectric focusing; digestion of the proteins 
with trypsin; enrichment of the digests for phosphopeptides with immobilized metal ion 
affinity chromatography (IMAC); analysis of the enriched digests by LC-MS/MS; and 
identification of the phosphorylated peptides/proteins through searches of the Swiss-Prot 
protein sequence database. With in-gel IEF based analytical platform, we have 
characterized over 600 different phosphorylation sites in 296 phosphoproteins in the 
LNCaP prostate cancer cell line. This panel of the LNCaP phosphoproteins was 3-fold 
larger than the panel obtained in our previous work, and is the largest phosphoprotein 
panel in prostate cancer reported to date. The phosphoproteins identified in this study 
belonged to various locations within the cell and were involved in various processes 
including cell differentiation, transcription regulation, and intercellular signal 
transduction.  
 
We also developed a 2-DE based platform, in combination with multiplexed 
staining and LC-MS/MS, for the identification of LNCaP phosphoproteins. In this study, 
we applied 2-DE as separation technique, Pro-QTM Diamond stain as phosphoprotein 
detection method, LC-MS/MS and database searches for protein identification to 
investigate the phosphoproteins in the LNCaP prostate cancer cell line. Proteins identified 
from spots of interest were shown to be highly relevant to prostate cancer. We 
demonstrated the feasibility of using 2-DE with phospho-specific stain and mass 
spectrometry to investigate the phosphoproteins in the LNCaP cell line. This 
methodology complements the in-gel IEF LC-MS/MS platform that we used for 
phosphoproteomics study; it will be of particular value for future comparative studies of 
phosphoproteins in various physiological states.  
 
For prostate cancer tissue, a gel-free approach was performed to analyze five 
prostate cancer tissue specimens to obtain phosphoproteomic signature of prostate cancer 
 vi
for biomarker discovery. Proteins were extracted with Trizol reagent, and then in-solution 
digested with trypsin. Phosphopeptides were enriched with IMAC, and analyzed the 
phosphorylated peptides/proteins by LC-MS/MS with identification through searches of 
the Swiss-Prot protein sequence database. The panels obtained for prostate cancer tissue 
contain 15-24 phosphoproteins. Some of the characterized phosphoproteins were present 
in all five specimens; in addition, each specimen also produced a unique set of 
phosphoproteins. The findings provided a direct glimpse into the phosphoprotein 
machinery operating within the human prostate cancer tissue. This pilot study focused on 
a small set of specimens. The phosphoprotein panels that were obtained contained a 
number of proteins that were unique to a particular specimen.   
 
Comparative proteomics study of drug effects in prostate cancer 
 
We carried out the first comparative proteomics study for the examination of the 
effects of bicalutamide/embelin combination treatment on prostate tumors by 
characterizing the alterations in protein expression that was induced upon treatment of 
mice bearing prostate tumors with anticancer combination therapy. 
 
A comparative proteomic strategy based on 2-DE coupled with LC-MS/MS was 
performed on mouse prostate tumor tissue. Proteins from the mouse prostate tumors were 
extracted with Trizol, and the protein mixtures were separated by 2-DE. Differences in 
the protein profiles for the different treatment groups were evaluated by computer-
assisted analysis of SYPRO Ruby stained 2-DE gels. LC-MS/MS and database searches 
were used to identify differentially expressed proteins. Pathway analysis was carried out 
on the dataset of identified proteins with the Ingenuity bioinformatics tool. Out of the 33 
differentially expressed protein spots, 30 protein spots were identified and grouped into 
various functional classes. The major protein categories were metabolism (52%), stress 
response (12%), protein biosynthesis (13%) and apoptosis (11%), suggesting that 
alterations in these processes may be involved in the mechanism of drug action. Proteins 
associated with oxidative stress were up-regulated, which indicated that treatment with 
bicalutamide/embelin may affect the redox balance within the prostate tumor, and this 
effect may contribute to tumor suppression. 
 
 
 
 
 vii
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CHAPTER 1. INTRODUCTION 
 
 
1.1 Prostate Cancer  
 
Prostate cancer is the most frequently diagnosed cancer and the second leading 
cause of cancer death among men in the United States (Ann. Intern. Med., 2008). 
According to Cancer Facts & Figures 2008 from American Cancer Society, an estimated 
186,320 American males will be diagnosed with prostate cancer and 28,660 deaths will 
result from prostate cancer in the US during 2008. Prostate cancer continues to represent 
a major health concern. 
 
Clinically, prostate cancer is diagnosed as local or advanced (Miller et al., 2003). 
During the initial period of prostate cancer, the tumor is dependent on androgen for 
growth, and therefore responses to therapies of surgical and/or pharmacological depletion 
of circulating androgens, such as radical local treatment or androgen-deprivation 
(androgen ablation) treatment. However, the success of the therapies is temporary; most 
tumors relapse within 2 years as a metastatic and androgen-independent state. Whereas 
surgery is curative for local prostate cancer, there are not effective treatments for 
androgen-independent prostate cancer. 
 
Therefore, understanding molecular mechanisms and biological activities of 
cancer development and progression is the key objective to improve the diagnosis and 
develop novel prostate cancer therapeutics. Currently, the main tools used for prostate 
cancer diagnosis include digital rectal examination (DRE), serum prostate specific 
antigen (PSA) screening and biopsy (Smith et al., 2009). 
 
In the late 1980s, serum PSA was introduced into clinical practice and became the 
most widely used biomarker for screening and early detection of prostate cancer (Farwell 
et al., 2007; Rao et al., 2008). The application of serum PSA measurement in clinical 
practice has dramatically changed detection and treatment of prostate cancer. The 
incidence of this tumor has increased whereas the impact on mortality rates is less evident. 
Over diagnosis leading to unnecessary treatment and associated adverse effects have been 
strongly implicated to occur (Lin et al., 2008).    
 
Using current recommended guidelines, the PSA test suffers from both poor 
specificity and low sensitivity (Ross et al., 2004). Although higher PSA levels are 
associated with the risk of cancer, PSA levels can change for many reasons other than 
cancer, such as enlargement of the prostate (benign prostatic hypertrophy (BPH)) and 
infection of the prostate (prostatitis). PSA level above 4.0 ng/ml is the traditional cutoff 
value for diagnosis of prostate cancer (Welch et al., 2005). However, a single PSA cutoff 
point lacks specificity and sensitivity needed for an accurate diagnosis of prostate cancer; 
in men with PSA below 4.0 ng/ml the risk of cancer is approximately 15% and 15% these 
patients have high grade disease. Conversely for PSA levels above 4.0 ng/ml, cancer is 
found on biopsy in only 25% to 30% of the men evaluated (Parekh et al., 2007; 
Thompson et al., 2004). 
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Several modifications of PSA measurement have been investigated, including 
PSA velocity, PSA density, PSA glycosylation and PSA doubling time (Carter et al., 
1992; Catalona et al., 1994; Fang et al., 2002; Meany et al., 2009). However, none of 
these modifications are superior to PSA in clinical practice, and since they are more 
difficult to measure than PSA, they are unlikely to replace PSA for prostate cancer 
screening and have not been found wide application in clinical practice. 
 
Therefore, new investigation into more accurate diagnostic and prognostic 
biomarkers to complement PSA is critical to assist in early detection and prognosis, 
monitor therapeutic response, and to determine the best course of therapy for cancer 
patients to improve the clinical outcomes. To date, with the advances in biotechnology 
such as immunohistochemical staining, proteomics, tissue microarray, DNA microarray, 
many promising biomarkers, such as human kallikrein, hepsin, have been identified and 
are under investigation and validation.  
 
 
1.2 Why Apply Proteomic Technologies for Biomarker Discovery in Prostate 
Cancer? 
 
Current biology research efforts often focus on describing the detailed complexity 
of particular aspects of the total system of cancer development and progression. It is of 
help to consider systems study, describing multitude of pathways and interactions that 
regulate biological processes. To capture all interactions and get a complete picture of 
what is really happening during pathogenesis and disease progression, conventional tools 
to study single protein or pathway are inadequate and large-scale, high throughput 
approaches are required to provide complementary information. 
 
Advances in new high throughput technologies, such as genomics, transcriptomics 
and proteomics, lead to the accelerating growth of information and the improved 
molecular tools for cancer diagnosis, prognosis and treatment. However, gene expression 
analysis can not accurately predict protein expression and post-translational modifications 
(such as phosphorylation) (Blackstock and Weir, 1999). Transcriptome represents a set of 
messenger RNA (mRNA) produced by a given cell and can reflect the gene expression 
under a specific condition. But transcriptome neither can completely reflect the 
underlying biology due to alternative splicing and post-translational modifications in 
response to changes of external conditions. As the ultimate products for gene expression, 
proteins are directly responsible for the molecular functions to mediate most changes at 
the cellular level in cancer. Therefore, protein-directed studies using advanced 
technologies are of significant interest and significance.  
 
Proteomics is the simultaneous study of multiple proteins on a large scale by high 
throughput analyses of body fluids, cells and tissues (Anderson and Anderson, 1998). The 
expansion of the field of proteomics has been enabled by concurrent developments: 
completion of the human genome project, advances in separation techniques, major 
improvements in mass spectrometry technologies, and progress in bioinformatics. 
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The speed, selectivity and sensitivity of mass spectrometry (MS) make MS-based 
proteomic methodologies a powerful alternative to traditional biological methods for 
analyses of proteins in complex biological systems (Feng et al., 2008). The distinct 
advantage of proteomics and the advances in proteomic technologies have created 
tremendous opportunities for biomarker discovery and for biological studies of cancer.  
 
Proteomics-based approaches have the potential to provide novel, systems-level 
insight into the underlying molecular mechanisms of prostate cancer, and also hold great 
promise for biomarker discovery in prostate cancer. 
 
 
1.3 Elements of Proteomics-based Approach 
 
The bioanalytical strategy of a proteomics-based study involves the incorporation 
of a number of technologies and knowledge of biochemistry, molecular biology, 
bioinformatics and bioanalytical chemistry (Patton, 1999). Although a number of options 
exist within each stage of the proteomic analysis, a typical approach includes the 
following components: sample preparation, protein separation, protein identification, and 
data mining (Figure 1-1). 
 
 
1.3.1 Sample Preparation 
 
The first, critically important step of a proteomics-based study is sample 
preparation. Proteins are isolated from biological samples and then solubilized for 
separation. The task of sample preparation is to maximally solubilize sample proteins 
under conditions compatible with subsequent method of analysis, without introducing 
artefactual modifications. There have been a number of reviews that discussed various 
approaches to sample preparation and solubilization of proteins for 2-DE (Rabilloud, 
1996; Rabilloud, 2009). The use of a protease and/or phosphatase inhibitor cocktail is 
often included to inhibit protein degradation and/or dephosphorylation. In addition, the 
application of various combinations of reducing agents, chaotropic agents and detergents 
is used to disrupt intra- and inter-protein interactions and maximize protein solubilization  
(Rabilloud et al., 1997).  
 
 
1.3.2 Protein Separation 
 
1.3.2.1 Two-dimensional Polyacrylamide Gel Electrophoresis (2-DE) 
 
2-DE is the most commonly applied technique for the separation of proteins in 
complex mixtures because of its efficiency and high resolution (Gorg et al., 2004).  The 
technique combines isoelectric focusing (IEF) in the first dimension, and sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) in the second dimension.  The 
superior separation power of 2-DE stems from the fact that proteins are separated based 
on two different physicochemical properties. Proteins are separated based on their
 4
 
 
 
 
Figure 1-1 Elements of proteomics-based study. 
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different isoelectric points in the first dimension, and based on molecular weight in the 
second dimension. Then proteins are visualized with various staining methods, such as 
Coomassie Blue, silver staining, or fluorescent stains. Protein profiles can be 
quantitatively analyzed through 2-DE gel imaging software (Dunn, 1987). Mass 
spectrometry has been intensively used for identification of proteins of interest in 2-DE-
based proteomics studies.    
 
 First dimension: Isoelectric focusing (IEF) is a technique for separating proteins 
by their electric charge differences. Proteins are amphoteric molecules with acidic and 
basic groups. A protein carries a charge depending on the pH of its surroundings. This 
characteristic is used for IEF in pH gradients. A protein will have positive net charge in a 
pH region below its isoelectric point (pI), and in an electric field it will migrate towards 
the cathode. During protein migration in a pH gradient, the charge will decrease until the 
protein reaches the pH region that corresponds to its pI. At this point it has no net charge 
and the migration stops. Analogously, negatively charged protein molecules will migrate 
towards the anode to the protein pI. As a result, the protein is focused into a sharp 
stationary band at its specific pI in the pH gradient.  
 
The great improvement of IEF is the introduction of the immobilized pH gradient 
(IPG) strips for the first dimension separation (Bjellqvist et al., 1982). IPG strips are 
composed of acidic and basic buffering groups covalently linked to large-pore 
polyacrylamide gel matrix. The polyacrylamide gel is cast onto a plastic backing that 
allows easy manipulation of the IPG strip. Compared with carrier ampholyte-based IEF, 
IPG-based IEF has a very high resolution, permits large amount of proteins loading, and 
presents more reproducible results (Gianazza and Righetti, 2009; Gorg et al., 2000). 
Moreover, there are pre-cast IPG strips with various lengths and pH ranges commercially 
available from several vendors.  The development and commercialization of the IPG 
technology has contributed to the expansion of 2-DE from a handful of highly specialized 
laboratories to many laboratories in diverse fields of life sciences. 
 
In terms of equipment, several different configurations are used to perform IEF 
separations. These configurations differ mainly in the procedure for strip rehydration, and 
in the maximum voltage that can be applied.  
 
Second dimension: Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) is used to separate proteins according to their molecular weight.  Unlike 
IEF, SDS-PAGE itself is a widely used, standard analytical technique for protein 
separation.  SDS is used to denature proteins by disrupting hydrogen bonds, blocking 
hydrophobic interactions and unfolding the proteins to eliminate protein tertiary and 
secondary structures. Reducing agent (such as DTT) is added to disrupt the disulphide 
bond between polypeptides and unfold proteins into flexible polypeptides. Then SDS 
masks the charge of the polypeptides and forms anionic SDS-protein complexes with a 
constant net negative charge per unit mass. The separation principle of SDS-PAGE 
involves differential migration of SDS-protein complexes through a restrictive 
polyacrylamide gel with a define pore size. Under the influence of an electric field, the 
SDS-protein complexes with a constant charge-to-mass ratio migrate towards the anode.  
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Smaller proteins experience less restriction in their movement through gel pores and 
hence travel the farthest; large proteins are impeded and hence travel the least distance.  
Thus proteins in a mixture become separated according to their molecular weight (Ibel et 
al., 1990). 
 
Depending on the specific application, the characteristics of the gel such as size, 
thickness and percentage of acrylamide should be taken into account. In addition, SDS-
PAGE systems are available in both horizontal and vertical configurations. Horizontal 
units are convenient for use with single gels. Vertical units allow simultaneous 
separations of multiple samples and are often performed for higher throughput analyses 
minimizing run-to-run variations (Gorg et al., 2004).  
 
Protein detection: After gel electrophoresis, proteins in 2-DE gels are visualized 
with various staining methods, such as Coomassie Blue, silver staining, or fluorescent 
stains. Each method has its advantages and disadvantages.  Staining with Coomassie Blue 
dye is simple and provides good linearity; however, the stain is not very sensitive.  Silver 
staining provides much higher detection limits but suffers from reproducibility and 
linearity issues. Recently, fluorescent stains become an attractive alternative to other 
staining methods for protein detection. Fluorescent stains (such as SYPRO stains) non-
covalently bind to proteins in 2-DE. Compared with Coomassie and silver stains, 
fluorescent stains offer a number of advantages, including wide dynamic range, high 
sensitivity, and simplicity of procedure. The SYPRO stains are fully compatible with  
mass spectrometry analyses, which is an important consideration (Patton, 2000). The 
shortcomings associated with fluorescent stains are high cost for the requirement of 
specialized imaging equipment.  
 
Protein imaging: Image analyses are performed with an imaging system that is 
able to acquire, analyze and store the 2-DE images. In general, image analysis includes 
spot detection, protein spots matching in different gels, and normalization for protein 
quantification. A number of computer-based software packages are commercially 
available for the analysis of 2D gel images, such as PDQuest (Bio-Rad, Hercules, CA), 
Progenesis (Nonlinear USA Inc, Durham, NC), Z3 2DE analysis system (Compugen, NJ). 
Although image analysis is a semi-automated procedure, several issues (such as gel 
distortions, variation in sample loading, staining intensities) require manual intervention. 
 
Recent development in 2-DE: Classical 2-DE, while powerful, suffers from 
limitations. The main issues include partial proteome coverage, and run-to-run variability.  
To address some of the issues, improvements of the 2-DE platform have been made. A 
significant new advancement is the introduction of two-dimensional difference gel 
electrophoresis (2D-DIGE).  2D-DIGE incorporates differential labeling of different 
sample populations through the use of fluorescent molecules (CyDyes) (Unlu et al., 1997). 
Up to three different protein samples can be covalently labeled with fluorescent dyes 
(Cy3, Cy5, and Cy2), combined and subjected to 2-DE. The differential labeling allows 
separation of multiple proteomes on a single gel, reducing the gel-to-gel variations. After 
the gel electrophoresis, images of the gel at different excitation/emission wavelengths 
(specific for each CyDye) are generated. Images can be overlaid directly by the 
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DeCyderTM software (GE Healthcare) to locate proteins that are differentially expressed 
between the samples. Advanced data analysis such as hierarchical clustering can be 
performed (Minden et al., 2009).  
 
1.3.2.2 Other Approaches 
 
 In addition to 2-DE based approaches, a number of different separation 
methodologies have been developed since the advent of proteomics. In general, these 
methodologies fall within two categories: 1D-gel-based, and gel-free. Furthermore, 
various methods aimed at reduction of the proteome complexity prior to analysis have 
been introduced. 
 
 One-dimensional gel-based proteomics strategies use a single dimension of 
electrophoretic separation at the protein level, combined with advanced LC-MS/MS for 
protein identification.  A combination of SDS-PAGE and LC-MS/MS, termed geLC-
MS/MS, has been developed and used for numerous applications.  Our group has 
developed a method that combines in-gel IEF at the protein level with LC-MS/MS.  This 
1D-gel strategy, named in-gel IEF LC-MS/MS, has been applied to analyses of the 
proteome in the human pituitary (Zhao et al., 2005) and human prostate tissue. 
 
 A well-known example of a gel-free proteomics strategy is the Multidimensional 
protein identification technology (MudPIT).  The technique is also known as shotgun 
proteomics.  MudPIT involves multidimensional chromatographic separation of complex 
mixtures at the peptide level. In brief, a whole protein mixture is digested directly and the 
resulting peptides are separated by two different types of liquid chromatography (ion 
exchange and reversed-phase LC), coupled to tandem mass spectrometry. Compared with 
2-DE, MudPIT method is unbiased, meaning that proteins that are normally under-
represented in 2D gels (low-abundance proteins, proteins with extremes in pI and MW, 
and membrane proteins) can be probed with MudPIT (Washburn et al., 2001).  
 
 Immunoprecipitation is an example of a strategy that aims at reducing the 
complexity of the mixture to be analyzed.  Instead of aiming to probe all proteins in a 
proteome, immunoprecipitation studies focus on targeted analyses of specific proteins or 
protein groups. Immunoprecipitation methods use an antibody that specifically isolates 
and concentrates a particular protein or group of proteins from a complex proteome 
sample.  For example, such strategy can be applied to study the composition of protein 
complexes, or to investigate post-translationally modified proteins. 
 
 
1.3.3 Mass Spectrometry 
 
Mass spectrometry (MS) is a powerful technology for the identification and 
characterization of peptides, proteins, and other biomolecules.  The development of 
advanced mass spectrometry instrumentation that allowed high-sensitivity, high-
throughput protein identification has been one of the enabling events underlying the 
expansion of proteomics (Yates, III, 2000). New and improved instruments are being 
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continuously developed, thus pushing the power of mass spectrometry to higher and 
higher levels. 
 
MS is an analytical technique that measures the molecular weight of molecules 
according to their mass-to-charge ratio.  A mass spectrometer is composed of three key 
components: ion source, mass analyzer and detector. Analytes are converted into gas-
phase ions within an ion source. The ions are then sorted and separated according to their 
mass-to-charge (m/z) ratio in a mass analyzer, and the signal is detected by a suitable 
device such as an electron multiplier. The resulting MS spectra are represented as ion 
intensity vs. the m/z values (Corthals et al., 2000). There are a number of different types 
of mass spectrometers that include different combination of ion sources and mass 
analyzers (Patterson and Aebersold, 1995; Yates et al., 2009). 
 
In general, protein identification by mass spectrometry involves cleaving the 
protein of interest into a set of peptides, which are then subjected to MS analysis.  
Production of gas-phase ions from peptides is therefore a critical step in mass 
spectrometry analysis.  There are two broadly used ionization methods in proteomics 
research, namely matrix-assisted laser desorption ionization (MALDI), and electrospray 
ionization (ESI) (Gevaert and Vandekerckhove 2000). MALDI sources are usually 
coupled to time-of-flight (TOF) mass analyzers while ESI sources are commonly linked 
to ion traps or quadrupole mass analyzers (Corthals et al., 2000).  
 
Ionization of analytes by MALDI involves the use of a UV-absorbing matrix.  A 
sample is co-crystallized with the matrix in a well on a samples plate; inside the ion 
source, the sample-matrix mixture is irradiated with a laser beam. This process results in 
vaporization of the matrix and analyte molecules are brought into a dense phase (plume) 
above the sample surface, where they are ionized by proton transfer reactions.  Peptides 
generally ionize through addition of a proton, forming a singly charged molecular ion, 
[M+H]+(Henzel et al., 1993). 
 
ESI can directly generate gas-phase ionized molecules from a liquid solution. This 
feature is of great benefit because it enables on-line coupling of ESI-based mass 
spectrometers with HPLC.  During ESI ionization, the LC eluent is sprayed from a tip of 
a needle held at a high voltage; through this process, a mist of highly charges droplets is 
created.  Gas and/or heat applied to the droplets causes evaporation of the solvent in the 
droplets.  As the size of droplets decreases, the charge density in the droplets increases. 
That leads to increase in the surface tension, the droplets dissociate into smaller ones and 
eventually gas-phase analyte ions are produced. Peptides ionized with ESI usually form 
multi-protonated molecular ions, [M+nH]n+, n = 2 or 3 depending on the number of basic 
sites in the peptide sequence.  The fact that multi-protonated ions are formed upon ESI 
has important implications for the ability to measure larger peptides, and for gas-phase 
dissociations of peptide ions (Fenn et al., 1989). 
 
The LTQ two-dimensional linear ion trap mass analyzer is one of commonly used 
mass analyzers, which is comprised of four parallel hyperbolic shaped rods, segmented in 
three secions. Ions are trapped radially in a radio frequency (RF) electric field and axially 
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in a static electric field using DC voltages. Through the application of appropriate 
voltages to all three segments, the trapped ions with specific m/z ratio are ejected in the 
radial direction through the two parallel slots in the center section of the linear ion trap. 
Two highly efficient detectors are placed on either side of the trap to maximize sensitivity. 
The unique configuration of this device improves the ion storage capacity, trapping 
efficiency and detection efficiency (Schwartz et al., 2002). 
 
Mass spectrometry measurements can be carried out in two general ways: as 
single-stage mass spectrometry (MS), or as tandem mass spectrometry (MS/MS).  An MS 
experiment includes ionization of the analytes, and measurement of the m/z ratios for the 
source-generated ions. For peptide ions such as singly-protonated ions produced upon 
MALDI, information about peptide MWs can be derived easily. This aspect, as it applies 
to protein identification, is discussed in more detail in the following paragraph.  An 
MS/MS experiment is more complex than MS and includes additional steps.  The steps in 
an MS/MS experiment are: ionization of the analyte molecules and formation of 
molecular ions; selection of one of the source-generated ions as the so-called precursor 
ion; activation of the mass selected precursor ion through collisions with a target gas 
followed by dissociation of the activated precursor ion into a series of structure-
determining product ions; mass analysis of the product ions and recording of the signal.  
In MS/MS, protonated peptide ions dissociate predominantly via cleavages along the 
peptide backbone, theoretically forming several different product ion series.  Under the 
conditions used in my research, two major ion series arise from cleavage of the peptide 
bond: the N-terminal ion series (b-ion series) and the C-terminal ion series (y-ion series) 
(Figure 1-2).  As shown in the figure, the m/z of the product ions can be used to derive 
amino acid sequence information for the peptide under analysis.  
 
Protein identification in proteomics studies may be achieved with MS. The MS-
based identification strategy is termed peptide mass fingerprinting (PMF) and it is 
commonly performed with a MALDI-TOF mass spectrometer. The method includes: 
cleavage of protein of interest into peptides with a specific enzyme (such as trypsin, 
which cleaves at the C-terminus of lysine and arginine); measurement of the m/z ratios of 
the peptide ions with MALDI-TOF; comparison of the observed peptide mass fingerprint 
to the theoretical mass fingerprints of proteins in a protein sequence database; generation 
of a list of possible candidate proteins based on peptide matching scores.  The PMF 
identification strategy is simple and provides high throughput. It has been applied widely 
for identification of proteins in 2D gel spots.  It should be noted that PMF is based on 
measurements of peptide masses, and that it is therefore applicable only to single proteins 
or simple protein mixtures.   
 
Protein identification may also be accomplished with MS/MS, commonly in 
conjunction with LC separation (LC-MS/MS).  As with PMF, the protein of interest is 
first cleaved into peptides, usually with trypsin.  The tryptic peptides are separated by LC, 
and the eluting peptides are analyzed by MS/MS.  The LC-MS/MS measurements on 
unknown peptide mixtures are performed using data-dependent acquisition (DDA).  
During DDA, the instrument cycles through MS and MS/MS (Spahr et al., 2000).  This 
principle is illustrated in Figure 1-3 for a cycle performed for ions eluting with the LC
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Figure 1-2 Peptide fragmentation series. 
 
 
retention time around 58.26 min.  The instrument acquired an MS spectrum that surveyed 
the analytes eluting at that particular time.  Based on the information from this MS 
spectrum, subsequent MS/MS measurements were performed on the precursor ions 
detected in the MS spectrum.  One of these MS/MS spectra, acquired for the precursor 
ion with m/z 942. The product ion m/z 893 is shown in the bottom section of the Figure 
1-3. During a single LC-MS/MS analysis, the instrument cycles through many of such 
MS-MS/MS sequences.  The entire MS/MS dataset is used to search a protein sequence 
database to identify the protein(s) of interest (Yates, III et al., 1995). It is important to 
point out that, in contrast to PMF that only measures peptide masses, sequence-diagnostic 
MS/MS data are obtained for each peptide being analyzed.  Based on LC-MS/MS data, 
proteins in 2D gel spots as well as in highly complex protein mixtures can be identified. 
Therefore, LC-MS/MS is an integral part of 1D-gel and gel-free bioanalytical platforms.   
 
 
1.3.4 Database Searches and Other Bioinformatics Analyses 
 
Identification of proteins of interest based on MS or MS/MS has been enabled by 
the creation of protein sequence databases that are being continuously updated, and on 
the development of database search software programs.  
 
In all my projects, sequence information derived from MS/MS was used for 
database searches with the SEQUEST search engine in the Swiss-Prot protein sequence 
database. Swiss-Prot is a curated protein sequence database that provides a high level of 
annotations (such as protein function, protein sequence, post-translational modifications, 
variants, etc.), minimizes the redundancy and integrates with other databases. Now the 
Swiss-Prot database has been merged into the UniProt database. SEQUEST is one of the 
two most widely used searching algorithms (Yates, III et al., 1995).  With SEQUEST, 
proteins in the database are cleaved in silico into peptides, and theoretical product-ion 
patterns are generated for these peptides.  These theoretical patterns are compared to the 
experimental MS/MS patterns; when a match is retrieved, it is evaluated with a scoring 
system.  Thus, the output of the database search is a list of proteins whose peptide 
sequences were matched based on MS/MS data.   
 
 H2N CHRCHR CHR COOH NH NH 
O
= 
 C 
O
= 
 C 
   x2       y2      z2       x1     y1      z1 
  a1       b1      c1       a2      b2       c2 
 11
 
 
 
Figure 1-3 An example of tandem MS/MS under data-dependent acquisition.  
 
The top section of the Figure1-3 is chromatogram of LC. The instrument acquired an MS 
spectrum that surveyed the analytes eluting at the LC retention time around 58.26 min.  
Based on the information from the MS spectrum, subsequent MS/MS measurements were 
performed on one of the precursor ions with m/z 942 detected in the MS spectrum. The 
product ion m/z 893 is shown in the MS/MS spectrum in the bottom section of the Figure 
1-3. 
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One of the important components of any proteomics research study is to integrate 
the information about both protein identifications and their corresponding functional 
characteristics. Gene ontology (GO) is a collection of controlled vocabularies describing 
the biology of a gene product in any organism (Khatri and Draghici, 2005). GO 
(http://bioinfo.vanderbilt.edu/webgestalt/) is performed to classify identified proteins 
according to molecular function, biological process, and molecular component 
(subcellular location). 
 
Ingenuity Pathway Analysis (IPA) is a powerful curated database and analysis 
system for understanding how proteins work together to effect cellular changes. It builds 
hypothetical networks from identified proteins and other proteins, based on published 
literature; these networks involve interactions between genes, proteins and other 
biological molecules (Hoorn et al., 2005; Raponi et al., 2004).  
 
 
1.4 Selected Proteomic Technologies Applied in Prostate Cancer Research 
 
 Recently, intense efforts have been involved in the application of various 
proteomics technologies to the study of prostate cancer (Table 1-1). Proteomic studies 
have generated numerous datasets of potential diagnostic, prognostic, and therapeutic 
significance for prostate cancer.  
 
 
1.4.1 In-gel-based Platform 
 
Gel-based protein separation is an extensively used proteomics methodology. 
Generally, proteins are separated with one-dimensional (IEF or SDS-PAGE) or two- 
dimensional (2-DE or 2D-DIGE) gels prior to mass spectrometry identification. The 
platforms are easily adapted to research projects in various labs and have been widely 
used.  
 
Malik et al. employed a combination of chemical pre-fractionation, SDS-PAGE, 
LC-MS/MS and SELDI-based immunoassay to identify discriminatory expression 
proteins of Dunning rat prostate tumor cell lines of varying metastatic potential (Malik et 
al., 2007). 
 
Liu et al. identified the alterations in protein expression patterns of LNCaP after 
incubation with Somatostatin/ Somatostatin derivative using 2-DE in combination with 
mass spectrometry, and found that Sms/smsdx triggered up-regulation of catalytic 
mitochondrial proteins and seemed to affect apoptosis-related proteins (Liu et al., 2007).  
 
Wu et al. identified key regulatory molecules involved in prostate cancer 
metastasis in two human androgen-independent Prostate cancer cell lines, highly 
metastatic 1E8-H and lowly metastatic 2B4-L cells through 2-DE and MS analyses, and 
demonstrated that up-regulation of vimentin expression positively correlates with the 
invasion and metastasis of androgen-independent prostate cancer (Wu et al., 2007). 
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Table 1-1 Summary of main proteomics methods used in prostate cancer studies. 
 
Platform Method  Sample Reference 
In-gel-based 
platform 
   
Sodium dodecyl 
sulfate 
polyacrylamide gel 
electrophoresis 
 (SDS-PAGE) 
SDS-PAGE, LC-MS/MS 
and SELDI-based 
immunoassay 
Dunning rat prostate tumor 
cell line 
Malik et 
al., 2007 
Two-dimensional 
polyacrylamide gel 
electrophoresis  
(2-DE) 
2-DE in combination with 
MS 
LNCaP after incubation with 
Somatostatin/ Somatostatin 
derivative 
Liu et al., 
2007 
 2-DE in combination with 
MS  
Two human androgen-
independent prostate cancer 
cell lines, highly metastatic 
1E8-H and lowly metastatic 
2B4-L cells 
Wu et al. 
2007 
 2-DE coupled with MS Conditioned medium from 
LNCaP, C4-2, and C4-2B 
cell 
Pang et al., 
2009 
 2-DE followed by matrix-
assisted laser 
desorption/time of flight 
mass spectrometry 
(MALDI-TOF-MS) 
The highly metastatic human 
prostate epithelial cell line 
PC-3M-1E8 (1E8-H) and the 
low metastatic line PC-3M-
2B4 (2B4-L) 
Wei et al, 
2008 
 2-DE and MALDI-TOF-
MS/MS 
Needle biopsy specimens 
from patients with prostate 
cancer or benign prostatic 
hyperplasia  
Lin et al., 
2007 
 2-DE coupled with MS Biopsy samples from benign 
prostate hyperplasia and 
prostate cancer 
Ummanni et 
al., 2008 
Two dimension 
difference gel 
electrophoresis  
(2D-DIGE) 
2D-DIGE technology 
coupled with LC-MS/MS 
LNCaP human prostate 
cancer cell line 
Rowland et 
al., 2007 
 2D-DIGE technology 
coupled with MS 
Human prostate cancer cells 
treated with enzymatically 
active free-PSA 
Bindukumar 
et al., 2008 
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Table 1-1 (continued). 
 
Platform Method  Sample Reference 
 2D-DIGE technology 
coupled with MS 
Three radioresistant 
prostate cancer cell lines  
Skvortsova et 
al., 2008 
 Immunoaffinity depletion 
and 2D-DIGE followed by 
LC-MS/MS 
Serum samples of patients 
with prostate cancer 
Byrne et al., 
2009 
Gel-free-based 
platform 
   
Multidimensional 
protein identification 
technology  
(MudPIT) 
2DLC-MS/MS  Conditioned medium from 
prostate cancer cell line 
PC3(AR)(6) 
Sardana et 
al., 2007 
 iTRAQ followed by 
2DLC-MS/MS  
The poorly metastatic 
LNCaP cell line and its 
highly metastatic variant 
LNCaP-LN3 cell line 
Glen et al., 
2008 
 Offline SCX followed by 
capillary RPLC-MS/MS 
Conditioned media of three 
prostate cancer cell lines: 
PC3, LNCaP, and 22Rv1 
Sardana et 
al., 2008 
 iTRAQ coupled with 
2DLC-MS/MS  
Tissue specimens from 
patients with benign 
prostatic hyperplasia and 
with prostate cancer 
Garbis et al., 
2008 
Immunoprecipitation Immunoprecipitation 
coupled with microLC-
ESI-MS/MS. 
C4-2 prostate cancer cells Dall’Era et 
al., 2007 
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Pang et al. analyzed conditioned medium (CM) from LNCaP, C4-2, and C4-2B 
cells using 2-DE coupled with mass spectrometry, and found that higher levels of 
ubiquitous mitochondrial creatine kinase (uMtCK) in the CM of androgen independent 
prostate cancer than that of androgen dependent prostate cancer cells (Pang et al., 2009). 
 
Wei et al. performed comparative proteomic analysis of the highly metastatic 
human prostate epithelial cell line PC-3M-1E8 (1E8-H) and the low metastatic line PC-
3M-2B4 (2B4-L) by 2-DE, followed by MALDI-TOF-MS. Highly expressed vimentin 
was detected in highly metastatic cell line compared to low metastatic cells (Wei et al., 
2008). 
 
Lin et al. defined the proteomic features of prostate needle biopsy specimens from 
patients with prostate cancer or benign prostatic hyperplasia to identify candidate 
biomarkers for prostate cancer. Using 2-DE, 52 protein spots were exhibited statistically 
significantly changes among prostate cancer and benign prostatic hyperplasia groups and 
identified by MALDI-TOF-MS/MS (Lin et al., 2007). 
 
Ummenni et al. investigated biopsy samples from benign prostate hyperplasia and 
prostate cancer patients by 2-DE and mass spectrometry to identify potential biomarkers 
which might distinguish the two clinical situations. Eighty eight protein spots were 
differentially expressed with statistical significance. Prohibitin was significantly up-
regulated in prostate cancer compared to benign prostatic hyperplasia (Ummanni et al., 
2008). 
 
Rowland et al. investigated the effect of androgen (R1881) and anti-androgen 
(bicalutamide) on the androgen-responsive prostate cancer LNCaP cell line using 2D-
DIGE proteomic approach. Out of 197 differentially expressed spots, 165 spots have been 
successfully identified corresponding to 125 distinct proteins. Identified proteins were 
involved in diverse processes including the stress response and intracellular signaling  
(Rowland et al., 2007). 
 
Bindukumar et al. identified proteins modulated in human prostate tumor cells 
treated with enzymatically active free-PSA by 2D-DIGE technology coupled with LC-
MS/MS. Several proteins involved in tumor progression had been shown to down-
regulate by the treatment of PSA (Bindukumar et al., 2008). 
 
Skvortsova et al. determined differences in the proteome profiles in three 
radioresistant human prostate carcinoma cell lines compared to parental cells using 2D-
DIGE followed by MS, to define the mechanism involved in the radioresistance 
development (Skvortsova et al., 2008). 
 
Byrne et al. subjected serum samples to immunoaffinity depletion and analyzed 
protein expression using 2D-DIGE. Out of 63 differential expression spots between the 
Gleason score 5 and 7 cohorts (p < 0.05), 13 spots were identified using LC-MS/MS. 
Pigment epithelium-derived factor (PEDF) has been validated in serum and tissue 
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samples from the original cohort and also from a larger independent cohort of patients, 
indicating to be a predictor of early stage prostate cancer (Byrne et al., 2009). 
 
 
1.4.2 Gel-free Platform 
 
 Although in-gel-based approaches are the mainstays for prostate cancer analysis, 
gel-free methodologies including Multidimensional Protein Identification Technology 
(MudPIT), and immunoprecipitation are emerging as alternative proteomic technologies 
for prostate cancer studies.  
 
 Using strong anion-exchange chromatography, Sardana et al. fractionated the 
conditioned medium from the prostate cancer cell line PC3(AR)(6), and then further 
fractionated tryptic fractions by reversed-phase C-18 chromatography before being 
subjected to ESI-MS/MS, and identified a novel candidate biomarker Mac-2BP (Sardana 
et al., 2007). 
 
 Using the poorly metastatic LNCaP cell line and its highly metastatic variant 
LNCaP-LN3 cell line as a model, Glen et al. employed a proteomic approach of isobaric 
tags for relative and absolute quantitation (iTRAQ), followed by strong cation exchange 
(SCX) chromatography coupled with capillary C-18 reversed-phase liquid 
chromatography-tandem mass spectrometry (RPLC-MS/MS). Out of the total 280 unique 
proteins identified, the relative expression data for 176 proteins was obtained. This was 
the first application of iTRAQ technology for the global proteomic profiling of prostate 
cancer cells (Glen et al., 2008). 
 
 Sardana et al. performed a proteomic analysis of the conditioned media of three 
prostate cancer cell lines (PC3, LNCaP, and 22Rv1) for discovering novel prostate cancer 
biomarkers. From the analysis, 2124 proteins were identified by using a bottom-up 
approach, consisting of offline SCX chromatography followed by RPLC-MS/MS 
(Sardana et al., 2008b). 
 
 Garbis et al. analyzed prostate tissue specimens from patients with benign 
prostatic hyperplasia and with prostate cancer by isobaric stable isotope labeling (iTRAQ) 
and two-dimensional liquid chromatography-tandem mass spectrometry (2DLC-MS/MS) 
approaches (Garbis et al., 2008). 
 
Dall’Era et al. isolated CD10-protein complexes from C4-2 prostate cancer cells 
by immunoprecipitation using anti-CD10 monoclonal antibodies. Eluted fractions were 
combined, trypsinized, and the resulting peptides were analyzed by LC-ESI-MS/MS. 
HSP27 and HSP70 were found to interact with CD10 in C4-2 prostate cancer cells 
(Dall'Era et al., 2007). 
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1.5 Phosphoproteomics Studies of Prostate Cancer 
 
Application of DNA microarray and proteomics to profile gene and protein 
expression shows a big promise in the discovery of prostate cancer markers. However, 
protein or gene expression does not necessarily reflect protein activity, which is often 
regulated by post-translational modifications. 
 
Protein phosphorylation is one of the most prominent prost-translational 
modifications and plays a critical role in the regulation of major cellular processes like 
proliferation, differentiation or apoptosis through signaling pathways. Phosphorylation of 
serine, threonine and tyrosine residue is the most common in mammalian cells. 
Researchers estimate that as many as 30-50% of proteins are phosphorylated at any given 
time (Kalume et al., 2003). Covalent attachment of phosphate group to amino acid 
changes the charge in the region of a protein and results in a conformation change of the 
whole protein, which affects both the folding and function of proteins. 
 
 Disruptions of phosphorylation-mediated cell signaling are associated with 
various diseases, including cancer (Benzeno et al., 2006; Iakoucheva et al., 2004; 
Stephens et al., 2005). Furthermore, distinct phosphotyrosine proteome of the breast and 
liver tumors were found (Lim et al., 2004; Lim, 2005; Meng et al., 2004). The evidence 
for the existence of tumor-specific phosphoproteome shows promising to mine the tumor 
phosphoproteome as potential prostate cancer biomarkers in cancer diagnosis and 
therapeutics. 
 
The phosphorylation status of proteins is regulated by a complex interplay 
between protein kinases and protein phosphatases. Protein kinases are the targets of 
several new cancer drugs and drug candidates. However, the functions of these protein 
kinases drugs are not fully understood. There is an urgent need to understand and monitor 
kinase signalling pathways (Ashman and Lopez, 2009). 
 
Thus, the analysis of protein phosphorylation in prostate cancer is of paramount 
importance. The long-term goal of studying of the phosphorylation status of proteins in 
prostate cancer with phosphoproteomics methods is to provide large phosphorylation 
databases for prostate cancer tissues and cell lines, aid in furthering our knowledge of 
phosphorylation-dependent events associated with prostate cancer, and lead to the 
identification of new target proteins for clinical research. 
 
Phosphoproteomics is the subdiscipline of proteomics that is focused on the 
comprehensive study of the extent and dynamics of protein phosphorylation. Its tasks 
include identification of the phosphoproteins, determination of the phosphorylation sites 
on the proteins, quantification of the phosphorylation under different conditions, 
prediction of protein kinases responsible for phosphorylation, and discovery of specific 
drug targets.  
 
  Compared with proteomics, phosphoproteomics faces more technical challenges 
due to the nature of the biomolecules being studied. Protein phosphorylation is a highly 
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dynamic, reversible process, and the ratio of phosphorylated to nonphosphorylated 
proteins is rather low in vivo. Therefore, phosphoproteomic approaches generally require 
additional enrichment steps to achieve sufficient sensitivity.  
 
 In fact, most phosphoproteomics studies to date have two features in common: 
protein or peptide fractionation and phosphospecific enrichment. Reduction of the sample 
complexity is a major step necessary for an effective analysis of low-abundance 
phosphoproteins; this reduction can be achieved by various fractionation techniques. 
Furthermore, considerable amount of effort has been devoted to development of methods 
for phosphospecific enrichment, compatible with mass spectrometry.  The objective of 
this enrichment is isolation of phosphoproteins and/or phosphopeptides. 
 
As the field of phosphoproteomics continues to develop, there have been a 
number of recent advances in phosphoproteomics technologies, including sample 
preparation, phospho-specific enrichment, characterization of phosphorylation sites by 
MS/MS, and bioinformatics analyses of protein phosphorylation. The following 
subchapters offer a detailed review of protein phosphorylation analysis, emphasizing 
advancements in MS-based phosphoproteomics platforms. 
 
 
1.5.1 Classical Approaches to Phosphoprotein Analysis 
 
There are several traditional approaches for detecting phosphoproteins. In general, 
protein samples are separated by one-dimensional or two-dimensional polyacrylamide gel 
electrophoresis (1-DE or 2-DE) depending on the complexity of the protein sample, and 
then phosphorylated species are visualized by radiolabeling, immunodetection or 
phosphospecific staining. 
 
1.5.1.1 32P/33P Radioactive Labeling 
 
Radioactive labeling is the most sensitive method for phosphoprotein detection, 
and it is possible to be used both in vivo and in vitro. Phosphoproteins can be 
radioactively labeled with 32P/33P and visualized by autoradiography. Several studies 
have been performed based on radiolabeling (Chen et al., 2004; Czupalla et al., 2003). 
However, the methodology is not widely used in current proteomics research due to the 
toxicity of 32P and the possibility of artificially triggered phosphorylation by exposure to 
32/33P-orthophosphate. 
 
1.5.1.2 Immunodetection 
 
Phosphoproteins can be detected by Western blotting using antibodies against 
phosphoamino acids. This antibody-based approach is widely used in biochemical studies 
and it is compatible with MS-based phosphoproteome analysis, provided that issues with 
protein amounts needed for Western blotting vs. those needed for MS are considered and 
addressed. However, the efficiency and specificity of the immunodetection method 
strongly depend on the quality of the applied antibody. While antibodies available for 
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phosphotyrosine (pTyr) show high selectivity and therefore can be used to specifically 
detect phosphotyrosine-containing proteins (Ide et al., 2002), antibodies against 
phosphoserine (pSer) and phosphothreonine (pThr) lack both selectivity and sensitivity, 
and are not routinely used (Kaufmann et al., 2001). 
  
1.5.1.3 Phosphospecific Staining  
 
Fluorescence-based protein detection methods have recently shown excellent 
promise in terms of quantitative accuracy, detection sensitivity, and compatibility with 
mass spectrometry. Pro-QTM Diamond dye has been developed to detect phosphoproteins 
directly in polyacrylamide gels or on nitrocellulose membranes after electrophoretic 
separation. In comparison with radiolabeling and immunodetection approaches, 
phosphospecific staining offers significant advantages, such as avoidance of radioactivity, 
no need for expensive antibodies, and direct detection of phosphorylated proteins 
obtained from cells, tissue, or body fluids. The stain noncovalently binds to 
phosphoproteins and it is fully compatible with mass spectrometry or Edman sequencing.  
Commonly, the phosphospecific staining is combined with generic protein staining in a 
multiplexed fashion – that is, Pro-QTM Diamond stain is applied to a gel to specifically 
detect phosphorylated proteins, and this staining is followed by detection of all proteins 
by Sypro Ruby fluorescent stain. Goodman et al detected phosphoproteins on 
nitrocellulose membranes using the Pro-QTM Diamond staining (Goodman et al., 2004). 
Stasyk et al. combined a standard 2D-DIGE protocol with subsequent post-staining of 
gels with phosphospecific fluorescent Pro-QTM Diamond dye for quantitative detection of 
phosphoproteins in 2-DE gels in mammary epithelial cells (Stasyk et al., 2005). Hopper 
et al. characterized the phosphoproteome of porcine heart mitochondria, as detected by 
Pro-QTM Diamond stain using 2-DE and 32P radioisotopic analysis as well as perform an 
initial screen for mitochondrial kinases and phosphatases associated with these protein 
phosphorylations (Hopper et al., 2006). Wu et al. devised a sequential protein staining 
procedure to visualize proteins separated by 2-DE, using Pro-QTM Diamond 
(phosphoprotein), followed by Pro-QTM Emerald 488 (glycoprotein), followed by 
SYPRO Ruby stain (general protein stain), and finally silver stain for total protein profile 
in spleen leukocytes (Wu et al., 2005). 
 
 
1.5.2 Mass Spectrometry-based Approaches 
 
 Phosphoproteomics requires proper sample preparation of proteins from 
biological samples, efficient enrichment of phosphorylated proteins or peptides, and the 
application of sensitive MS to the identification of phosphorylated proteins and 
characterization of exact phosphorylation sites. 
 
1.5.2.1 Sample Preparation 
 
In addition to the general concerns discussed previously in the context of protein 
sample preparation, minimizing phosphatase activities is an important point that needs to 
be considered for phosphoprotein sample preparation. Performing all sample preparation 
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at low temperature will reduce the activities of phosphatases; furthermore, adding 
phosphatase inhibitors to buffers in the initial step of sample solubilization will inhibit 
phosphatase action and thus preserve original phosphorylation patterns (Zahedi et al., 
2006).  
 
1.5.2.2 Enrichment of Phosphorylated Species 
 
MS approaches are site-specific analyses of protein phosphorylation, requiring 
that phosphoproteins first be cleaved by site-specific proteases in order to produce 
phosphopeptides that are amenable to MS analysis. However, digestion of a protein 
mixture will generate phosphorylated as well as non-phosphorylated peptides.  The 
phosphopeptides will comprise only a small portion of the digest.  Furthermore, 
phosphopeptides are not easy to analyze by MS because of lower ionization efficiency of 
phosphopeptides in the presence of high-abundance nonphosphorylated peptides. To 
account for these drawbacks, phosphoproteins and/or phosphopeptides must be 
specifically enriched prior to MS in order to reduce background and thereby increase 
sensitivity and improve characterization effectiveness. There are a number of 
phosphospecific enrichment strategies currently available. Here I will discuss two widely 
used enrichment methods: immobilized metal ion affinity chromatography (IMAC) and 
titanium dioxide chromatography (TiO2). 
 
Immobilized metal ion affinity chromatography (IMAC): To date, IMAC is an 
extensively used affinity technique for the isolation of phosphopeptides from peptide 
mixtures prior to MS analysis (Albuquerque et al., 2008; Gioeli et al., 2002; Hoffmann et 
al., 2005; Moser and White, 2006; Posewitz and Tempst, 1999).  The technique is based 
on the electrostatic interaction between negatively charged phosphopeptides at low pH 
and positively charged metal ions (Fe3+,Ga3+, Al3+, Zr4+), which are chelated to 
nitrilotriacetic acid (NTA) or iminodiacetic acid (IDA) immobilized onto a solid support. 
Typically, a peptide digest is applied to an IMAC column and the phosphopeptides 
contained in this digest will bind, while other peptides will wash through.  Elution with a 
suitable buffer will release the bound phosphopeptides. However, IMAC often suffers 
from limitations, most importantly issues related to specificity, and to recovery of 
phosphopeptides carrying multiple phosphate groups.  
 
Nonspecific binding of peptides containing acidic amino acid residues to the 
IMAC columns is one of the main drawbacks associated with the IMAC technique. 
Peptides containing multiple acidic amino acid residues are often co-purified with the 
phosphopeptides, thereby reducing the selectivity of the method. To diminish nonspecific 
binding of acidic peptides, Ficarro and co-workers derivatized the carboxylic groups on 
acidic amino acid residues in peptides by O-methyl esterification and thereby improved 
phosphopeptide enrichment (Ficarro et al., 2002). Salomon et al. developed an effective 
method for the large-scale determination of sites of tyrosine phosphorylation, applying 
the strategy of phosphotyrosine immunoprecipitation combined with methyl esterification 
and IMAC of tryptic peptides, and MS identification (Salomon et al., 2003). Kim et al. 
provided a list of protein phosphorylation sites identified from HT-29 human colon 
adenocarcinoma cell line by methyl esterification of carboxyl groups on the tryptic 
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peptides prior to IMAC enrichment combined with LC-MS/MS analysis (Kim et al., 
2005). However, it is argued that reaction conditions of esterification procedure have to 
be optimized to avoid introducing byproducts and increasing sample complexity.  
 
Furthermore, IMAC is generally biased against multiply phosphorylated peptides 
due to the strong binding of multiple phosphorylated peptides to IMAC resins, resulting 
in the reduction of elution efficiency. Optimization of binding, washing and elution 
conditions of IMAC could improve the efficiency of phosphopeptide enrichment 
(Dubrovska and Souchelnytskyi, 2005; Hart et al., 2002; Ndassa et al., 2006; Tsai et al., 
2008). 
 
Titanium dioxide (TiO2) chromatography: Recently, TiO2 chromatography has 
been introduced as a promising alternative to IMAC. Originally, TiO2 was utilized in 
bioelectrochemical studies of protein functions using the adsorption of proteins to TiO2 
films (Topoglidis et al., 2000) and enrichment of  phospholipids (Csucs and Ramsden, 
1998), which phosphate groups build self-assembling monolayers on TiO2 surface. The 
approach is based on the selective interaction of phosphates with porous titanium dioxide 
microspheres. Phosphopeptides are captured in a TiO2 precolumn under acidic conditions 
and released under basic conditions. Selective interaction with phosphate and the 
chemical stability make TiO2 a promising enrichment for phosphopeptides. Pinkse et al. 
presented an online 2D LC-MS/MS strategy for phosphopeptide analysis on the 
femtomole level, using titanium dioxide precolumn as the first dimension for 
phosphopeptides enrichment and reverse phase column as the second dimension (Pinkse 
et al., 2004).  
 
To reduce co-purified acidic peptides, Larsen et al. reported the improvement of 
the selectivity of TiO2 to phosphopeptide by adding 2,5-dihydroxybenzoic acid (DHB) to 
the loading buffer. DHB seems to efficiently reduce the binding of nonphosphorylated 
peptides to TiO2 while keeping its high binding affinity for phosphorylated peptides 
(Larsen et al., 2005; Thingholm et al., 2006). Yu et al. improved TiO2 enrichment of 
phosphopeptides from HeLa cells by the use of NH4Glu for a TiO2 column wash, which 
significantly increased the efficiency of TiO2 phosphopeptide enrichment (Yu et al., 
2007a). 
 
The utility of zirconium dioxide microtips for phosphopeptide isolation prior to 
mass spectrometric analysis has been reported. These microtips display similar overall 
performance as TiO2 microtips. But a slight difference was shown in the selectivity; 
compared to ZrO2, TiO2 preferentially enriched multiply phosphorylated peptides 
(Kweon and Hakansson, 2006). 
 
Although metal oxides are still not as widespread as IMAC in proteome research, 
high efficiency for enrichment of phosphopeptides and chemical stability of TiO2 
chromatography make the method a potential alternative to IMAC for phosphoproteomic 
research (Kweon and Hakansson, 2008; Li et al., 2008; Marcantonio et al., 2008). 
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1.5.2.3 Phosphopeptide Sequencing by Tandem Mass Spectrometry 
 
Today most phosphopeptides are identified by MS/MS combined with database 
searches; analysis is performed to obtain MS/MS data diagnostic of the phosphopeptide 
sequences and to the location of the phosphorylated residues.  
 
Phosphate group-specific dissociation in MS/MS can serve as supporting 
evidence for the presence of phosphopeptides. When peptide is phosphorylated, the 
amino acid residue (such as serine, threonine or tyrosine) will have a mass shift owing to 
the gain of a phosphate group (80 Da). Detection of phosphopeptides by ion trap MS in 
the positive mode can be achieved on the basis of their tendency to lose the elements of 
phosphoric acid under low energy dissociation conditions. Under these conditions, 
MS/MS spectrum of peptides containing phosphoserine or phosphothreonine presents a 
predominant neutral loss of 98 Da (owing to H3PO4 loss) during fragmentation by low 
energy collisions, while peptides bearing phosphotyrosine rarely exhibit a loss of 98 Da 
in their MS/MS spectra (Figure 1-4) (Tholey et al., 1999). The evidence of the loss of 98 
Da can be used as a signature for phosphopeptides and peptide sequence information can 
be used for determination of phosphorylation site in an ion trap (DeGnore and Qin, 1998). 
 
Low energy CID is widely used to achieve gas-phase dissociation of peptide 
backbone and to produce ions for sequence analysis and identification of phosphorylation 
sites. However, the CID process often leads to elimination of phosphoric acid as the 
major dissociation channel for phospho-serine and phospho-threonine-containing 
peptides, without sufficient dissociation of the amide bonds along the peptide backbone.  
This low dissociation extent may result in lack of sequence information in MS/MS 
spectra. Leitner et al. have recently reported to improve the dissociation efficiency of 
poorly fragmenting peptides and phosphopeptides during CID by malondialdehyde 
modification of arginine residues (Leitner et al., 2007). Despite significant technological 
advancements in peptide sequencing by mass spectrometry, poor fragmentation upon 
CID remains a challenge for analyzing phosphopeptides.  
 
Electron transfer dissociation (ETD) and Electron capture dissociation (ECD) 
have been recently introduced as alternatives to CID. These alternative ion activation 
methods provide a more comprehensive coverage of phosphopeptide sequences (Chi et 
al., 2007; Molina et al., 2007; Sweet et al., 2006).  
 
1.5.2.4 Bioinformatics Resources for Phosphoproteomics 
 
Identification of phosphopeptides and proteins based on MS/MS data is 
accomplished using the same principles that were discussed in section 1.3.4.  MS/MS 
datasets are submitted for searches of a protein sequence database; these searches are 
performed with a suitable search engine such as SEQUEST.  For phosphorylation 
analysis, database search conditions are set to include modifications of Ser, Thr, and/or 
Tyr residues. Because not all such amino acid residues are modified, phosphorylation is 
considered as either/or “dynamic” modification.  
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Figure 1-4 A representative MS/MS spectrum of a phosphopeptide. 
The MS/MS spectrum is acquired for the precursor ion with m/z 942. The product ion 
m/z 893, a predominant neutral loss of 98 Da (owing to H3PO4 loss), presents in the 
MS/MS spectrum.  
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Phosphoproteomics research is generating a wealth of novel information. Studies 
provide important information such as: a list of known phosphoproteins in a particular 
biological system; novel phosphorylation sites in known phosphoproteins; 
phosphorylated proteins which have not previously been reported to be phosphorylated; 
phosphorylation of a novel protein. Therefore, major efforts have been directed towards 
integration of this information, and towards an effective dissemination to the scientific 
community.  
 
An important compilation of information on protein phosphorylation (and on 
other PTMs) is contained in the annotations of the Swiss-Prot protein sequence database.  
A Swiss-Prot annotation page for a particular protein entry will include information on 
the location of a phosphorylation site as well as relevant literature references. In addition 
to Swiss-Prot annotations, new resources related to phosphorylation and other PTMs have 
been developed.  Table 1-2 lists some of the Internet-based resources for 
phosphoproteomics research. 
 
 Several knowledgebases dedicated to protein phosphorylation have been created.  
One of the most comprehensive knowledgebases is PhosphoSite.  PhosphoSite 
(www.phosphosite.org) is a systems biology resource focused on in vivo protein 
phosphorylation sites in human, mouse, and other mammalian proteomes. It includes a 
wealth of information such as the phosphorylated residue, orthologous sites, domains and 
motifs, additional functionalities etc.  Thus, PhosphoSite provides an accurate, 
comprehensive source of information about mammalian protein phosphorylation sites.  
 
To further the insight derived form large-scale phosphoproteomics studies, 
bioinformatics tools for additional phosphorylation-related examination have been 
developed.  For example, phosphopeptide sequences identified from phosphoproteomic 
screens can be analyzed with the Scansite tool to predict protein kinases and/or 
phosphorylation-dependent binding motifs. Scansite (http://scansite.mit.edu) searches for 
motifs within proteins that are likely to be phosphorylated by specific protein kinases or 
bind to domains (Obenauer et al., 2003).  
 
 
1.6 Summary and Research Aims 
 
Rapid development of proteomic technologies for studying prostate cancer shows 
a great promise for gaining new scientific knowledge that will contribute to the ultimate 
goal of finding more effective cancer diagnostic methods and therapies. In-gel and gel-
free-based methodologies have already been applied in prostate cancer studies of cultured 
cells and tissue specimens. In the last few years proteomic studies have generated new 
information of potential diagnostic, prognostic, and therapeutic significance.  
 
Diverse proteomics technologies have adapted for phosphoproteomics. Mass 
spectrometry-based phosphoproteomic platforms play a major role in current 
phosphoproteomics research, and advancements in the various components that comprise 
these platforms have been made, including optimized procedures for sample preparation,
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Table 1-2 A list of major websites for phosphoproteomics. 
 
Name Comments URL 
Phosphorylation-
site database 
  
Swiss-Prot Protein annotation including 
phosphorylation sites and other post 
translational modification 
http://expasy.org 
PhosphoSite Search known phosphorylation sites 
in human, mouse or rat 
http://www.phosphosite.org 
Phospho.ELM Search phosphorylation sites in 
proteins 
http://phospho.elm.eu.org 
Phosphorylation-
site prediction 
  
Scansite Search for potential kinase motifs  http://scansite.mit.edu 
Prosite Database of protein domains, families 
and functional sites 
http://expasy.org/prosite 
Ascore Phosphorylation site localization 
based on the presence and intensity of 
site-determining ions in MS/MS 
spectra. 
http://ascore.med.harvard.edu 
 
 
specific and sensitive methods for phosphospecific enrichment, mass spectrometers with 
lower detection limits and improved mass accuracy, alternative gas-phase dissociation 
strategies, expanded protein knowledgebases and other bioinformatics resources. These 
technological advances make it feasible to perform large-scale phosphoproteomic 
examinations of prostate cancer. 
 
It is an accepted fact that no single bioanalytical platform can be universally 
applied to proteomics or phosphoproteomics. Due to diverse nature of biological samples, 
different research objectives, different resources available to investigators, various 
bioanalytical platforms are being utilized for phosphoproteomics (Neverova and Van Eyk, 
2005). Each bioanalytical platform has its unique strengths (and also limitations).  
Improvements of existing platforms and development of new platforms is a critical aspect 
of the field of proteomics, since a continued expansion of analytical capabilities will 
bring more power to penetrate deeper into a proteome or phosphoproteome, to more 
accurately capture its dynamics, and to integrate information into a systems-level 
understanding. 
 
In our research group, the long-term focus is on proteomics of human cells, 
tissues, and biological fluids. Our team has contributed to the efforts directed towards 
analytical method development.  We introduced a new platform that combines IEF and 
tandem mass spectrometry, and adapted this platform to phosphoproteomics (Beranova-
Giorgianni et al., 2006; Giorgianni et al., 2004; Zhao et al., 2005).   
 
Over the past years, our group has pursued research on the prostate cancer 
proteome and phosphoproteome, focusing on cultured prostate cancer cell lines and on 
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human tumor specimens. There were two broad objectives that I set out to achieve in my 
doctoral research: (1) to build on the successful foundation from previous research in our 
laboratory to obtain an expanded atlas of the human prostate cancer phosphoproteome; 
and (2) to complete a first phase of a new collaborative research program aimed at 
differential profiling of prostate cancer tissue for mechanistic studies of molecular effects 
of novel anticancer therapies.   
 
The specific aims of my research were: 
 
Specific aim 1 (Chapter 2) was to adapt our newly developed analytical method - 
termed in-gel IEF LC-MS/MS - to mapping of prostate cancer phosphoproteome to 
characterize on a global scale the phosphoproteome in the LNCaP human prostate cancer 
cell line. 
 
Specific aim 2 (Chapter 3) was to apply a gel-free analytical platform to mapping 
the phosphoprotein signatures in human prostate cancer tissues for biomarkers discovery.  
 
Specific aim 3 (Chapter 4) was to develop a 2-DE based platform combined with 
phospho-specific staining to characterize the phosphoproteome in the LNCaP prostate 
cancer cells. 
 
Specific aim 4 (Chapter 5) was to identify proteins that are differentially 
expressed in control and bicalutamide/embelin treated mouse prostate tumor specimens, 
which will aid in the revealing of molecular mechanism of bicalutamide/embelin 
combination therapy.  
 27
CHAPTER 2. CHARACTERIZATION OF THE PHOSPHOPROTEOME IN 
LNCAP PROSTATE CANCER CELLS BY IN-GEL ISOELECTRIC 
FOCUSING AND TANDEM MASS SPECTROMETRY  
 
 
2.1 Introduction 
 
Prostate cancer is a leading type of cancer in men, and it is the second leading 
cause of cancer death (Jemal et al., 2008).  Despite recent declines in the mortality from 
prostate cancer, prostate cancer remains a serious public health issue.  Therefore, a large 
number of research efforts aims to increase our understanding of the mechanisms 
underlying the formation and progression of prostate cancer, in order to improve current 
diagnostic methods and to discover new drug targets.  Analysis of the molecular 
machinery in prostate cancer cells by proteomics approaches is an integral part of these 
efforts.  
 
Phosphoproteomics has recently emerged as an approach that focuses on 
examination of protein phosphorylation on a global-scale.  Many fundamental cellular 
processes are controlled by reversible protein phosphorylation; it is estimated that in 
mammalian cells, 30% of proteins are phosphorylated at any given time (Cohen, 2000).  
Disruptions of phosphorylation-mediated cell signaling are associated with various 
diseases, including cancer (Benzeno et al., 2006; Iakoucheva et al., 2004; Lim, 2005; 
Stephens et al., 2005). Therefore, large-scale examination of the prostate cancer 
phosphoproteome will bring unique mechanistic insight about perturbations of protein 
networks relevant to cancer.  Several recent reviews summarized numerous 
phosphoproteomic methodologies that have been developed. These methodologies used 
various combinations of separation strategies, in conjunction with mass spectrometry 
(Collins et al., 2007; Gafken and Lampe, 2006; Hoffert and Knepper, 2008).   
 
In our research group, the long-term focus is on proteomics of prostate cancer.  
We have initiated a phosphoproteomic study that aims to map the phosphoproteome in 
the LNCaP cell line, including an exact description of the sites of phosphorylation. 
Towards the aim, we have recently applied a simple gel-free analytical methodology to 
obtain a first panel of the LNCaP phosphoproteins, 137 phosphorylation sites in 81 
phosphoproteins (Giorgianni et al., 2007).  That pilot study underscored the need to 
enhance the coverage of the LNCaP phosphoproteome through modifications of our 
analytical strategy.  
 
The aim of this study was to adapt a newly developed analytical methodology, 
termed in-gel IEF LC-MS/MS (Giorgianni et al., 2003; Zhao et al., 2005), to 
phosphoproteomics study for prostate cancer, to characterize on a global scale the 
phosphoproteome in LNCaP human prostate cancer cell line. An outline of the in-gel IEF 
LC-MS/MS strategy is shown in Figure 2-1. 
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Figure 2-1 Outline of the in-gel IEF LC-MS/MS strategy. 
The LNCaP proteins were extracted with Trizol reagent, and separated by IEF in IPG 
strips.  After sectioning of the strips, the proteins in each gel section were fixed, and 
digested with trypsin.  The digests were subjected to IMAC to isolate phosphorylated 
peptides. The samples were desalted and concentrated by SPE, and analyzed with LC-
MS/MS.  The LC-MS/MS datasets were used to identify the phosphorylated peptides and 
proteins via searches of a protein sequence database.   
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2.2 Materials and Methods 
 
 
2.2.1 Protein Extraction from LNCaP Cells 
 
The LNCaP human prostate cancer cells (American Type Culture Collection, 
Manassas, VA) were cultured under conditions described previously (Giorgianni et al., 
2007).  Briefly, the LNCaP cells were cultured in RPMI-1640 with 2 mM L-glutamine 
(American Type Culture Collection, Manassas, VA) supplemented with 10% fetal bovine 
serum (Hyclone, Logan, UT) in a 37 °C, 5% CO2 incubator. The cells were collected 
while in log-phase growth (approximately 85% confluency). The media were aspirated 
from the plates; 0.25% trypsin-0.53 mM EDTA (American Type Culture Collection) was 
added. After a few minutes, complete media were added to the plates to stop the 
trypsinization, and cells were resuspended and transferred to a conical tube for 
centrifugation. Cells were pelleted at 150×g for 4 min, and resuspended in PBS. The cells 
were processed for protein extraction in two tubes, each containing 5×106 cells.  The cells 
in each tube were resuspended in 1.0 mL of Trizol reagent (Invitrogen, Carlsbad, CA) 
containing 5 µL of a phosphatase inhibitor cocktail (Sigma, St. Louis, MO), and the cells 
were lysed by repetitive pipetting. A total of 1 mg of protein was extracted using Trizol 
reagent following a procedure provided by the manufacturer.  
 
Briefly, cells were resuspended in 1.0 mL of Trizol reagent containing 5 µL of a 
phosphatase inhibitor cocktail, and the samples were pipetted until full disruption of the 
cells was achieved. The samples were incubated for 5 minutes at room temperature to 
permit the complete dissociation of nucleoprotein complexes. Chloroform was added at a 
proportion of 0.2 mL per 1 mL of Trizol reagent. The mixtures were vigorously mixed by 
hand for 15 seconds. The mixtures were incubated at room temperature for 3 minutes. 
Centrifugation was performed at 12,000 x g for 15 minutes at 4 °C. Following 
centrifugation, the mixture separated into a lower red phenol-chloroform phase, an 
interphase and a colorless upper aqueous phase. The organic phase was retained after 
carefully removing the aqueous phase (containing RNA). Absolute ethanol was added at 
a proportion of 0.3 mL per 1 mL of Trizol reagent used for the initial homogenization. 
Samples were mixed by inversion, and were incubated at room temperature for 3 minutes 
followed by sedimentation of DNA by centrifugation at 2,000 x g for 5 minutes at 4 °C. 
The protein-containing phenol-ethanol supernatant was retained. Isopropyl alcohol was 
added to the supernatant at a proportion of 1.5 mL per 1 mL of Trizol reagent used for the 
initial homogenization. The mixture was stored at room temperature for 10 minutes 
followed by protein sedimentation by centrifugation at 12,000 x g for 10 minutes at 4 °C. 
Supernatant was removed and protein pellets were washed twice with 0.3 M guanidinium 
hydrochloride in 95% ethanol, followed by a single wash with ethanol.  The proteins 
were dried in vacuum centrifuge for 5 minutes. 
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2.2.2 In-gel IEF 
 
The proteins were solubilized in 600 µL of a rehydration buffer containing urea (7 
M), thiourea (2 M), CHAPS (2%, w/v), IPG buffer pH 3-10 (2%, w/v), DTT (0.3%, w/v), 
and a trace of Bromophenol Blue dye. The mixture was kept at room temperature for 1 h; 
during that time, the mixture was sonicated for 20 s three times. The mixture was divided 
into three aliquots and centrifuged for 5 min at 12,000×g. The aliquots of the sample 
solution were loaded onto three IPG strips (pH 3-10, 11cm; GE Healthcare). The strips 
were allowed to rehydrate overnight in a reswelling tray.  The IEF was carried out in a 
Multiphor II unit (GE Healthcare, Piscataway, NJ) according to manufacturer’s 
instructions. In brief, the Multitemp water circulator was set to 20 °C, and apparatus was 
leveled, and all cables were connected. The DryStrip tray and the Immobiline strip 
aligner were placed according to the instructions. The grooves were lined up with the 
pattern on the cooling plate. The rehydrated IPG strip was taken out of the reswelling tray, 
and was rinsed slightly with water to remove any residual oil. The strip was placed into a 
groove in the strip aligner with the gel side up, and anode towards the rear. Two 
moistened electrode strips were placed on top of the aligned strip, one across the cathode 
and one across the anode edges. The strip made at least partial contact with the gel 
surface. Oil was used to completely cover the IPG strip. Focusing was performed at 20 ºC 
under the following conditions: 100 V (gradient over 1 min); 100 V (fixed for 120 min); 
500 V (gradient over 1 min); 3500 V (gradient over 90 min); 3500 V (fixed for 6 h). After 
IEF, the IPG strips were stored at -80 ºC until further analysis. 
 
 
2.2.3 In-gel Digestion  
 
After IEF, the IPG strips were rinsed with water, and cut into 10 sections of 
identical size (1.10 cm× 0.36 cm). The gel sections were peeled off from the plastic 
backing with a clean scalpel. The same gel sections from the three strips were combined.  
Proteins in the IPG strip sections were fixed in 20% trichloroacetic acid (TCA) for 30min 
(Zhao et al., 2005).  All gel pieces were washed with water and incubated in 200 µL of 
200 mM ammonium bicarbonate for 10 min, followed by dehydration with 200 µL of 
acetonitrile (ACN).  The gel pieces were dried in a vacuum centrifuge. The gel pieces 
were rehydrated with 100 µL of ammonium bicarbonate (50 mM) containing sequencing-
grade trypsin (Promega, Madison, WI) at a concentration of 40 ng/µL.  The samples were 
incubated overnight at 37 ºC.  
 
 
2.2.4 Enrichment of Phosphopeptides with IMAC 
 
The digests from each gel section were dried in a vacuum centrifuge, and re-
dissolved in 50 µL of 10% acetic acid.  The phosphopeptides were isolated with an 
IMAC Gallium (III) spin-column (Phosphopeptide Isolation Kit; Pierce, Rockford, IL). 
The sample solution was bound to the column by incubation at room temperature for 1 h. 
The column was washed with the following solutions: two portions of 40 µL of 0.1% 
AcOH, two portions of 40 µL of 0.1% AcOH/10% ACN, and two portions of 40 µL of 
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water. The phosphopeptides were eluted from the IMAC column with two aliquots of 
30µL of 200 mM sodium phosphate (pH 8.4), followed by a single elution with 30 µL of 
100 mM sodium phosphate/ 50% ACN. The eluates were combined and dried under 
vacuum. Prior to LC-MS/MS analyses, the IMAC-enriched phosphopeptides were 
reconstituted with 15 µL of 0.1% trifloroacetic acid (TFA) and desalted with ZipTipC18 
(Millipore, Billerica, MA), using the procedure provided by the manufacturer. In brief, 
the ZipTipC18 column was conditioned with 10 µL ACN / 0.1% TFA (3 times), 50% 
ACN / 0.1% TFA (3 times) and water / 0.1% TFA (3 times). The peptide mixture was 
aspirated 10 times in order for the peptides to bind to the cartridge. The cartridge was 
washed 3 times with 10 µL 0.1% TFA / water.  The phosphopeptides were eluted from 
the ZipTipC18 column with 3 µL of 50% ACN/0.1% TFA, and diluted with 3 µL of 0.1% 
AcOH. 
 
 
2.2.5 LC-MS/MS Analysis 
 
LC-MS/MS experiments were performed on an LTQ linear ion trap mass 
spectrometer (Thermo Electron, San Jose, CA) coupled to a nanoflow LC system (Dionex, 
Sunnyvale, CA).  Each IMAC-enriched digest obtained from specific IPG gel section was 
analyzed in triplicate.  The peptide mixtures were manually injected onto a PicoTip 
fused-silica micro-capillary column/spray needle (15 cm length, 75 µm ID; New 
Objective, MA) packed in-house with C18 stationary phase (Michrom Bioresources, 
Auburn, CA). The peptides were separated using a 90 min-gradient from 0% to 90% 
mobile phase B.  The composition of mobile phase B was 90% MeOH/10 %water/0.05% 
FA; the composition of mobile phase A was 2% MeOH/98% water/0.05% FA. The LTQ 
mass spectrometer was operated in positive ion mode and data-dependent acquisition was 
performed.  One data-dependent acquisition cycle encompassed a full-range MS scan 
followed by 7 MS/MS scans on the most abundant ions from the MS scan.   
 
 
2.2.6 Database Searches 
 
The datasets obtained in the LC-MS/MS analyses of the enriched digests from 
each gel section were used for database searches with the TurboSEQUEST search engine 
(Thermo Electron) that is part of Bioworks version 3.2.  Using the target-decoy database 
searching strategy (Ballif et al., 2008; Elias and Gygi, 2007),  the data were searched 
against a composite database containing human protein sequences and their reversed 
complements. The searches were performed with the following parameters: full-trypsin 
specificity, dynamic modification of oxidized Met (+15.9949), and dynamic 
modifications of phosphorylated Ser, Thr, and Tyr (+79.9663).  The search results were 
filtered using the cutoffs of ∆Cn = 0.14, and XCorr of 3.0, 4.0 for doubly and triply 
charged precursor ions, respectively; this filtering procedure produced a phosphopeptide 
set with an estimated false-positive rate of 0.8% (Elias and Gygi, 2007).  All entries 
within this set were manually validated.  In addition, lower-scoring phosphopeptides were 
subjected to manual validation, and those peptides that fulfilled the validation criteria 
were included in the final phosphopeptide panel.  The manual validation involved 
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inspection of the corresponding MS/MS data.  The criteria used for manual validation 
included: the presence of a diagnostic product ion corresponding to neutral loss of 
phosphoric acid (DeGnore and Qin, 1998); and high-quality spectrum in terms of signal-
to-noise ratio for the sequence-determining product ions. Furthermore, assignments of 
exact sites of phosphorylation were validated manually through inspection of the 
corresponding product ions. 
 
 
2.3 Results and Discussion 
 
 
2.3.1 In-gel IEF LC-MS/MS Approach 
 
The analytical methodology, outlined in Figure 2-1, encompassed seven steps: (1) 
Trizol-based extraction of proteins from the LNCaP cells; (2) separation of the protein 
mixture by isoelectric focusing in immobilized pH gradient (IPG) strips; (3) sectioning of 
the IPG strips; (4) protein fixation followed by digestion of the proteins in each gel 
section; (5) enrichment of phosphopeptides in the digests by IMAC; (6) analysis of the 
enriched digests by LC-MS/MS; and (7) identification of the phosphopeptides/proteins 
through database searches, and assignment of the sites of phosphorylation in these 
proteins.  A representative example of an MS/MS spectrum from the LC-MS/MS datasets 
is shown in Figure 2-2. 
 
The objective of the study presented here was to obtain an expanded panel of the 
LNCaP phosphoproteome through application of an improved analytical strategy.  In-gel 
IEF LC-MS/MS, which included separation of the prostate proteins by IEF, was used to 
provide an additional dimension of separation of the complex mixture. Fractionation of 
the original protein mixture simplified the samples to be subsequently analyzed by LC-
MS/MS.  The concomitant decrease in throughput (multiple fractions had to be analyzed) 
was offset by the increase in the amount of information that was gained in the overall 
output of the analysis.   
 
In combination with IEF separation, phosphopeptide enrichment and a more 
sensitive mass spectrometer (LTQ vs LCQ Deca XP plus), this bioanalytical strategy 
yielded a significantly larger phosphoprotein panel, compared to our pilot study of the 
LNCaP phosphoproteome (Giorgianni et al., 2007). As shown in Table 2-1, a total of 625 
phosphorylation sites were identified in 558 phosphopeptides.  Together, these 
phosphopeptides mapped to 296 different proteins.  This panel of the LNCaP 
phosphoproteins was 3.6-fold larger than the panel obtained in our previous work, which 
attested to the power of the chosen analytical methodology.  A full list of the 
phosphopeptides and phosphoproteins characterized in this study is provided in Table A-
1. Phosphorylation sites were assigned based on manual inspection of product ion series 
in the MS/MS spectrum. The full information for each phosphorylation site assignment is 
provided in Table A-2. 
 
One of tasks we faced in the analysis of tandem mass spectra was to validate  
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Figure 2-2 A representative MS/MS spectrum obtained in the LC-MS/MS analysis of 
IMAC-enriched digest from gel section 4. 
 
The spectrum contains a phosphate-diagnostic product ion at m/z 952, and series of other 
product ions that determine the sequence of the peptide. Based on these data, the 
phosphopeptide FNDpSEGDDTEETEDYR (m/z of the [M+2H]2+ molecular ion is 
1001.4, marked as * into the spectrum) was identified that belongs to Bcl-2-Associated 
Transcription Factor 1.   
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Table 2-1 Summary of the LNCaP phosphoproteome characterization results: in-gel IEF 
LC-MS/MS vs. gel-free methodology. 
 
Method Number of 
phosphosites
Number of 
phosphopeptides 
Number of 
phosphoproteins 
Gel-free platform 137 115 81 
    
In-gel IEF LC-MS/MS 625 558 296 
 
 
peptide-spectrum matched identification. Tandem mass based peptide identifications are 
dependent on the quality of the match between the observed and predicted sequence 
spectra. However, in practice matches between observed and expected spectra are not 
perfect. Therefore, manual inspection of MS/MS spectra of the individual search results 
is very critical after database search. For the large phosphorylation data set generated by 
in-gel IEF LC-MS/MS study, we performed a composite target-decoy search strategy  
(Ballif et al., 2008; Elias and Gygi, 2007),  the data were searched against a composite 
database containing human protein sequences and their reversed complements. The 
target-decoy strategy helped to estimate how many false positive were associated with the 
entire data set. We determined the cutoff value for the filters required to achieve a < 1% 
false-positive rate. Moreover, we performed manual validation of all hits and included the 
lower-scoring validated hits in our final panel. Combination the target-decoy strategy and 
the manual validation strategy allowed us to balance the need to minimize false positive 
with the need to also reduce false negatives.  
 
 
2.3.2 Characteristics of Identified Phosphoproteins/phosphopeptides 
 
Distribution of the identified phosphoprotein/phosphopeptides across the IPG 
strip is shown in Figure 2-3. As expected, the largest numbers of phosphoproteins were 
found in gel sections 4 and 5, corresponding to pH range 5.1 to 6.5.  In addition, a 
number of acidic or basic phosphoproteins were found at the extreme positions in the pH 
3-10 IPG strip. For example, a high-pI protein, Cysteine and Glycine-Rich Protein 1 
(theoretical pI is 8.90) was identified in gel section 9.  These results showed that 
phosphoproteins with a wide range of physicochemical characteristics were probed by 
our methodology.  It should be noted that the experimental pI information on the intact 
protein was preserved, unlike in the gel-free approach or other methods that focus on 
analyses at the peptide level.  As shown in Figure 2-4, the majority of the identified 
phosphopeptides were singly phosphorylated; doubly phosphorylated peptides accounted 
for 20-30 % of all phosphopeptides, and fewer than 10% were triply phosphorylated. 
 
The phosphoproteins characterized in the study were evaluated based on their 
subcellular locations and function, as presented below.  The full information for each 
phosphoprotein is available in Table A-3. 
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Figure 2-3 Distribution of phosphoproteins/phosphopeptides in the IPG strip sections.         
 
An 11-cm IPG strip (pH range 3-10L) was used and divided into 10 sections of equal size. 
The labels on the x axis showed the IPG strip section numbers and corresponding pI 
values. 
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Figure 2-4 Distribution of singly, doubly, and triply phosphorylated peptides.  
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2.3.3 Classifications of Identified Phosphoproteins 
 
The characterized phosphoproteins belong to various subcellular locations. The 
subcellular locations of the identified phosphoproteins were assigned based on Swiss-Prot 
annotations: among the 296 phosphoproteins, 205 proteins were annotated and 91 
proteins could not be classified. As depicted in Figure 2-5, proteins from various 
subcellular compartments were sampled: nucleus, cytoplasm, multiple (that is, proteins 
that can be found in more than one subcellular location), membrane and mitochondria. It 
should be noted that the largest group sampled in the study were nuclear proteins and 
proteins that belong to a cytoplasm/nucleus subgroup within the “multiple” category. 
 
The phosphoproteins characterized in the study are functionally diverse. We 
grouped the identified phosphoproteins into several categories based on their biological 
function as annotated in the Swiss-Prot database. The distribution of the phosphoproteins 
among the various functional categories is shown in Figure 2-6.  The largest group was 
represented by proteins playing a role in transcription, including transcription factors and 
RNA-processing proteins. Other two large groups were represented by proteins involved 
in translation and signal transduction.  
 
 
2.3.4 Selected Examples of Identified Phosphoproteins 
 
Selected examples of identified phosphoproteins that are of particular interest in 
the normal and disease prostate physiology included kinases, steroid-receptor interacting 
proteins, and other proteins relevant to cancer.   
 
The LNCaP phosphoprotein panel included a number of kinases, for example 
RAC-alpha Serine/threonine-Protein Kinase, Mitogen-Activated Protein Kinase 2, 
Serine/threonine-Protein Kinase TAO2, Serine/threonine-protein Kinase D1, and Protein 
Kinase C. Some of these kinases were known to play a role in prostate cancer.  For 
example, RAC-Alpha Serine/Threonine-Protein Kinase (Protein Kinase B) is part of a 
central signaling pathway in prostate cancer (Lee et al., 2008); phosphorylation of the site 
that was found in this study (S473) regulates the activity of this kinase, and 
phosphorylation at S473 correlates with clinical outcome in prostate cancer (Kreisberg et 
al., 2004).  
 
A number of other cancer-relevant proteins were identified. RNA-Binding Protein 
5 is a tumor suppressor protein that promotes apoptosis and cell cycle arrest. Bcl-2-
Associated Transcription Factor 1 is a transcriptional repressor that promotes apoptosis. 
Transforming Acidic Coiled-Coil-Containing Protein 2 is a candidate breast tumor 
suppressor and biomarker for tumor progression. It may protect nonmalignant cells from 
tumorigenic conversion by promoting proper cellular organization and tissue 
morphogenesis (Chen et al., 2000). Programmed Cell Death Protein 4 (Pdcd4) is a novel 
tumor suppressor. The Pdcd4 gene was first identified as a differentially expressed 
mRNA when cells were treated with apoptosis inducers. Pdcd4 might suppress tumor 
progression by regulating the expression of the kinase MAP4K1 (Yang et al., 2006). 
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Figure 2-5 Summary of the sub-cellular locations of the LNCaP phosphoproteins 
characterized by in-gel IEF LC-MS/MS.  
Note: The information was compiled from Swiss-Prot annotations. 
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Figure 2-6 Classification of the characterized LNCaP phosphoproteins based on their 
involvement in cellular processes.   
 
Note: This information was gathered based on Swiss-Prot annotations.
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Several members of the androgen receptor (AR) response pathway were 
characterized. Several phosphorylated sites in protein from the heat-shock protein (HSP) 
family were found, such as HSP86, HSPB1 and HSP84.  HSPs are bound by the ligand-
free AR which is sequestered in the cytoplasm. HSPs function as chaperones to stabilize 
the AR during folding, protecting it from degradation. When dihydrotestosterone (DHT) 
binds to the AR, inducing a conformation change, which allows dissociation of HSPs, AR 
then forms a homo-dimer and is phosphorylated at several sites (Edwards and Bartlett, 
2005; Lee and Chang, 2003). 
 
Phosphorylation sites were identified for mitogen-activated protein kinase 
(MAPK) Ser164, Ser331 and protein kinase C (PKC) Ser354. These kinases help AR 
sensitize low circulating level of DHT to induce phosphorylation at specific sites of AR 
and then translocate AR to the nucleus (Rochette-Egly, 2003).  PKC is a phospholipid-
dependent cytoplasmic, serine/threonine kinase, which may be activated by TGF-β or 
intercellular activators such as calcium and diacylglycerol (Lahn et al., 2004).  There are 
PKC phosphorylation consensus sites on the AR at Ser81 and Ser650. This indicates that 
activating PKC signaling can affect AR phosphorylation. 
 
We also identified proteins involved in Ras signaling: Ras GTPase-activating 
protein-binding protein 1 (G3BP-1), Ras GTPase-activating protein-binding protein 2 
(G3BP-2), and Rab-GTPase. Ras subfamily proteins control signal transduction between 
the membrane and the nucleus, and activation of Ras-mediated signaling has been 
implicated in the progression of prostate cancer to androgen independence (Gioeli, 2005). 
 
 
2.4 Conclusions 
 
 With in-gel IEF based analytical platform, we have characterized over 600 
different phosphorylation sites in 296 phosphoproteins in the LNCaP prostate cancer cell 
line. This panel of the LNCaP phosphoproteins was 3-fold larger than the panel obtained 
in our previous work, and was the largest phosphoproteins panel in prostate cancer to date. 
The phosphoproteins identified in this study belonged to various locations within the cell 
and were involved in various processes including cell differentiation, transcription 
regulation, and intercellular signal transduction. The expanded phosphoproteome map 
obtained in this study was of a satisfactory size to serve as a foundation for future 
quantitative studies of the effects of pharmaceuticals on the LNCaP prostate cancer cells. 
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CHAPTER 3. INVESTIGATION OF PHOSPHOPROTEIN SIGNATURES IN 
ARCHIVED HUMAN PROSTATE CANCER TISSUES VIA 
PROTEOMIC ANALYSIS 
 
 
3.1 Introduction 
 
Early stage detection and diagnosis of cancers decrease the mortality rate of these 
diseases. The prostate specific antigen (PSA) screen is a commonly used, serum based, 
biomarker test for the early detection of prostate cancer. It is well known that the PSA 
screen suffers for low specificity and poor sensitivity (Lin et al., 2007). Therefore, the 
discovery of new biomarkers of prostate cancer, featuring high specificity and sensitivity, 
would dramatically improve the survival rate of prostate cancer patients. 
 
Because of its importance, the human prostate tissue has been a prime target of 
proteomics research efforts. To date, several studies have applied the proteomics 
approach to study the protein expression patterns in prostate cancer (Sardana et al., 2008b; 
Semmes et al., 2006; Solassol et al., 2005) as compared to healthy prostate tissues.  Most 
of these studies had a common goal: the discovery of novel biomarkers, and all studies 
used mass spectrometry (MS) based platforms for their discovery efforts. As a result of 
these efforts, a large number of molecular markers have been identified; to date none of 
them has reached clinical use (Sardana et al., 2008a). It is thought that patterns revealed 
in a panel of proteins (known as a “protein signature”) associated with a form of cancer 
might have better diagnostic and predictive capabilities than the current “one biomarker” 
approach. 
 
An alternative approach to protein expression analysis for the discovery of disease 
biomarkers is the comprehensive characterization of protein phosphorylation. Protein 
phosphorylation is the most widespread signaling mechanism in eukaryotic cells, and it is 
involved in all fundamental cellular processes. Reversible phosphorylation forms the 
basis of cell signaling networks and phosphorylation-based signaling networks are key to 
the cell ability to quickly respond to external and internal environmental changes. The 
elucidation of the phosphoprotein networks in prostate cancer would therefore deepen our 
understanding of the mechanisms involved in its formation and progression, and it would 
improve the accuracy of early detection and it would speed up the discovery rate of 
targeted and more effective drugs.  
 
We have already applied the gel-free platform to study phosphoproteins in LNCaP 
cells to obtain the first phosphoprotein networks in a prostate cancer cell line (Giorgianni 
et al., 2007).  Since tissues based proteomic analyses are considered to be potentially 
more useful for relating protein status directly to diseases, the aim of this study was to 
apply the gel-free analytical platform to identify phosphoproteins on a global scale in 
archived prostate cancer tissues for biomarker discovery. An outline of the gel-free 
approach is shown in Figure 3-1.  
 
 42
 
 
Figure 3-1 Outline of the gel-free analytical methodology. 
 
Proteins from prostate cancer tissues were extracted with Trizol reagent, and then in-
solution digested with trypsin.  The digests were subjected to IMAC to isolate 
phosphorylated peptides. Enriched peptides were analyzed with LC-MS/MS.  The 
MS/MS datasets were used to identify the phosphorylated peptides and proteins via 
searches of a protein sequence database. Bioinformatics analyses were performed for the 
panel of characterized phosphoproteins. 
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3.2 Materials and Methods 
 
 
3.2.1 Characteristics of Clinical Samples 
 
A total of 5 bulk prostate cancer specimens (99-010, 99-029, 98-065, 99-045, 99-
067) have been used in the study. The specimens were obtained from the University of 
Tennessee Department of Urology Specimen and Tissue Bank. The research project was 
approved by the UTHSC IRB. The specimens were procured during radical 
prostatectomy, and were stored in liquid nitrogen until transfer from the Bank; afterwards, 
they were stored at -80 °C until processing. All specimens have been evaluated by a 
pathologist to confirm the presence of cancer, and to determine the Gleason score. The 
characteristics of specimens are summarized in Table 3-1. 
 
 
3.2.2 Protein Extraction  
 
Each prostate tumor tissue specimen (50-200 mg wet weight) was quickly minced 
with a scalpel and the pieces were suspended in 1.0 mL of Trizol reagent (Invitrogen, 
Carlsbad, CA) containing 5 µL of phosphatase inhibitor cocktail (Sigma, St. Louis, MO). 
The samples were homogenized until full disruption of the tissue was achieved. The 
protein, free of nucleic acids, was extracted from each lysate using Trizol reagent 
according the manufacturer’s instruction (details described in Chapter 2).  Protein pellets 
were washed three times with 0.3 M Guanidinium hydrochloride in 95% ethanol, 
followed by a single wash with ethanol. Proteins were dried under vacuum for 30 min, 
and were resuspended in 50 mM ammonium bicarbonate. The protein concentration of 
the extracts was determined by Bradford assay (GE Healthcare, Piscataway, NJ). 
 
 
3.2.3 In-solution Digestion of Proteins  
 
The extracted proteins (approximately 1 mg) were re-suspended in 50 mM 
ammonium bicarbonate buffer (pH 8) through vigorous vortexing. To produce a 
homogeneous protein suspension, the samples were sonicated three times for 20 s each 
time, with 30 s intervals between the sonication.  Sequencing-grade trypsin (Promega, 
 
Table 3-1 Characteristics of prostate cancer specimens used in the study. 
 
Specimen code Donor age Donor race Diagnosis (total 
Gleason score) 
99-010 50 African American Cancer (5) 
99-029 59 African American Cancer (7) 
98-065 62 African American Cancer (6) 
99-045 66 Caucasian Cancer (6) 
99-067 67 Caucasian Cancer (6) 
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Madison, WI, USA) was added to the protein mixture at an enzyme-to-protein ratio of 
1:60 (w/w). The digestion proceeded overnight at 37 °C with gentle agitation.  After 16 
hours of digestion, undigested protein was visible in some of the samples.  Therefore, 
additional trypsin was added to achieve complete digestion. 
 
 
3.2.4 Enrichment of Phosphopeptides with IMAC  
 
The tryptic digests were dried in a vacuum centrifuge, and re-dissolved in 50 µL 
of 90% water/10% AcOH.  The resulting solution was applied to an IMAC spin-column 
(Phosphopeptide Isolation Kit; Pierce, Rockford, IL), and the phosphopeptides were 
bound by incubation at room temperature for 1 h. The column was washed with the 
following solutions: 40 µL of 0.1% AcOH (2 washes), 40 µL of 0.1% AcOH/10% ACN 
(2 washes), and 40 µL of water (2 washes). The phosphopeptides were eluted from the 
IMAC column with three 30 µL-aliquots of 200 mM sodium phosphate (pH 8.4), 
followed by a single elution with 30 µL of 100 mM sodium phosphate/50% ACN. The 
eluates were combined and dried under vacuum. Prior to LC-MS/MS analysis, the 
IMAC-enriched phosphopeptides were reconstituted with 15 µL of water/2.5% FA and 
desalted with ZipTipC18 (Millipore, Billerica, MA), using the procedure provided by the 
manufacturer. The phosphopeptides retained on the ZipTipC18 column were eluted with 
3 µL of 50% ACN/0.1% FA and diluted with 6 µL of 0.5% FA, then analyzed by LC-
MS/MS. 
 
 
3.2.5 LC-MS/MS  
 
LC-MS/MS experiments were performed on a LTQ linear ion trap mass 
spectrometer (Thermo Electron, San Jose, CA) coupled to a nanoflow HPLC system 
(Dionex, Sunnyvale, CA). Each sample was analyzed in triplicate. Peptide mixtures were 
loaded onto a fused-silica micro-capillary column/spray needle (PicofritTM , 15 cm length, 
75 µm ID; New Objective, MA)  packed in-house with C18 stationary phase (Michrom 
Bioresources, Inc., Auburn, CA).  The peptides were separated using a 90-min linear 
gradient from 0% to 90% mobile phase B.  Mobile phase B was 10% water/90% 
MeOH/0.05% FA; mobile phase A was 98% water/2% MeOH/0.05% FA.  The LTQ 
mass spectrometer was operated in positive ion mode and data-dependent acquisition was 
performed. In brief, a scan cycle was initiated with a full MS, which was followed by 
MS/MS scans on the 7 most abundant precursor ions. 
 
 
3.2.6 Database Searches 
 
The MS/MS data were used to search the Swiss-Prot database (subset of human 
proteins) with the TurboSEQUEST search engine that was part of Bioworks version 3.2 
software suite (Thermo Electron). Searches were performed with the following 
parameters: full-trypsin specificity, static modifications of oxidized Met (+15.9949), and 
dynamic modifications of phosphorylated Ser, Thr, and Tyr (+79.9663). All peptide 
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matches were filtered to include peptides retrieved with XCorr values ≥ 3.00, 2.00, and 
3.50 for singly, doubly and triply charged ions, respectively. The MS/MS spectra of all 
phosphopeptide candidates that had passed this initial filtering were manually validated 
through inspection of the MS/MS spectra.  This manual validation assessed the following: 
(1) whether a neutral-loss signal corresponding to [M+2H-98]2+ for doubly charged ions 
or [M+3H-98]3+ for triply charged ions was present in the spectrum; and  (2) whether a 
good portion of the peptide sequence was covered by the b- and/or y product-ion series. 
The exact phosphorylation site assignment was validated by inspecting the b- and/or y- 
product ions that flanked the phosphorylation site assigned by software. 
 
 
3.2.7 Additional Bioinformatics Analysis 
 
 Annotations of the Swiss-Prot database, and the PhosphoSite knowledgebase 
(www.phosphosite.org) were used to assess whether a particular site has been identified 
previously in prostate cancer tissue or in other biological systems.  Gene Ontology 
(bioinfor.vanderbilt.edu/webgestalt) was used to classify identified proteins according to 
molecular function. The bioinformatics tool Scansite (scansite.mit.edu) was used to 
obtain information about potential kinase and/or phosphorylation-dependent binding 
motifs. 
 
 
3.3 Results 
 
In this study, a gel-free bioanalytical strategy was used to map the 
phosphoproteins in archived primary human prostate cancer tissue. One milligram of 
protein extracted from the tissue specimen was digested in-solution with trypsin. 
Generally, Trizol-extracted protein mixtures are denatured with 8 M urea and then diluted 
to 1-2 M urea prior to trypsin digestion. This strategy is used to digest highly complex 
protein mixtures, particularly when sample availability is a major concern. However, the 
urea present in the resulting digest complicates subsequent analysis. A clean, more 
efficient method for in-solution digestion of protein mixture has been recently reported 
(Kim et al., 2006), and this method was used in the study reported here.  In this method, 
the extracted proteins were suspended in ammonium bicarbonate and digested with 
trypsin. The resulting tryptic peptides were dried in a speed vacuum concentrator to 
remove solvent and volatile buffers. This digestion method eliminated the need for 
removal of salts, urea or detergents prior to the IMAC step, and thus minimized sample 
loss.   
 
A group of five archived human prostate tissue specimens was analyzed to obtain 
initial data on the prostate cancer tissue phosphoproteome.  Peptide digests from each 
specimen were subjected to IMAC to enrich for phosphopeptides, and the enriched 
digests were analyzed by LC-MS/MS with an LTQ linear ion trap instrument.  The 
phosphopeptides present in each digest were identified through searches of the Swiss-Prot 
protein sequence database.  The identifications were based on MS/MS data that provide 
information on the peptide sequence and on location of the phosphorylation site(s) in the 
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peptide.  The database search results were filtered to exclude low-scoring hits, and the 
phosphopeptides that passed the filters were validated through manual inspection of the 
corresponding MS/MS data.  One of the features that provided supporting evidence for a 
phosphopeptide was the presence of a phosphate-diagnostic product ion in the MS/MS 
spectrum. An example of an MS/MS spectrum that illustrated this well-known 
phenomenon is shown in Figure 3-2. This spectrum displayed a prominent product ion at 
m/z 812.7, which corresponded to the loss of the elements of phosphoric acid from the 
doubly-charged precursor ion.     
 
From each specimen, a number of phosphopeptides were detected; these 
phosphopeptides mapped to different phosphoproteins.  A summary of the results is 
shown in Table 3-2. These results demonstrated that direct phosphoproteomics of 
archived tumor specimens was feasible.  The size of the phosphoprotein panels ranged 
from 19 to 34 phosphoproteins encompassing between 25-45 different phosphorylation 
sites (Table 3-2).  The phosphopeptides and sites found for each phosphoprotein are 
shown in Table 3-3. Additional details on the phosphopeptide/protein identification are 
provided in Table A-4.  Based on an in silico analyses using the Scansite tool, some of 
the phosphorylation sites were part of known sequence motifs involved in kinase and/or 
phosphorylation-dependent binding interaction.  Information on sites involved in such 
motifs is provided in Table A-5.  
 
The phosphopeptide signatures varied from specimen to specimen.  The overall 
distribution of the identified phosphopeptides is shown in Figure 3-3. Fifty-three percent 
of phosphopeptides were uniquely found in each specimen; 17% were common to all the 
specimens; 13% found in 4 out of 5 specimens and 17% in 2 or 3 out of 5 specimens. The 
results highlighted the heterogeneity of tissue samples and the need to investigate a larger 
specimen group. Nevertheless, a number of phosphoproteins were consistenly present in 
multiple specimens. Among the identified phosphoproteins, nine phosphoproteins were 
found in most of the specimens.  These phosphoproteins included Caldesmone, Desmin, 
Heat Shock protein beta-6 (HSPB6), Heat Shock protein beta-1 (HSPB1), Synaptopodin-
2, Filamin-C, DnaJ homolog subfamily C member 5, Tensin-1, and Glyceraldehyde-3-
phosphate dehydrogenase. Eleven phosphoproteins were found in two or three out of five 
specimens, such as Myosin-11(MYH11), Septin-2, Desmocollin-1 precursor, Cysteine 
and glycine-rich protein 1, Transgelin, and Vimentin (Table 3-3).  
 
The characterized phosphoproteins were grouped into functional categories based 
on GO annotation of the level 2 (Figure 3-4).  The characterized phosphoproteins were 
involved in various cellular functions, such as binding, catalytic activity, enzyme 
regulator, signal transduction, cell structure, and transcription regulation.  
 
 
3.4 Discussion 
 
Advances in mass spectrometry-based technologies make it feasible to 
characterize phosphoproteins in complex mixtures, in a high-throughput, large-scale 
fashion. These technologies have been applied to investigations of cell cultures, tissues 
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Figure 3-2 An example of MS/MS spectrum of GQLpSDDEKFLFVDK. 
The spectrum contains a phosphate diagnostic product ion at m/z 812, and series of other 
product ions that determine the sequence of the peptide. Based on these data, the 
phosphopeptide with the sequence GQLpSDDEKFLFVDK (m/z of the [M+2H]2+ 
molecular ion is 861.4) was retrieved. The sequence mapped to protein Myosin-11 and 
included a phosphorylated serine at position 8. 
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Table 3-2 Summary of results for the analyses of the phosphoproteome in human prostate 
cancer tissue. 
 
Specimen Number of 
phosphorylation sites 
Number of 
phosphopeptides 
Number of 
phosphoproteins 
99-010 27 24 24 
99-029 27 24 19 
98-065 25 26 21 
99-045 45 40 34 
99-067 31 34 25 
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Table 3-3 Phosphoproteins characterized in the prostate cancer specimens. 
 
Accession 
number 
Protein Peptide Site 
Phosphoproteins found in all 5 specimens 
Q05682 Caldesmon  RGS*IGENQVEVMVEEK S202 
  RGS*IGENQVEVM#VEEK S202 
P17661 Desmin TFGGAPGFPLGSPLSS*PVFPR S32 
  TFGGAPGFPLGS*PLSSPVFPR S28 
  TFGGAPGFPLGS*PLSS*PVFPR S32 
P04792 Heat-shock protein beta-1 QLS*SGVSEIR S82 
  GPS*WDPFR S15 
  GPS*WDPFRDWYPHSR S15 
Q9UMS6 Synaptopodin-2  AQS*PTPSLPASWK S902 
  AQS*PTPS*LPASWK S906 
  TAKPFPGSVNQPATPFS*PTR S604 
  PFPGSVNQPATPFS*PTR S604 
  GVSS*PIAGPAQPPPWPQPAPWSQPAF
YDSSER 
S638 
  SKS*PDPDPNLSHDR S226 
   
Phosphoproteins found in 4 out of 5 specimens 
O14558 Heat-shock protein beta-6 
(Heat-shock 20 kDa-like 
protein) 
RAS*APLPGLSAPGR S16 
Q14315 Filamin-C  LGS*FGSITR S2233 
Q9H3Z4 DnaJ homolog subfamily 
C member 5  
S*LSTSGESLYHVLGLDK S8 
  SLSTS*GESLYHVLGLDK S12 
Q9HBL0 Tensin-1 RMS*VGDR S1393 
  WDS*YDNFSGHR S338 
  EAT*SDPSRTPEEEPLNLEGLVAHR T854 
  T*PTQPLLESGFR T1105 
  EATSDPSRT*PEEEPLNLEGLVAHR T860 
  SQS*FSEAEPQLPPAPVR S621 
P04406 Glyceraldehyde-3-
phosphate dehydrogenase  
VIHDNFGIVEGLMTTVHAITAT*QK T182 
   
Phosphoproteins found in 3 out of 5 specimens 
P35749 Myosin-11  GQLS*DDEKFLFVDK S8 
  VIENADGS*EEETDTR S1954 
  RVIENADGS*EEETDTR S1954 
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Table 3-3 (continued). 
 
Accession 
number 
Protein Peptide Site 
Phosphoproteins found in 2 out of 5 specimens 
Q15019 Septin-2  IYHLPDAES*DEDEDFKEQTR S218 
Q08554 Desmocollin-1 precursor  MKVQDQDLPNT*PHSK T385 
P21291 Cysteine and glycine-rich 
protein 1  
GFGFGQGAGALVHS*E S192 
Q8N283 Ankyrin repeat domain-
containing protein 35 
QS*VGLLT*NELAM#EK S672; 
T677 
Q01995 Transgelin  HVIGLQMGS*NR S181 
P08670 Vimentin ISLPLPNFS*SLNLR S419 
Q6P597 Kinesin light chain 3  APRTLSAST*QDLS*PH T493; 
S497 
O95425 Supervillin  S*LSDFTGPPQLQALK S547 
Q15746 Myosin light chain kinase KSS*TGSPTSPLNAEK S1773 
Q63ZY3 Ankyrin repeat domain-
containing protein 25  
ALAMPGRPES*PPVFR S375 
  KIS*ITER S406 
    
Phosphoproteins found in 1 out of 5 specimens 
Q92736 Ryanodine receptor 2  SSSENAKVTS*LDS*SSHR S4546; 
S4549 
P13796 Plastin-2  GS*VSDEEMMELR S5 
Q15283 Ras GTPase-activating 
protein 2  
S*SFKETFMCEFFK S559 
P43353 Aldehyde dehydrogenase 
3B1  
FDY*IFFTGS*PR Y183; 
S189 
P24844 Myosin regulatory light 
chain 2  
ATS*NVFAMFDQSQIQEFK S20 
P27816 Microtubule-associated 
protein 4  
DMES*PTKLDVTLAK S280 
P17252 Protein kinase C alpha 
type 
STLNPQWNES*FTFK S226 
Q8IYX7 Uncharacterized protein 
C9orf138 
EY*QKGPIPMEGLTTSR Y59 
O75069 Transmembrane and 
coiled-coil domains 
protein 2  
GAS*LHS*SSGGGSS*GSSSRRTK S166; 
S169 
P27216 Annexin A13  YQKS*LSDMVRSDTSGDFR S294 
Q6PCE3 Phosphoglucomutase-2-
like 1  
AVAGVMITAS*HNR S175 
P01854 Ig epsilon chain C region VAHTPS*STDWVDNK S92 
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Table 3-3 (continued). 
 
Accession 
number 
Protein Peptide Site 
Q8TCU4 Alstrom syndrome protein 
1 
SPLQEAES*KVSMALEETLR S2367 
P80421 Ig heavy chain V-I region 
DOT 
DRLVMSSDTSANTVS*MQLR S79 
Q8TAP8 Putative uncharacterized 
protein C7orf47 
S*SLALGLELR S108 
P36871 Phosphoglucomutase-1  AIGGIILTAS*HNPGGPNGDFGIK S117 
P60174 Triosephosphate isomerase KQS*LGELIGTLNAAK S21 
Q9NZN4 EH domain-containing 
protein 2 
GPDEAMEDGEEGS*DDEAEWVVTK S438 
P22059 Oxysterol-binding protein 
1 
GDMS*DEDDENEFFDAPEIITMPENL
GHK 
S351 
Q32MZ4 Leucine-rich repeat 
flightless-interacting 
protein 1 
RGS*GDTSISIDTEASIR S120 
Q9UBT6 DNA polymerase kappa  CDS*YKDDLLLR S10 
Q9Y385 Ubiquitin-conjugating 
enzyme E2 J1 
RLS*TSPDVIQGHQPR S266 
Q86SQ6 Probable G-protein 
coupled receptor 123 
QVT*KKAPLCLDTDQPPYPR T833 
Q9Y618 Nuclear receptor 
corepressor 2  
REGTPPPPPPS*R S1390 
Q9H2J4 Phosducin-like protein 3  LS*ES*GAIMTDLEENPK S199; 
S201 
P09496 Clathrin light chain A  LQS*EPESIR S105 
O43237 Cytoplasmic dynein 1 light 
intermediate chain 2 
SGQKT*VLSNVQEELDR T463 
P35558 Phosphoenolpyruvate 
carboxykinase  
WM#S*EEDFEK S118 
P05386 60S acidic ribosomal 
protein P1 
KEES*EES*DDDMGFGLFD S101; 
S104 
P13861 cAMP-dependent protein 
kinase type II-alpha 
regulatory subunit 
GDS*ES*EEDEDLEVPVPSR S77; 
S79 
Q6P9B9 Integrator complex subunit 
5 
FQAPSPS*TLLR S1012 
Q14195 Dihydropyrimidinase-
related protein 3  
GSPT*RPNPPVR T524 
Q13618 Cullin-3  FLLES*FNNDRLFK S359 
P48681 Nestin S*LGEQDQMTLRPPEK S767 
Q9NSE4 Isoleucyl-tRNA synthetase GLVYRS*Y*KPVFWSPSSR S239; 
Y240 
O43432 Eukaryotic translation 
initiation factor 4 gamma 3 
SS*ASSLNR S1194 
P27824 Calnexin precursor AEEDEILNRS*PR S583 
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Table 3-3 (continued). 
 
Accession 
number 
Protein Peptide Site 
Q96KP6 TNFAIP3-interacting 
protein 3  
CS*FSEDCLR S175 
P20711 Aromatic-L-amino-acid 
decarboxylase  
GLQAY*IR Y377 
O76041 Nebulette  SMQHS*PNLR S953 
P08238 Heat shock protein HSP 90-
beta (HSP 90) 
IEDVGS*DEEDDSGKDKK S254 
O75385 Serine/threonine-protein 
kinase ULK1  
KM#S*LGGGR S495 
Q9Y5C1 Angiopoietin-related 
protein 3 precursor  
NMSLELNS*K S122 
Q6KC79 Nipped-B-like protein  QNEST*IVEPK T667 
P58107 Epiplakin QPLQAT*FRGLRKQVS*AR T1495, 
S1504 
P02545 Lamin A/C  LRLS*PSPTSQR S390 
Q13242 Splicing factor, 
arginine/serine-rich 9  
GS*PHYFSPFRPY S211 
Q13263 Transcription intermediary 
factor 1-beta 
SRS*GEGEVSGLMR S473  
P07197 Neurofilament triplet M 
protein 
GKSPVPKS*PVEEK S645 
P15924 Desmoplakin  GLPSPYNMSSAPGS*R S2825 
O00264 Membrane associated 
progesterone receptor 
component 1  
LLKEGEEPTVYS*DEEEPKDESAR S180 
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Figure 3-3 Distribution of identified phosphopeptides in five prostate tissues analyzed. 
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Figure 3-4 Classification of identified phosphoproteins by molecular function according 
to GO annotation at the level 2.  
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and biological fluids to discover cancer biomarkers (Lin et al., 2007; Sardana et al., 
2008b; Semmes et al., 2006). Extensive efforts were involved in exploring theapplication 
of proteomic strategy to study biomarkers in prostate cancer cell lines or tissues, such as 
2-DE, 2D-DIGE, multiple dimensional chromatography (Johansson et al., 2006; Lin et al., 
2007; Rowland et al., 2007; Sardana et al., 2007; Ummanni et al., 2008; Whitaker et al., 
2007). The cell lines PC-3, DU 145, and LNCaP are spontaneously established from 
human prostate cancer metastases and are frequently used in prostate cancer research. 
However, these cell lines only partly mimic the biology of prostate cancer. Recently, 
increased efforts have been directed towards tissue-based proteomic analysis because it 
can directly reflect the relationship of proteins to diseases. A gel-free bioanalytical 
methodology has been used in our group to map the phosphoproteome in the LNCaP 
human prostate cancer cell line (Giorgianni et al., 2007).  Recently, we have produced an 
expanded LNCaP phosphoproteome panel through the application of in-gel IEF LC-
MS/MS, which involves one-dimensional protein separation. 
 
In this study, we employed a gel-free methodology to investigate phosphoprotein 
signatures in archived human prostate cancer tissues.  Because of the limited size of a 
human tissue sample compared to that of cultured cells, it is critical to minimize the loss 
of sample during the various steps in the analytical workflow. In our previous study of 
cultured cells (LNCaP) phosphoproteome, we used guanidinium hydrochloride to aid 
protein solubilization prior to in-solution digestion.  With this procedure, the peptide 
digest had to be subjected to solid phase extraction (SPE) cleanup with a C18 Sep-Pak 
cartridge before IMAC enrichment.  For the present work on human prostate tissue, we 
sought to avoid this SPE step that may be associated with significant sample loss.  
Therefore, we adopted a modified protein digestion methodology to our study that was 
based on recently published report. 
 
 Genetic and environmental variability, together with sampling variations due to 
different cell types, results in the heterogeneity of human prostate cancer tissue 
specimens.  A unique set of phosphoproteins was identified in each tissue specimen. 
Nevertheless, it was also demonstrated that a subset of the phosphoprotein panel was 
preserved across multiple specimens; 30% of the phosphopeptides were identified in ≥4 
out of the 5 specimens analyzed. 
 
 The characterized phosphoproteins were functionally diverse. Based on published 
literature, a number of these phosphoproteins were relevant to prostate cancer mechanism. 
Some of the identified phosphoproteins have previously been reported to be differentially 
regulated in tumors, including prostate tumors. For example, HSPB1, MYH11, VIME, 
DESM, TAGL, HSP90A and SEPT2 have been reported as differentially expressed in 
prostate cancer (Lin et al., 2007; Rowland et al., 2007). 
 
 Among the groups of phosphoproteins identified, there were several chaperones, 
including HSPB1 (HSP27), HSPB6 and HS90B. HSP27, which has been reported up-
regulated in prostate cancer (Rocchi et al., 2004), is involved in various cellular processes 
including apoptosis, cell growth and differentiation, actin reorganization and polypeptide 
renaturation. Cell proliferative activity in prostate cancer specimens was significantly 
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associated with HSP27 expression (Kurahashi et al., 2007). HSP 27 is involved in 
cooperative interaction with androgen receptor (AR), which enhances AR stability, 
shuttling, and transcriptional activity, thereby increasing prostate cancer cell survival. 
Androgen-bound AR induces rapid HSP27 phosphorylation on Ser (78) and Ser (82) 
residues. Phosphorylated HSP27 displaces HSP90 from a complex with AR to chaperone 
AR into the nucleus and interact with its response elements to enhance its genomic 
activity. Inhibition of HSP27 phosphorylation, or knockdown using the antisense drug, 
shifted the association of AR with HSP90 to MDM2, increased AR degradation, 
decreased AR transcriptional activity, and increased prostate cancer LNCaP cell apoptotic 
rates (Zoubeidi et al., 2007). Previous study showed increased HSP27 expression was 
linked with hormone resistance and a poor prostate cancer prognosis (Miyake et al., 
2006). HSP27 expression was also highly up-regulated in prostate cancer cells after 
androgen withdrawal or chemotherapy, to become uniformly highly expressed in 
androgen-independent prostate cancer. Silencing of HSP27 in prostate cancer cells by 
siRNA increased apoptotic rates and caused inhibition of cell growth in LNCaP and PC-3 
cells (Rocchi et al., 2006). These findings suggested the expression level of HSP27 in 
prostate cancer tissue could be used as a useful predictor of prostate cancer, and also 
illustrated the potential utility of HSP27 as future targeted therapy in enhancing the 
efficacy of chemotherapy in advanced prostate cancer.  
 
 Tensin was another important protein found in prostate tissues, which is one of 
components of  phosphatase and tensin homologue deleted on chromosome 10 (PTEN). 
PTEN has been shown to be inactivated in a wide variety of cancers, and the role of this 
gene as a tumor suppressor has been well established. PTEN has been found to work as a 
predictor of prostate cancer in combination with other proteins. Differentiation related 
gene 1(Drg-1) gene, one of the potential targets of PTEN, has been shown to suppress 
tumor metastasis in animal models of prostate and colon cancer, and the expression of 
this gene was significantly reduced with advancement of prostate and breast cancers in 
clinical setting. PTEN controls Drg-1 by an Akt-dependent pathway, overexpression of 
PTEN significantly augments the endogenous expression of Drg-1 protein. Combination 
of the two markers, PTEN and Drg-1, emerged as a significantly better predictor of 
prostate and breast cancer patient survival than either marker alone (Bandyopadhyay et 
al., 2004). PTEN, in combination with pAkt, was a better predictor of the risk of 
biochemical recurrence compared with pAkt alone. Loss of PTEN expression, together 
with increased Akt phosphorylation and Gleason score, was of significant predictive 
value for determining, at the time of prostatectomy, the risk of biochemical recurrence 
(Bedolla et al., 2007). PTEN was found to strongly inhibit the growth of human prostate 
tumors, especially when combined with radiation therapy, and this effect was mediated 
by the induction of apoptosis and by the inhibition of angiogenesis and cellular 
proliferation (Anai et al., 2006).  PTEN/phosphatidylinositol 3-kinase (PI3K)/AKT 
constitute an important pathway regulating the signaling of multiple biological processes 
such as apoptosis, metabolism, cell proliferation and cell growth. Tissue-specific 
deletions of PTEN usually provoke cancer. Moreover, an absence of PTEN cooperated 
with an absence of p53 to promote cancer (Blanco-Aparicio et al., 2007). 
 
 A number of filament proteins (desmin, vimentin and caldesmon) were identified 
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in our study. Intermediate filaments (IFs) are an important structural feature of eukaryotic 
cells. They, along with microtubules and actin microfilaments, make up the cytoskeleton. 
Based on current knowledge, a main function of IFs is to provide protection against 
various mechanical or other types of stresses. IFs are also involved in maintaining cell 
shape, and providing flexible scaffold, which undergoes disassembly and reorganization 
during certain cellular processes including cell division, migration and shape changes in 
response to their alterations in the microenvironment (Coulombe and Wong, 2004). IFs in 
smooth muscle are formed by polymerization of the proteins vimentin and desmin and 
constitute one of the major components of the cytoskeleton (Chang and Goldman, 2004).  
 
 Desmin is class-III intermediate filament found in muscle cells. Desmin is 
important in muscle cell architecture and structure since it connects many components of 
the cytoplasm. It has been shown that desmin phosphorylation occurred in cells/tissues in 
response to biological signal/treatment. It is possible that desmin phosphorylation may 
influence the temporal and spatial array of structural proteins or signal partners in smooth 
muscle (Tang, 2008). 
 
 Vimentin is also a member of class-III intermediate filament family of proteins. 
Vimentin has been found to be attached to the nucleus, endoplasmic reticulum, and 
mitochondria, either laterally or terminally. Therefore, vimentin played a significant role 
in supporting and anchoring the position of the organelles in the cytosol. Vimentin 
phosphorylation was also found to be associated with its disassembly and spatial 
reorganization in smooth muscle cells and tissues during agonist activation (Li et al., 
2006). Vimentin has been shown to affect motility and invasiveness of prostate cancer 
cells. A low level of vimentin was expressed in the less invasive cell line, LNCaP, in 
contrast to the higher level in more aggressive cell lines, DU-145 and PC3 (Mitchell et al., 
2000). Downregulation of vimentin expression in PC-3 cells led to a significant decrease 
in tumor cells motility and invasive activity (Wei et al., 2008; Zhao et al., 2008).  
 
 Caldesmon (CaD), a component of microfilaments in all cells and thin filaments 
in smooth muscle cells, is known to bind to actin, tropomyosin, calmodulin, and myosin 
and to inhibit actin-activated ATP hydrolysis by smooth muscle myosin. Thus, it is 
believed to regulate smooth muscle contraction, cell motility and the cytoskeletal 
structure. CaD has been found to bind to vimentin and desmin proteins. Assembly of 
vimentin and desmin into IF was also affected by CaD silencing, although their 
expression was not significantly altered when CaD was silenced. It indicated that CaD 
was necessary for the maintenance of actin microfilaments and IF in the cytoskeletal 
structure. Thus, the alternation of CaD expression might affect the cytoskeletal structure 
in smooth muscle, as in smooth muscle de-differentiation and in certain pathological 
conditions (Deng et al., 2007). 
 
 
3.5 Conclusions 
 
In this study, a gel-free approach was applied to characterize phosphoproteins of 
archived primary human prostate cancer tissue for biomarker discovery. The panels 
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obtained for human prostate cancer tissue contained 15-24 phosphoproteins. Some of the 
characterized phosphoproteins were present in all specimens; in addition, each specimen 
also produced a unique set of phosphoproteins. The findings provided a direct glimpse 
into the phosphoprotein machinery operating within the human prostate cancer tissue and 
demonstrated that phosphoproteins can be characterized directly from archived tissue 
specimens.  
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CHAPTER 4. IDENTIFICATION OF PHOSPHOPROTEINS IN THE LNCAP 
HUMAN PROSTATE CANCER CELL LINE BY A 2-DE AND 
PHOSPHO-SPECIFIC STAINING-BASED PROTEOMICS 
PLATFORM 
 
 
4.1 Introduction 
 
Two-dimensional polyacrylamide gel electrophoresis (2-DE) is one of the most 
commonly used protein separation techniques (Gorg et al., 2000). It can separate 
thousands of proteins in a specific cell, tissue or biological fluid. It has high resolution 
and high reproducibility. 2-DE coupled with mass spectrometry (MS) and database 
searches is a widely used platform in proteomics studies (Gorg et al., 2004). 2-DE 
combined with MS is able to get a rapid overview of proteomic alterations in different 
biological systems or physiological states. Combination with multiplexed protein staining 
makes it possible to investigate various post-translationally modified proteins by 2-DE 
(Wu et al., 2005).  
 
Pro-QTM Diamond is a fluorescent stain specific for detection of phosphoproteins 
(Schulenberg et al., 2004; Steinberg et al., 2003).  Pro-QTM Diamond can be used to 
detect phosphorylated serine, tyrosine, or threonine residues. It has been reported that 
Pro-QTM Diamond, combined with SDS-PAGE or 2-DE, was applied to efficiently detect 
phosphoproteins and to quantitatively measure phosphoprotein expression in various 
biological systems, such as spleen leukocytes (Wu et al., 2005), eye lenses (Schaefer et 
al., 2006), dentate gyrus (Chardonnet et al., 2008), heart muscle (Jacques et al., 2008), 
skeletal muscle (Gannon et al., 2008) et al. 
 
The sub-aims of our study were: (1) to develop a platform for the identification of 
LNCaP phosphoproteins. This sub-aim included incorporation of multiplexed staining, 
and evaluation of selected technical aspects. (2) to apply the platform to identify selected 
phosphoproteins from the LNCaP phosphoproteome. In this study, we applied 2-DE as 
separation technique, Pro-QTM Diamond as detection method, LC-MS/MS and database 
searches as protein identification tools to investigate the phosphoproteins in the LNCaP 
prostate cancer cell line. An outline of the 2-DE with phsopho-specific staining strategy 
is shown in Figure 4-1.This approach did not require the pre-selection of protein 
candidates for analysis, rapidly generated a snapshot of the phosphoproteome in the 
LNCaP cells, and it was particularly useful for an initial screening of the 
phosphoproteome to evaluate the phosphoproteome coverage for further study of the 
expression of phosphoproteins in various physiological states. 
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Figure 4-1 Schematic of 2-DE and phospho-specific staining based proteomics platform. 
The LNCaP proteins were extracted with Trizol reagent. Proteins were separated with 2-
DE. Gels were sequentially stained with Pro-QTM Diamond and SYPRO Ruby staining. 
Gel images were computer-assisted analyzed. The spots of interest were excised and 
digested with trypsin.  The digests were analyzed with LC-MS/MS.  Proteins were 
identified through database searches and bioinformatics examination of the identified 
proteins was performed.  
 
 
 
 
 
 
 
 
 
 
Extract proteins 
Employ 2-DE 
Stain gels with Pro-QTM Diamond and SYPRO Ruby 
Analyze gel images, select interest spots  
Excise spots, digest with trypsin and analyze by LC-MS/MS 
Perform database searches and bioinformatics examination 
LNCaP cells 
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4.2 Materials and Methods 
 
 
4.2.1 Protein Extraction from LNCaP Cells 
 
A cell pellet containing 5×106 LNCaP cells was resuspended in 1.0 mL of Trizol 
reagent (Invitrogen, Carlsbad, CA) with 5 µL of phosphatase inhibitor cocktail (Sigma, St. 
Louis, MO). The cells were lysed thoroughly by repetitive pipetting. Approximately 1.0 
mg of protein, free of nucleic acids, was extracted from this cell lysate using Trizol 
reagent according to the manufacturer’s instructions (details described in Chapter 2). 
Protein pellets were washed twice with 0.3 M Guanidinium hydrochloride in 95% ethanol, 
followed by a single wash with ethanol. The protein pellet was dried with a vacuum 
centrifuge for 30 minutes, and was stored at -80 °C for further analysis. 
 
   
4.2.2 Sample Preparation 
 
4.2.2.1 Standard Rehydration Buffer 
 
For 2-DE separations, the protein pellet was dissolved with a rehydration buffer 
that contained urea (7 M), thiourea (2 M), CHAPS detergent (2% w/v), IPG buffer 3-10 
(2% v/v), DTT (0.3%, w/v) and a trace amount of Bromophenol Blue dye.  The protein 
concentration of the extracts was determined by Bradford assay (GE Healthcare, 
Piscataway, NJ). The final protein concentration in the rehydration buffer was 0.61 μg/μL.  
The mixture was vortexed for 1 hour at room temperature.  Following solubilization, the 
sample was centrifuged for 30 minutes at 21,000 x g.  Protein sample (215 μg in 350 μL 
of rehydration buffer) was loaded onto a pre-cast immobilized pH gradient (IPG) strip 
(pH 3-10NL, 18 cm; GE Healthcare, Piscataway, NJ), and the strip was allowed to 
rehydrate overnight in a re-swelling tray or a strip holder. 
 
4.2.2.2 Destreak Rehydration Buffer 
For 2-DE separations, the protein pellet was dissolved with a DeStreak 
rehydration solution(Olsson et al., 2002) (GE Healthcare, Piscataway, NJ) with IPG 
buffer 3-10 (2% v/v), DTT (20 mM) and a trace amount of Bromophenol Blue dye.  
Protein concentration was determined by 2-D Quant Kit (GE Healthcare, Piscataway, NJ). 
The resulting solution (200 μg of proteins in 350 μL of the rehydration buffer) was 
vortexed for 1 hour at room temperature, followed by the centrifugation for 30 minutes at 
21,000 x g.  The supernatant was loaded onto a pre-cast IPG strip (pH 3-10NL, 18 cm), 
and the strip was allowed to rehydrate overnight in a re-swelling tray. 
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4.2.3 First Dimension: Isoelectric Focusing  
 
4.2.3.1 IEF with Multiphor Unit 
 
Isoelectric focusing was performed with a Multiphor II apparatus (GE Healthcare, 
Piscataway, NJ) according to manufacturer’s instructions (details described in Chapter 2). 
The isoelectric focusing was performed under the following voltage program: 100 V 
(gradient over 1 minute); 100 V (fixed for 2 hours); 500 V (gradient over 1 minute); 3500 
V (gradient over 90 minutes); 3500 V (fixed for 8 hours). After the focusing, the strip 
was wrapped loosely in plastic wrap and was stored at -80 °C until the next step.  
 
4.2.3.2 IEF with IPGphor Unit  
 
Isoelectric focusing was performed with the IPGphor apparatus (GE Healthcare, 
Piscataway, NJ) according to manufacturer’s instructions. Briefly, the strip holder was 
chosen, and 350 μL of rehydration solution was applied into the holder. IPG strip was 
positioned in the holder with the gel side down and without bubbles, making sure that the 
IPG strip was in contact with the strip holder electrodes at each end. Cover fluid was 
applied to IPG strip and the cover was placed on the holder. The strip holder was 
positioned on the IPGphor platform with the two external electrodes of the instrument 
making contact with the electrodes of the strip holder. The isoelectric focusing was 
performed under the following voltage program: 30 V (fixed for 16 hours); 200 V (fixed 
for 1 hour); 500 V (fixed for 1 hour); 1000 V (fixed for 1 hour); 8000 V (gradient over 30 
minutes); 8000 V (fixed for 4 hours ). After the focusing, the strip was wrapped loosely 
in plastic wrap and was stored at -80 °C until the next step.  
 
 
 4.2.4 Second Dimension: SDS-PAGE 
 
4.2.4.1 Gel Casting 
 
To prepare eight of 12%, 20 × 20 cm SDS-PAGE gels, gel plates and plastic pads 
were assembled sequentially into the casting chamber placed on a flat surface. The 
casting chamber was clamped and the plates were leveled on the bottom. The casting 
chamber was put on the stand. All reagents were combined, including 120 mL of 40% 
acrylamide/bis, 100 mL of 1.5 M Tris-HCl (pH 8.8) and 180 mL distilled water and 
degassed for 15 minutes. When ready to pour the gel, the reagents of 2 mL of 10% 
ammonium persulfate and 100 µL TEMED were quickly added and gently mixed. The 
gel solution was transferred between the glass plates in the casting chamber to about 3/4 
inch below the short plate. A small layer of butanol was added on the top of the gel prior 
to polymerization to straighten the level of the gel and remove unwanted air bubbles that 
may be present. Once the gel polymerized, the butanol was removed by rinsing the top 
layer of the gel with distilled water prior to the use. 
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4.2.4.2 SDS-PAGE with Dodeca Cell Unit 
 
SDS-PAGE was performed with a ProteanPlus Dodeca Cell apparatus (Bio-Rad, 
Hercules, CA). The IPG strip was incubated for 15 minutes in an equilibration buffer (50 
mM Tris/HCl pH 8.8, 6 M urea, 30% glycerol, 2% SDS) with 2.0% DTT and then in 
equilibration buffer with 2.5% iodoacetamide and a trace amount of bromophenol blue 
dye for an additional 15 minutes. The strip and a sample application piece with the 
Marker 12 MW maker (Invitrogen, Carisbad, CA) were put on the top of the self-cast 
12%, 20 x 20 cm SDS-PAGE gel and were sealed with 1% agarose in gel running buffer, 
which contained 25 mM Tris (pH 8.3), 192 mM glycine and 0.1% SDS. The SDS-PAGE 
separation was performed with according to the manufacturer’s instructions. Briefly, the 
temperature setting for the electrophoresis was 15 °C, the voltage applied was 200 V 
constant and the electrophoresis time was ca. 8 hours. The SDS-PAGE separation was 
completed when the Bromophenol Blue dye front migrated to the bottom of the gel.  
 
 
4.2.5 Gel Staining 
 
4.2.5.1 Pro-QTM Diamond Staining 
 
A series of stains was applied to each 2-DE gel, which was compatible with 
subsequent mass spectrometric analysis. Briefly, 2-DE gel was fixed in 200 mL of 
fixation solution (50% MeOH /10% AcOH /40% water) for 30 minutes or overnight. The 
gel was washed three times with distilled water with gentle agitation for 15 minutes each. 
The gel was incubated in dark with 170~190 mL of Pro-QTM Diamond phosphoprotein 
gel stain (Molecular Probes, Eugene, OR) with gentle agitation for 2.5 hours. The gel was 
incubated with 190 mL of Pro-QTM Diamond phosphoprotein gel destaining solution 
(Molecular Probes, Eugene, OR) for 2 hours with gentle agitation, followed by two 
washes with distilled water for 5 minutes each.  
 
4.2.5.2 SYPRO Ruby Staining 
 
After detection of phosphoproteins, the gel was stained in SYPRO Ruby protein 
stain (Molecular Probes, Eugene, OR). 2-DE gel was rinsed twice with distilled water for 
15 minutes each, followed by incubation in 170 mL of SYPRO Ruby staining solution for 
3 hours to overnight in the dark with gentle agitation. After incubation of the staining, the 
gel was incubated in 200 mL of 10% of MeOH /7% of AcOH /83% water for 30 minutes. 
The gel was rinsed twice with distilled water for 5 minutes each. 
 
 
4.2.6 Gel Imaging 
 
The images were acquired with an FX Fluorescence Laser Scanner (Bio-Rad, 
Hercules, CA). For Pro-QTM Diamond stain, the laser was used with 532 nm excitation 
and 555 nm band pass emission; for SYPRO Ruby stain, proteins were detected using the 
laser scanner with the excitation 488 nm and 555 nm band pass emission. The images 
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were displayed with Adobe Photoshop 5.0 LE software, and saved as .TIFF files for 
future analysis. The Pro-QTM Diamond and SYPRO Ruby images were analyzed using 
the software PDQuest 7.1.0 (Bio-Rad, Hercules, CA). 
 
 
4.2.7 Spot Excision   
 
Spots in 2-DE gels were excised with cut-to-size 1 mL pipette tips, and the gel 
pieces were put into 1.5 mL siliconized Eppendorf microcentrifuge tubes. 
 
 
4.2.8 In-gel Tryptic Digestion 
 
The gel pieces were incubated in 50 mM ammonium bicarbonate for 10 minutes. 
After the incubation, the buffer was removed and the gel pieces were washed three times 
with 50% ACN/50% 50 mM ammonium bicarbonate for 10 minutes each. Gel pieces 
were dried under vacuum for 30 minutes. The dried gel pieces were rehydrated in a 
trypsin solution that contained 16.7 ng/µL trypsin (Promega, Madison, WI) in 50 mM 
ammonium bicarbonate (pH 8). The digestion solution was incubated at 37 °C overnight. 
 
 
4.2.9 Peptide Processing  
 
The tryptic digest was centrifuged at 1,000 x g for 1 minute, and the supernatant 
was transferred to a new 0.6 mL siliconized microcentrifuge tube. The gel piece was 
extracted with 60% ACN/0.01% TFA three times for 15 minutes each with gentle 
agitation or sonication. All supernatants were combined and dried with a vacuum 
centrifuge. Prior to LC-MS/MS analysis, the digest was reconstituted with 15 µL of 2.5% 
FA/97.5% water and desalted with ZipTipC18 column (Millipore, Billerica, MA, USA), 
using the procedure provided by the manufacturer (details described in Chapter 2). The 
peptides retained on the ZipTipC18 column were eluted with 1.5 µL of 50% ACN/0.1% 
FA and diluted with 2.5 µL of 0.5% FA. 
 
 
4.2.10 LC-MS/MS Analysis 
 
LC-MS/MS experiments were performed on a LTQ linear ion trap mass 
spectrometer (Thermo Electron, San Jose, CA). Peptide mixtures were loaded onto a 
fused-silica microcapillary column (15 cm length, 75 µm ID; New Objective, MA)  
packed in-house with C18 resin (Michrom Bioresources, Inc., Auburn, CA) and were 
separated using a 30-minute linear gradient from 0% to 90% solvent B (0.05% FA/90% 
MeOH/10% water). Solvent A was 0.05% FA/ 2% MeOH/98% water. The LTQ mass 
spectrometer was operated in positive ion mode and data-dependent acquisition was 
performed. In brief, a scan cycle was initiated with a full MS scan of wide mass range 
(m/z 400-2000), which was followed by MS/MS scans on the 7 most abundant precursor 
ions with dynamic exclusion of previously selected ions.  
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4.2.11 Database Searches 
 
The MS/MS data were used to search the Swiss-Prot database (subset of human 
proteins) with the TurboSEQUEST search engine that is part of Bioworks version 3.2 
(Thermo Electron, San Jose, CA). Searches were performed with the following 
parameters: full-trypsin specificity, dynamic modifications of phosphorylated Ser, Thr, 
and Tyr; dynamic modifications of oxidized methionine, and static modifications of 
cysteine by carbamidomethylation. All peptide matches were filtered by XCorr larger 
than 3.00, 2.50, and 3.50 used for singly, doubly and triply charged ions, respectively; 
peptide probability less than 1.0E-3; different peptides; and only top matches were 
considered. The peptides retrieved by the searches were validated by manual inspection 
of the MS/MS data. Criteria used for manual validation included: a high-quality spectrum 
with product ions clearly above the baseline noise; and sequential members of the b- 
and/or y-series present in the mass spectra. 
 
 
4.2.12 Inspection of Protein Information 
 
The experimental pI was estimated according to the pH gradient chart provided by 
the manufacturer (GE Healthcare, Piscataway, NJ) based on the relative migration of 
each protein spot. 
 
A series of protein markers with known molecular weights were used to 
determine the experimental molecular weight of unknown proteins by comparing the 
migration distance relative to the markers. The relative migration (Rm) value of protein 
spots was determined by dividing the total distance they migrated by the distance 
migrated by the bromphenol blue dye. A straight reference line was plotted, using the Rm 
of each MW marker spot and the logarithm of that molecular weight. The relative 
molecular weight of each protein spot was calculated from that equation. 
 
The theoretical pI and MW were computed with Swiss-Prot Compute pI/MW tool 
for each UniProt Knowledgebase entry. The status of protein phosphorylation was 
inspected in the Swiss-Prot annotations and the PhosphoSite knowledgebase. Information 
of protein function and subcellualr location was collected from Gene Ontology 
(http://bioinfo.vanderbilt.edu/webgestalt/) and Swiss-Prot annotation. 
 
 
4.3 Results 
 
 
4.3.1 Application of Different Rehydration Buffers: Standard vs. Destreak 
 
In order to address the issue of streaking in the basic region of the pH gradient 
(pH 7-9), we employed the Destreak Rehydration solution in the sample preparation for 
the first dimension.  Destreak Rehydration solution has been reported to transform the 
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protein thiol groups into a stable disulfides and hence to protect the disulfide groups from 
unspecific oxidation (Olsson et al., 2002). 
 
We performed side-by-side separations of LNCaP proteins that were solubilized 
with standard rehydration buffer or with Destreak Rehydration solution.  Comparison of 
2-DE gel images of samples using standard rehydration buffer (Figure 4-2a) or Destreak 
rehydration solution (Figure 4-2b) showed that the protein spot pattern of Destreak-
solubilized sample has somewhat improved compared to the patterns obtained using 
standard rehydration buffer; however, the streaking was not totally eliminated. Therefore, 
we opted to use IPG strips with pH range of 4-7 for subsequent experiments. 
 
 
4.3.2 IPGphor vs. Multiphor 
 
As the first dimension of 2-DE, the quality of IEF is critical for the overall 
success of 2-DE separation. Different configurations of IPG-based IEF equipment are 
commercially available. The IPGphor and Multiphor II are two widely used systems for 
IEF. 
 
In the method development phase of our study, we assessed the 2-DE spot 
patterns of LNCaP proteins produced by the IPGphor and by the Multiphor units. The 
same amount of protein was loaded onto two 18-cm IPG strips (pH 4-7), and the strips 
were focused in Multiphor II and IPGphor, respectively.  
 
Comparison of the 2-DE gel images from the Multiphor II (Figure 4-3a) and the 
IPGphor (Figure 4-3b) indicated both IEF systems separated proteins with a satisfactory 
resolution. Multiphor yielded a better separation of proteins in the basic region of the gel.  
 
 
4.3.3 Detection of Proteins by Sequential Staining 
 
In the study, 2-DE gels were first stained with the Pro-QTM Diamond stain; the 
gels were imaged to capture the phosphoprotein patterns.  Subsequently, the gels were 
stained with SYPRO Ruby total protein stain, and images were obtained to detect the 
total protein pattern. It has been reported that Pro-QTM Diamond stain did not interfere 
with the SYPRO Ruby stain, even though there is some overlap in the wavelengths of 
fluorescence (Wu et al., 2005).  The images obtained with Pro-QTM Diamond and with 
SYPRO Ruby stain are shown in Figure 4-4a and 4-4b, respectively.  
 
Several spots seen with Pro-QTM Diamond stain were not present in the SYPRO 
Ruby-stained gel. Furthermore, intensities of some spots on Pro-QTM Diamond and 
SYPRO Ruby stain images are different.  
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 (a) 
(b)  
 
Figure 4-2 2-DE gels of LNCaP proteins with pH 3-10NL using different rehydration 
buffers (a) Standard rehydration buffer (b) Destreak rehydration solution. 
 68
 
 (a) 
 
 (b) 
 
Figure 4-3 2-DE gels of LNCaP using different IEF units (a) Multiphor II (b) IPGphor.
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(a) 
 
 (b) 
 
Figure 4-4 2-DE gels of LNCaP proteins detected with multiplexed staining (a) Pro-QTM 
Diamond Phosphoprotein staining (b) SYPRO Ruby staining. 
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4.3.4 Protein Identification 
 
We identified a set of proteins that were detected as intense spots in the Pro-QTM 
Diamond-stained gels.  For the identification, we selected 16 spots from the gel with pH 
range of 4-7.  These spots are labeled in Figure 4-5.  In addition, we selected 14 spots 
from another Pro-QTM Diamond stained gel that included pH range 3-10 (Figure 4-6).  As 
discussed above, the spot quality in the pH 3-10 gel was not sufficient for 2-DE-based 
analysis; however, we used this wide range pH gradient in our in-gel IEF LC-MS/MS 
phosphoproteomics platform (see Chapter 2).  Therefore, we opted to identify proteins 
from the pH 3-10 gel to allow direct comparison of the data. 
 
For identification, the spots were excised and subjected to in-gel tryptic digestion. 
The extracted peptides were analyzed by LC-MS/MS and the LC-MS/MS data were used 
for database searches to identify the proteins. Overall, proteins were identified from all 
thirty protein spots. The identification was based on the presence of ≥2 peptides. Since 
the spots were taken from a single gel (no pooling), the 100% success rate attested to the 
sensitivity of the LC-MS/MS system and to the overall power of our protein 
identification procedure. Protein identification results for the 14 spots from 2-DE gel with 
pH 3-10 are shown in Table 4-1; results for the16 spots from 2-DE gel with pH 4-7 are 
shown in Table 4-2.  It should be noted that some of the proteins were identified in 
multiple spots; furthermore, some of the spots contained more than one protein.  Both 
scenarios are frequently encountered in these types of analyses.  For example, if several 
forms of the same protein are present in the mixture, each form will give rise to a 
different spot.  Conversely, different proteins with very similar pI and MW values may 
co-migrate in 2-DE.   
 
 
4.3.5. Additional Examination of the Phosphoprotein Panel 
 
Inspection of the Swiss-Prot annotations and survey of the PhosphoSite 
knowledgebase revealed that most of the proteins identified in our study are known to be 
phosphorylated. This indicated a high specificity of the Pro-QTM Diamond stain. 
 
Gene Ontology and Swiss-Prot annotations were inspected to gather information 
on subcellular location and on protein function.  This information is included in Tables 4-
1 and 4-2. 
 
We compared the phosphoprotein panel obtained in this study to the panel that 
was produced with in-gel IEF LC-MS/MS (Chapter 2).  Out of the 30 proteins, 3 proteins 
(Lupus la protein, Stress-induced-phosphoprotein1 and Nucleophosmin) were also found 
with in-gel IEF LC-MS/MS. These results showed that the two platforms provided 
complementary data on the LNCaP phosphoproteome. 
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Figure 4-5 16 protein spots selected from 2-DE gel with pH 4-7.
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Figure 4-6 14 protein spots selected from 2-DE gel with pH 3-10. 
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Table 4-1 Protein identification results for Pro-QTM Diamond-stained spots from pH 3-10 gel. 
 
Spot Swiss-Prot 
accession number 
Protein name MW 
Exp(Theo）
pI 
Exp(Theo)
Function a Location a Phospho
rylated b  
1 P32119 
PRDX2_HUMAN 
Peroxiredoxin-2 25.8 (21.9) 5.8 (5.66) response to oxidative stress | 
regulation of apoptosis | anti-
apoptosis  
cytoplasm Yes 
 Q06830 
PRDX1_HUMAN 
Peroxiredoxin-1 25.8 (22.1) 5.8 (8.27) cell proliferation | skeletal 
development 
cytoplasm; 
melanoso
me 
Yes 
2 P04083 
ANXA1_HUMAN 
Annexin A1  42.9 (38.7) 6.3 (6.57) cell surface receptor linked signal 
transduction | inflammatory 
response | keratinocyte 
differentiation | lipid metabolism 
| peptide cross-linking | anti-
apoptosis | cell motility  
nucleus; 
cytoplasm 
Yes 
3 P05388 
RLA0_HUMAN 
60S acidic 
ribosomal protein 
P0  
42.9(34.3) 6.5 (5.72) translational elongation | protein 
biosynthesis | ribosome 
biogenesis and assembly  
cytosolic 
large 
ribosomal 
subunit 
Yes 
 P07195 
LDHB_HUMAN 
L-lactate 
dehydrogenase B 
chain  
42.9 (36.6) 6.5 (5.71) tricarboxylic acid cycle 
intermediate metabolism | 
anaerobic glycolysis  
cytoplasm Yes 
4 P37837 
TALDO_HUMAN 
Transaldolase 46.2 (37.5) 6.6 (6.36) metabolism | pentose-phosphate 
shunt | carbohydrate metabolism  
cytoplasm Yes 
5 P49411 
EFTU_HUMAN 
Elongation factor 
Tu, mitochondrial 
precursor  
55.5 (49.5) 7.2 (7.26) translational elongation | protein 
biosynthesis  
mitochond
rion 
Yes 
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Table 4-1 (continued). 
 
Spot Swiss-Prot 
accession number 
Protein name MW 
Exp(Theo） 
pI 
Exp(Theo)
Function a Location a Phospho
rylated b  
6 P06733 
ENOA_HUMAN 
Alpha-enolase  58.6 (47.2) 7.2 (7.01) glycolysis | growth control | 
hypoxia tolerance | allergic 
response | transcriptional 
repressor 
cytoplasm; 
cell 
membrane 
nucleus 
Yes 
 P05455 
LA_HUMAN 
Lupus La protein  58.6 (46.8) 7.2 (6.68) transcription from RNA 
polymerase III promoter | tRNA 
modification | RNA processing | 
RNA export from nucleus | 
histone mRNA metabolism  
nucleus Yes 
7 P06733 
ENOA_HUMAN 
Alpha-enolase  58.6 (47.2) 6.9 (7.01) glycolysis | growth control | 
hypoxia tolerance | allergic 
response | transcriptional 
repressor 
cytoplasm; 
cell 
membrane 
nucleus 
Yes 
 P05455 
LA_HUMAN 
Lupus La protein  58.6 (46.8) 6.9 (6.68) transcription from RNA 
polymerase III promoter | tRNA 
modification | RNA processing | 
RNA export from nucleus | 
histone mRNA metabolism  
nucleus Yes 
8 P26641 
EF1G_HUMAN 
Elongation factor 1-
gamma  
57.6 (50.1) 6.6 (6.25) translational elongation | protein 
biosynthesis 
cytosol Yes 
9 P31948 
STIP1_HUMAN 
Stress-induced-
phosphoprotein 1  
70.5 (62.6) 6.5 (6.40) response to stress cytoplasm; 
nucleus 
Yes 
 75
Table 4-1 (continued). 
 
Spot Swiss-Prot 
accession number 
Protein name MW 
Exp(Theo） 
pI 
Exp(Theo) 
Function a Location a Phospho
rylated b  
10 P40227 
TCPZ_HUMAN 
T-complex protein 1 
subunit zeta  
67.9 (58.0) 6.3 (6.24) nucleotide binding | ATP binding 
| unfolded protein binding |  
cytoplasm Yes 
11 P49368 
TCPG_HUMAN 
T-complex protein 1 
subunit gamma  
69.2 (60.5) 6.1 (6.10) nucleotide binding | ATP binding 
| unfolded protein binding |  
cytoplasm Yes 
12 P14923 
PLAK_HUMAN 
Junction 
plakoglobin  
61.9 (81.6) 5.6 (5.95) structural molecule activity | 
cytoskeletal protein binding |  
cell 
junction; 
cytoplasm; 
membrane 
Yes 
 P49368 
TCPG_HUMAN 
T-complex protein 1 
subunit gamma  
61.9 (60.5) 5.6 (6.10) nucleotide binding | ATP binding 
| unfolded protein binding |  
cytoplasm Yes 
13 P06748 
NPM_HUMAN 
Nucleophosmin  45.3 (32.6) 4.6 (4.64) Nucleotide binding | the assembly 
and/or transport of ribosome 
nucleus Yes 
14 P32119 
PRDX2_HUMAN 
Peroxiredoxin-2  25.8 (21.9) 5.7 (5.66) response to oxidative stress | 
regulation of apoptosis | anti-
apoptosis 
cytoplasm Yes 
a. Protein function and sucellular location were obtained based on Gene Ontology and Swiss-Prot annotation. 
b. Status of protein phosphorylation was inspected in Swiss-Prot and PhosphoSite. 
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Table 4-2 Protein identification results for Pro-QTM Diamond-stained spots from pH 4-7 gel. 
 
Spot Swiss-Prot 
accession number 
Protein name MW 
Exp(Theo） 
pI 
Exp(Theo)
Function a Location a Phospho
rylated b  
1 P53999 
TCP4_HUMAN 
Activated RNA 
polymerase II 
transcriptional 
coactivator p15  
16.7 (14.4) 5.3 (9.6) single-stranded DNA binding 
| transcription coactivator 
activity | DNA binding  
nucleus Yes 
2 P23528 
COF1_HUMAN 
Cofilin-1  18.8 (18.5) 6.5 (8.22) actin binding | protein 
binding  
nucleus Yes 
3 Q9Y5S9 
RBM8A_HUMAN 
RNA-binding 
protein 8A 
22.3 (19.9) 5.0 (5.5) mRNA binding | protein 
binding | nucleotide binding  
cytoplasm; 
nucleus 
Yes 
 Q13185 
CBX3_HUMAN 
Chromobox protein 
homolog 3  
22.3 (20.8) 5.0 (5.23)  nucleus Yes 
4 O43399 
TPD54_HUMAN 
Tumor protein D54 31.3 (22.2) 5.1 (5.26) protein binding  unclassified Yes 
 P25788 
PSA3_HUMAN 
Proteasome subunit 
alpha type 3  
31.3 (28.4) 5.1 (5.19) threonine endopeptidase 
activity | protein binding  
cytoplasm; 
nucleus 
Yes 
5 P04792 
HSPB1_HUMAN 
Heat-shock protein 
beta-1  
30.4 (22.8) 5.6 (5.98) protein binding cytoplasm; 
nucleus 
Yes 
 O75489 
NDUS3_HUMAN 
NADH 
dehydrogenase 
[ubiquinone] iron-
sulfur protein 3 
30.4 (30.2) 5.6 (6.98) NADH dehydrogenase 
activity | NADH 
dehydrogenase (ubiquinone) 
activity   
mitochondrion Yes 
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Table 4-2 (continued). 
 
Spot Swiss-Prot 
accession number 
Protein name MW 
Exp(Theo） 
pI 
Exp(Theo) 
Function a Location a Phospho
rylated b  
 Q9BTE7 
DCNL5_HUMAN 
DCN1-like protein 5  30.4 (27.5) 5.6 (5.44)  unclassified No 
6 O00487 
PSDE_HUMAN 
26S proteasome non-
ATPase regulatory 
subunit 14  
43.9 (34.6) 6.2 (6.06) ubiquitin-dependent protein 
catabolism  
unclassified Yes 
 Q14847 
LASP1_HUMAN 
LIM and SH3 domain 
protein 1  
43.9 (29.7) 6.2 (6.61) ion transporter activity | 
metal ion binding | actin 
binding | SH3/SH2 adaptor 
activity | zinc ion binding  
cytoplasm Yes 
7 P05388 
RLA0_HUMAN 
60S acidic ribosomal 
protein P0  
43.9 (34.3) 5.5 (5.72) structural constituent of 
ribosome | RNA binding | 
protein binding   
unclassified Yes 
 P06748 
NPM_HUMAN 
Nucleophosmin  43.9 (32.6) 5.5 (5.0) Nucleotide binding | the 
assembly and/or transport 
of ribosome 
nucleus Yes 
8 O75874 
IDHC_HUMAN 
Isocitrate 
dehydrogenase 
[NADP] 
56.1 (46.7) 6.9 (6.53) oxidoreductase activity | 
isocitrate dehydrogenase 
(NADP+) activity | 
oxidoreductase activity, 
acting on NADH or 
NADPH, NAD or NADP as 
acceptor | 
cytoplasm Yes  
9 P50395 
GDIB_HUMAN 
Rab GDP 
dissociation inhibitor 
beta  
60.5 (50.7) 6.3 (6.11) Rab GDP-dissociation 
inhibitor activity | GTPase 
activator activity  
cytoplasm; 
membrane 
Yes 
 P31150 
GDIA_HUMAN 
Rab GDP 
dissociation inhibitor 
alpha  
60.5 (50.6) 6.3 (5.0) Rab GDP-dissociation 
inhibitor activity | GTPase 
activator activity  
cytoplasm Yes  
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Table 4-2 (continued). 
 
Spot Swiss-Prot  
accession number 
Protein name MW 
Exp(Theo） 
pI  
Exp(Theo) 
Function a Location a Phospho
rylated b  
10 Q99816 
TS101_HUMAN 
Tumor 
susceptibility gene 
101 protein 
59.4 (43.9) 6.1 (6.06) protein binding | 
transcription corepressor 
activity | DNA binding | 
ubiquitin-protein ligase 
activity  
cytoplasm; 
membrane 
Yes 
 O75439 
MPPB_HUMAN 
Mitochondrial-
processing 
peptidase subunit 
beta  
59.4 (54.4) 6.1 (6.38) mitochondrial processing 
peptidase activity | metal 
ion binding | zinc ion 
binding  
mitochondrion No 
 Q9UQ80 
PA2G4_HUMAN 
Proliferation-
associated protein 
2G4  
59.4 (43.8) 6.1 (6.13) methionyl 
aminopeptidase activity | 
protein binding | 
transcription factor 
activity | hydrolase 
activity | RNA binding | 
cobalt ion binding  
cytoplasm; 
nucleus 
Yes 
11 P31930 
UQCR1_HUMAN 
Ubiquinol-
cytochrome-c 
reductase complex 
core protein 1 
56.7 (52.6) 5.5 (5.94) oxidoreductase activity | 
ubiquinol-cytochrome-c 
reductase activity  
mitochondrion Yes 
 P02647 
APOA1_HUMAN 
Apolipoprotein A-
I precursor  
56.7 (30.8) 5.5 (5.56) lipid binding | high-
density lipoprotein 
binding | protein binding | 
lipid transporter activity 
secreted No 
12 Q16222 
UAP1_HUMAN 
UDP-N-
acetylhexosamine 
pyrophosphorylase 
70.4 (58.8) 6.1 (5.92) UDP-N-
acetylglucosamine 
diphosphorylase activity | 
nucleotidyltransferase 
activity 
cytoplasm No 
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Table 4-2 (continued). 
 
Spot Swiss-Prot  
accession number 
Protein name MW 
Exp(Theo）
pI 
Exp(Theo) 
Function a Location a Phospho
rylated b 
13 P10809 
CH60_HUMAN 
60 kDa heat shock 
protein, 
mitochondrial 
precursor  
67.8 (61.1) 5.1 (5.7) protein binding | nucleotide 
binding | chaperone binding | 
unfolded protein binding | 
ATP binding   
mitochondrion Yes 
14 P61978 
HNRPK_HUNMAN 
Heterogeneous 
nuclear 
ribonucleoprotein K 
69.1 (51.0) 5.0 (5.39) nucleic acid binding | RNA 
binding | DNA binding | 
protein binding  
cytoplasm/ 
nucleus 
Yes 
15 P45974 
UBP5_HUMAN 
Ubiquitin carboxyl-
terminal hydrolase 
5  
75.9 (95.8) 4.9 (4.91) protein binding | zinc ion 
binding | metal ion binding | 
cysteine-type endopeptidase 
activity | ubiquitin-specific 
protease 5 activity   
unclassified Yes 
 P08238 
HS90B_HUMAN 
Heat shock protein 
HSP 90-beta  
75.9 (83.3) 4.9 (4.97) nitric-oxide synthase 
regulator activity | 
nucleotide binding | TPR 
domain binding  
cytoplasm/ 
melanosome 
Yes 
 P07900 
HS90A_HUMAN 
Heat shock protein 
HSP 90-alpha 
75.9 (84.7) 4.9 (4.94) nitric-oxide synthase 
regulator activity | 
nucleotide binding | protein 
homodimerization activity | 
unfolded protein binding | 
molecular function unknown 
| ATP binding  
cytoplasm/ 
melanosome 
Yes 
16 P05388 
RLA0_HUMAN 
60S acidic 
ribosomal protein 
P0  
43.9 (34.3) 6.1 (5.72) structural constituent of 
ribosome | RNA binding | 
protein binding   
unclassified Yes 
a. Protein function and sucellular location were obtained based on Gene Ontology and Swiss-Prot annotation. 
b. Status of protein phosphorylation was inspected in Swiss-Prot and PhosphoSite. 
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4.4 Discussion 
 
Proteomic technologies enable the study of proteins and their interactions in a 
systematic manner. Because of the critical role that phosphorylation plays in biological 
systems, intensive efforts have been centered on the development of improved 
phosphoproteomic strategies, and many analytical options are available. Before large-
scale application of a chosen bioanalytical platform to a new biological system, in a new 
setting, it is necessary to tailor the chosen strategy to the particular task, and to evaluate 
its performance.  In this study, we applied 2-DE with multiplexed Pro-QTM Diamond 
phsopho-specific stain and SYPRO Ruby stain, followed by protein identification of 
selected spots using LC-MS/MS, to obtain an overview of phosphoproteins in the LNCaP 
human prostate cancer cell line.  
 
 We found that streaks were present in the pH range of 7-9 in our 2-DE gels. It is 
common that horizontal streaking is present at the basic pH range of 7-9 in a 2-DE gel. 
The primary reason of streaking is due to the depletion of the reducing agent at the basic 
end during IEF (Gorg et al., 2000; Olsson et al., 2002). Reducing agent, dithiothreitol 
(DTT), is a weak acid and therefore charged at a basic pH, which results in the migration 
of DTT towards the anode during IEF. The depletion of DTT at the cathode leads to 
oxidation of protein thiol groups and re-formation of inter- and intra- molecular disulfide 
bridges.  
 
Destreak rehydration solution has been reported to transform the protein thiol 
groups into a stable disulfide and to protect the disulfide groups from unspecific 
oxidation (Olsson et al., 2002). We partially reduced streaks and improved the spot 
patterns on 2-DE gels with pH range of 3-10 by using the Destreak Rehydration solution. 
However, the major improvement expected was not reached. Another option to address 
this issue would be to perform two separations with two different strips: pH 4-7 and pH 
6-9 (Hoving et al., 2002; Pennington et al., 2004).  However, this would mean additional 
sample and time requirements, plus modification of the experimental procedure. 
Therefore, we decided to use IPG strips with pH range of 4-7 for subsequent experiments; 
with this option we can achieve an increased resolution in the pH region where most 
proteins appear. 
 
Sample application plays an important role in the IPG-based isoelectric focusing. 
Previous studies showed the best protein recoveries are obtained for all protein loads 
when samples are applied to IPG strips during rehydration using a single device for both 
rehydration and IEF. In contrast, the recoveries are poorest when rehydration and IEF are 
performed in separate devices, and increasing protein loads using separate devices 
extensively increases sample losses (Zuo and Speicher, 2000).  
 
Compared to Multiphor II that employs separate rehydration and IEF chambers, 
the IPGphor is an integrated equipment that consists of a high voltage power supply and a 
solid state cooling system. IPG strips are rehydrated and focused in the same strip holder 
by automatically programming the initial rehydration step, thus avoiding transfer of the 
IPG strip from the re-swelling tray to an IEF tray and eliminating further handling of the 
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strip. In addition, the advantage of the strip holder over the reswelling tray is that proteins 
that do not enter the IPG gel during rehydration can enter the gel during the focusing step. 
Zuo and Speicher reported that the application of low voltage during rehydration did not 
appear to significantly improve overall protein recovery, but it was beneficial for entry of 
specific proteins (Zuo and Speicher, 2000). In our study, both IEF systems demonstrated 
a satisfactory protein separation; either one can be applied in further study. 
 
Both Pro-QTM Diamond stain and SYPRO Ruby stain are fluorescent stains and 
have similar sensitivity. They can be used subsequently to detect phosphoproteins and 
total proteins in a single gel. SYPRO Ruby stain has a low background, high resolution 
and dynamic range, and is easy to manipulate (Lopez et al., 2000). However, Pro-QTM 
Diamond staining is affected by the expertise that an investigator has with the technique. 
The stain and destain time points will affect background and resolution. We found that 
some of the spots that were present on both images sometimes differed in intensity; and 
there were a few spots only present on Pro-QTM Diamond image but not on SYPRO Ruby. 
This may be due to the specific proteins that are particularly sensitive to one staining but 
not to the other (Wu et al., 2005). This sequential staining of proteins in a single gel 
provided parallel determination of protein expression and preliminary characterization of 
post-translational modifications of proteins in individual spots on 2-DE gels. 
 
In our determination of the protein identities, we considered the possibility of 
phosphorylation in our database searches; however, no phosphopeptides were retrieved 
for the identified proteins. This result was expected.  In order to maximize the chance of 
direct detection of the phosphorylated peptide, an IMAC enrichment step must be 
included at the peptide level (analogously to the method in Chapter 2).  This strategy is 
possible, and has been used to characterize exact phosphorylation sites, e.g. in the human 
growth hormone (Zhan et al., 2005).  However, the strategy requires a much higher 
protein amount.  In our 2-DE survey of LNCaP phosphoproteins, we chose to focus on 
maximizing the success rate of determination of protein identity, and we used 
information from published literature to provide supporting evidence for the 
phosphorylation status of the identified proteins.  To gather this information, we used two 
bioinformatics resources.  First, we inspected the Swiss-Prot annotations for each protein.  
These annotations summarize information on each Swiss-Prot database entry, including 
post-translational modifications.  Second, we used the PhosphoSite knowledgebase to 
retrieve information on protein phosphorylation.  This strategy takes advantage of the 
publicly available information sources. Instead of using PubMed, we performed our 
inspection in Swiss-Prot and PhosphoSite annotation because both of them are populated 
with information derived from published literatures and as complete and up-to-date as 
possible. 
 
Another characteristic that we addressed for our phosphoprotein panel concerned 
relevance of the identified proteins to prostate cancer.  Because our study was intended as 
a prelude to future differential expression studies in the context of prostate cancer, it is 
important to evaluate whether the phosphoproteins that we probed with the chosen 
bioanalytical strategy bear potential relevance to cancer.  We evaluated this aspect by 
reviewing published literature. A number of identified proteins have been previously 
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reported to be differentially expressed in prostate cancer cell line, such as Peroxiredoxin-2, 
Annexin A1, Transaldolase, Nucleophosmin et al. The findings indicated that 2-DE strategy 
is feasible to study the phosphoprotein differential expression in LNCaP. A number of 
cancer relevant phosphoproteins identified in the present study was shown in Table 4-3 
based on their functions. 
 
Peroxiredoxins (PRDXs) are antioxidant enzymes expressed by most free-living 
organisms, often in multiple isoforms. Shen et al. demonstrated that prostate cancer cells 
were more sensitive to hydrogen peroxide or an organic hydroperoxide when PRDX1, 2, 
or 3  was partially suppressed (Shen and Nathan, 2002). Park et al. reported that PRDX1 
acted as a key mediator in stimulating the activation of androgen receptor (AR). The high 
level of PRDX1 was expressed in the aggressive LN3, C4-2, and C4-2B prostate cancer 
cell lines derived from LNCaP, which displayed PRDX1 is able to sensitize a ligand-
stimulated AR and serve as a new target in the management of prostate cancer (Park et al., 
2007). PRDX2 have been reported to significantly up-regulate in highly metastatic 
prostate cancer cell line 1E8-H cells (Wu et al., 2007). Nevertheless, PRDX 2 and 
PRDX1 have been found lacking significant change in prostate needle biopsy speciments 
(Lin et al., 2007).   
 
Annexin I (ANX I) is a promising prostate cancer biomarker identified by 2-DE 
and mass spectrometry. Studies have confirmed that ANX I was underexpressed in a 
majority of early stage prostate cancers (Kang et al., 2002; Ornstein and Tyson, 2006). 
ANX I expression were also decreased in androgen stimulated prostate cancer, androgen-
independent prostate cancer and metastatic prostate cancer cell line (Smitherman et al., 
2004; Wu et al., 2007). Although reduced expression levels of ANX I protein is a 
common finding in all stages of prostate cancer, a causative relationship between ANX I 
dysregulation and prostate cancer development has not yet been established. ANX I may 
have tumor suppressor functions in prostate cancer. Hsiang et al. reported that ANX I 
displayed its pro-apoptotic effect through involving in the activation of p38 and JNK, 
which appeared to shift the balance of signal transduction away from proliferation and 
toward apoptosis (Hsiang et al., 2006).  
 
The nuclear protein B23, nucleophosmin (NPM), is an RNA-associated nucleolus 
phosphoprotein reported to be more abundant in malignant and growing cells than in 
 
 
Table 4-3 Example of cancer relevant phosphorproteins identified in LNCaP.  
 
Functional categories Protein name 
Apoptosis modulated protein Peroxiredoxin-2, Annexin A1 
Molecular chaperones T-complex protein 1 subunit zeta, T-
complex protein 1 subunit gamma, 
Nucleophosmin 
Multifunctional enzyme Alpha-enolase 
Carbohydrate metabolism enzyme Transaldolase 
Stress response protein Stress-induced-phosphoprotein 1, 
Peroxiredoxin-2 
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normal nondividing cells (Subong et al., 1999). Leotoing et al. reported the potential of 
NPM as a tumor marker for human prostate cancer. They found that NPM was 
overexpressed in prostate cancer compared to normal adjacent tissues, and could 
modulate AR functions by promoting assembly of AR-containing regulatory complexes. 
Thus, the high levels of NPM might alter AR functions in prostate cancer (Leotoing et al., 
2008).   
 
Two T-complex protein 1 (TCP) isoforms, T-complex protein 1 subunit zeta and 
T-complex protein 1 subunit gamma, were identified in the study. TCP’s function is the 
binding of nucleotide, ATP and/or unfolded protein (Li et al., 1994).  It involves the 
process of protein folding. Up-regulated TCP was found in highly metastatic prostate 
cancer cell line 1E8-H (Wu et al., 2007) and the cell line M12 (Liu et al., 2003). The high 
levels of TCP may reflect the alter AR functions in prostate cancer. 
 
Enolase (ENOA or ENO1) is a multifunctional protein. Besides its role in basic 
metabolism, Enolase serves as a surface receptor for the binding of plasminogen 
(Andronicos et al., 1997; Lopez-Alemany et al., 2003). ENO1 has been implicated in 
numerous diseases, including cancers (Kanemoto et al., 2006; Katayama et al., 2006). 
Plow et al. have found that ENO1 involved tumor cell invasion and metastasis via 
initiating the activity of plasminogen activity on the cell surface (Plow et al., 1995). 
ENO1 has been reported highly expressed in tumor cells (Altenberg et al., 2006; 
Altenberg and Greulich, 2004). Pancholi demonstrated that the increased expression of 
ENO1 both at DNA level and at the protein level directly correlated the progression of 
tumors (Pancholi, 2001). 
 
Transaldolase plays an important role in central metabolism. It is involved in 
oxidative stress and apoptosis, in multiple sclerosis, and in cancer (Samland and Sprenger, 
2009). Transaldolase deficiency has been found to associate with liver cirrhosis in a new 
inborn (Verhoeven et al., 2001). Recently, Basta et al. demonstrated that genetic 
polymorphisms in Transaldolase were associated with squamous cell carcinoma of the 
head and neck (Basta et al., 2008). 
 
 
4.5 Conclusions 
 
In this study, we demonstrated the feasibility of using 2-DE with phsopho-specific 
staining and tandem mass spectrometry to investigate the phosphoproteins in the LNCaP 
human prostate cancer cell line. This methodology complements the other platforms that 
we used for prostate cancer phosphoproteomics research; it will be of particular value for 
future comparative studies of phosphoproteins in various physiological states. The 
phosphoproteins probed with the chosen analytical platform are known to be relevant to 
prostate cancer.  
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CHAPTER 5. PROTEOMIC ANALYSIS OF PROTEIN ALTERATIONS IN 
MOUSE PROSTATE CANCER TISSUE INDUCED BY 
BICALUTAMIDE/EMBELIN COMBINATION TREATMENT 
 
 
5.1 Introduction  
 
Prostate cancer is a major health problem in Western countries. It is the most 
common cancer and the third leading cause of male cancer death (Jemal et al., 2006). 
During the initial stage of prostate cancer, the tumor is dependent on androgen for growth 
(Isaacs, 1994; Miller et al., 2003). For those without metastatic disease, androgen 
withdrawal/androgen ablation is the most effective therapy. Early treatment with the non-
steroidal antiandrogen bicalutamide significantly improves survival in patients with 
localized disease (Blackledge, 1996). However, the therapeutic success is temporary. 
Prolonged treatment results in the mutation of androgen receptor, which converts 
bicalutamide from an antagonist into an agonist, leading to drug resistance.  Hence, in the 
majority of cases, the disease reappears within a few years as an androgen-independent 
form. There are no effective treatments for androgen-independent prostate cancer. 
Recently, clinical trials showed that docetaxel, in combination with estramustine could 
improve the survival of patients with metastatic, androgen-independent prostate cancer, 
as compared with mitoxantrone and prednisone (Petrylak et al., 2004). The combination 
of an androgen receptor antagonist (bicalutamide) and XIAP inhibitor (embelin) has been 
reported to cause regression of prostate tumors (Danquah et al., 2009). That result 
indicates that a treatment strategy with novel drug combination, delivered in a more 
effective way, is a promising way to treat androgen-independent prostate cancer. 
 
X-Linked inhibitor of apoptosis protein (XIAP) is a promising molecular target 
for the design of new anticancer drugs aiming at promoting apoptosis in cancer cells. 
Embelin is a novel cell-permeable inhibitor of XIAP, which binds to the XIAP BIR3 
domain to which Smac and caspase-9 bind. Embelin selectively inhibits cell growth, 
induces apoptosis, and activates caspase-9 in prostate cancer cells (Chen et al., 2006; 
Nikolovska-Coleska et al., 2004).  
 
Bicalutamide is a non-steroidal antiandrogen with affinity for androgen receptor. 
The low solubility/dissolution rate of bicalutamide is still a key factor limiting its oral 
bioavailability (Le et al., 2009). The use of amphiphilic copolymer micelles as effective 
carriers for tumor-drug delivery has drawn more attention in the last few years (Blanco et 
al., 2007; Ishihara et al., 2008; Lee et al., 2006; Yang et al., 2008; Yasugi et al., 1999). 
The amphiphilic copolymer can form a micelle structure with a hydrophobic inner core 
and a hydrophilic outer shell in aqueous environments. The core-shell structure makes it 
easy to incorporate hydrophobic drugs and results in an increased drug concentration in 
body fluids.  
 
Proteomics is a powerful approach which enables to survey a large number of 
proteins simultaneously. It has been extensively applied to examine protein expression in 
various types of human cancers and in the context of  resistance to several drugs 
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(Cicchillitti et al., 2009; Di Michele et al., 2009; Ou et al., 2008; Rondepierre et al., 2009). 
Thus, proteomics offers excellent possibilities for determining proteins involved in the 
complex pharmacological effects of anticancer agents, and to provide an insight into the 
molecular mechanism of anticancer agents in prostate cancer.  
 
The aim of this study was to identify proteins that are differentially expressed in 
control and bicalutamide/embelin treated mouse prostate tumor specimens. This study 
will aid in the revealing of molecular mechanism of bicalutamide/embelin combination 
therapy. A comparative proteomic approach based on 2-DE coupled with mass 
spectrometry (LC-MS/MS) was applied to mouse prostate tumors with 
bicalutamide/embelin combination treatment. An outline of the 2-DE based strategy is 
shown in Figure 5-1. 
 
 
5.2 Materials and Methods 
 
 
5.2.1 In Vivo Studies 
 
This was a collaboration study with the group of Dr. Ram I. Mahato from the 
Department of Pharmaceutical Sciences, UTHSC.  Dr. Mahato’s group performed the in 
vivo studies. Briefly, all animal experiments were performed in accordance with NIH 
animal use guidelines and protocol approved by the Animal Care and Use Committee at 
the University of Tennessee Health Science Center. Xenograft flank tumors were induced 
in 8-weeks-old male BALB/C nude mice purchased from The Jackson Laboratory (Bar 
Harbor, ME) by subcutaneous injection of three million LNCaP cells suspended in 1:1 
media and matrigel. When tumors reached approximately 150mm3, mice were 
randomized into three groups of five mice, minimizing weight and tumor size difference. 
Each group was treated with intratumoral injection of saline, sonicated bicalutamide 
suspension or bicalutamide entrapped in PEG-PLA micelles (20 mg/kg) three times a 
week. Mice were treated for three weeks. After three weeks, treatments with bicalutamide 
were terminated, and treatment with embelin was commenced and continued for two 
weeks. Mice were sacrificed after bicalutamide /embelin combination treatment. Tumors 
were surgically removed, frozen in liquid nitrogen and stored at -80 ºC.  
 
 
5.2.2 Protein Preparation 
 
Proteins were extracted from 200 mg of crushed tumor tissues by using 2 mL of 
Trizol reagent  (Invitrogen, Carlsbad, CA) with 5 µL of protease inhibitor cocktail 
(Sigma, St. Louis, MO) according the manufacturer’s instruction (details described in 
Chapter 2). For 2-DE separations, protein pellet was dissolved with a rehydration buffer 
that contained urea (7 M), thiourea (2 M), CHAPS detergent (2% w/v), IPG buffer 3-10 
(2% v/v), DTT (0.3%, w/v) and a trace amount of Bromophenol Blue dye.  The protein 
concentration of the extracts was determined by Bradford assay (GE Healthcare, 
Piscataway, NJ). 
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Figure 5-1 Outline of 2-DE based comparative proteomics platform. 
Proteins were extracted from mouse prostate tumor tissues, and then separated by 2-
DE. Protein spots on 2-DE gels were visualized by staining with SYPRO Ruby and 
gel images were analyzed with computer-assisted gel image analysis software. The 
spots found to be statistically significant (p<0.05) were excised, digested with trypsin, 
and analyzed by LC-MS/MS. Proteins were identified through database searches, and 
bioinformatics analyses were performed for final identified proteins. 
Control Free bicalutamide/embelin 
treatment  
Extract proteins 
Employ 2-DE Employ 2-DE 
Stain gels with SYPRO Ruby 
Computer-assisted analyze gel images, select spots with differential 
expression in three states 
Excise spots, digest with trypsin and analyze by LC-MS/MS 
Perform bioinformatics analysis for identified protein sets 
(Gene Ontology, Ingenuity Pathway Analysis) 
Extract proteins 
Micellar bicalutamide/embelin 
treatment 
Employ 2-DE 
Extract proteins 
Identify proteins through database searches 
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5.2.3 2-DE 
 
For the first dimension, protein samples (250 µg of protein in 350 µL of 
rehydration buffer) were loaded on pre-cast, 18-cm long immobilized pH gradient (IPG) 
stripes (pH 4-7) (GE Healthcare, Piscataway, NJ). Isoelectric focusing was performed 
with the IPGphor apparatus (GE Healthcare, Piscataway, NJ) according to manufacturer’s 
instructions (details described in Chapter 4). The isoelectric focusing was performed 
under the following voltage program: 30 V (fixed for 16 hours); 200 V (fixed for 1 hour); 
500 V (fixed for 1 hour); 1000 V (fixed for 1 hour); 8000 V (gradient over 30 minutes); 
8000 V (fixed for 4 hours ).  
 
IPG strips were then incubated for 15 minutes in an equilibration buffer (50 mM 
Tris/HCl pH 8.8, 6 M urea, 30% glycerol, 2% SDS) with 2.0% DTT and then in 
equilibration buffer with 2.5% iodoacetamide for an additional 15 minutes. The second 
dimensional separations were carried out on 12% SDS- PAGE gels at 15 °C with 200 V 
constant voltage applied for about 8 hours in a Protean Plus Dodeca Cell (Bio-Rad, 
Hercules, CA), until the bromophenol blue dye front reached the end of the gels. 
 
  
5.2.4 Gel Staining and Imaging 
 
Gels were stained with SYPRO Ruby protein stain (Molecular Probes, Eugene, 
OR). The image was acquired on an FX Fluorescence Laser Scanner (Bio-Rad, Hercules, 
CA) with 488 nm laser excitation and 555 nm band pass emission filter for SYPRO Ruby 
stain. The images were displayed with Adobe Photoshop 5.0 LE software, and saved 
as .TIFF files for future analysis. The gel images were analyzed using two independent 
and commercially available image analysis software packages, PDQuest version 7.1.0 
(Bio-Rad, Hercules, CA) and Progenesis SameSpots version 3.3 (Nonlinear USA Inc, 
Durham, NC).  
 
Using PDQuest software package, gel images were performed with the 
“Automated spot detection and matching wizard” tool. After grouping the gels within a 
specified match set (control, free bicalutamide, or micelle bicalutamide) and spot 
detection, the software automatically generated a “match set master gel” image, which is 
a synthetic gel image made up of all the spots that were detected within the match set by 
PDQuest. Each spots was assigned a unique identified number across all the gels by the 
software to permit comparison between groups. The density of each spot was normalized 
to the total density in the gel image and was expressed in parts per million (PPM). 
 
The same 2-DE gel images were also analyzed using Progenesis SameSpot 
software package. Briefly, gel images were grouped into three categories (control, free 
bicalutamide and micelle bicalutamide) for comparative analysis. A reference gel was 
selected from all gel set to serve as a universal index for spot numbering prior to 
matching analysis. Spot detection, filtering, and background subtraction were 
automatically performed by the software using its unique nonparametric algorithm and 
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applied to all the subgels in the particular group. Spots that did not match were manually 
warped and updated at the individual and reference gels. 
 
Following confirmation of appropriate spot detection, matching and normalization, 
spot statistics were reviewed. ANOVA test was performed to quantify differential 
expression of spots among three groups. The spots found to be statistically significant (p< 
0.05) were isolated for further investigation. 
 
 
5.2.5 In-gel Tryptic Digestion 
 
Spots of interest were excised from the gels. The gel pieces were extensively 
washed with 50 mM ammonium bicarbonate in 50% ACN for three times, and then dried 
under vacuum for 30 minutes. The dried gel pieces were rehydrated in a trypsin solution 
that contained 16.7 ng/µL of trypsin (Promega, Madison, WI) in 50 mM ammonium 
bicarbonate (pH 8). The digestion solution was incubated at 37 °C overnight. The 
resulting peptides were extracted with 0.01% TFA/ 60% ACN three times. All 
supernatants were combined and dried with a vacuum centrifuge. Prior to LC-MS/MS 
analysis, the digestions were reconstituted with 15 µL of 2.5% FA and desalted with 
ZipTipC18 (Millipore, Billerica, MA), using the procedure provided by the manufacturer 
(details described in Chapter 2). The peptides retained on the ZipTipC18 column were 
eluted with 1.5 µL of 50% ACN/0.1% FA and diluted with 2.5 µL of 0.5% FA. 
 
 
5.2.6 LC-MS/MS Analysis 
 
LC-MS/MS experiments were performed on a LTQ linear ion trap mass 
spectrometer (Thermo Electron, San Jose, CA). Peptide mixtures were loaded onto a 
fused-silica microcapillary column (15 cm length, 75 µm ID; New Objective, MA)  
packed in-house with C18 resin (Michrom Bioresources, Inc., Auburn, CA) and were 
separated using a 30-min gradient from 0% to 90% solvent B (0.05% FA/90% MeOH). 
Solvent A was 0.05% FA/ 2% MeOH. The LTQ mass spectrometer was operated in 
positive ion mode and data-dependent acquisition was performed. In brief, a scan cycle 
was initiated with a full scan of wide mass accuracy (m/z 400-2000) in the ion trap, 
which was followed by MS/MS scans in the linear ion trap on the 7 most abundant 
precursor ions with dynamic exclusion of previously selected ions.  
 
 
5.2.7 Database Searches 
 
The MS/MS data were used to search the Swiss-Prot database (subset of mouse 
proteins) with the TurboSEQUEST search engine (Thermo Electron) that is part of 
Bioworks version 3.2 (Thermo Electron, San Jose, CA). Searches were performed with 
the following parameters: full-trypsin specificity, dynamic modifications of oxidized 
methionine, and static modifications of cystein by carbamidomethylation. All peptide 
matches were filtered by XCorr larger than 3.00, 2.50, and 3.50 used for singly, doubly 
 89
and triply charged ions, respectively; peptide probability less than 1.0E-3; different 
peptides; and only the top matches were considered. The peptides retrieved by the 
searches were validated by manual inspection of the MS/MS data. Criteria used for 
manual validation included: the spectrum must be of good quality with fragment ion 
clearly above the baseline noise; sequential members of the b- or y-series were 
observable in the mass spectra. 
 
 
5.2.8 Bioinformatics and Network Analysis 
 
The proteins identified as being differentially expressed among treatment groups 
were compared to all annotated proteins using gene ontology (GO). This analysis was 
carried out using the Web-accessible program (http://bioinfo.vanderbilt.edu/webgestalt/). 
Proteins were classified with GO annotation at level 4 according to the molecular 
function that proteins normally carry out, the biological process that proteins are involved 
in, and the molecular component (subcellular location) of the proteins.  
 
Identified proteins were also analyzed by Ingenuity Pathway Analysis (IPA; 
Ingenuity System, Mountain View, CA). IPA is a powerful curated database and analysis 
system for understanding how proteins work together to affect cellular changes. It builds 
hypothetical networks from identified proteins and other proteins, based on a regularly 
updated database which consists of millions of individual relationships between genes, 
proteins and other biological molecules, based on information compiled from published 
literature. It enables to pinpoint the biological mechanisms, pathways and functions most 
relevant to the experimental datasets or genes of interest. IPA generates a score for each 
possible network, which is calculated according to the fit of that network to the input 
proteins. The higher score indicates a lower possibility that the input proteins occur in a 
given network by random chance. Networks with scores of 10 or higher have a high 
confidence of not being generated by random chance alone. 
 
 
5.3 Results 
 
The aim of the study was to identify proteins whose differential expression relates 
to bicalutamide/embelin treatment in mouse prostate tumors and to reveal the molecular 
mechanism of prostate tumor regression induced by the combination of anticancer drugs.  
 
 We employed a 2-DE based approach coupled with mass spectrometry for protein 
identification. For gaining insight into the mechanisms of drug action, the ability to 
reproducibly measure the protein expression levels across the experiments is a key 
challenge. Hence, it is important to realize the contribution of technical variations in 
measuring quantitative differences. In the present study, technical variation was 
determined by employing three gels per sample.  
 
Correlation analysis was used to determine the reproducibility of the spot volume 
within and between a set of gels (Zhan and Desiderio, 2003). The coefficient of 
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correlation of the normalized spot volum across three replicates per sample ranged from 
0.89 to 0.98. The coefficient of variation (CV) is a quantitative index, describing the 
amount of the variation of volume among the matched-spots. The average CV was 
calculated from all spots matched on gels within an experiment set. The average CV for 
replicate 2-DE gels of all three sample types was 20.7±15.8%, which was comparable 
with the reported results 35.7±20.8% for Dodeca system by Zhan and Desiderio (Zhan 
and Desiderio, 2003). This result was also consistent with several other published reports 
on the degree of variation attributed to 2-DE in the hands of the users (Molloy et al., 2003; 
Saldanha et al., 2008).  
 
In order to describe in the detail of the difference in the amount of variation of the 
normalized volume of the matched-spots, the proportion of the matched-spots among the 
different CV ranges of the normalized volume is described in Table 5-1. The majority of 
spots was matched within the low CV range (70% of matched spots with CV< 25 %, 90% 
of matched spots with CV< 50%). Small proportion of spots was matched in high CV 
range. The results was also similar to the previous reported results based on the Dodeca 
system of the study (77% of matched spots with CV< 50%)  (Zhan and Desiderio, 2003). 
The degree of technical variation due to the 2-DE process established an important 
baseline for uncoupling biological variation from technical variation. 
 
 
5.3.1 Profile of Mouse Prostate Tumor Specimens 
 
To study the molecular mechanisms of bicalutamide/embelin combination therapy 
in prostate cancer, three groups of mouse prostate tumor specimens were used in this 
work. Prostate tumors from mice treated with saline were used as controls. The controls 
were compared to two combination treatments: free-bicalutamide/embelin and PEG-PLA 
bicalutamide micelles/embelin.  
 
 
5.3.2 Proteomic Patterns of Bicalutamide/embelin Combination Treatment 
 
2-DE was used to separate protein mixture and to locate differentially expressed 
proteins among control, free-bicalutamide/embelin and PEG-PLA bicalutamide 
micelles/embelin treated mouse prostate cancer tissues. Patterns from three different 
mouse specimens were analyzed and three replicate 2-DE gels per specimen were used. 
Figure 5-2 shows a representative 2-DE gel of proteins for mouse prostate tumor obtained 
by using an IPG 4-7 strips and a 12% SDS-PAGE gel. 2-DE patterns from the three 
treatment groups were obtained and analyzed with two different image analysis software 
packages (Bio-Rad PDQuest Version 7.1 software and Progenesis Samespots v3.3 
software). Overall, more than 600 spots were resolved in the 2-DE gels and the protein 
expression profiles among the three groups were similar; a set of 33 protein spots 
exhibiting significantly differential expression by ANOVA test (p< 0.05) are located 
(Figure 5-2) and analyzed by nano-LC-MS/MS. 
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Table 5-1 Proportion of the matched spots among the different ranges of the CV of the 
normalized volume. 
 
Control Free bicalutamide Micelle bicalutamide  
CV of 
normalized 
volume (%) 
Number of 
matched 
spots 
Propor-
tion (%) 
Number of 
matched 
spots 
Propor- 
tion (%) 
Number of 
matched  
spots 
Propor-
tion (%) 
<10 93 20.9 220 49.4 95 21.3 
10-25 175 39.4 189 42.5 192 43.2 
25-50 123 27.6 30 6.7 107 24.1 
50-75 41 9.2 6 1.4 45 10.1 
75-100 10 2.2 0 0 5 1.1 
>100 3 0.7 0 0 1 0.2 
Total 445 100 445 100 445 100 
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(a) 
 
(b) 
 
Figure 5-2 Representative 2-DE gels of mouse prostate cancer proteome (a) Control (b) 
Free bicalutamide/embelin treatment.  
33 protein spots marked on the maps were differentially expressed (p<0.05) in the 
comparisons between control and treated samples; these proteins were identified by MS.  
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5.3.3 Identification of Candidate Protein Spots from 2-DE Gels 
 
The selected protein spots from SYPRO Ruby stained gels were excised and 
subjected to in-gel tryptic digestion. The extracted peptides were analyzed by LC-MS/MS 
to generate sequence-diagnostic MS/MS data. Out of the 33 differentially expressed 
protein spots, 30 protein spots were successfully identified, corresponding to 38 different 
proteins (Table 5-2 and Table 5-3). Overall, 19 proteins were identified in protein spots 
which were significantly up-regulated in bicalutamide/embelin treated specimens 
compared with control tumor specimens, such as peroxiredoxin-1, Glutathione 
peroxidase 1, enolase, and peroxiredoxin-2. Moreover, 19 proteins were identified from 
down-regulated protein spots in bicalutamide/embelin treated specimens compared with 
control tumor specimens, including plasminogen, annexin 5 and pre-mRNA-splicing 
factor SPF27. The summary score, protein coverage, and change fold for spots are shown 
in Table 5-2 and Table 5-3. It should be noted that some of the proteins were identified in 
multiple spots; furthermore, some of the spots contained more than one protein. 
 
 
5.3.4 Classification of Identified Proteins 
 
To interpret the results systematically, identified proteins were classified with GO 
annotation of the level 4 according to molecular function that proteins normally carry out, 
biological process that proteins are involved in, and molecular component (subcellular 
location).  
 
The majority of the identified proteins were associated with metabolic processes 
(cellular metabolism 51.5%, primary metabolism 51.5%, and macromolecular 
metabolism 33.3%). In addition to metabolic process, the biological processes which the 
differentially expressed proteins were involved in included localization (51.5%), 
transport (33.3%), response to stress (12.1%) and apoptosis (12.1%) (Figure 5-3). Based 
on GO annotations, identified proteins were involved in various molecular functions 
(Figure 5-4), such as binding (cation binding 21%, metal ion binding 24%, RNA binding 
9%), oxidoreductase activity (9%), and peptidase activity (9%). The classification is 
redundant since a protein can be classified into more than one category. 
 
To gain further insight in the differentially expressed protein results, separation 
was made into up-regulated and down-regulated identified proteins (Table 5-4). 
According to GO annotations, most identified proteins in both groups involved “binding” 
in molecular function. But proteins in the up-regulated group were associated with 
“oxidoreductase activity”, while very few proteins belonged to that category in the down-
regulated group. In the category of biological process, both up- and down-regulated 
proteins were classified into “cellular physiological process” and “metabolism”. 
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Table 5-2 List of identified protein spots down-regulated by bicalutamide/embelin treatment. 
 
Spot  Accession 
number 
Protein name Theor 
MW 
(kDa)/pI 
Peptide 
number 
Coverage  
(%) 
Fold change 
(Progenesis) 
P-value 
(Progenesis) 
Fold 
change 
(PDQuest) 
P-value 
(PDQuest) 
1 P60909 
RS3_MOUSE 
40 S ribosomal 
protein S3 
26.7/9.6 1 5.3 1.9 < 0.05 2 < 0.01 
2 P01843 
LAC1_MOUSE 
Ig lambd-1 
chain C region 
11.6/5.8 3 46.7 1.6 < 0.05 3.2 < 0.01 
3 P63159 
HMGB1_MOUS
E 
High mobility 
group protein 
B1 
24.9/5.6 4 19.1 2.6 < 0.01 Out of 
range 
< 0.01 
4 Q9D287 
BCAS2_MOUSE 
Pre-mRNA-
splicing factor 
SPF27 
26.1/5.4 2 11.1 1.3 > 0.05 1.2 < 0.01 
5 Q61990 
PCBP2_MOUSE 
Poly(rC)-
binding protein 
2 
38.2/6.3 9 33.1 1.4 > 0.05 1.4 < 0.01 
 P61161 
ARP2_MOUSE 
Actin-related 
protein 2 
44.8/6.2 6 19.8     
6 Q64674 
SPEE_MOUSE 
Spermidine 
synthase 
33.9/5.3 5 29.1 1.6 < 0.05 1.1 < 0.01 
7 Q99PT1 
GDIR_MOUSE 
Rho GDP-
dissociation 
inhibitor 1 
23.4/5.1 7 38.2 1.3 < 0.05 Out of 
range 
< 0.01 
8 P23506 
PIMT_MOUSE 
Protein-L-
isoaspartate(D-
aspartate) O-
methyltransfera
se 
24.6/7.1 5 26.4 1.8 < 0.05 2.6 < 0.01 
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Table 5-2 (continued). 
 
Spot  Accession 
number 
Protein name Theor 
MW 
(kDa)/pI
Peptide 
number 
Coverage 
(%) 
Fold change 
(Progenesis) 
P-value 
(Progenesis)
Fold 
change 
(PDQuest) 
P-value 
(PDQuest) 
9 Q99PT1 
GDIR_MOUSE 
Rho GDP-
dissociation 
inhibitor 1 
23.4/5.1 6 49.5 1.3 > 0.05 Out of 
range 
< 0.01 
 P34022 
RANG_MOUSE 
Ran-specific 
GTPase-
activating 
protein 
23.6/5.1 3 15.3     
10 Q8K0E8 
FIBB_MOUSE 
Fibrinogen beta 
chain precusor 
54.8/6.6 15 33 2.5 < 0.01 Out of 
range 
< 0.01 
11 P20918 
PLMN_MOUSE 
Plasminogen 
precursor 
90.8/6.2 18 31 2.3 < 0.05 5.6 < 0.01 
 P07724 
ALBU_MOUSE 
Serum albumin 
precursor 
68.7/5.7 23 49     
 Q91X72 
HEMO_MOUSE 
Hemopexin 
precursor 
51.3/7.9 10 33.9     
12 Q00623 
APOA1_MOUSE 
Apolipoprotein 
A-I precursor 
30.6/5.6 5 17.4 1.9 > 0.05 2.4 < 0.01 
13 P48036 
ANXA5_MOUSE 
Annexin A5 35.8/4.8 7 22.3 1.7 < 0.01 Out of 
range 
< 0.01 
14 Q9R1P4 
PSA1_MOUSE 
Proteasome 
subunit alpha 
type-1 
29.5/6.0 3 17.49 1.5 < 0.05 5.6 < 0.01 
15 Q4R4X8 
TBB4_MOUSE 
Tubulin beta-4 
chain 
49.6/4.7 23 59.7 2.1 < 0.01 Out of 
range 
< 0.01 
Protein name, accession number and theoretical pI and MW are from Swiss-Prot database (release 20090311) 
Out of range indicates spot was absent in replicate gels or was below the detection parameters set for the software package. 
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Table 5-3 List of identified protein spots up-regulated by bicalutamide/embelin treatment. 
 
Spot  Accession 
number 
Protein name Theor 
MW/pI 
Peptide 
number 
Coverage 
 (%) 
Fold  
change 
(Progenesis) 
P-value 
(Progenesis) 
Fold  
change 
(PDQuest) 
P-value 
(PDQuest) 
16 P29391 
FRIL1_MOUSE 
Ferritin light 
chain1 
20.8/5.6 6 47.0 1.3 > 0.05 Out of 
range 
< 0.01 
17 P09528 
FRIH_MOUSE 
Ferritin heavy 
chain 
21.1/5.5 6 40.1 1.8 < 0.01 2.4 < 0.01 
18 P35700 
PRDX1_MOUS
E 
Peroxiredoxin-1 22.2/8.2 5 25.1 1.3 > 0.05 Out of 
range 
< 0.01 
19 P46638 
RB11B_MOUS
E 
Ras-related 
protein Rab-11B 
24.5/5.6 2 10.6 2.4 < 0.01 2.2 < 0.01 
20 P11352 
GPX1_MOUSE 
Glutathione 
peroxidase 1 
22.2/6.7 8 55.7 2 > 0.05 Out of 
range 
< 0.01 
 Q99LX0 
PARK7_MOUS
E 
Protein DJ-1 20.0/6.3 1 7.90     
21 P29391 
FRIL1_MOUSE 
Ferritin light 
chain1 
20.8/5.6 5 34.4 1.4 > 0.05 1.8 < 0.01 
22 P50247 
SAHH_MOUS
E 
Adenosylhomo-
cysteinase 
47.7/6.1 10 25.7 1.6 < 0.01 Out of 
range 
< 0.01 
23 Q9D8N0 
EF1G_MOUSE 
Elongation factor 
1-gamma 
50.1/6.3 10 30.4 1.9 < 0.05 Out of 
range 
< 0.01 
 P17182 
ENOA_MOUS
E 
Alpha-enolase 47.1/6.3 3 8.80     
24 P01837 
KAC_MOUSE 
Ig kappa chain C 
region 
11.8/5.2 2 26.4 ND NA Out of 
range 
< 0.01 
25 P09528 
FRIH_MOUSE 
Ferritin heavy 
chain 
21.1/5.5 7 40.66 2.2 < 0.01 2.1 < 0.01 
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Table 5-3 (continued). 
 
Spot  Accession 
number 
Protein name Theor 
MW/pI 
Peptide 
number 
Coverage 
 (%) 
Fold  
change 
(Progenesis) 
P-value 
(Progenesis) 
Fold  
change 
(PDQuest) 
P-value 
(PDQuest) 
26 P21614 
VTDB_MOUSE 
Vitamin D-
binding protein 
precuosor 
53.6/5.4 21 55.5 1.3 > 0.05 4.1 < 0.01 
 Q9D554 
SF3A3_MOUSE 
Splicing factor 
3A subunit 3 
58.8/5.2 5 14.2     
27 P29391 
FRIL1_MOUSE 
Ferritin light 
chain 1 
20.8/5.6 8 55.2 2.2 < 0.01 Out of 
range 
< 0.01 
 Q61171 
PRDX2_MOUSE 
Peroxiredoxin-2 21.8/5.2 1 5.50     
28 P60842 
IF2A1_MOUSE 
Eukaryotic 
initiation factor 
4A-I 
46.2/5.3 24 48.5 1.1 > 0.05 Out of 
range 
< 0.01 
 P10630 
IF4A2_MOUSE 
Eukaryotic 
initiation factor 
4A-II 
46.4/5.3 2 8.3     
 Q5RFJ1 
ILF2_MOUSE 
Interleukin 
enhancer-
binding factor 2 
43.1/5.2 5 21.0     
29 Q3U0B3 
DHR11_MOUSE 
Dehydrogenase/
reductase SDP 
family member 
11 precursor 
28.3/5.9 2 11.5 1.4 > 0.05 1.8 < 0.01 
 Q9QUM9 
PSA6_MOUSE 
Proteasome 
subunit alpha 
type-6 
27.4/6.3 5 22.8     
30 Q04447 
KCRB_MOUSE 
Creatine kinase 
B-type 
42.7/5.4 11 35.7 1.7 > 0.05 2.6 < 0.01 
Protein name, accession number and theoretical pI and MW are from Swiss-Prot database (release 20090311) 
Out of range indicates spot was absent in replicate gels or was below the detection parameters set for the software package. ND means 
spots not been detected. 
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Figure 5-3 Classification of biological processes of identified proteins according to GO 
annotations. 
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Figure 5-4 Classification of molecular functions of identified proteins according to GO 
annotations. 
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Table 5-4 Protein categories by Gene Ontology.  
 
Molecular function Ratio Biological process Ratio 
Up-regulated proteins    
Protein binding 2/8 Cellular physiological process 14/24 
Ion binding 3/8 Metabolism 10/18 
Nucleic binding 3/6 Localization 6/13 
Hydrolase activity 2/5 Response to stress 4/8 
Oxidoreductase activity 5/5 death 2/4 
    
Down-regulated proteins    
Protein binding 6/8 Cellular physiological process 10/24 
Ion binding 5/8 Metabolism 8/18 
Nucleic binding 3/6 Localization 7/13 
Hydrolase activity 3/5 Response to stress 4/8 
Oxidoreductase activity 0/5 death 2/4 
 
 
5.3.5 Pathway Analysis of Proteins Modulated in Bicalutamide/embelin Treatment  
 
To reveal the potential molecular mechanism of bicalutamide/embelin 
combination treatment in prostate cancer, pathway analysis was carried out on the dataset 
of identified proteins through the use of Ingenuity Pathway Analysis software. The most 
significant interaction networks associated with identified proteins were determined by 
using published interactions between genes, proteins and other biological molecules. 
Three high ranking networks were identified: (a) Small molecule biochemistry, tissue 
morphology; (b) RNA post-transcriptional modification, gene expression, RNA 
trafficking; (c) Behavior, cancer and carbohydrate metabolism (Table 5-5). Canonical 
pathways associated with altered proteins included acute phase response signaling, and 
metabolism. Figure 5-5 is the highest scored cluster of small molecule biochemistry. The 
score for the depicted network was 32, which indicated the possibility of matching the 
indicated proteins by a random chance was 10-32.  
 
 
5.4 Discussion 
 
In the present work, a comparative proteomic study using 2-DE and mass 
spectrometry was performed and led to the identification of a set of differentially 
expressed proteins associated with bicalutamide/embelin treatment in mouse prostate 
tumors. This was the pilot study that examined the effects of bicalutamide/embelin 
combination treatment on prostate cancer. In this phase, we established a comparative 
proteomic methodology tailored to mouse tumor tissue, and obtained preliminary results 
on the effects of this new therapeutic strategy.  
 
There are many proteomic technologies currently available, but 2-DE remains the 
most accessible platform to separate thousands of proteins simultaneously from multiple 
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Table 5-5 Representative networks associated with identified proteins by IPA software. 
 
ID Molecules in network Score Focus 
molecules 
Top functions 
1  ALB, APOA1, CDCP1, CLEC7A, 
DHRS11, ENO1, FTH1, FTL, FTMT, 
GPX1, HMGB1 (includes EG:25459), 
Ho, HPX, IGKC, IL1, IL1F5, IL1F6, 
IL1F8, IL1F9, KRT9, KRT16, LSP1, 
MIRN198 (includes EG:406975), NFkB 
(complex), PCMT1, PELI1, PLG, 
PRDX1, PRDX2, PRDX4, SETX, 
SRXN1, Tcf 1/3/4, TRPC4AP, UMOD 
32 14 Small molecule 
biochemistry, tissue 
morphology, hair 
and skin 
development and 
function 
2  ACTR2, AHCY, AHCYL2, ANXA5, 
ARHGDIA, CCDC44, CD44, CDC42, 
COMMD9, EEF1G, EIF4A1, EIF4A2, 
EPB41, ERLIN1, FAM62A, FTSJ1, GC, 
GOLIM4, HAL, HNF4A, MRP63, 
MRPL49, MRTO4, NUDT11, PABPC1, 
PAIP1, PCBP2, PSMA1, PSMA6, 
RAB11B, SCYL3, SF3A3, SLC2A4, 
TRAF6, TUT1 
29 13 RNA post-
transcriptional 
modification, gene 
expression, RNA 
trafficking 
3  ALDH7A1, BCAS2, beta-estradiol, 
C1QTNF6, C21ORF126, CKB, DSCR3, 
ESR1, FAM105B, FGB, GHSR, 
GREB1, HCG 401283, HSF2BP, 
HSPA13, IL1B, KRT13, KRTAP10-6, 
LOC389842, LOC391282, LOC391322, 
MED7 (includes EG:66213), MMP2, 
NCRNA00162, ODF3B, PARK7, 
PNRC2 (includes EG:55629), PRDM2, 
SAPS2, SMS, SRM, UCRC, UMODL1, 
ZMAT5, ZNF398 
11 6 Cellular growth and 
proliferation, cell-
to-cell signaling and 
interaction, cancer 
Genes in 2-DE analysis are shown with bold. 
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Figure 5-5 Network of small molecule biochemistry associated with modulated proteins 
identified in bicalutamide/embelin treatment in mouse prostate tumor tissue. 
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samples for subsequent protein identification and quantitative comparison (Li et al., 2009; 
Rondepierre et al., 2009; Tilton et al., 2007; Wu et al., 2007). To ensure high confidence 
in the identification of differentially expressed protein spots, two independent image 
analysis software packages, PDQUEST and Progenesis Samespots, were applied to 
analyze all 2-DE gel images in the study. In total, 33 spots were identified as having 
statistically significant differential expression, between both software packages. However, 
only 17 of these were identified using both programs, which is most likely due to the 
variations in algorithms between the software packages, such as background subtraction 
or noise correction (Saldanha et al., 2008). The scenarios have been reported by a number 
of previous publications about the use of independent image analysis packages for the 
analysis of a gel data set (Byrne et al., 2009; Rosengren et al., 2003; Saldanha et al., 
2008). 
 
Analysis of the gel images using PDQuest demanded extensive manual inspection 
of all gels and subsequent alignment of overlapping gel spots to the master gel image. 
Parameters were needed to be set up for the examination of the match for the individual 
gel images to the master gel. Whereas, the Progenesis analysis was entirely automated 
with minimal manual intervention. Although labor intensive, manual 2-DE image 
analysis allowed greater accuracy in definition of spot boundaries, especially for low 
abundance or poorly resolved spots (Saldanha et al., 2008). Apart from confident 
identification of differentially expressed spots, the application of two independent 
software programs could increase the coverage of candidate protein spots which might be 
missed because of different detection cutoff criteria used in the software packages. 
  
In the present study, LC-MS/MS was used for protein spots identification.  
Protein identification was based on matching of peptide sequence data. Out of the 33 
differentially expressed protein spots, 30 spots were identified with adequate coverage. 
Among the identified protein spots, we found some of the spots contained more than one 
protein with very similar pI and MW values. Furthermore, some of the proteins were 
identified in multiple spots, which may be due to post-translational modifications. Both 
scenarios are frequently encountered in these types of analyses. Multiple proteins in the 
same spot would require an independent confirmation through application of biochemical 
technologies (such as western blotting) to unambiguously pinpoint the exact differentially 
expressed protein.   
 
 Thirty eight differentially expressed proteins induced by bicalutamide/embellin 
treatment were identified by using 2-DE followed with MS. Both GO analysis and IPA 
indicated that metabolism and stress response were the two major biological processes 
associated with differentially expressed proteins in bicalutamide/embellin treatment. 
Small molecular biochemistry was the pathway in which most of identified proteins were 
involved.  Some of the identified proteins have previously been reported to be modulated 
in bicalutamide-treated prostate cancer cell lines, supporting the findings of our study 
(Rowland et al., 2007). 
 
The largest group of identified proteins belonged to the functional class of 
metabolism. The identified proteins and enzymes, such as Apolipoprotein A-I precursor, 
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Vitamin D-binding protein precursor, Dehydrogenase/reductase SDP family member 11, 
Proteasome subunit alpha type-6 and Proteasome subunit alpha type-1, were involved in 
different metabolic pathways. Enolase is a glycolytic enzyme expressed on the surface of 
eukaryotic cells and also serves as a surface receptor for the binding of plasminogen. 
Alpha enolase (ENO1) has been implicated in numerous diseases including cancers 
(Kanemoto et al., 2006; Katayama et al., 2006) and was highly expressed in tumor cells 
(Altenberg et al., 2006; Altenberg and Greulich, 2004).  The role of ENO1 in tumor cell 
invasion and metastasis may be explained by initiating the activity of plasminogen 
activity on the cell surface, which implicates various physiological and pathological 
events such as wound healing, tissue modeling, embryogenesis and the cell spreading 
(Plow et al., 1995). Up-regulation of alpha-enolase may contribute to an increased 
metabolic capacity, but not to increased plasminogen activation in our study. 
 
Apart from metabolism, another major group of proteins modulated by the 
combination treatment were proteins involved in stress response. Proteins in this group 
are mainly associated with oxidative stress. All proteins identified in this group were up-
regulated in treated tissue, including peroxiredoxin 1 (PRDX1), peroxiredoxin 2 
(PRDX2), glutathione peroxidase 1 (GPX1), protein DJ-1 (PARK7), and 
Dehydrogenase/reductase SDR family member 11 (DHR11). 
 
Reactive oxygen species (ROS) are oxygen-containing free radicals, including 
superoxide radical (O2.-), hydroxyl radical (.OH), hydrogen peroxide (H2O2) and reactive 
nitrogen species nitric oxide (NO) and peroxynitrite radical (ONOO.).  These species can 
be generated either through endogenous sources (such as the mitochondrial respiratory 
chain, the cytochrome P450 metabolic pathway, the inflammatory response etc.), or from 
external sources (such as chlorinated compounds, metal ions and radiation) (Apel and 
Hirt, 2004). ROS, at normal physiological concentrations, play important roles in a 
variety of cellular processes (Muller et al., 2007; Stadtman, 1992).  
 
 Oxidative stress occurs through disturbance in the balance between ROS 
formation and the efficiency of antioxidant processes, which means the net amount of 
ROS exceeds the antioxidant capacity. Oxidative stress has been linked to a wide range 
of diseases including Parkinson's disease (Fang et al., 2007), Asthma (Larsen et al., 2006) 
and cancer (Visconti and Grieco, 2009). A high level of ROS in cancer cells may lead to 
a variety of biological responses, such as increased proliferation rate, induction of DNA 
mutations and genetic instability, and resistance to some drugs in anticancer therapy. To 
date, it is unclear if oxidative stress is the trigger of the disease, or if it is a consequence 
of the disease and causes the disease symptoms. Recently, Cohen et al.(Cohen et al., 2008) 
studied the dynamics and variability of the protein response of human cancer cells to a 
chemotherapy drug, camptothecin. All cells showed rapid translocation of proteins 
specific to the drug target, and slower nuclear localization changes including the 
oxidative stress response pathway. This indicated that the anticancer drug treatment led to 
the modulation of oxidative stress. 
 
It has been reported that patients with prostate cancer or other pathological 
processes, such as chronic prostatitis or atrophic prostatitis, presented a decreased 
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antioxidant power and an increase of lipidic peroxidation (Lopez Laur et al., 2008). GPX 
is one of primary antioxidant enzymes; it reduces peroxides to their corresponding 
hydroxylated compounds using glutathione as a hydrogen donor. A recent study showed 
that the levels of antioxidant enzymes such Superoxide dismutase (SOD) and GPX in 
prostate cancer subjects were lower than in subjects with benign prostate hyperplasia and 
control subjects (Aydin et al., 2006). Overexpression of GPX3 in prostate cancer cell 
lines induced the suppression of colony formation and anchorage-independent growth of 
PC3, LNCaP, and Du145 cells (Yu et al., 2007b).  Peroxiredoxins (PRDXs) are 
antioxidant enzymes expressed by most free-living organisms, often in multiple isoforms. 
Prostate cancer cells were shown to be more sensitive to hydrogen peroxide or an organic 
hydroperoxide when PRDX1, 2, or 3  was partially suppressed (Shen and Nathan, 2002). 
In the present study, overexpression of GPX, PRDX1 and PRDX2 indicated that 
administering bicalutamide/embelin perhaps shifts the redox balance within the tumor 
milieu, ultimately resulting in tumor suppression. 
 
Protein DJ-1, also known as PARK7, is a multifunctional protein related to male 
fertility, identified as a hydroperoxide-responsive protein, and responsible for Parkinson's 
disease. Overexpression of DJ-1 has been associated with multiple cancers, including 
prostate cancer. It is known that  DJ-1 is up-regulated by both androgen and antiandrogen 
treatment and that this increase is due to DJ-1 and androgen receptor protein stability 
(Pitkanen-Arsiola et al., 2006). It has also been shown that modulation of DJ-1 
expression regulated AR transcriptional activity and may be involved in the development 
of androgen independence (Tillman et al., 2007). In our study, bicalutamide, as an 
antiandrogen in the combination treatment, resulted in overexpression of DJ-1 in mouse 
prostate tumors.  
 
Another subgroup of differentially expressed proteins is comprised by proteins 
that are related to cancer cell metastasis. Annexin A5 is a calcium-dependent 
phospholipid binding protein, which is commonly used as a probe in Annexin A5 affinity 
assay to detect cell death. It was reported that down-regulated Annexin A5 reduced 
migration and invasion capacity of HaCaT cells which was even stronger in the oral 
carcinoma (Wehder et al., 2009). High mobility group protein B1 (HMGB1) is known to 
increase expression in carcinomas and exhibit association with proliferation and 
metastasis in many tumor types (Suzuki et al., 2009). Breast cancer amplified sequence 2 
(BCAS2) was initially identified as a gene that was overexpressed and amplified in some 
breast cancer cell lines (Qi et al., 2005). In our study, expression levels of these proteins 
were down-regulated by bicalutamide/embelin combination treatment, indicating the 
decrease of cancer cell metastasis potential.  
 
Several proteins involved in protein biosynthesis and modification were 
modulated by the combination treatment. Translation initiation factors (IF2A1, IF4A2) 
and elongation factor (EF1G) were up-regulated. Furthermore, 40S ribosomal protein 
(RS3), protein-L-isoaspartate(D-aspartate) O-methyltransferase (PIMT) and spermidine 
synthase (SPEE) were down-regulated.  
 
In conclusion, bicalutamide/embelin treatment modulated molecular functions of 
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metabolism and biosynthesis, and in particular increased the expression levels of 
antioxidants to reduce oxidative stress. 
 
 
5.5 Conclusions 
 
The present study was the first comparative proteomics examination of the effects 
of bicalutamide/embelin combination treatment on prostate tumors. Protein alterations of 
mouse prostate tumors induced by bicalutamide/embelin treatment have been studied 
using 2-DE and mass spectrometry. This analytical strategy involved total protein 
separation with 2-DE and protein identification by using nanoLC-MS/MS. Differentially 
expressed proteins were further investigated by bioinformatics tools (GO and IPA) to 
reveal the associations with important biological functions and processes. The major 
functions were related to cancer, inflammatory disease, connective tissue disorders, and 
skeletal and muscular disorders. The molecular functions of differentially expressed 
protein were associated with metabolism and stress response.  
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CHAPTER 6. SUMMARY  
 
 
Advances in technology and understanding of systems biology have provided 
tremendous strides towards improvement in modern human medicine. Recently, 
extensive efforts have been involved in the application of various proteomics 
technologies to the study of prostate cancer to obtain new mechanistic knowledge and to 
discover novel biomarkers. The desired outcomes of the efforts are markers that will aid 
in early detection and prognosis of prostate cancer, in monitoring of therapeutic response, 
and determining best course of therapy for cancer patients to improve clinical outcomes. 
Despite all these considerable efforts, it remains a challenge to perform a comprehensive 
proteome analysis.  
 
In the current dissertation, I focused on the development and application of 
multiple mass spectrometry-based bioanalytical platforms for phosphoproteomic 
characterization in cell culture and clinical specimens of prostate cancer; and on 
application of optimized methods to analysis of differential protein expression to reveal 
molecular mechanism of drug action in mouse model of prostate cancer.  
 
 
6.1 Discussion of Selected Analytical Aspects 
 
In combination with IEF separation and phosphopeptide enrichment, in-gel IEF 
LC-MS/MS strategy yielded a significantly expanded phosphoprotein panel. This panel 
of the LNCaP phosphoproteins was 3.6-fold larger than the panel obtained in our 
previous work, which attests to the power of the chosen analytical methodology. The 
expanded phosphoproteome map obtained in this study will serve as a foundation for 
future quantitative studies of the effects of pharmaceuticals on the LNCaP prostate cancer 
cells; for this purpose, in-gel IEF LC-MS/MS will be combined with stable-isotope 
labeling such as stable isotope labeling with amino acids in cell culture (SILAC) (Mann, 
2006). Furthermore, additional improvements of the in-gel IEF LC-MS/MS methodology 
will further enhance the coverage of the LNCaP phosphoproteome. 
 
2-DE was one of the main separation methods applied in our studies. We applied 
2-DE based platforms to investigation of phosphoproteins in the LNCaP prostate cancer 
cells, and to obtain protein profiling in mouse prostate tumor tissue treated by anticancer 
drugs. As an improvement, 2D-DIGE can be integrated into the platform for future 
continuation of this line of research. 2D-DIGE incorporates labeling of different protein 
populations with fluorescent molecules (CyDyes) prior to separation by 2-DE. Up to 
three different protein samples can be covalently labeled with fluorescent dyes and be 
separated by 2-DE in a single gel. The technique significantly reduces the inter-gel 
variability encountered with traditional 2-DE platforms (Alban et al., 2003; Minden et al., 
2009). 
 
Phosphorylation site assignment is one of challenges for site-specific 
identification in phosphoproteomics. In our mass spectrometry analyses, CID is the ion 
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activation/dissociation method for fragmentation of the peptide backbone and production 
of ions for sequence analysis and identification of phosphorylation sites. However, CID 
process often leads to elimination of the molecule of phosphoric acid from peptide ions 
containing phosphorylated serine and threonine residues; this predominant dissociation 
pathway results in lack of sequence information in MS/MS spectra. Assignment of 
phosphorylation sites, especially for peptides containing multiple phosphorylation sites, 
becomes a challenge. Recently, alternative dissociation methods, such as ETD(Chi et al., 
2007; Molina et al., 2007), have been introduced as promising alternatives that provide 
more comprehensive backbone fragment ion series without loss of water, phosphate 
groups or phosphoric acid.  
 
In our previous studies, protein function and subcellular location were manually 
classified based on Swiss-Prot annotations. In large-scale proteome studies, manual 
annotation strategy is subjective and also labor-intensive. Gene ontology (GO) is a 
collection of controlled vocabularies describing the biology of a gene product in any 
organism andit is commonly used to analyze results from high-throughput studies (Khatri 
and Draghici, 2005; Rhee et al., 2008). GO provides researchers with a broad overview of 
predominant activities of a specific group of proteins and assists in understanding of  
large-scale complex biological changes (Dimmer et al., 2008). GO analysis is broadly 
used in the proteomics community. To interpret our results systematically and to share 
our results with the research community, GO analysis was adopted in our studies to 
classify identified proteins according to molecular function, biological process, and 
molecular component (subcellular location).  
 
Another bioinformatics resource newly applied in our research is the Ingenuity 
Pathway Analysis. IPA is a powerful curated database and analysis system, which can 
build hypothetical networks of physical and functional relationships between genes, 
proteins, and chemicals based on Ingenuity knowledge base. It can help to understand 
how proteins work together to effect cellular changes (Hoorn et al., 2005; Raponi et al., 
2004). Ingenuity helped us to identify the biological mechanisms, pathways and functions 
most relevant to our experimental datasets of interest.  
 
 
6.2 Summary 
 
 
6.2.1 Characterization of the Phosphoproteome in Prostate Cancer 
 
Our research aimed towards description of the phosphoproteome in prostate 
cancer focused on the LNCaP human prostate cancer cell line, and on human prostate 
cancer tissue.  
 
For the LNCaP prostate cancer cell line, we applied a combination of analytical 
platforms: (1) a novel in-gel IEF LC-MS/MS analytical platform; (2) a 2-DE based 
platform combined with phospho-specific staining.  
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The in-gel IEF LC-MS/MS analytical methodology used in the study included 
separation of the LNCaP proteins by in-gel isoelectric focusing; digestion of the proteins 
with trypsin; enrichment of the digests for phosphopeptides with IMAC; analysis of the 
enriched digests by LC-MS/MS; and identification of the phosphorylated 
peptides/proteins through searches of the Swiss-Prot protein sequence database. With in-
gel IEF based analytical platform, we have characterized over 600 different 
phosphorylation sites in 296 phosphoproteins in the LNCaP prostate cancer cell line. This 
panel of the LNCaP phosphoproteins was 3-fold larger than the panel obtained in our 
previous work (Giorgianni et al., 2007), and is the largest phosphoprotein panel in 
prostate cancer reported to date. The phosphoproteins identified in this study belonged to 
various locations within the cell and were involved in various processes including cell 
differentiation, transcription regulation, and intercellular signal transduction. The 
expanded phosphoproteome map obtained in this study was of a satisfactory size to serve 
as a foundation for future quantitative studies of the effects of pharmaceuticals on the 
LNCaP prostate cancer cells. 
 
We also developed a 2-DE based platform, in combination with multiplexed 
staining and LC-MS/MS, for the identification of LNCaP phosphoproteins. In this study, 
we applied 2-DE as separation technique, Pro-QTM Diamond stain as phosphoprotein 
detection method, LC-MS/MS and database searches for protein identification to 
investigate the phosphoproteins in the LNCaP prostate cancer cell line. Proteins identified 
from spots of interest were shown to be highly relevant to prostate cancer. We 
demonstrated the feasibility of using 2-DE with phospho-specific stain and mass 
spectrometry to investigate the phosphoproteins in the LNCaP cell line. This 
methodology complements the in-gel IEF LC-MS/MS platform that we used for 
phosphoproteomics study; it will be of particular value for future comparative studies of 
phosphoproteins in various physiological states.  
 
For prostate cancer tissue, a gel-free approach was applied to analyze five prostate 
cancer tissue specimens to obtain phosphoproteomic signatures of prostate cancer for 
biomarker discovery. Proteins were extracted with Trizol reagent, and then in-solution 
digested with trypsin. Phosphopeptides were enriched with IMAC, and the enriched 
digests were analzyed by LC-MS/MS with identification through searches of the Swiss-
Prot protein sequence database. The panels obtained for prostate cancer tissue contain 15-
24 phosphoproteins. Some of the characterized phosphoproteins were present in all five 
specimens; in addition, each specimen also produced a unique set of phosphoproteins. 
The findings provided a direct glimpse into the phosphoprotein machinery operating 
within the human prostate cancer tissue. This pilot study focused on a small set of 
specimens. The phosphoprotein panels that were obtained contained a number of proteins 
that were unique to a particular specimen. Analyses of a larger group of specimens will 
provide further knowledge on the phosphoprotein signatures to build the foundation for 
differential phosphoprotein profiling of cancer vs. control tissue for biomarker discovery.  
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6.2.2 Comparative Proteomics Study of Drug Effects in Prostate Cancer 
 
We carried out the first comparative proteomics study of the effects of 
bicalutamide/embelin combination treatment on prostate tumors by characterizing the 
alterations in protein expression that were induced upon treatment of mice bearing 
prostate tumors with anticancer combination therapy. 
 
A comparative proteomic strategy based on 2-DE coupled with LC-MS/MS was 
applied to analysis of mouse prostate tumor tissue. Proteins from the mouse prostate 
tumors were extracted with Trizol, and the protein mixtures were separated by 2-DE. 
Differences in the protein profiles for the different treatment groups were evaluated by 
computer-assisted analysis of SYPRO Ruby stained 2-DE gels. LC-MS/MS and database 
searches were used to identify differentially expressed proteins. Pathway analysis was 
carried out on the dataset of identified proteins with the Ingenuity bioinformatics tool. 
Out of the 33 differentially expressed protein spots, 30 protein spots were identified and 
grouped into various functional classes. The major protein categories were metabolism 
(52%), stress response (12%), protein biosynthesis (13%) and apoptosis (11%), 
suggesting that alterations in these processes may be involved in the mechanism of drug 
action. Proteins associated with oxidative stress were up-regulated, which indicated that 
treatment with bicalutamide/embelin may affect the redox balance within the prostate 
tumor, and this effect may contribute to tumor suppression. 
 
Future plans for continuation of this study include incorporation of DIGE into the 
analytical methodology, examination of a larger group so that biological variability can 
be taken into account, evaluation of the proteomes at different points during the treatment 
course, etc. Ultimately, this research will bring new insights into the molecular 
mechanism of anticancer combination therapy. 
 
In conclusion, in the research presented in this dissertation, multiple MS-based 
bioanalytical platforms were applied successfully to study the phosphoproteome and 
proteome in prostate cancer. The disease-related proteomic information obtained in my 
research will contribute to our understanding of the pathogenesis, and it will bring 
improvements in the diagnosis and treatment of prostate cancer.  
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APPENDIX 
 
 
Table A-1 Full list of phosphopeptides and phosphoproteins characterized in LNCaP cells. 
 
Accession 
number 
Peptide MH+ z XC Site # in Swiss/Phosphosite 
(06/17/08) 
Present in Phosphosite 
(06/17/08) 
P07900 HS90A_HUMAN Heat shock protein HSP 90-alpha (HSP 86)   20.21    
  K.ESEDKPEIEDVGS*DEEEEK.K 2272.88640 2 4.15 263 Swiss/ 263 phos Yes 
  K.ESEDKPEIEDVGS*DEEEEKK.D 2400.98137 3 3.93 see line 4  
  R.DKEVS*DDEAEEK.E 1473.56282 2 4.89 231 Swiss/ 231 phos Yes 
Q15019 SEPT2_HUMAN Septin-2 (Protein NEDD5)   10.27    
  K.IYHLPDAES*DEDEDFKEQTR.L 2517.04530 3 4.28 see line 10  
  R.YLHDES*GLNR.R 1283.54158 2 2.41 134 NEW No 
  K.IYHLPDAES*DEDEDFK.E 2002.79534 2 3.37 218 Swiss/ 218 phos Yes 
Q15185 TEBP_HUMAN Prostaglandin E synthase 3 (Cytosolic prostaglandin E2 synthase) 10.35   
  K.DWEDDS*DEDMSNFDR.F 1955.62729 2 5.85 113 Swiss/ 113 phos Yes 
  K.DWEDDS*DEDM#SNFDR.F 1971.62219 2 2.92 see line 12  
O60716 CTND1_HUMAN Catenin delta-1 (p120 catenin)    70.35    
  R.LRSY*EDMIGEEVPSDQYYWAPLAQHER.G 3362.48235 3 6.95 321 Swiss/ 321 phos Yes 
  R.HYEDGYPGGSDNYGS*LSR.V 2053.79232 2 4.83 230 Swiss/ 230 phos Yes 
  R.SQSSHSYDDST*LPLIDR.N 2000.85968 3 4.73 869 Swiss No 
  R.S*YEDMIGEEVPSDQYYWAPLAQHER.G 3093.29718 3 3.65 320 Swiss/ 320 phos Yes 
  R.VGGS*SVDLHR.F 1106.49898 2 3.19 268 Swiss/ 268 phos Yes 
  R.S*GDLGDMEPLK.G 1241.51192 2 3.14 920 NEW No 
  R.TLDRS*GDLGDMEPLK.G 1726.77171 2 2.77 920 NEW No 
  R.S*MGYDDLDYGMMSDYGTAR.R 2227.80177 2 5.45 288 Swiss/ 288 phos Yes 
  R.T*LDRSGDLGDMEPLK.G 1726.77171 2 2.65 916 Swiss/ 916 phos Yes 
  R.HYEDGYPGGS*DNY*GSLSRVT*RIEER.Y 3097.21249 3 3.04 228 Swiss/ 228 phos Yes 
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Table A-1 (continued). 
 
Accession 
number 
Peptide MH+ z XC Site # in Swiss/Phosphosite 
(06/17/08) 
Present in Phosphosite 
(06/17/08) 
  R.S*MGYDDLDYGMMSDYGTAR.R 2227.80177 2 3.41 see line 22  
  R.VGGS*SVDLHR.F 1106.49898 2 2.44 see line 19  
  K.WAHDKFS*GEEGEIEDDES*GTENR.E 2797.02977 3 6.50 939 Swiss/ 939 phos Yes 
  K.WAHDKFS*GEEGEIEDDESGTENR.E 2717.06347 3 5.99 928 Swiss/ 928 phos Yes 
  K.WAHDKFS*GEEGEIEDDESGT*ENREEK.D 3183.20992 3 3.70 941 Swiss/ 941 phos Yes 
  R.ERS*PALKS*PLQSVVVR.R 1925.96089 3 3.42 248 Swiss/248 phos & 253 
Swiss/ 253 phos 
Yes 
  R.IDIS*PSTFR.K 1115.51324 2 3.28 682 Swiss/ 682 phos Yes 
  R.ASAVSELS*PR.E 1096.50340 2 3.01 243 Swiss/ 243 phos Yes 
  K.S*PPSTGSTYGSSQK.E 1463.60496 2 2.82 320 Swiss/ 320 phos Yes 
  R.DSS*HS*RERS*AEK.T 1628.55019 2 2.35 747 NEW & 749 NEW & 753 
NEW 
No 
  R.RIDIS*PSTFR.K 1271.61435 2 2.15 see line 32  
  K.SPPSTGST*Y*GSS*QK.E 1623.53756 2 2.09 324 Swiss/ 324 phos & 325 
NEW & 328 NEW 
Yes & No & No 
P08651 NFIC_HUMAN Nuclear factor 1 C-type (Nuclear factor 1/C)   20.25    
  R.NWTEDMEGGISS*PVK.K 1729.71386 2 4.96 323 Swiss/ 323 phos Yes 
  R.NWTEDMEGGISS*PVKK.T 1857.80883 2 4.41 see line 39  
Q13283 G3BP1_HUMAN Ras GTPase-activating protein-binding protein 1 (G3BP-1)  20.26    
  K.SSS*PAPADIAQTVQEDLR.T 1964.89606 2 4.55 232 Swiss/ 232 phos Yes 
  R.YQDEVFGGFVTEPQEES*EEEVEEPEER.Q 3296.33143 3 3.25 149 Swiss/ 149 phos Yes 
Q9Y608 LRRF2_HUMAN Leucine-rich repeat flightless-interacting protein 2   20.25    
  R.RGS*GDTSSLIDPDTSLSELR.D 2185.99723 2 4.94 328 Swiss/ 328 phos Yes 
  R.IS*S*ARSS*PGFTNDDTASIVSSDRASR.G 2924.18594 3 3.04 231 NEW & 232 NEW & 236 
NEW 
No 
  R.PSSRNS*ASATT*PLSGNSS*R.R 2116.80966 2 2.34 312 NEW & 317 NEW & 324 
NEW 
Yes 
Q5VTR2 BRE1A_HUMAN Ubiquitin-protein ligase BRE1A (BRE1-A)    20.18    
  K.ALVVPEPEPDSDS*NQER.K 1961.84878 2 3.70 138 Swiss/ 138 phos Yes 
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Table A-1 (continued). 
 
Accession 
number 
Peptide MH+ z XC Site # in Swiss/Phosphosite 
(06/17/08) 
Present in Phosphosite 
(06/17/08) 
  K.PDSEDLSSQSS*AS*KASQEDANEIK.S 
 
2683.06549 3 3.42 548 NEW & 550 NEW No 
Q8N6T3 ARFG1_HUMAN ADP-ribosylation factor GTPase-activating protein 1   20.21    
  R.RSS*DSWEVWGSASTNR.N 1904.79226 2 3.98 see line 54  
  R.EFLESQEDY*DPCWS*LQEK.Y 2405.89201 2 2.15 93 New & 98 New No 
  R.SS*DSWEVWGSASTNR.N 1748.69115 2 4.03 361 Swiss/ New in phos No 
  K.ASELGHS*LNENVLKPAQEK.V 2144.03831 3 3.39 246 Swiss/ 246 phos Yes 
Q9Y6G9 DC1L1_HUMAN Cytoplasmic dynein 1 light intermediate chain 1   30.31    
  R.DFQEYVEPGEDFPAS*PQR.R 2190.90154 2 5.94 207 Swiss/ 207 phos Yes 
  K.KTGSPGGPGVSGGS*PAGGAGGGSS*GLPPSTKK.S 2811.27095 3 3.77 468 NEW & 478 NEW No 
  K.PVT*VS*PTTPTSPTEGEAS* 1997.74287 2 2.22 508 NEW & 510 Swiss/510 
phos & 523 NEW 
No & Yes & No 
Q9Y2U5 M3K2_HUMAN Mitogen-activated protein kinase kinase kinase 2   40.21    
  R.DRSS*PPPGYIPDELHQVAR.N 2214.03389 3 4.27 164 Swiss/ 164 phos Yes 
  R.AQS*YPDNHQEFSDYDNPIFEK.F 2624.06129 3 3.87 239 NEW No 
  K.RLS*IIGPTSR.D 1179.62452 2 2.62 153 NEW No 
  R.GS*DIDNPT*LTVM#DISPPSR.S 2190.90250 2 2.38 331 Swiss/ 331 phos & 337 
NEW 
Yes & No 
O00193 SMAP_HUMAN Small acidic protein   10.34    
  R.S*ASPDDDLGSSNWEAADLGNEER.K 2514.98925 2 6.76 15 Swiss/ 15 phos Yes 
O95218 ZRAB2_HUMAN Zinc finger Ran-binding domain-containing protein 2   20.20    
  R.ENVEYIEREES*DGEYDEFGR.K 2545.00383 3 3.45 see line 69  
  R.EES*DGEYDEFGR.K 1512.51621 2 3.21 120 Swiss/ 120 phos Yes 
  K.YNLDAS*EEEDSNK.K 1593.59519 2 5.17 188 Swiss/ 188 phos Yes 
  K.EVEDKES*EGEEEDEDEDLSK.Y 2419.90318 3 3.62 153 Swiss/ 153 phos Yes 
  R.S*SSRS*S*SPSSSRSR.S 1694.59312 2 2.06 213 NEW & 217 NEW & 
218 NEW 
No 
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Table A-1 (continued). 
 
Accession 
number 
Peptide MH+ z XC Site # in Swiss/Phosphosite 
(06/17/08) 
Present in Phosphosite 
(06/17/08) 
Q8N5F7 NKAP_HUMAN NF-kappa-B-activating protein   10.23    
  R.IGELGAPEVWGLS*PK.N 1632.80327 2 4.59 149 Swiss/ 149 phos Yes 
  K.Y*S*EDS*DSDSDSETDSSDEDNK.R 2566.70622 3 3.41 209 NEW & 210 NEW & 
213 NEW 
No 
Q9NSK0 KLC4_HUMAN Kinesin light chain 4 (KLC 4) (Kinesin-like protein 8)  10.25    
  R.AAS*LNYLNQPSAAPLQVSR.G 2080.02226 2 5.05 590 Swiss/ 590 phos Yes 
Q9H1E3 NUCKS_HUMAN Nuclear ubiquitous casein and cyclin-dependent kinases substrate 10.28    
  K.VVDYSQFQES*DDADEDYGR.D 2317.87684 2 5.65 19 Swiss/ 19 phos Yes 
Q92625 ANKS1_HUMAN Ankyrin repeat and SAM domain-containing protein 1A (Odin) 10.21   
  K.SPS*FASEWDEIEK.I 1604.65158 2 4.30 663 Swiss/ 662 phos Yes (same AA, diff #) 
O00192 ARVC_HUMAN Armadillo repeat protein deleted in velo-cardio-facial syndrome 20.28    
  R.S*LAADDEGGPELEPDYGTATR.R 2243.93396 2 5.66 267 Swiss/ 267 phos Yes 
  R.NFDT*LDLPK.R 1142.51290 2 2.61 642 Swiss/ 642 phos Yes 
O15027 K0310_HUMAN Uncharacterized protein KIAA0310   10.23    
  R.FTGS*FDDDPDPHRDPYGEEVDR.R 2646.04162 3 4.15 1149 Swiss/ New in phos No 
Q14247 SRC8_HUMAN Src substrate cortactin (Amplaxin) (Oncogene EMS1)  30.24    
  R.LPSS*PVYEDAASFK.A 1590.70870 2 4.83 418 Swiss/ 418 phos Yes 
  K.TQT*PPVS*PAPQPTEER.L 1894.79830 2 4.19 401 Swiss/ 401 phos & 405 
Swiss/ 405 phos 
Yes & Yes 
  R.VDKSAVGFDY*QGKT*EK.H 1931.81871 2 2.19 178 NEW in Swiss/ 178 
phos & 182 NEW 
Yes & No 
  K.GRY*GLFPANY*VELR.Q 1814.80260 3 3.27 538 NEW & 545 NEW No 
  K.LS*KHCS*QVDSVRGFGGK.F 1964.84488 2 2.12 109 NEW & 113 Swiss/ 113 
phos 
No & Yes 
  R.LPSS*PVY*EDAASFK.A 1670.67500 2 2.47 418 Swiss/ 418 phos & 412 
Swiss/ 412 phos 
Yes & Yes 
Q14498 RBM39_HUMAN RNA-binding protein 39 (RNA-binding motif protein 39)   20.26    
  K.DKS*PVREPIDNLTPEER.D 2074.98046 3 5.11 136 Swiss/ 136 phos  
  R.YRS*PYSGPK.F 1134.49792 2 2.90 97 Swiss/ 97 phos  
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Table A-1 (continued). 
 
Accession 
number 
Peptide MH+ z XC Site # in Swiss/Phosphosite 
(06/17/08) 
Present in Phosphosite 
(06/17/08) 
Q6ICG6 CV009_HUMAN Uncharacterized protein C22orf9   10.20    
  K.SHS*ANDSEEFFR.E 1505.56925 2 3.98 324 NEW  No 
Q9NYF8 BCLF1_HUMAN Bcl-2-associated transcription factor 1 (Btf)  80.23    
  K.FNDS*EGDDTEETEDYR.Q 2001.68692 2 4.61 397 Swiss/ 397 phos Yes 
  R.AEGEWEDQEALDYFS*DKESGK.Q 2513.00277 3 4.42 385 Swiss/ 385 phos Yes 
  K.KAEGEPQEES*PLK.S 1521.68321 2 4.20 177 Swiss/ 177 phos Yes 
  K.DLFDYS*PPLHK.N 1411.62933 2 3.84 512 Swiss/ 512 phos Yes 
  K.LKDLFDYS*PPLHK.N 1652.80836 3 3.04 see line 103  
  R.IDIS*PSTLR.K 1081.52889 2 2.83 658 Swiss/ 658 phos Yes 
  R.YSPS*QNS*PIHHIPSR.R 1879.78874 2 2.81 287 Swiss/ 287 phos & 290 
Swiss/ 290 phos 
Yes & Yes 
  R.AEGEWEDQEALDYFS*DK.E 2111.81172 2 2.64 385 Swiss/ 385 phos Yes 
  R.RIDIS*PSTLR.K 1237.63000 2 2.02 see line 105  
  R.SSSSS*AS*PSSPSS*REEK.E 1936.66093 2 2.10 755 NEW & 757 NEW & 
763 NEW 
No & No & No 
  R.S*SSSRSSSPYSKSPVS*K.R 1917.79903 2 2.01 141 NEW & 156 NEW No & No  
  R.YSPS*QNS*PIHHIPSR.R 1879.78874 2 2.34 see line 106  
P42167 LAP2B_HUMAN Lamina-associated polypeptide 2, isoforms beta/gamma  20.23    
  K.GPPDFS*SDEEREPTPVLGSGAAAAGR.S 2650.17805 3 4.54 66 Swiss/ 66 phos Yes 
  R.SST*PLPTISSSAENTR.Q 1727.78472 2 2.99 160 Swiss/ 160 NEW in 
phos 
No 
  K.GPPDFSSDEEREPT*PVLGSGAAAAGR.S 2650.17805 3 4.12 174 Swiss/ 173 phos Yes (same AA, diff #) 
  R.EQGTES*RSST*PLPTISSSAENTR.Q 2595.09706 3 3.03 156 Swiss/ 155 phos & 160 
Swiss/ 159 phos 
Yes (same AA, diff #) 
P54578 UBP14_HUMAN Ubiquitin carboxyl-terminal hydrolase 14    10.30    
  R.AS*GEMASAQYITAALR.D 1719.77713 2 5.99 143 Swiss/ 142 phos Yes (same AA, diff #) 
  R.AS*GEM#ASAQYITAALR.D 1735.77203 2 2.67 see line 118  
  K.S*S*KISRLPAYLTIQMVR.F 2123.04833 2 2.06 314 NEW & 315 NEW No & No 
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Table A-1 (continued). 
 
Accession 
number 
Peptide MH+ z XC Site # in Swiss/Phosphosite 
(06/17/08) 
Present in Phosphosite 
(06/17/08) 
Q8NDX5 PHC3_HUMAN Polyhomeotic-like protein 3 (hPH3) (Homolog of polyhomeotic 3)  10.33    
  R.MDRT*PPPPTLS*PAAITVGR.G 2136.99121 3 5.84 609 Swiss/ 609 phos & 616 
Swiss/ 616 phos 
Yes & Yes 
Q8IYB3 SRRM1_HUMAN Serine/arginine repetitive matrix protein 1    50.35    
  K.KETES*EAEDNLDDLEK.H 1944.79574 2 6.65 874 Swiss/ 874 phos Yes 
  K.KPPAPPS*PVQSQS*PSTNWSPAVPVK.K 2743.28916 3 5.37 769 Swiss/ 769 phos & 775 
Swiss/ 775 phos 
Yes & Yes 
  K.KPPAPPS*PVQSQS*PSTNWS*PAVPVK.K 2823.25546 3 4.63 see line 125 also 781 Swiss/ 
781 phos 
Yes 
  K.EKT*PELPEPSVK.V 1433.69232 2 2.41 220 Swiss/ 220 phos Yes 
  K.SRVS*VS*PGR.T 1104.45980 2 2.06 429 Swiss/ 429 phos & 431 
Swiss/ 431 phos 
Yes & Yes 
  R.RYS*PPIQR.R 1096.52989 2 2.20 597 Swiss/ 597 phos Yes 
  R.RLS*PSAS*PPR.R 1227.52822 2 2.09 389 Swiss/ 389 phos & 393 
Swiss/ 393 phos 
Yes & Yes 
  R.HRPS*PPAT*PPPK.T 1441.63883 2 2.56 402 Swiss/ 402 phos & 406 
Swiss/ 406 phos 
Yes & Yes 
P10644 KAP0_HUMAN cAMP-dependent protein kinase type I-alpha regulatory subunit  10.20    
  R.EDEIS*PPPPNPVVK.G 1597.75090 2 3.90 83 Swiss/ 83 phos Yes 
  R.TDSREDEIS*PPPPNPVVK.G 2056.95866 2 2.86 see line 133  
P06748 NPM_HUMAN Nucleophosmin (NPM) (Nucleolar phosphoprotein B23)   20.30    
  K.DELHIVEAEAMNYEGS*PIK.V 2224.98316 2 5.47 70 Swiss/ 70 phos Yes 
  K.DELHIVEAEAMNYEGS*PIKVTLATLK.M 2951.44714 3 3.33 see line 136  
P31943 HNRH1_HUMAN Heterogeneous nuclear ribonucleoprotein H (hnRNP H)  10.30    
  R.PSGEAFVELES*EDEVK.L 1844.78372 2 3.17 63 Swiss/ New in phos No 
P16949 STMN1_HUMAN Stathmin (Phosphoprotein p19) (pp19)    10.15   
  K.ESVPEFPLS*PPK.K 1406.66029 2 2.42 38 Swiss/ 37 in phos Yes (same AA, diff #) 
  R.ASGQAFELILS*PR.S 1468.71954 2 4.00 25 Swiss/ 24 in phos Yes (same AA, diff #) 
Q14694 UBP10_HUMAN Ubiquitin carboxyl-terminal hydrolase 10    10.27    
  K.NHSVNEEEQEEQGEGS*EDEWEQVGPR.N 3107.21338 3 5.31 576 Swiss/ 576 phos Yes 
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Table A-1 (continued). 
 
Accession 
number 
Peptide MH+ z XC Site # in Swiss/Phosphosite 
(06/17/08) 
Present in Phosphosite 
(06/17/08) 
Q9UK76 HN1_HUMAN Hematological and neurological expressed 1 protein   10.29    
  R.RNS*SEASSGDFLDLK.G 1705.74285 2 5.40 87 Swiss/ 87 phos Yes 
  R.NS*SEASSGDFLDLK.G 1549.64174 2 5.22 see line 146  
Q13263 TIF1B_HUMAN Transcription intermediary factor 1-beta (TIF1-beta)   20.24    
  R.STAPSAAASASASAAASS*PAGGGAEALELLEHCGVCR.E 3408.51954 3 4.90 50 Swiss/ New in phos No 
  R.SRS*GEGEVSGLMR.K 1444.62499 2 2.88 473 Swiss/ 473 phos Yes 
  R.S*GEGEVSGLMR.K 1201.49185 2 4.01 see line 150  
Q53SF7 CBLL1_HUMAN Cordon-bleu protein-like 1   10.24    
  R.AGS*LQLSSMSAGNSSLR.R 1745.78876 2 4.78 382 NEW No 
  R.QS*SLTFQSSDPEQMR.Q 1820.75204 2 2.48 1146 Swiss/ New in phos No 
O75821 IF34_HUMAN Eukaryotic translation initiation factor 3 subunit 4 (eIF-3 delta) 10.19    
  K.GIPLATGDT*SPEPELLPGAPLPPPK.E 2544.29967 3 3.15 41 Swiss/ 41 phos Yes 
Q9UKL0 RCOR1_HUMAN REST corepressor 1 (Protein CoREST)   10.17    
  R.EREES*EDELEEANGNNPIDIEVDQNK.E 3095.29605 3 3.44 257 Swiss/ 257 phos Yes 
Q6PKG0 LARP1_HUMAN La-related protein 1    30.23    
  K.GLSAS*LPDLDSENWIEVK.K 2052.95251 2 4.67 548 Swiss/ 548 phos Yes 
  R.S*LPTTVPESPNY*R.N 1620.67058 2 2.21 766 Swiss/ 766 phos Yes 
  R.SLPTTVPES*PNYR.N 1540.70428 2 2.17 774 Swiss/ 774 phos Yes 
  K.ILIVTQT*PHYMR.R 1551.77528 2 3.86 649 Swiss/ 649 phos Yes 
  R.EHRPRTASISSS*PSEGTPT*VGSYGCTPQSLPK.F 3474.53959 3 3.77 851 Swiss/ 851 phos & 858 
New in Swiss/ 858 phos 
Yes & Yes 
  K.QEVENFKKVNM#IS*R.E 1817.86152 2 2.70 716 NEW No 
O43741 AAKB2_HUMAN 5'-AMP-activated protein kinase subunit beta-2 (AMPK beta-2 chain) 10.18    
  R.DLSSS*PPGPYGQEMYAFR.S 2081.86740 2 3.58 184 New in Swiss/ 184 phos Yes 
 
 
 137
 Table A-1 (continued). 
 
Accession 
number 
Peptide MH+ z XC Site # in Swiss/Phosphosite 
(06/17/08) 
Present in Phosphosite 
(06/17/08) 
Q9Y2V2 CHSP1_HUMAN Calcium-regulated heat stable protein 1    10.12    
  R.GNVVPS*PLPTR.R 1216.60853 2 2.47 41 Swiss/ 41 phos Yes 
P12694 ODBA_HUMAN 2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial precursor 20.23    
  R.S*VDEVNYWDK.Q 1334.53001 2 4.36 347 Swiss/ 347 phos Yes 
  R.IGHHS*TSDDSSAYR.S 1612.63872 3 3.68 337 Swiss/ 337 phos Yes 
Q8NEY8 PPHLN_HUMAN Periphilin-1 (Gastric cancer antigen Ga50)   10.16    
  R.DNTFFRES*PVGR.K 1504.65800 2 3.12 133 Swiss/ 133 phos Yes 
Q96JM3 K1802_HUMAN Zinc finger protein KIAA1802   70.24    
  R.KPSPSES*PEPWKPFPAVS*PEPR.R 2606.17274 3 3.89 286 Swiss/ New in phos & 
297 NEW 
No & No 
  R.KPSGS*PDLWK.L 1194.55544 2 3.88 445 Swiss/ New in phos No 
  R.KPS*PS*ESPEPWKPFPAVSPEPR.R 2606.17274 3 3.41 282 Swiss/ New in phos & 
284 NEW 
No & No 
  K.TAPTLS*PEHWK.A 1346.61401 2 3.05 405 Swiss/ New in phos No 
  R.RPAPAVS*PGSWK.P 1332.64598 2 2.96 308 Swiss/ 308 phos Yes 
  R.GGS*PDLWK.S 939.39714 2 2.23 476 Swiss/ 476 phos Yes 
  R.KPGPPLS*PEIR.S 1270.65548 2 2.17 427 Swiss/ 427 phos Yes 
  R.KTS*PASLDFPESQK.S 1614.74106 2 4.31 459 Swiss/ New in phos No 
  R.KT*SPASLDFPES*QKS*SR.G 2104.83883 2 2.27 458 NEW & 468 NEW & 
471 NEW 
No & No & No 
Q15459 SF3A1_HUMAN Splicing factor 3 subunit 1 (Spliceosome-associated protein 114)  10.25    
  K.FGESEEVEMEVES*DEEDDKQEK.A 2697.02806 3 3.62 329 Swiss/ 329 phos Yes 
Q9UL54 TAOK2_HUMAN Serine/threonine-protein kinase TAO2    20.19    
  K.MLLARHS*LDQDLLR.E 1760.88769 3 3.51 656 NEW No 
  R.HS*LDQDLLR.E 1176.54085 2 2.14 see line 188  
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Table A-1 (continued).  
 
Accession 
number 
Peptide MH+ z XC Site # in Swiss/Phosphosite 
(06/17/08) 
Present in Phosphosite 
(06/17/08) 
Q15139 KPCD1_HUMAN Serine/threonine-protein kinase D1 (nPKC-D1)   20.21    
  R.RLS*NVS*LTGVSTIR.T 1662.79752 2 4.19 205 Swiss/ 205 phos & 208 
New in Swiss/ 208 phos 
Yes & Yes 
  R.RLS*NVSLTGVSTIR.T 1582.83122 2 3.50 see line 191  
  R.T*SS*AELST*SAPDEPLLQKSPSESFIGREK.R 3331.44188 3 3.04 217 NEW & 219 New in 
Swiss/ 219 phos & 224 
NEW 
No & Yes & No 
Q9UEW8 STK39_HUMAN STE20/SPS1-related proline-alanine-rich protein kinase   20.27    
  K.TEDGDWEWS*DDEMDEK.S 2066.68447 2 4.93 387 New in Swiss/ 387 phos Yes 
  K.ADMWSFGITAIELATGAAPY*HKY*PPMK.V 3126.39053 3 3.26 275 NEW & 278 NEW No & No 
Q9H0B6 KLC2_HUMAN Kinesin light chain 2 (KLC 2)   30.21    
  R.RDS*APYGEYGSWYK.A 1758.71591 2 4.27 428 NEW No 
  R.ASS*LNFLNK.S 1073.50267 2 3.81 528 Swiss/ 528 phos Yes 
  R.TLSSS*SMDLSR.R 1263.52863 2 3.67 610 New in Swiss/ 610 phos Yes 
Q32MZ4 LRRF1_HUMAN Leucine-rich repeat flightless-interacting protein 1   10.20    
  R.RGS*GDTSISIDTEASIR.E 1844.83855 2 3.99 120 New in Swiss/ 120 phos Yes 
Q15052 ARHG6_HUMAN Rho guanine nucleotide exchange factor 6   10.16    
  R.MS*GFIYQGK.I 1110.46893 2 2.94 488 Swiss/ 488 phos Yes 
P21127 CD2L1_HUMAN PITSLRE serine/threonine-protein kinase CDC2L1   10.13    
  K.AYT*PVVVTLWYR.A 1547.76576 2 2.68 595 Swiss/ 595 phos Yes 
P17812 PYRG1_HUMAN CTP synthase 1 (UTP--ammonia ligase 1)    20.29    
  R.SGSSS*PDSEITELK.F 1516.64141 2 4.44 575 Swiss/ 575 phos Yes 
  K.YIDSADLEPITS*QEEPVR.Y 2141.96381 2 2.29 347 NEW No 
P25490 TYY1_HUMAN Transcriptional repressor protein YY1 (Yin and yang 1) (YY-1)  20.22    
  K.DIDHETVVEEQIIGENS*PPDYSEYMTGK.K 3275.39735 3 4.41 247 Swiss/ 247 phos Yes 
  R.EEVVGGDDS*DGLR.A 1427.56858 2 2.26 118 Swiss/ 118 phos Yes 
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Table A-1 (continued). 
 
Accession 
number 
Peptide MH+ z XC Site # in Swiss/Phosphosite 
(06/17/08) 
Present in Phosphosite 
(06/17/08) 
Q16637 SMN_HUMAN Survival motor neuron protein (Component of gems 1) (Gemin-1) 10.23    
  R.GTGQS*DDSDIWDDTALIK.A 2016.84336 2 4.67 28 Swiss/ 28 phos Yes 
Q13177 PAK2_HUMAN Serine/threonine-protein kinase PAK 2 (p21-activated kinase 2)  10.19    
  K.YLS*FTPPEK.D 1161.52274 2 3.52 141 Swiss/ 141 phos Yes 
Q08945 SSRP1_HUMAN FACT complex subunit SSRP1    10.22    
  K.EGMNPSYDEYADS*DEDQHDAYLER.M 2929.07780 3 4.21 444 Swiss/ 444 phos Yes 
P35221 CTNA1_HUMAN Catenin alpha-1 (Cadherin-associated protein)   20.28    
  R.S*RTS*VQTEDDQLIAGQSAR.A 2221.94855 2 5.64 652 Swiss/ 652 phos & 655 
Swiss/ 655 phos 
Yes & Yes 
  R.T*SVQTEDDQLIAGQSAR.A 1898.84911 2 2.85 654 Swiss/ 654 phos Yes 
Q13242 SFRS9_HUMAN Splicing factor, arginine/serine-rich 9    30.19    
  R.GSPHYFS*PFRPY 1534.65146 2 3.57 216 Swiss/ 216 phos Yes 
  R.GS*PHYFS*PFRPY 1614.61776 2 2.81 211 Swiss/ 211 phos & 216 
Swiss/ 216 phos 
Yes & Yes 
  R.STS*YGYSR.S 1000.37714 2 2.13 189 Swiss/ 189 phos Yes 
  R.GRDS*PYQSR.G 1145.47350 2 2.73 204 Swiss/ 204 phos Yes 
O93594 AGM1_HUMAN Phosphoacetylglucosamine mutase (PAGM)   10.24    
  K.STIGVMVTAS*HNPEEDNGVK.L 2164.95801 2 4.61 64 Swiss/ New in phos No 
Q9Y6X9 MORC2_HUMAN MORC family CW-type zinc finger protein 2   10.26    
  R.SVAVS*DEEEVEEEAER.R 1886.75387 2 5.30 743 Swiss/ 743 phos Yes 
Q92934 BAD_HUMAN Bcl2 antagonist of cell death (BAD) (Bcl-2-binding component 6) 30.23    
  R.RMS*DEFVDSFK.K 1440.58648 2 4.58 118 Swiss/ 118 phos Yes 
  R.HSS*YPAGTEDDEGMGEEPSPFR.G 2474.94421 2 3.50 75 Swiss/ 75 phos Yes 
  R.S*APPNLWAAQR.Y 1290.59903 2 3.42 99 Swiss/ 99 phos Yes 
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Table A-1 (continued). 
 
Accession 
number 
Peptide MH+ z XC Site # in Swiss/Phosphosite 
(06/17/08) 
Present in Phosphosite 
(06/17/08) 
Q9C0C2 TB182_HUMAN 182 kDa tankyrase 1-binding protein   10.20    
  R.RFS*EGVLQSPSQDQEK.L 1914.85928 2 3.98 429 New in Swiss/ 429 
phosq 
Yes 
  R.S*QEADVQDWEFR.K 1589.62676 2 3.95 836 Swiss/ 836 phos Yes 
  K.VST*LRES*SAMAS*PLPR.E 1941.79413 2 2.04 5 NEW & 9 NEW & 14 
NEW 
No & No & No 
Q96B36 AKTS1_HUMAN Proline-rich AKT1 substrate 1 (40 kDa proline-rich AKT substrate) 10.22    
  R.AATAARPPAPPPAPQPPS*PTPS*PPRPTLAR.E 3124.54923 3 4.30 88 Swiss/ 88 phos & 92 
Swiss/ 92 phos 
Yes & Yes 
  K.S*LPVSVPVWGFK.E 1395.70718 2 3.70 183 Swiss/ 183 phos Yes 
  R.LNT*SDFQK.L 1032.43974 2 2.56 246 Swiss/ 246 phos Yes 
  R.AAT*AARPPAPPPAPQPPS*PT*PSPPR.P 2666.19280 2 2.55 73 NEW & 88 Swiss/ 88 
phos & 90 NEW 
No & Yes & No 
Q14671 PUM1_HUMAN Pumilio homolog 1 (Pumilio-1) (HsPUM)   10.20    
  R.RDS*LTGSSDLYK.R 1421.63079 2 4.05 709 New in Swiss/ 709 phos Yes 
  R.S*ASSASSLFSPSSTLFSS*SR.L 2152.88349 2 2.23 797 NEW No 
P08559 ODPA_HUMAN Pyruvate dehydrogenase E1 component alpha subunit  20.25    
  R.YHGHS*MSDPGVS*YR.T 1752.62365 2 4.94 293 Swiss/ 293 phos & 300 
Swiss/ 300 phos 
Yes & Yes 
  R.YGMGTS*VER.A 1079.42271 2 3.43 232 Swiss/ 232 phos Yes 
  R.YHGHSMS*DPGVSYR.T 1672.65735 3 3.83 295 Swiss/ 295 phos Yes 
Q9UQ35 SRRM2_HUMAN Serine/arginine repetitive matrix protein 2    30.31    
  R.HGGS*PQPLATTPLSQEPVNPPSEAS*PTR.D 3012.34993 3 6.13 377 Swiss/ 377 phos & 398 
Swiss/ 398 phos 
Yes & Yes 
  K.SST*PPGESYFGVSSLQLK.G 1963.90483 2 3.36 1043 Swiss/ 1043 phos Yes 
  R.S*RT*PLLPR.K 1099.50603 2 2.13 2032 Swiss/ 2032 phos & 
2034 Swiss/ 2034 phos 
Yes & Yes 
  R.GPS*PEGSS*ST*ESSPEHPPK.S 2133.74499 2 2.18 1648 NEW & 1653 NEW & 
1655 NEW 
No & No & No 
  R.AHRSTSADS*ASSS*DTS*R.S 1962.66266 2 2.07 268 NEW & 272 NEW & 
275 NEW 
No & No & No 
  R.QS*PSRS*SSPQPK.V 1445.58210 2 2.01 908 Swiss/ 908 phos & 912 
NEW 
Yes & No 
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Table A-1 (continued). 
 
Accession 
number 
Peptide MH+ z XC Site # in Swiss/Phosphosite 
(06/17/08) 
Present in Phosphosite 
(06/17/08) 
P98175 RBM10_HUMAN RNA-binding protein 10 (RNA-binding motif protein 10)  20.16    
  R.HRHS*PTGPPGFPR.D 1522.70629 3 3.06 189 NEW No 
  R.Y*GATDRSQDDGGENRS*R.D 2043.75527 2 2.07 16 NEW No 
Q9BW71 HIRP3_HUMAN HIRA-interacting protein 3   10.24    
  K.SLKES*EQES*EEEILAQK.K 2136.89847 2 4.73 223 Swiss/ 223 phos & 227 
Swiss/ 227 phos 
Yes 
Q9BSJ8 FA62A_HUMAN Protein FAM62A (Membrane-bound C2 domain-containing protein) 10.12    
  R.KLDVSVKSNS*SFMS*R.E 1844.80128 2 2.43 1063 NEW & 1067 NEW No & No 
Q9UKS6 PACN3_HUMAN Protein kinase C and casein kinase substrate in neurons protein 3 10.23    
  R.DGTAPPPQSPGSPGTGQDEEWS*DEESPR.K 2990.19594 3 4.58 354 Swiss/ 354 phos Yes 
P24844 MLRN_HUMAN Myosin regulatory light chain 2, smooth muscle isoform   10.19    
  R.ATS*NVFAMFDQSQIQEFK.E 2170.95147 2 3.81 20 Swiss/ 20 phos Yes 
P04792 HSPB1_HUMAN Heat-shock protein beta-1 (HspB1) (Heat shock 27 kDa protein)  20.26    
  R.QLS*SGVSEIR.H 1155.54051 2 2.96 82 Swiss/ 82 phos Yes 
  R.GPS*WDPFR.D 1041.41894 2 2.81 15 Swiss/ 15 phos Yes 
P05455 LA_HUMAN Lupus La protein (Sjoegren syndrome type B antigen)  20.26    
  K.FAS*DDEHDEHDENGATGPVK.R 2249.86186 3 3.37 366 Swiss/ 366 phos Yes 
  R.SPS*KPLPEVTDEYK.N 1669.77203 2 3.12 94 NEW No 
O60841 IF2P_HUMAN Eukaryotic translation initiation factor 5B (eIF-5B)   10.20    
  K.NKPGPNIES*GNEDDDASFK.I 2113.87097 2 4.07 214 Swiss/ 214 phos Yes 
P51114 FXR1_HUMAN Fragile X mental retardation syndrome-related protein 1 (hFXR1p) 20.27    
  R.RGPNYTSGYGTNSELSNPS*ETESER.K 2812.16934 3 5.34 409 Swiss/ 409 phos Yes 
  R.RGPNYTSGYGTNSELS*NPS*ETESER.K 2892.13564 3 3.84 406 Swiss/ 406 phos & 409 
Swiss/ 409 phos 
Yes & Yes 
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Table A-1 (continued). 
 
Accession 
number 
Peptide MH+ z XC Site # in Swiss/Phosphosite 
(06/17/08) 
Present in Phosphosite 
(06/17/08) 
P08238 HS90B_HUMAN Heat shock protein HSP 90-beta (HSP 84) (HSP 90)  30.23    
  K.IEDVGS*DEEDDSGKDK.K 1817.69602 2 4.59 255 Swiss/ 254 phos Yes (same AA, diff #) 
  K.IEDVGS*DEEDDSGK.D 1574.57412 2 3.78 see line 281  
  K.IEDVGS*DEEDDSGKDKK.K 1945.79099 3 3.00 see line 281  
  R.EKEIS*DDEAEEEK.G 1630.63672 2 4.07 226 Swiss/ 225 phos Yes (same AA, diff #) 
Q9UEE9 CFDP1_HUMAN Craniofacial development protein 1 (Bucentaur)  10.18    
  K.LDWES*FKEEEGIGEELAIHNR.G 2581.16061 3 3.66 250 New in Swiss/ 250 phos Yes 
Q9Y383 LC7L2_HUMAN Putative RNA-binding protein Luc7-like 2   10.18    
  R.AMLDQLMGTS*R.D 1302.55815 2 3.69 18 New in Swiss/ 18 phos Yes 
Q99613 IF38_HUMAN Eukaryotic translation initiation factor 3 subunit 8 (eIF3 p110)  10.13    
  K.QPLLLS*EDEEDTKR.V 1752.80512 2 2.05 39 Swiss 39 phos Yes 
O14974 MYPT1_HUMAN Protein phosphatase 1 regulatory subunit 12A   20.22    
  K.TGS*YGALAEITASK.E 1448.66684 2 4.43 445 Swiss/ 445 phos Yes 
  K.SPLIES*TANMDNNQSQKTFKNK.E 2575.18578 2 2.49 304 NEW No 
  R.RST*QGVTLTDLQEAEK.T 1855.87968 2 5.08 696 Swiss/ 696 phos Yes 
  R.KTGS*YGALAEITASK.E 1576.76180 2 4.22 see line 292  
Q9Y3S2 ZN330_HUMAN Zinc finger protein 330 (Nucleolar cysteine-rich protein)   10.20    
  R.KDS*DTESSDLFTNLNLGR.T 2091.92300 2 4.00 291 NEW No 
P61978 HNRPK_HUMAN Heterogeneous nuclear ribonucleoprotein K   20.27    
  R.GSY*GDLGGPIITTQVTIPK.D 1996.99907 2 4.79 380 New in Swiss/ 380 phos Yes 
  R.RDYDDMS*PR.R 1234.45580 2 2.26 284 Swiss/ 284 phos Yes 
  R.GSY*GDLGGPIITT*QVTIPK.D 2076.96537 2 3.32 see line 299  
  R.DYDDMS*PR.R 1078.35469 2 2.55 see line 300  
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Accession 
number 
Peptide MH+ z XC Site # in Swiss/Phosphosite 
(06/17/08) 
Present in Phosphosite 
(06/17/08) 
        
P51858 HDGF_HUMAN Hepatoma-derived growth factor (HDGF)    10.13    
  R.AGDLLEDS*PK.R 1124.48708 2 2.54 165 Swiss/ 165 phos Yes 
  R.RAGDLLEDS*PK.R 1280.58819 2 3.54 see line 304  
  R.AGDLLEDS*PKRPK.E 1505.73592 2 2.64 see line 304  
  K.GNAEGS*S*DEEGKLVIDEPAK.E 2204.89953 2 5.87 132 Swiss/ 132 phos & 133 
Swiss/ 133 phos 
Yes & Yes 
  K.KGNAEGS*S*DEEGKLVIDEPAK.E 2332.99450 3 3.80 see line 307  
  K.GNAEGS*SDEEGKLVIDEPAK.E 2124.93323 2 4.76 132 Swiss/ 132 phos Yes 
P22059 OSBP1_HUMAN Oxysterol-binding protein 1   20.20   
  R.TGS*NISGASSDISLDEQYK.H 2051.88047 2 4.00 379 Swiss/ 379 phos Yes 
  K.GDMS*DEDDENEFFDAPEIITMPENLGHK.R 3275.30682 3 3.34 351 Swiss/ 351 phos Yes 
Q8NE71 ABCF1_HUMAN ATP-binding cassette sub-family F member 1   20.17    
  K.LSVPTS*DEEDEVPAPK.P 1792.78880 2 3.36 109 Swiss/ 109 phos Yes 
  K.LSVPTS*DEEDEVPAPKPR.G 2045.94268 2 3.26 see line 314  
P55795 HNRH2_HUMAN Heterogeneous nuclear ribonucleoprotein H' (hnRNP H') (FTP-3) 10.28    
  K.HTGPNS*PDTANDGFVR.L 1764.73369 2 4.12 104 Swiss/ 104 phos Yes 
Q9BYG3 MK67I_HUMAN MKI67 FHA domain-interacting nucleolar phosphoprotein   10.19    
  K.S*QVAELNDDDKDDEIVFK.Q 2159.93799 2 3.71 247 Swiss/ 247 phos Yes 
P02545 LMNA_HUMAN Lamin-A/C (70 kDa lamin) (Renal carcinoma antigen NY-REN-32) 30.20    
  R.NKS*NEDQSMGNWQIK.R 1858.77892 2 3.00 458 NEW No 
  R.LRLS*PSPTSQR.S 1321.66236 2 2.65 390 Swiss/ 390 phos Yes 
  R.KLEST*ES*RSSFSQHAR.T 2009.84771 2 2.05 424 Swiss/ 424 phos Yes 
  R.LRLS*PS*PTSQR.S 1401.62866 2 3.69 390 Swiss/ 390 phos & 392 
Swiss/ 392 phos 
Yes & Yes 
  R.SVGGS*GGGSFGDNLVTR.S 1646.71697 2 2.11 632 Swiss/ 632 phos Yes 
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Table A-1 (continued). 
 
Accession 
number 
Peptide MH+ z XC Site # in Swiss/Phosphosite 
(06/17/08) 
Present in Phosphosite 
(06/17/08) 
P06493 CDC2_HUMAN Cell division control protein 2 homolog (p34 protein kinase) 10.16    
  R.VYT*HEVVTLWYR.S 1645.77739 2 3.27 161 Swiss/ 161 phos Yes 
P49585 PCY1A_HUMAN Choline-phosphate cytidylyltransferase A   10.23    
  R.MLQAIS*PK.Q 967.46820 2 2.61 315 Swiss/ 315 phos Yes 
  K.T*SPPCS*PANLSR.H 1389.52690 2 3.20 342 New in Swiss/ 324 phos 
& 347 Swiss/ 347 phos 
Yes & Yes 
Q16204 CCDC6_HUMAN Coiled-coil domain-containing protein 6 (H4 protein)  40.26    
  R.PIS*PGLSYASHTVGFTPPTSLTR.A 2466.20644 3 5.14 367 Swiss/ New in phos No 
  R.T*VSSPIPYTPSPSSSR.P 1742.79964 2 4.29 349 NEW No 
  R.PIS*PGLSYASHTVGFT*PPTSLTR.A 2546.17274 3 3.02 367 Swiss/ New in phos & 
380 NEW 
No & No 
  R.QLSESES*SLEMDDER.Y 1834.70481 2 2.68 327 NEW No 
  K.LDQPVS*APPS*PR.D 1423.60178 2 3.09 240 Swiss/ 240 phos & 244 
Swiss/ 244 phos 
Yes & Yes 
Q9NTJ3 SMC4_HUMAN Structural maintenance of chromosomes protein 4   10.16    
  R.T*ESPATAAETASEELDNR.S 1971.81787 2 3.25 39 NEW No 
  K.S*S*LAMNRS*R.G 1261.41964 2 2.25 588 NEW & 589 NEW & 595 
NEW 
No 
Q8TAQ2 SMRC2_HUMAN SWI/SNF-related matrix-associated actin-dependent regulator of chromatin 
subfamily C member 2 
10.15    
  R.KRS*PSPSPT*PEAK.K 1541.67600 2 2.81 302 Swiss/ 302 phos Yes 
  K.DMDEPS*PVPNVEEVTLPK.T 2075.92425 2 3.05 347 Swiss/ 347 phos Yes 
Q14676 MDC1_HUMAN Mediator of DNA damage checkpoint protein 1   10.14    
  R.LLLAEDS*EEEVDFLSER.R 2073.92636 2 2.88 168 Swiss/ 168 phos Yes 
Q8WUA2 PPIL4_HUMAN Peptidyl-prolyl cis-trans isomerase-like 4 (PPIase)  10.16    
  R.INHTVILDDPFDDPPDLLIPDRSPEPT*R.E 3277.57763 3 3.15 182 NEW No 
  R.INHTVILDDPFDDPPDLLIPDRS*PEPTR.E 3277.57763 3 5.89 178 Swiss/ 178 phos Yes 
P18887 XRCC1_HUMAN DNA-repair protein XRCC1    10.20    
  K.TKPTQAAGPSS*PQKPPT*PEETK.A 2437.10472 3 4.07 447 Swiss/ 447 phos & 453 
Swiss/ 453 phos 
Yes & Yes 
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Accession 
number 
Peptide MH+ z XC Site # in Swiss/Phosphosite 
(06/17/08) 
Present in Phosphosite 
(06/17/08) 
P07814 SYEP_HUMAN Bifunctional aminoacyl-tRNA synthetase    10.14    
 6580 K.EYIPGQPPLSQSSDSS*PTR.N 2125.94374 2 2.87 886 Swiss/ 886 phos Yes 
 7439 R.AKIDM#SS*NNGCMRDPTLY*R.C 2347.92695 2 2.07 346 NEW No 
 9047 K.HPKNPEVGLKPVWY*S*PK.V 2136.00784 2 2.00 546 NEW & 547 NEW No & No 
P27824 CALX_HUMAN Calnexin precursor    10.10    
  K.AEEDEILNRS*PR.N 1508.67405 2 2.01 583 Swiss/ 583 phos Yes 
O75494 FUSIP_HUMAN FUS-interacting serine-arginine-rich protein 1   10.23    
  R.S*FDYNYR.R 1044.38222 2 3.10 133 Swiss/ 133 phos Yes 
  R.S*RS*FDYNYR.R 1367.48166 2 2.14 131 Swiss/ 131 phos & 133 
Swiss/ 133 phos 
Yes & Yes 
Q15773 MLF2_HUMAN Myeloid leukemia factor 2    20.16    
  R.QHMS*RMLSGGFGY*SPFLSIT*DGNMPGTR.P 3284.31644 3 3.26 29 NEW & 37 NEW & 44 
NEW 
No & No & No 
  R.LAIQGPEDS*PSR.Q 1349.60966 2 2.53 238 Swiss/ 238 phos Yes 
Q15366 PCBP2_HUMAN Poly(rC)-binding protein 2 (Alpha-CP2) (hnRNP-E2)  10.16    
  K.PSSS*PVIFAGGQDR.Y 1497.67332 2 3.22 189 Swiss/ 189 phos Yes 
P30622 CLIP1_HUMAN Restin (Cytoplasmic linker protein 170 alpha-2) (CLIP-170)  20.21    
  K.LT*NLQENLSEVSQVKETLEK.E 2382.17995 2 3.75 822 Swiss/ 822 phos  Yes 
  K.TISSEKAS*S*TPSS*ETQEEFVDDFRVGER.V 3358.34362 3 3.20 43 NEW & 44 NEW & 48 
NEW 
No & No & No 
  R.VM#ATTSASLKRSPSASSLSSMS*SVASS*VSSR.P 3222.44184 3 3.19 320 NEW & 325 NEW No & No 
  R.SPSASSLS*SMS*SVASSVSSRPSR.T 2401.01016 2 2.02 317 NEW & 320 NEW No & No 
  K.RS*PSASS*LSSM#SSVASSVSSR.P 2232.92027 2 2.01 310 NEW & 315 NEW No & No 
  K.EPSATPPIS*NLTKTAS*ESISNLSEAGS*IK.K 3169.39895 3 3.11 186 NEW & 193 NEW & 204 
Swiss/ 204 phos 
No & No & Yes 
P11717 MPRI_HUMAN Cation-independent mannose-6-phosphate receptor precursor  30.17    
  K.LVSFHDDS*DEDLLHI 1834.78947 2 2.22 2484 Swiss/ 2484 phos Yes 
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Accession 
number 
Peptide MH+ z XC Site # in Swiss/Phosphosite 
(06/17/08) 
Present in Phosphosite 
(06/17/08) 
O00567 NOP56_HUMAN Nucleolar protein Nop56 (Nucleolar protein 5A)  10.15    
  K.EELMSS*DLEETAGSTSIPK.R 2103.90391 2 3.07 520 Swiss/ 520 phos Yes 
P52756 RBM5_HUMAN RNA-binding protein 5 (RNA-binding motif protein 5)   10.18    
  R.GLVAAYSGDS*DNEEELVER.L 2132.90193 2 3.53 624 Swiss/ 624 phos Yes 
Q8ND30 LIPB2_HUMAN Liprin-beta-2    10.16    
  R.T*QSGNFYTDTLGMAEFR.R 2017.83610 2 3.11 510 NEW No 
P40222 TXLNA_HUMAN Alpha-taxilin   10.13    
  R.RPEGPGAQAPSS*PR.V 1486.67980 2 2.58 515 Swiss/ 515 phos Yes 
Q8IWS0 PHF6_HUMAN PHD finger protein 6 (PHD-like zinc finger protein)  10.17    
  K.TAHNSEADLEESFNEHELEPSS*PK.S 2777.15737 3 3.42 155 Swiss/ 155 phos Yes 
Q13595 TRA2A_HUMAN Transformer-2 protein homolog (TRA-2 alpha)  30.15    
  R.PTHS*GGGGGGGGGGGGGGGGRRR.D 1901.82228 3 3.05 215 NEW No 
  R.AHT*PTPGIYMGR.P 1380.61297 2 2.77 202 NEW  No 
  R.RS*PS*PYYSR.Y 1272.48093 2 2.09 260 Swiss/ 260 phos & 262 
Swiss/ 262 phos 
Yes & Yes 
  R.S*PS*PYYSR.Y 1116.37982 2 2.99 see line 386  
  R.RRDSY*YDR.G 1210.50005 2 2.27 237 NEW No 
  R.RRS*PSPYY*SR.Y 1428.58204 2 2.02 260 Swiss/ 260 phos & 265 
New in Swiss/ 265 in phos 
Yes & Yes 
Q13489 BIRC3_HUMAN Baculoviral IAP repeat-containing protein 3   10.19    
  -.M#NIVENS*IFLS*NLMK.S 1928.82979 2 3.74 7 NEW & 11 NEW No & No 
P49736 MCM2_HUMAN DNA replication licensing factor MCM2    10.15    
  R.GLLYDS*DEEDEERPAR.K 1973.81239 2 2.73 139 Swiss/ 139 phos Yes 
  R.VM#LES*FIDTQK.F 1406.62726 2 2.69 801 NEW No 
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Accession 
number 
Peptide MH+ z XC Site # in Swiss/Phosphosite 
(06/17/08) 
Present in Phosphosite 
(06/17/08) 
Q12968 NFAC3_HUMAN Nuclear factor of activated T-cells, cytoplasmic 3 (NF-ATc3)  10.13    
  R.PS*S*DSGCSHDSVLS*GQR.S 1958.63875 2 2.66 730 NEW & 731 NEW & 742 
NEW 
No & No & No 
Q9H410 CT172_HUMAN Uncharacterized protein C20orf172   10.20    
  K.SLHLS*PQEQSASYQDR.R 1925.83888 2 3.94 81 NEW No 
Q9ULU4 PKCB1_HUMAN Protein kinase C-binding protein 1 (Rack7)   10.15    
  R.RIS*LSDMPR.S 1154.53874 2 2.48 425 New in Swiss/ 425 phos Yes 
  K.S*DSSDSEYISDDEQK.S 1784.63817 2 2.95 595 NEW No 
P31321 KAP1_HUMAN cAMP-dependent protein kinase type I-beta regulatory subunit 10.14    
  -.M#ASPPACPS*EEDESLK.G 1786.69106 2 2.77 9 NEW No 
Q7L7X3 TAOK1_HUMAN Serine/threonine-protein kinase TAO1   10.14    
  R.AS*DPQSPPQVS*R.H 1428.55555 2 2.22 417 New in Swiss/ 417 phos Yes 
P51587 BRCA2_HUMAN Breast cancer type 2 susceptibility protein   10.15   
  K.VFADIQS*EEILQHNQNMSGLEKVS*K.I 3004.35223 3 3.01 1926 NEW No 
Q8TF66 LRC15_HUMAN Leucine-rich repeat-containing protein 15 precursor (hLib) 10.13   
  R.M#LANLQNIS*LQNNRLR.Q 1994.00007 2 2.64 371 NEW No 
Q5VT25 MRCKA_HUMAN Serine/threonine-protein kinase MRCK alpha   20.12   
  R.HSTAS*NSS*NLSSPPS*PASPR.K 2220.83587 2 2.16 1700 NEW & 1703 NEW & 
1710 NEW 
No & No & No 
  R.TVFSGS*VSIPS*ITK.S 1582.71647 2 2.05 1611 NEW & 1616 NEW No & No 
Q9UMY1 NOL7_HUMAN Nucleolar protein 7 (Nucleolar protein of 27 kDa)  10.15   
  K.VQSVS*QNKSY*LAVRLK.D 1979.97146 2 2.94 167 NEW & 172 NEW No & No 
P28161 GSTM2_HUMAN Glutathione S-transferase Mu 2 (GSTM2-2) (GST class-mu 2) 10.16   
  K.S*S*RFLPRPVFTK.M 1594.75419 2 3.02 200 NEW & 201 NEW No & No 
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Accession 
number 
Peptide MH+ z XC Site # in Swiss/Phosphosite 
(06/17/08) 
Present in Phosphosite 
(06/17/08) 
Q9UKX3 MYH13_HUMAN Myosin-13 (Myosin heavy chain 13)   10.14   
  R.VEEKES*LISQLT*K.S 1663.75906 2 2.79 1300 NEW & 1306 NEW No & No 
P55199 ELL_HUMAN RNA polymerase II elongation factor ELL    10.14   
  R.KSGAS*AVSGGS*GVS*QR.P 1674.62844 2 2.82 194 NEW & 200 NEW & 203 
NEW 
No & No & No 
Q9BXT6 M10L1_HUMAN Putative helicase Mov10l1    20.13   
  K.WEDDSRNHGSPS*DCGPR.V 1994.74466 2 2.63 113 NEW  No 
  K.SSQALT*S*AKTTVVVTAQK.R 1979.94497 2 2.59 472 NEW & 473 NEW No & No 
Q14181 DPOA2_HUMAN DNA polymerase subunit alpha B    10.17   
  R.GGAGNIS*LKVLGCPEALTGSYKSMFQK.L 2836.37728 3 3.42 192 NEW No 
Q12824 SNF5_HUMAN SWI/SNF-related matrix-associated actin-dependent regulator of chromatin 
subfamily B member 1 
10.14   
  R.YPS*LWRRLATVEER.K 1855.92143 2 2.26 49 NEW No 
Q8IWV8 UBR2_HUMAN E3 ubiquitin-protein ligase UBR2 (N-recognin-2)   20.16   
  K.M#RES*SPTSPVAET*EGTIMEESSRDK.D 2930.18316 3 3.28 1005 NEW & 1014 NEW No & No 
  K.MRESS*PT*SPVAETEGTIMEES*SRDK.D 2994.15456 3 3.01 1006 NEW & 1008 NEW & 
1022 NEW 
No & No & No 
P49006 MRP_HUMAN MARCKS-related protein (MARCKS-like protein 1)   30.22   
  R.GDVTAEEAAGAS*PAK.A 1453.62061 2 4.03 22 Swiss/ 21 phos Yes (same AA, diff #) 
  K.LSGLS*FK.R 831.40117 2 2.35 104 Swiss/ 103 phos Yes (same AA, diff #) 
  K.LSGLS*FKR.N 987.50228 2 2.21 see line 433  
Q99733 NP1L4_HUMAN Nucleosome assembly protein 1-like 4    10.24   
  R.REFITGDVEPTDAESEWHS*ENEEEEK.L 3172.29024 3 3.40 125 Swiss/ 125 phos Yes  
Q13541 4EBP1_HUMAN Eukaryotic translation initiation factor 4E-binding protein 1  20.24   
  R.VVLGDGVQLPPGDYSTT*PGGTLFSTT*PGGTR.I 3207.46462 3 4.48 37 Swiss/ 36 phos & 46 
Swiss/ 45 phos 
Yes (same AA, diff #) 
  R.RVVLGDGVQLPPGDYSTT*PGGTLFSTT*PGGTR.I 3363.56573 3 4.23 see line 438  
 
 149
Table A-1 (continued). 
 
Accession 
number 
Peptide MH+ z XC Site # in Swiss/Phosphosite 
(06/17/08) 
Present in Phosphosite 
(06/17/08) 
Q9H6Z4 RANB3_HUMAN Ran-binding protein 3 (RanBP3)   10.18   
  R.TSS*LTQFPPSQSEER.S 1773.76907 2 3.57 126 Swiss/ 126 phos Yes 
P42566 EP15_HUMAN Epidermal growth factor receptor substrate 15 (Protein Eps15)  10.17   
  R.S*SPELLPSGVTDENEVTTAVTEK.V 2483.14362 2 3.43 562 Swiss/ New in phos No 
P62258 1433E_HUMAN 14-3-3 protein epsilon (14-3-3E)   10.32   
  K.AAFDDAIAELDTLS*EESYK.D 2167.93184 2 3.58 210 Swiss/ New in phos No 
O46021 RL1D1_HUMAN Ribosomal L1 domain-containing protein 1    10.12   
  K.ATNES*EDEIPQLVPIGK.K 1919.89975 2 2.09 361 Swiss/ 361 phos Yes 
P29966 MARCS_HUMAN Myristoylated alanine-rich C-kinase substrate (MARCKS)  20.11   
  K.LSGFS*FK.K 865.38552 2 2.27 170 Swiss/ 170 phos Yes 
  K.LSGFS*FKK.N 993.48048 2 2.25 see line 449  
O95400 CD2B2_HUMAN CD2 antigen cytoplasmic tail-binding protein 2   10.19   
  K.HSLDS*DEEEDDDDGGSSK.Y 2016.68256 2 3.71 49 Swiss/ 49 phos Yes 
P05783 K1C18_HUMAN Keratin, type I cytoskeletal 18 (Cytokeratin-18)   50.33   
  R.PVSSAAS*VYAGAGGSGSR.I 1660.73262 2 6.03 34 Swiss/ 33 phos Yes (Same AA, diff #) 
  R.LLEDGEDFNLGDALDSSNS*MQTIQK.T 2820.22810 3 4.90 401 Swiss/ 400 phos Yes (Same AA, diff #) 
  R.STS*FRGGM#GSGGLATGIAGGLAGMGGIQNEK.E 2935.34374 3 3.62 53 Swiss/ 52 phos Yes (Same AA, diff #) 
  R.ST*FSTNYR.S 1055.41934 2 2.57 8 Swiss/ 7 phos Yes (Same AA, diff #) 
  R.S*LGSVQAPSYGAR.P 1372.62564 2 2.47 15 Swiss/ New in phos No 
Q96QR8 PURB_HUMAN Transcriptional activator protein Pur-beta    30.26   
  R.DSLGDFIEHYAQLGPSS*PEQLAAGAEEGGGPR.R 3335.48519 3 5.18 101 Swiss/ 101 phos Yes  
  R.RGGGS*GGGEES*EGEEVDED 2011.64371 2 2.62 298 Swiss/ 298 phos & 304 Swiss/ 
304 phos 
Yes & Yes 
  R.RGGGSGGGEES*EGEEVDED 1931.67741 2 2.41 see line 461  
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Accession 
number 
Peptide MH+ z XC Site # in Swiss/Phosphosite 
(06/17/08) 
Present in Phosphosite 
(06/17/08) 
Q5BKZ1 ZN326_HUMAN Zinc finger protein 326   10.21   
  R.SMDSYLNQS*YGMDNHSGGGGGSR.F 2456.92310 3 4.21 56 NEW No 
P29692 EF1D_HUMAN Elongation factor 1-delta (EF-1-delta)    10.20   
  R.ATAPQTQHVS*PMR.Q 1503.67736 2 3.75 133 Swiss/ New in phos No 
Q9UGV2 NDRG3_HUMAN Protein NDRG3   10.25   
  R.THS*TSSSLGSGESPFSR.S 1803.75448 2 5.00 331 Swiss/ 331 phos Yes 
Q05519 SFR11_HUMAN Splicing factor arginine/serine-rich 11    20.21   
  K.LNHVAAGLVS*PSLK.S 1485.78248 2 4.28 207 Swiss/ 207 New in pho No 
  R.DYDEEEQGYDS*EKEK.K 1943.70659 2 3.00 434 Swiss/ 434 phso Yes 
P25788 PSA3_HUMAN Proteasome subunit alpha type 3 (Proteasome component C8)  10.28   
  K.ESLKEEDES*DDDNM 1735.58878 2 5.58 250 Swiss/ 249 phos Yes (Same AA, diff #) 
Q6UN15 FIP1_HUMAN Pre-mRNA 3'-end-processing factor FIP1 (FIP1-like 1)   10.20   
  R.DHS*PTPSVFNSDEER.Y 1796.71228 2 3.83 492 Swiss/ 492 pho Yes 
Q9NYB0 TE2IP_HUMAN Telomeric repeat-binding factor 2-interacting protein 1   10.21   
  K.YLLGDAPVS*PSSQK.L 1541.72469 2 4.30 203 Swiss/ 203 phos Yes 
P27816 MAP4_HUMAN Microtubule-associated protein 4 (MAP 4)   40.27   
  K.DMES*PTKLDVTLAK.D 1627.76484 2 4.73 280 Swiss/ 280 phos Yes 
  K.VGS*LDNVGHLPAGGAVK.T 1670.82613 2 3.62 1073 Swiss/ 1073 phos Yes 
  K.DMS*PLSETEMALGK.D 1588.66341 2 3.06 507 Swiss/ 507 phos Yes 
  K.T*STSKAKTQPTSLPK.Q 1654.84111 2 2.19 712 NEW No 
  K.VGS*TENIK.H 927.41827 2 2.02 941 NEW No 
P08729 K2C7_HUMAN Keratin, type II cytoskeletal 7 (Cytokeratin-7)  20.32   
  R.T*LNETELTELQS*QISDTSVVLSMDNSR.S 3170.38472 3 6.39 227 NEW & 238 NEW No & No 
  R.T*LNETELT*ELQSQISDTSVVLSM#DNSR.S 3186.37962 3 4.13 227 NEW & 234 NEW No & No 
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Accession 
number 
Peptide MH+ z XC Site # in Swiss/Phosphosite 
(06/17/08) 
Present in Phosphosite 
(06/17/08) 
Q9H307 PININ_HUMAN Pinin (140 kDa nuclear and cell adhesion-related phosphoprotein) 10.20   
  K.S*LSPGKENVSALDMEK.E 1784.81358 2 3.95 441 Swiss/ 440 phos Yes (Same AA, diff #) 
Q9BQE3 TBA6_HUMAN Tubulin alpha-6 chain (Alpha-tubulin 6)   10.31   
  K.TIGGGDDS*FNTFFSETGAGK.H 2087.85934 2 5.65 48 Swiss/ 48 phos Yes 
Q93009 UBP7_HUMAN Ubiquitin carboxyl-terminal hydrolase 7 (Ubiquitin thioesterase 7) 10.21   
  K.AGEQQLS*EPEDMEMEAGDTDDPPR.I 2727.04333 3 4.29 18 Swiss/ 18 phos Yes 
P52597 HNRPF_HUMAN Heterogeneous nuclear ribonucleoprotein F (hnRNP F)   10.32   
  K.ATENDIYNFFS*PLNPVR.V 2076.94262 2 3.97 310 Swiss/ New in pho  No 
Q13185 CBX3_HUMAN Chromobox protein homolog 3    10.27   
  K.SLS*DSESDDSK.S 1249.44673 2 3.53 95 Swiss/ 95 phos Yes 
Q8TE77 SSH3_HUMAN Protein phosphatase Slingshot homolog 3 (SSH-3L) (hSSH-3L) 20.26   
  R.S*PPGSGASTPVGPWDQAVQR.R 2073.93893 2 4.31 4 NEW No 
  R.RQS*FAVLR.G 1056.53497 2 3.05 37 New in Swiss/ 37 phos Yes 
Q9NR30 DDX21_HUMAN Nucleolar RNA helicase 2 (Nucleolar RNA helicase II)   10.20   
  K.NEEPS*EEEIDAPKPK.K 1791.76840 2 4.09 121 Swiss/ 121 pho Yes 
O95359 TACC2_HUMAN Transforming acidic coiled-coil-containing protein 2   10.18   
  K.LDNTPAS*PPRS*PAEPNDIPIAK.G 2460.12070 3 3.68 2317 Swiss/ New in phos & 2321 
NEW 
No & No 
Q86W92 LIPB1_HUMAN Liprin-beta-1    10.26   
  R.SQS*TTFNPDDMSEPEFK.R 2039.79396 2 5.12 601 Swiss/ New in phos No 
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Accession 
number 
Peptide MH+ z XC Site # in Swiss/Phosphosite 
(06/17/08) 
Present in Phosphosite 
(06/17/08) 
P23588 IF4B_HUMAN Eukaryotic translation initiation factor 4B (eIF-4B)  50.27   
  K.SPPY*TAFLGNLPYDVTEESIK.E 2421.12612 2 4.84 96 NEW No 
  R.RES*EKS*LENETLNK.E 1836.77757 2 3.92 442 NEW & 445 Swiss/ New in 
phos 
No & No 
  R.ARPATDS*FDDYPPR.R 1687.71116 2 3.20 207 NEW No 
  R.HPS*WRS*EETQER.E 1701.64174 2 2.11 406 Swiss/ 406 phos & 409 NEW Yes & No 
  K.PRST*PEEDDSS*AS*TSQSTR.A 2277.79446 2 2.07 341 NEW & 348 NEW & 350 NEW No & No & No 
  K.YAALS*VDGEDENEGEDYAE 2155.78630 2 4.50 597 Swiss/ New in phos No 
O15164 TIF1A_HUMAN Transcription intermediary factor 1-alpha (TIF1-alpha)   20.16   
  K.SEWLDPSQKS*PLHVGETR.K 2145.99644 3 3.26 811 Swiss/ New in phos No 
  R.SILTSLLLNSS*QSS*T*SEETVLR.S 2605.14458 2 2.00 768 Swiss/ 768 phos & 771 NEW & 
772 NEW 
Yes & No & No 
P46821 MAP1B_HUMAN Microtubule-associated protein 1B (MAP 1B)   20.18   
  K.LGDVS*PTQIDVSQFGSFK.E 2004.93138 2 3.59 1501 Swiss/ 1501 phos Yes 
  K.TTSPPEVS*GYS*Y*EK.T 1784.61039 2 2.12 1970 NEW & 1973 NEW & 1974 
Swiss/ 1974 phos 
No & No & Yes 
Q06265 EXOS9_HUMAN Exosome complex exonuclease RRP45 (Exosome component 9)  20.20   
  K.APIDTS*DVEEK.A 1283.54024 2 3.89 306 NEW No 
Q8WUZ0 BCL7C_HUMAN B-cell CLL/lymphoma 7 protein family member C  20.28   
  K.GTEPS*PGGTPQPSRPVS*PAGPPEGVPEEAQPPR.L 3419.53041 3 5.64 114 Swiss/ 114 phos & 126 Swiss/ 
126 phos 
Yes & Yes 
  K.GTEPS*PGGT*PQPSRPVSPAGPPEGVPEEAQPPR.L 3419.53041 3 3.07 118 Swiss/ 118 phos Yes 
O43290 SNUT1_HUMAN U4/U6.U5 tri-snRNP-associated protein 1    10.26   
  R.RVS*EVEEEKEPVPQPLPSDDTR.V 2616.21885 3 5.18 448 Swiss/ 448 phos Yes 
  R.DLQGLT*VEHAIDSFREGETMILT*LKDK.G 3219.50438 3 3.16 258 NEW No 
  K.KMSSS*DT*PLGT*VALLQEK.Q 2144.89865 2 2.08 762 NEW & 764 NEW & 768 NEW No & No & No 
  K.KMS*S*S*DTPLGTVALLQEKQK.A 2401.05220 2 2.36 760 NEW & 761 NEW & 762 NEW No & No & No 
  K.M#SS*SDT*PLGTVALLQEK.Q 1952.83229 2 2.13 761 NEW & 764 NEW No & No 
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Accession 
number 
Peptide MH+ z XC Site # in Swiss/Phosphosite 
(06/17/08) 
Present in Phosphosite 
(06/17/08) 
P30291 WEE1_HUMAN Wee1-like protein kinase (Wee1A kinase) (WEE1hu)  20.15   
  K.S*PAAPY*FLGSSFS*PVRCGGPGDASPR.G 2820.12888 3 3.04 127 Swiss/ New in phos & 132 
NEW & 139 Swiss/ 139 phos 
No & No & Yes 
  K.S*RYTTEFHELEKIGS*GEFGSVFK.C 2808.23171 3 3.03 293 NEW & 307 NEW No & No 
P16333 NCK1_HUMAN Cytoplasmic protein NCK1 (NCK adaptor protein 1)   10.17   
  K.RKPS*VPDSASPADDSFVDPGER.L 2409.07179 3 3.42 85 Swiss/ 85 phos Yes 
Q9UNE7 STUB1_HUMAN STIP1 homology and U box-containing protein 1   10.20   
  R.LGAGGGS*PEKS*PSAQELK.E 1872.81395 2 3.92 19 Swiss/ 19 phos & 23 Swiss/ 23 
phos 
Yes & Yes 
Q9BTC0 DIDO1_HUMAN Death-inducer obliterator 1 (DIO-1)    10.18   
  R.RNS*VERPAEPVAGAATPSLVEQQK.M 2614.29844 3 3.66 1456 Swiss/ New in phos No 
Q96I25 SPF45_HUMAN Splicing factor 45 (45 kDa-splicing factor)    20.20   
  R.S*MGGAAIAPPTSLVEK.D 1608.77026 2 4.06 169 NEW No 
  R.SPT*GPSNSFLANMGGTVAHK.I 2052.92084 2 3.75 224 NEW No 
Q53EL6 PDCD4_HUMAN Programmed cell death protein 4 (Nuclear antigen H731-like)  30.20   
  R.KDS*VWGSGGGQQSVNHLVK.E 2062.97056 3 3.98 313 NEW No 
  R.SGLTVPTS*PK.G 1066.51799 2 2.62 94 Swiss/ 94 phos Yes 
  K.NSSRDS*GRGDS*VS*DSGSDALR.S 2364.84896 2 2.17 71 NEW & 76 Swiss/ New in phos No & No 
Q9H2U2 IPYR2_HUMAN Inorganic pyrophosphatase 2, mitochondrial precursor (PPase 2)  20.28   
  R.SLVESVSSS*PNKESNEEEQVWHFLGK 3026.37787 3 5.60 317 Swiss/ 317 phos Yes 
  K.FKPGYLEATLNWFRLY*K.V 2226.11471 3 3.71 241 New in Swiss/ 241 phos Yes 
Q8ND56 LS14A_HUMAN LSM14 protein homolog A (Protein SCD6 homolog)   20.17   
  K.S*PTMEQAVQTASAHLPAPAAVGR.R 2370.12714 3 3.50 192 Swiss/ 192 phos Yes 
  R.SS*PQLDPLR.K 1092.50849 2 2.38 183 Swiss/ 183 phos Yes 
Q13247 SFRS6_HUMAN Splicing factor, arginine/serine-rich 6    20.18   
  R.SNS*PLPVPPSK.A 1202.58165 2 3.19 303 Swiss/ 303 phos Yes 
  R.LIVENLSS*R.C 1110.55544 2 3.14 119 NEW No 
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Accession 
number 
Peptide MH+ z XC Site # in Swiss/Phosphosite 
(06/17/08) 
Present in Phosphosite 
(06/17/08) 
Q9H7L9 SDS3_HUMAN Sin3 histone deacetylase corepressor complex component SDS3  10.24   
  K.RPAS*PSS*PEHLPATPAESPAQR.F 2443.08023 3 4.74 234 Swiss/ 234 phos Yes 
Q9BXP5 ARS2_HUMAN Arsenite-resistance protein 2   20.17   
  R.TQLWASEPGT*PPLPTSLPSQNPILK.N 2752.39569 3 3.35 544 Swiss/ 544 phos Yes 
  R.HELS*PPQK.R 1015.46081 2 2.44 74 Swiss/ 74 phos Yes 
P68366 TBA1_HUMAN Tubulin alpha-1 chain (Alpha-tubulin 1)    10.16   
  R.EDM#AALEKDY*EEVGIDSYEDEDEGEE 3105.14492 3 3.15 432 NEW No 
Q96D71 REPS1_HUMAN RalBP1-associated Eps domain-containing protein 1  30.20   
  R.TSADAQEPASPVVSPQQS*PPTS*PHTWR.K 3018.30298 3 4.01 118 Swiss/ New in phos & 122 
Swiss/ New in phos 
No & No 
  R.RQS*SSYDDPWK.I 1448.58417 2 3.75 220 Swiss/ New in phos No 
  R.HAAS*YS*SDSENQGSY*SGVIPPPPGRGQVKK.G 3340.40717 3 3.14 63 NEW & 65 NEW & 74 New in 
Swis/s 74 phos 
No & No & Yes 
O94888 UBXD7_HUMAN UBX domain-containing protein 7   10.17   
  R.SESLIDASEDS*QLEAAIR.A 2013.90121 2 3.34 288 Swiss/ 288 phos Yes 
  R.SES*LIDASEDSQLEAAIR.A 2013.90121 2 5.19 280 Swiss/ 280 phos Yes 
  R.DFQT*ET*IRQEQELR.N 1952.81502 2 2.66 116 NEW & 118 NEW No & No 
P67809 YBOX1_HUMAN Nuclease sensitive element-binding protein 1   20.24   
  R.NYQQNYQNS*ESGEKNEGSESAPEGQAQQR.R 3337.36251 3 4.15 165 Swiss/ 165 phos Yes 
  K.NEGSES*APEGQAQQR.R 1667.66567 2 2.98 176 Swiss/ 176 phso Yes 
Q9UN36 NDRG2_HUMAN Protein NDRG2 (Protein Syld709613)   10.24   
  R.SRT*AS*LTSAASVDGNR.S 1752.73129 2 4.75 330 Swiss/ 330 phos & 332 Swiss/ 
332 phos 
Yes & Yes 
O00264 PGRC1_HUMAN Membrane-associated progesterone receptor component 1 (mPR) 10.17   
  K.EGEEPTVYS*DEEEPKDESAR.K 2375.93984 3 3.38 181 Swiss/ 180 phos Yes (Same AA, diff #) 
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Accession 
number 
Peptide MH+ z XC Site # in Swiss/Phosphosite 
(06/17/08) 
Present in Phosphosite 
(06/17/08) 
Q9UBC2 EP15R_HUMAN Epidermal growth factor receptor substrate 15-like 1   20.23   
 7476 K.FHDTS*SPLMVTPPSAEAHWAVR.V 2516.14279 3 4.60 107 NEW No 
 9686 K.DS*LRSTPS*HGSVSSLNSTGSLSPKHS*LK.Q 3106.36424 3 3.07 235 NEW & 241 Swiss/ 241 phos No & Yes 
O00499 BIN1_HUMAN Myc box-dependent-interacting protein 1 (Bridging integrator 1) 20.22   
  K.S*PSPPDGS*PAATPEIR.V 1738.70843 2 4.46 296 Swiss/ 296 phos & 303 Swiss/ 
303 phos 
Yes & Yes 
  K.S*PSPPDGSPAATPEIR.V 1658.74213 2 3.86 see line 582  
Q9BQI5 SGIP1_HUMAN SH3-containing GRB2-like protein 3-interacting protein 1  10.12   
  K.WVHFSDTSPEHVTPELT*PR.E 2315.04921 2 2.12 328 NEW  No 
O95460 MATN4_HUMAN Matrilin-4 precursor   10.16   
  R.VGVIQYS*SQVQSVFPLR.A 1987.00482 2 3.13 79 NEW No 
Q9ULM3 YETS2_HUMAN YEATS domain-containing protein 2   10.14   
  K.T*EES*S*ELGNYVIK.I 1708.61548 2 2.85 1131 NEW & 1134 NEW & 1135 
NEW 
No & No & No 
Q9Y233 PDE10_HUMAN cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A 10.15   
  K.S*QHLTGLTDEKVK.A 1535.74648 2 2.90 8 NEW No 
Q15054 DPOD3_HUMAN DNA polymerase subunit delta 3 (DNA polymerase subunit delta p66) 20.14   
  K.TEPEPPSVKS*S*SGENK.R 1832.73504 2 2.76 374 NEW & 375 NEW & 376 NEW No & No & No 
  K.S*KLAVT*ASIHVY*SIQK.A 1984.89450 2 2.16 90 NEW & 95 NEW & 101 NEW No & No & No 
  R.VALS*DDETKETENMR.K 1817.76227 2 2.38 307 Swiss/ New in phos No 
Q9UNZ2 NSF1C_HUMAN NSFL1 cofactor p47 (p97 cofactor p47)   10.17   
  R.KKS*PNELVDDLFK.G 1612.79818 2 3.44 114 Swiss/ 114 phos  Yes 
Q9Y6W5 WASF2_HUMAN Wiskott-Aldrich syndrome protein family member 2   10.23   
  K.RS*SVVSPSHPPPAPPLGSPPGPK.P 2325.17508 3 4.64 292 NEW No 
  R.S*S*VVS*PSHPPPAPPLGSPPGPK.P 2329.00657 3 3.68 292 NEW & 293 NEW & 296 NEW No & No & No 
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(06/17/08) 
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(06/17/08) 
Q9BQA1 MEP50_HUMAN Methylosome protein 50 (MEP50 protein) (WD repeat protein 77) 10.16   
  R.KET*PPPLVPPAAR.E 1452.76101 2 3.22 5 Swiss/ 5 phos Yes 
P49407 ARRB1_HUMAN Beta-arrestin-1 (Arrestin beta 1)   10.16   
  R.KDLFVANVQS*FPPAPEDK.K 2081.99432 2 3.22 86 NEW No 
        
Q9P2B4 CT2NL_HUMAN CTTNBP2 N-terminal-like protein   10.12   
 7470 K.EQKKLS*SQLEEER.S 1683.79489 2 2.45 165 NEW No 
Q5JTD0 TJAP1_HUMAN Tight junction-associated protein 1 (Tight junction protein 4)  10.16   
  R.KDS*LTQAQEQGNLLN 1738.80070 2 3.19 545 Swiss/ 545 phos Yes 
P24043 LAMA2_HUMAN Laminin subunit alpha-2 precursor (Laminin M chain)  10.16   
  R.NS*HIAIAFDDT*KVKNR.L 1988.89902 2 3.24 2772 NEW & 2781 NEW No & No 
Q6Y7W6 PERQ2_HUMAN PERQ amino acid-rich with GYF domain-containing protein 2  10.14   
  R.PGT*PSDHQSQEASQFER.K 1980.80831 2 2.51 382 Swiss/ New in phos No 
Q86WB0 NIPA_HUMAN Nuclear-interacting partner of ALK    20.16   
  K.QSSQPAETDS*MSLSEKS*RK.V 2255.92504 3 3.15 479 NEW & 486 NEW No & No 
  R.SMGTGDT*PGLEVPSS*PLR.K 1960.81224 2 2.26 387 NEW & 395 Swiss/ 395 phos No & Yes 
Q12955 ANK3_HUMAN Ankyrin-3 (ANK-3) (Ankyrin-G)   10.15   
  R.RQS*FASLALR.K 1228.61977 2 2.97 1459 Swiss/ 1459 phos Yes 
Q15642 CIP4_HUMAN Cdc42-interacting protein 4    10.15   
  R.APSDS*SLGTPSDGRPELR.G 1921.86510 2 3.04 298 New in Swiss/ 298 phos Yes 
O15173 PGRC2_HUMAN Membrane-associated progesterone receptor component 2  10.18   
  R.LLKPGEEPSEY*TDEEDTK.D 2159.92675 3 3.57 210 New in Swiss/ 210 phos Yes 
Q8N5S9 KKCC1_HUMAN Calcium/calmodulin-dependent protein kinase kinase 1   20.12   
  R.KLS*LQER.P 953.48154 2 2.35 74 Swiss/ 74 phos Yes 
  R.LIPS*WTT*VILVKS*MLRK.R 2225.09690 2 2.14 443 NEW & 446 NEW & 452 NEW No & No & No 
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Accession 
number 
Peptide MH+ z XC Site # in Swiss/Phosphosite 
(06/17/08) 
Present in Phosphosite 
(06/17/08) 
P30086 PEBP1_HUMAN Phosphatidylethanolamine-binding protein 1 (PEBP-1)   10.23   
  K.NRPTS*ISWDGLDSGK.L 1712.76392 2 4.63 52 Swiss/ New in phos No 
Q9UQB8 BAIP2_HUMAN Brain-specific angiogenesis inhibitor 1-associated protein 2  10.22   
  K.LSDSYSNT*LPVR.K 1431.65152 2 3.93 340 New in Swiss/ 340 phos Yes 
O15530 PDPK1_HUMAN 3-phosphoinositide-dependent protein kinase 1 (hPDK1)  10.31   
  R.ANS*FVGTAQYVSPELLTEK.S 2134.01036 2 6.10 241 Swiss/ 241 phos Yes 
Q9H788 SH24A_HUMAN SH2 domain-containing protein 4A (Protein SH(2)A)  10.21   
  R.TLS*SSAQEDIIR.W 1399.64644 2 4.13 315 Swiss/ 315 phos Yes 
P18615 NELFE_HUMAN Negative elongation factor E (NELF-E) (RD protein)  10.18   
  R.SIS*ADDDLQESSR.R 1502.60061 2 3.56 115 Swiss/ 115 phos Yes 
  K.QPMLDAAT*GKSVWGS*LAVQNS*PKGCHR.D 3078.31268 3 3.44 340 NEW & 347 NEW & 353 
Swiss/ 353 phos 
No & No & Yes 
  R.S*LSEQPVMDTATATEQAK.Q 1986.87255 2 3.56 49 NEW No 
Q9H1B7 CN004_HUMAN Protein C14orf4   20.18   
 3477 R.KAS*PEPPDSAEGALK.L 1576.72541 2 3.57 547 Swiss/ 547 phos Yes 
 3488 R.RNS*SS*PVSPASVPGQR.R 1785.76801 2 3.32 657 Swiss/ 657 phos & 659 Swiss/ 
659 phos 
Yes & Yes 
 8184 R.QSPNSSSAAAS*VAS*RR.G 1735.71597 2 2.23 224 NEW & 227 Swiss/ New in 
phos 
No & No   
Q12857 NFIA_HUMAN Nuclear factor 1 A-type (Nuclear factor 1/A)   20.24   
  R.S*PGSGSQSSGWHEVEPGMPSPTTLK.K 2620.13849 3 4.79 300 Swiss/ 300 phos Yes 
  R.RSLPSTS*ST*SSTKR.L 1654.71966 2 2.49 273 NEW & 275 NEW No & No 
Q5UE93 PI3R6_HUMAN Phosphoinositide 3-kinase regulatory subunit 6   10.16   
  R.PS*GDGEM#LPGVSRLHTAR.V 1975.90551 2 3.21 401 NEW No 
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number 
Peptide MH+ z XC Site # in Swiss/Phosphosite 
(06/17/08) 
Present in Phosphosite 
(06/17/08) 
P21675 TAF1_HUMAN Transcription initiation factor TFIID subunit 1   30.15   
  R.M#LLAAGS*AASGNNHRDDDTASVTSLNS*SATGR.C 3323.39946 3 3.04 1138 NEW & 1158 NEW No & No 
  R.TDPMVTLSSILES*IINDM#R.D 2231.03347 2 2.21 1391 NEW No 
  R.VGT*TVHCDYLNR.P 1457.62426 2 2.17   
  R.VGTTVHCDY*LNRPHK.S 1819.83090 2 2.89 1366 NEW No 
Q8N1N0 CLC4F_HUMAN C-type lectin domain family 4 member F    10.13   
  K.SSFDNT*S*AEIQFLR.G 1774.70843 2 2.70 313 NEW & 314 NEW No & No 
Q04726 TLE3_HUMAN Transducin-like enhancer protein 3 (ESG3)   20.18   
  R.ESSANNSVS*PSESLR.A 1643.69082 2 3.65 203 Swiss/ 203 phos Yes 
  K.DLGHNDKS*STPGLKSNTPT*PR.N 2382.04860 2 2.32 310 NEW No 
  K.SDDLVVDVSNEDPAT*PRVSPAHS*PPENGLDK.A 3417.48827 3 3.78 259 Swiss/ 259 New in phos & 
267 Swiss/ 267 phos 
No & Yes 
  R.VS*PAHS*PPENGLDK.A 1607.65018 2 2.57 263 Swiss/ 263 phos & 267 
Swiss/ 267 phos 
Yes & Yes 
Q5VV41 ARHGG_HUMAN Rho guanine nucleotide exchange factor 16  10.17   
  R.HQS*FGAAVLSR.E 1252.58338 2 3.25 107 NEW No 
Q12906 ILF3_HUMAN Interleukin enhancer-binding factor 3    10.16   
  K.RPMEEDGEEKS*PSK.K 1698.70403 3 3.13 382 Swiss/ 382 phos Yes 
Q96IT1 ZN496_HUMAN Zinc finger protein 496   10.16   
  R.PPS*QLS*GDPVLQDAFLLQEENVR.D 2712.23171 2 2.93 185 Swiss/ New in phos & 188 
NEW 
No & No 
Q9UN86 G3BP2_HUMAN Ras GTPase-activating protein-binding protein 2 (G3BP-2)  10.17   
  K.STT*PPPAEPVSLPQEPPK.A 1951.94122 2 3.33 227 Swiss/ 227 phos Yes 
P55317 HNF3A_HUMAN Hepatocyte nuclear factor 3-alpha (HNF-3A)   10.17   
  K.TGQLEGAPAPGPAAS*PQTLDHSGATATGGASELK.T 3225.50593 3 3.46 332 NEW No 
P35579 MYH9_HUMAN Myosin-9 (Myosin heavy chain 9)    10.17   
  K.KMEDS*VGCLET*AEEVK.R 1927.74653 2 3.31 1376 NEW & 1382 NEW No & No 
 
 159
Table A-1 (continued). 
 
Accession 
number 
Peptide MH+ z XC Site # in Swiss/Phosphosite 
(06/17/08) 
Present in Phosphosite 
(06/17/08) 
P08621 RU17_HUMAN U1 small nuclear ribonucleoprotein 70 kDa (U1 snRNP 70 kDa)  10.18   
  R.YDERPGPS*PLPHR.D 1600.72675 3 3.68 226 Swiss/ 226 phos Yes 
  R.GGGGGQDNGLEGLGNDS*R.D 1739.69803 2 3.35 410 Swiss/ 410 phos Yes 
Q13315 ATM_HUMAN Serine-protein kinase ATM (Ataxia telangiectasia mutated)  20.16   
  K.RSLES*VYS*LYPTLSR.L 1930.87107 2 3.21 2165 NEW & 2168 NEW No & No 
  K.M#LQPIT*R.L 954.44778 2 2.01 2031 NEW No 
Q9UKM9 RALY_HUMAN RNA-binding protein Raly    10.13   
  R.GRLS*PVPVPR.A 1157.61904 2 2.68 135 Swiss/ 135 phos Yes 
  R.AAS*AIYSGYIFDYDYYR.D 2117.88918 2 5.64 206 NEW No 
Q9BSG1 ZNF2_HUMAN Zinc finger protein 2 (Zinc finger 2.2) (Zinc finger protein 661) 10.15   
  K.VFSSKS*SVIQHQR.R 1582.77370 2 2.67 410 NEW No 
Q6ZMT1 STAC2_HUMAN SH3 and cysteine-rich domain-containing protein 2   10.19   
  R.SSFSS*T*SESPTRSLSER.D 2004.79468 2 3.71 224 NEW & 225 NEW No & No 
P85037 FOXK1_HUMAN Forkhead box protein K1 (Myocyte nuclear factor)   20.14   
  R.S*APAS*PTHPGLMSPR.S 1665.68552 2 2.77 416 Swiss/ 416 phos & 420 
Swiss/ 420 phos 
Yes & Yes 
  R.EGS*PIPHDPEFGSK.L 1576.66790 2 2.13 445 Swiss/ 445 phos  
O15062 ZBTB5_HUMAN Zinc finger and BTB domain-containing protein 5  10.13   
  K.HYLTTRTLPMS*PPSER.V 1965.92519 2 2.59 127 NEW No\ 
Q9H2M9 RBGPR_HUMAN Rab3 GTPase-activating protein non-catalytic subunit   10.16   
  K.QDFS*PEVLKLANEER.D 1854.86330 2 3.28 952 NEW No 
P22626 ROA2_HUMAN Heterogeneous nuclear ribonucleoproteins A2/B1 (hnRNP A2 / hnRNP B1) 30.33   
  R.GFGDGYNGYGGGPGGGNFGGS*PGYGGGR.G 2575.00584 3 6.53 259 Swiss/ 259 pho Yes 
  R.NMGGPYGGGNYGPGGSGGS*GGYGGR.S 2269.87165 2 6.11 see line 693  
  R.GGNFGFGDS*R.G 1093.40983 2 3.41 212 Swiss/ 212 phos Yes 
  R.NMGGPYGGGNYGPGGS*GGSGGYGGR.S 2269.87165 2 3.97 341 Swiss/ 341 phos Yes 
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Peptide MH+ z XC Site # in Swiss/Phosphosite 
(06/17/08) 
Present in Phosphosite 
(06/17/08) 
Q9UHD8 SEPT9_HUMAN Septin-9 (MLL septin-like fusion protein)    10.29   
  R.S*FEVEEVETPNSTPPR.R 1897.82150 2 5.71 30 Swiss/ 30 phos Yes 
  K.RS*FEVEEVETPNSTPPR.R 2053.92261 2 3.64 see line 698  
  R.S*FEVEEVET*PNSTPPR.R 1977.78780 2 2.43 38 NEW & 30 Swiss/ 30 phos No & Yes 
Q8TEA8 DTD1_HUMAN Probable D-tyrosyl-tRNA(Tyr) deacylase 1   30.18   
  R.S*ASSGAEGDVSSEREP 1644.63845 2 3.65 194 NEW No 
  K.EDRS*ASSGAEGDVS*S*EREP 2204.74170 2 2.43 194 NEW & 204 Swiss/ 204 
phos & 205 Swiss/ 205 phos 
No & Yes & Yes 
  K.EDRSAS*SGAEGDVS*S*ER.E 1978.64634 2 2.37 196 Swiss/ 196 phos & see line 
703 for 204 & 205 
Yes & Yes & Yes 
Q5JSZ5 K0515_HUMAN Uncharacterized protein KIAA0515   10.22   
  K.LKFS*DDEEEEEVVK.D 1775.76225 2 4.37 388 Swiss/ 388 phos Yes 
P25205 MCM3_HUMAN DNA replication licensing factor MCM3    10.18   
  K.DGDSYDPYDFS*DTEEEMPQVHTPK.T 2882.10223 3 3.58 711 Swiss/ 711 phos Yes 
O95248 MTMR5_HUMAN SET-binding factor 1 (Sbf1) (Myotubularin-related protein 5) 10.16   
  R.RTTVPSGPPMT*AILER.C 1805.89792 2 3.18 546 NEW No 
Q6P6C2 ALKB5_HUMAN Alkylated repair protein alkB homolog 5   10.14   
  R.RGS*FSSENYWR.K 1468.60049 2 2.75 361 Swiss/ 361 phos Yes 
  K.YQEDS*DPERSDYEEQQLQK.E 2466.99327 3 3.45 64 New in Swiss/ 64 phos Yes 
  R.GS*FSSENYWR.K 1312.49938 2 2.31 see line 712  
  R.LET*KS*LSSSVLPPSYASDRLSGNNR.D 2838.30700 3 3.15 294 NEW & 296 NEW Yes & Yes   
Q9NX63 CHCH3_HUMAN Coiled-coil-helix-coiled-coil-helix domain-containing protein 3 10.26   
  R.YS*GAYGASVSDEELK.R 1655.68361 2 5.21 50 Swiss/ 50 phos Yes 
P21796 VDAC1_HUMAN Voltage-dependent anion-selective channel protein 1 (VDAC-1) 10.20   
  K.LTFDSSFS*PNTGK.K 1480.63554 2 3.97 104 Swiss/ 103 pho Yes (Same AA, diff #) 
Q76KP1 B4GN4_HUMAN N-acetyl-beta-glucosaminyl-glycoprotein 4-beta-N-acetylgalactosam 10.14   
  R.TLGPAAPTVDS*NLS*SEAR.P 1945.83033 2 2.81 616 NEW & 619 NEW No & No 
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Q13573 SNW1_HUMAN SNW domain-containing protein 1 (Nuclear protein SkiP)   10.20   
  R.GPPS*PPAPVMHS*PSR.K 1673.69061 2 3.62 224 Swiss/ 224 phos & 232 
Swiss/ 232 phos 
Yes & Yes 
Q9NPH0 PPA6_HUMAN Lysophosphatidic acid phosphatase type 6 precursor   10.13   
  R.GRRQTAS*LQPGIS*EDLK.K 2015.93105 2 2.42 223 NEW & 229 NEW No & No 
Q6WKZ4 RFIP1_HUMAN Rab11 family-interacting protein 1 (Rab11-FIP1)  10.27   
  K.HLFSS*TENLAAGSWK.E 1727.77885 2 5.33 357 Swiss/ New in phos No 
P23193 TCEA1_HUMAN Transcription elongation factor A protein 1   10.27   
  K.EPAITSQNS*PEAR.E 1479.64750 2 2.81 100 Swiss/ 100 phos Yes 
  K.KKEPAITSQNS*PEAR.E 1735.83742 3 3.12 see line 729  
O75446 SAP30_HUMAN Histone deacetylase complex subunit SAP30   10.15   
  K.DTLTYFIY*SVKNDK.N 1786.82988 2 3.06 202 NEW No 
Q07666 SAM68_HUMAN KH domain-containing, RNA-binding, signal transduction-associated protein 1 10.16   
  R.SGS*MDPSGAHPSVR.Q 1464.59369 2 3.21 20 Swiss/ 20 phos Yes 
Q9UHR4 BI2L1_HUMAN Brain-specific angiogenesis inhibitor 1-associated protein 2-like protein 1 10.21   
  K.TPASTPVSGT*PQAS*PMIER.S 2086.89155 2 4.27 257 Swis/ 257 phos & 261 Swiss/ 
261 phos 
Yes & Yes 
P09651 ROA1_HUMAN Heterogeneous nuclear ribonucleoprotein A1   10.32   
  K.S*ESPKEPEQLR.K 1379.62022 2 2.54 4 Swiss/ 4 phos Yes 
  R.SS*GPYGGGGQYFAK.P 1455.59401 2 2.23 338 Swiss/ 338 phos Yes 
Q9Y446 PKP3_HUMAN Plakophilin-3   10.21   
  R.LS*SGFDDIDLPSAVK.Y 1643.75638 2 4.14 313 Swiss/ New in phos No 
  R.ADYDTLS*LR.S 1133.48742 2 2.91 180 New in Swiss/ 180 phos Yes 
Q96T21 SEBP2_HUMAN SECIS-binding protein 2    10.15   
  K.S*ARGSHHLSIYAENSLK.S 1949.92288 2 2.43 174 NEW No 
P52948 NUP98_HUMAN Nuclear pore complex protein Nup98-Nup96 precursor   10.17   
  R.DSENLAS*PSEYPENGER.F 1973.77601 2 3.38 623 Swiss/ 623 phos Yes 
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P35527 K1C9_HUMAN Keratin, type I cytoskeletal 9 (Cytokeratin-9)   20.18   
  R.GSRGGSGGSY*GGGGS*GGGYGGGSGS*R.G 2331.78121 2 3.63 497 NEW & 502 NEW & 512 NEW No & No & No 
  R.GSRGGSGGS*Y*GGGGSGGGYGGGS*GSR.G 2331.78121 2 2.82 496 NEW & 497 NEW & 510 NEW No & No & No 
P51991 ROA3_HUMAN Heterogeneous nuclear ribonucleoprotein A3 (hnRNP A3) 20.29   
  R.SSGS*PYGGGYGSGGGSGGYGSR.R 1990.75627 2 5.90 358 Swiss/ 358 phos Yes 
  R.SSGSPY*GGGYGS*GGGS*GGYGSR.R 2150.68887 2 2.04 360 Swiss/ 360 phos & 366 NEW & 
370 Swiss/ 370 phos 
Yes & No & Yes 
  R.SS*GSPY*GGGYGSGGGS*GGYGSRRF 2453.85840 3 3.00 356 Swiss/ 356 phos & see line 758 
for 360 and 370 
Yes & Yes & Yes 
Q6P5R6 RL22L_HUMAN Ribosomal protein L22-like 1   10.19   
  R.YFQISQDEDES*ESED 1900.66439 2 3.83 118 Swiss/ 118 phos Yes 
Q96T37 RBM15_HUMAN Putative RNA-binding protein 15 (RNA-binding motif protein 15) 20.21   
  R.SLS*PGGAALGYR.D 1228.57215 2 2.74 294 Swiss/ 294 phos Yes 
  K.NS*S*GGGESRSSSRGGGGES*R.S 2107.72263 2 2.34 134 NEW & 135 NEW & 151 NEW No & No & No 
  R.SRS*PLDKDTY*PPSASVVGASVGGHR.H 2700.21779 3 4.27 259 New in Swiss/ 259 phos & 266 
NEW 
Yes & No 
Q9UQF2 JIP1_HUMAN C-jun-amino-terminal kinase-interacting protein 1   10.14   
  K.QFVEYT*CPTEDIYLE 1929.78636 2 2.89 702 NEW No 
O96013 PAK4_HUMAN Serine/threonine-protein kinase PAK 4 (p21-activated kinase 4)  10.14   
  R.PFNT*YPR.A 974.41313 2 2.17 207 Swiss/ New in phos No 
Q15233 NONO_HUMAN Non-POU domain-containing octamer-binding protein (NonO protein) 10.24   
  R.FGQAATMEGIGAIGGT*PPAFNR.A 2243.03145 3 3.66 450 Swiss/ 450 phos Yes 
Q96PK6 RBM14_HUMAN RNA-binding protein 14 (RNA-binding motif protein 14)   10.13   
  R.RLS*ESQLSFR.R 1302.62016 2 2.27 618 Swiss/ 618 phos Yes 
P21291 CSRP1_HUMAN Cysteine and glycine-rich protein 1 (Cysteine-rich protein 1)  10.16   
  K.GFGFGQGAGALVHS*E 1513.64710 2 2.84 192 Swiss/ 191 phos Yes (Same AA, diff #) 
Q9P2K5 MYEF2_HUMAN Myelin expression factor 2 (MyEF-2) (MST156)  10.18   
  K.AEVPGATGGDS*PHLQPAEPPGEPR.R 2446.10343 3 3.66 17 Swiss/ 17 phos Yes 
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Q96J84 KIRR1_HUMAN Kin of IRRE-like protein 1 precursor    10.15   
  R.FSQEPADQT*VVAGQR.A 1712.76392 2 2.98 31 NEW No 
Q9UHL0 DDX25_HUMAN ATP-dependent RNA helicase DDX25 (DEAD box protein 25)  10.18   
  K.WLTVEMIQDGHQVS*LLS*GELTVEQR.A 3028.38862 3 3.50 366 NEW & 369 NEW No & No 
Q5T8P6 RBM26_HUMAN RNA-binding protein 26 (RNA-binding motif protein 26)   10.13   
  K.T*QMQKELLDT*ELDLYKK.M 2256.02698 2 2.67 808 NEW & 817 NEW No & No 
Q9Y3Q4 HCN4_HUMAN Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated 
channel 4 
10.12   
  R.RGTPPLT*PGR.L 1131.56700 2 2.47 1075 NEW No 
Q8TEW8 PAR3L_HUMAN Partitioning-defective 3 homolog B (PAR3-beta)   10.20   
  R.T*QEELVAMLRST*K.Q 1665.73180 2 4.02 445 NEW No 
O60825 F262_HUMAN 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2   10.16   
  R.RNS*FTPLSSSNTIR.R 1659.78499 2 3.16 446 Swiss/ 446 phos Yes 
Q96JC9 EAF1_HUMAN ELL-associated factor 1   10.16   
  K.T*SPLKDNPS*PEPQLDDIKR.E 2310.04139 2 3.15 158 Swiss/ 158 phos & 165 Swiss/ 
165 phos 
Yes & Yes 
O43583 DENR_HUMAN Density-regulated protein (DRP) (Protein DRP1)   20.30   
  K.LTVENS*PKQEAGISEGQGTAGEEEEK.K 2797.24110 3 5.95 73 Swiss/ 73 phos Yes 
Q9C0C2 TB182_HUMAN 182 kDa tankyrase 1-binding protein   40.21   
  R.SPS*QDFSFIEDTEILDSAMYR.S 2531.06835 2 4.20 1554 Swiss/ 1554 phos Yes 
O14745 NHERF_HUMAN Ezrin-radixin-moesin-binding phosphoprotein 50 (EBP50)  30.33   
  R.S*ASSDTSEELNSQDSPPK.Q 1958.78624 2 6.59 288 Swiss/ 287 phos Yes (Same AA, diff #) 
  R.SAS*SDTSEELNSQDSPPK.Q 1958.78624 2 6.11 290 Swiss/ 289 phos Yes (Same AA, diff #) 
  R.EALAEAALES*PRPALVR.S 1872.95787 2 2.72 280 Swiss/ 279 phos Yes (Same AA, diff #) 
P42858 HD_HUMAN Huntingtin (Huntington disease protein) (HD protein)  10.16   
  R.VNHCLTICENIVAQS*VR.N 1978.92381 2 3.27 116 NEW No 
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Q9Y266 NUDC_HUMAN Nuclear migration protein nudC    20.23   
  K.NGSLDS*PGKQDTEEDEEEDEKDK.G 2674.05230 3 4.56 139 Swiss/ 139 phos Yes 
O00264 PGRC1_HUMAN Membrane-associated progesterone receptor component 1 (mPR) 40.17   
  K.EGEEPTVYS*DEEEPK.D 1817.70005 2 2.75 181 Swiss/ 180 phos Yes (Same AA, diff #) 
Q9BVG4 CX026_HUMAN UPF0368 protein Cxorf26   10.16   
  K.GADS*GEEKEEGINR.E 1570.63806 2 3.20 197 NEW No 
Q13286 CLN3_HUMAN Battenin (Protein CLN3) (Batten disease protein)  10.14   
  R.RFS*DS*EGEET*VPEPR.L 1974.69183 2 2.88 12 Swiss/ 12 phos & 14 Swiss/ 14 
phos & 19 NEW 
Yes & Yes & No 
Q5JTV8 TOIP1_HUMAN Torsin-1A-interacting protein 1   30.23   
  R.LQQQHSEQPPLQPS*PVMTR.R 2281.07946 3 3.90 143 Swiss/ 143 New in phos No 
  K.VNFSEEGET*EEDDQDSSHSSVTTVK.A 2836.13161 3 3.60 220 Swiss/ 220 New in phos No 
Q13501 SQSTM_HUMAN Sequestosome-1    10.15   
  R.LTPVS*PESSSTEEK.S 1570.68836 2 2.56 272 Swiss/ 272 phos Yes 
P20700 LMNB1_HUMAN Lamin-B1   30.30   
  R.LKLS*PS*PSSR.V 1231.54828 2 3.11 391 Swiss/ 390 phos & 393 Swiss/ 
392 phos 
Yes (Same AA, diff #) 
  R.LKLS*PSPSSR.V 1151.58198 2 2.63 see line 810  
Q8IXT5 RB12B_HUMAN RNA-binding protein 12B (RNA-binding motif protein 12B) 20.18   
  R.FPPEDFRHS*PEDFR.R 1855.77991 3 3.55 575 Swiss/ 575 phos Yes 
O14578 CTRO_HUMAN Citron Rho-interacting kinase (CRIK)    10.16   
  R.TPLSQVNKVWDQS*S*V 1847.79758 2 2.53 2025 NEW & 2026 NEW No & No 
Q8WWM7 ATX2L_HUMAN Ataxin-2-like protein (Ataxin-2 domain protein)   10.17   
  K.EVDGLLTSEPMGS*PVSSK.T 1912.86092 2 3.27 594 Swiss/ 594 phos Yes 
P62995 TRA2B_HUMAN Arginine/serine-rich-splicing factor 10 (Transformer-2-beta)  10.26   
  K.RPHT*PTPGIYMGR.P 1562.72973 3 3.52 201 Swiss/ 201 phos Yes 
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Q14157 UBP2L_HUMAN Ubiquitin-associated protein 2-like (Protein NICE-4)  30.22   
  R.RYPSSISSS*PQK.D 1416.65185 2 2.58 609 Swiss/ 609 phos Yes 
  K.NPS*DSAVHSPFTK.R 1466.63112 2 2.57 410 NEW No 
P31749 AKT1_HUMAN RAC-alpha serine/threonine-protein kinase (RAC-PK-alpha)  20.18   
  R.RPHFPQFS*YSASGTA 1732.74788 2 2.83 473 Swiss/ 473 phos Yes 
O14646 CHD1_HUMAN Chromodomain-helicase-DNA-binding protein 1   20.17   
  K.S*DSSPLPSEKSDEDDDK.L 1930.74370 2 3.06 1353 Swiss/ 1353 phos Yes 
  K.SDS*SPLPSEKSDEDDDK.L 1930.74370 2 2.75 1355 Swiss/ 1355 phos Yes 
O00257 CBX4_HUMAN E3 SUMO-protein ligase CBX4 (Chromobox protein homolog 4)  20.16   
  R.EEEVSGVS*DPQPQDAGSR.K 1966.80255 2 3.20 334 NEW No 
O14874 BCKD_HUMAN [3-methyl-2-oxobutanoate dehydrogenase [lipoamide]] kinase 20.15   
  R.ARS*TSAT*DTHHVEMAR.E 1929.76736 2 3.10 31 Swiss/ 31 phos & 35 Swiss/ 35 
phos 
Yes & Yes 
Q15056 IF4H_HUMAN Eukaryotic translation initiation factor 4H (eIF-4H)   10.26   
  R.AY*SS*FGGGR.G 1061.34886 2 2.54 12 Swiss/ 11 phos & 14 NEW Yes (Same AA, diff #) & 
No 
Q8NC51 PAIRB_HUMAN Plasminogen activator inhibitor 1 RNA-binding protein   10.25   
  K.SKS*EEAHAEDSVMDHHFR.K 2191.88624 3 3.62 330 Swiss/ 330 phos Yes 
Q9Y478 AAKB1_HUMAN 5'-AMP-activated protein kinase subunit beta-1   10.24   
  R.S*HNNFVAILDLPEGEHQYK.F 2291.04921 3 4.80 108 Swiss/ 107 phos Yes (Same AA, diff #) 
P43243 MATR3_HUMAN Matrin-3   10.23   
  R.RDS*FDDR.G 990.36763 2 2.57 188 Swiss/ 188 phos Yes 
P18669 PGAM1_HUMAN Phosphoglycerate mutase 1 (Phosphoglycerate mutase isozyme B)  10.21   
  R.HGES*AWNLENR.F 1392.56919 2 3.91 11 Swiss/ 13 phos Yes (Same AA, diff #) 
Q96AT1 K1143_HUMAN Uncharacterized protein KIAA1143   10.20   
  R.IQPQPPDEDGDHS*DKEDEQPQVVVLK.K 3022.36770 3 3.96 50 Swiss/ 50 phos Yes 
 
 166
Table A-1 (continued). 
 
Accession 
number 
Peptide MH+ z XC Site # in Swiss/Phosphosite 
(06/17/08) 
Present in Phosphosite 
(06/17/08) 
        
P47736 RGP2_HUMAN Rap1 GTPase-activating protein 1 (Rap1GAP)  10.18   
  R.RSS*AIGIENIQEVQEK.R 1880.91132 2 3.68 499 NEW No 
Q9BUZ4 TRAF4_HUMAN TNF receptor-associated factor 4    10.17   
  R.GS*LDESSLGFGYPK.F 1536.66175 2 3.48 426 NEW No 
Q96T58 MINT_HUMAN Msx2-interacting protein (SPEN homolog)    10.17   
  K.FGKVTSVQIHGTS*EER.Y 1854.87454 2 2.66 374 NEW No 
Q5HYJ3 FA76B_HUMAN Protein FAM76B   10.17   
  K.ISNLS*PEEEQGLWK.Q 1709.77818 2 2.64 193 Swiss/ 193 phos Yes 
Q13427 PPIG_HUMAN Peptidyl-prolyl cis-trans isomerase G    10.17   
  R.RS*ET*PPHWR.Q 1325.51872 2 2.81 356 Swiss/ 356 phos & 358 Swiss/ 
358 phos 
Yes & Yes 
Q9UDY2 ZO2_HUMAN Tight junction protein ZO-2 (Zonula occludens 2 protein)   10.16   
  R.DNS*PPPAFKPEPPK.A 1600.74067 2 3.20 986 Swiss/ 986 phos Yes 
Q9HC52 CBX8_HUMAN Chromobox protein homolog 8 (Polycomb 3 homolog)   10.14   
  R.HGS*GPPSSGGGLYR.D 1408.60049 2 2.62 311 New in Swiss/ 311 phos Yes 
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Table A-2  Phosphorylation sites assigned by product ions in MS/MS spectrum. 
 
Accession 
number 
Scan(s) Peptide  Phosphorylation sites 
P07900 HS90A_HUMAN Heat shock 
protein HSP 90-alpha (HSP 
86)  
   
  K.ESEDKPEIEDVGS*DEEEEK.K S263 confirmed by y6, y7  
S252 not phosphorylated by b4, b5 
  K.ESEDKPEIEDVGS*DEEEEKK.
D 
S263 confirmed by y7, y9 
S252 not phosphorylated by b4, b6 
  R.DKEVS*DDEAEEK.E S231 confirmed by y7, y8 
Q15019 SEPT2_HUMAN Septin-2 
(Protein NEDD5) 
   
  K.IYHLPDAES*DEDEDFKEQTR.
L 
S218 confirmed by y11 and y12 
Y211 not phosphorylated by b2, b3 
T228 not phosphorylated by y2, y4 
  R.YLHDES*GLNR.R S134 confirmed by y3, y5 
Y129 not phosphorylated by b2, b4 
  K.IYHLPDAES*DEDEDFK.E S218 confirmed by y6, y10 
Q15185 TEBP_HUMAN 
Prostaglandin E synthase 3 
(Cytosolic prostaglandin E2 
synthase) 
  
  K.DWEDDS*DEDMSNFDR.F S113 confirmed by y9, y10 
  K.DWEDDS*DEDM#SNFDR.F  
O60716 CTND1_HUMAN Catenin 
delta-1 (p120 catenin)  
   
  R.LRSY*EDMIGEEVPSDQYYW
APLAQHER.G 
S320 not confirmed 
Y321 not confirmed  
S331 not phosphorylated by y13, 
y14 
Y334 not phosphorylated by y10, 
y11 
Y335 not phosphorylated by y9, y10 
  R.HYEDGYPGGSDNYGS*LSR.V S230 confirmed by y3, y5 
Y217 not phosphorylated by b2, b3 
Y221 not phosphorylated by b5, b6 
S225 not phosphorylated by y8, y9 
Y228 not phosphorylated by b12, 
b13 
S232 not phosphorylated by y3 
  R.SQSSHSYDDST*LPLIDR.N T869 confirmed by  y6, y7 
  R.S*YEDMIGEEVPSDQYYWAP
LAQHER.G 
S320 not confirmed 
  R.VGGS*SVDLHR.F S268 confirmed by y6, y7  
  R.S*GDLGDMEPLK.G S920 confirmed by b3 and b4 
  R.TLDRS*GDLGDMEPLK.G S920 confirmed by y10, y11  
  R.S*MGYDDLDYGMMSDYGTA
R.R 
S288 confirmed by b3 
S300 not phosphorylated by y7 
  R.T*LDRSGDLGDMEPLK.G T916 confirmed by b3 
  R.HYEDGYPGGS*DNY*GSLSR
VT*RIEER.Y 
Y228 not confirmed 
  R.S*MGYDDLDYGMMSDYGTA
R.R 
S288 
  R.VGGS*SVDLHR.F S268 
Q9Y2W1 TR150_HUMAN Thyroid 
hormone receptor-associated 
protein 3 
   
  K.WAHDKFS*GEEGEIEDDES*G
TENR.E 
S928 confirmed by b6, b9 
S939 confirmed by y5, y6 
  K.WAHDKFS*GEEGEIEDDESGT
ENR.E 
S928 confirmed by b6, b9 
S939 not phosphorylated by  y5, y6 
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Table A-2 (continued).  
 
Accession 
number 
Scan(s) Peptide  Phosphorylation sites 
  K.WAHDKFS*GEEGEIEDDESGT
*ENREEK.D 
S928 confirmed by b6, b9 
S939 not phosphorylated by  y8, y9 
T941 confirmed by y5, y8 
  R.ERS*PALKS*PLQSVVVR.R S248 not confirmed 
S253 confirmed by y8, y9 
  R.IDIS*PSTFR.K S682 confirmed by y5, y6 
  R.ASAVSELS*PR.E S243 confirmed by y2, y3. 
S240 not phosphorylated by y5, y6 
S237 not phosphorylated by y8, y9 
  K.S*PPSTGSTYGSSQK.E S32o confirmed by b3 
S323 not phosphorylated by y10, 
y11 
S326 not phosphorylated by y7, y8 
S330 not phosphorylated by y3, y4 
  R.DSS*HS*RERS*AEK.T S747 confirmed by y9, y10. 
S749 not confirmed. 
S753 confirmed by y3, y4 
  R.RIDIS*PSTFR.K S682 confirmed by y5, y6 
  K.SPPSTGST*Y*GSS*QK.E T324 confirmed by  b7, b8 
Y325 confirmed by  b8, b9 
S328 not confirmed 
P08651 NFIC_HUMAN Nuclear 
factor 1 C-type (Nuclear 
factor 1/C)  
   
  R.NWTEDMEGGISS*PVK.K S323 confirmed by y3, y4 
S322 not phosphorylated by y4, y5  
T313 not phosphorylated by y12, 
y13 
  R.NWTEDMEGGISS*PVKK.T S323 confirmed by y4, y5 
S322 not phosphorylated by y5, y6  
T313 not phosphorylated by y13, 
y14 
Q13283 G3BP1_HUMAN Ras 
GTPase-activating protein-
binding protein 1 (G3BP-1)  
   
  K.SSS*PAPADIAQTVQEDLR.T S232 confirmed by y15, y16 
T241 not phosphorylated by y6, y7 
  R.YQDEVFGGFVTEPQEES*EEE
VEEPEER.Q 
S149 confirmed by y7, y14 
Q9Y608 LRRF2_HUMAN Leucine-
rich repeat flightless-
interacting protein 2  
   
  R.RGS*GDTSSLIDPDTSLSELR.D S328 confirmed by y17, y18 
T331 not phosphorylated by y14, 
y15 
  R.IS*S*ARSS*PGFTNDDTASIVS
SDRASR.G 
S231 & S232 & S236 not 
confirmed 
  R.PSSRNS*ASATT*PLSGNSS*R.
R 
S312 & T317 & S324 not 
confirmed 
Q5VTR2 BRE1A_HUMAN Ubiquitin-
protein ligase BRE1A 
(BRE1-A)  
   
  K.ALVVPEPEPDSDS*NQER.K S138 confirmed by y4, y5 
S136 not phosphorylated by y5, y7 
  K.PDSEDLSSQSS*AS*KASQEDA
NEIK.S 
S548 confirmed by b10,b11 
S550 confirmed by y11, y12 
Q8N6T3 ARFG1_HUMAN ADP-
ribosylation factor GTPase-
activating protein 1  
   
  R.RSS*DSWEVWGSASTNR.N S361 confirmed by y13, y14 
 169
Table A-2 (continued). 
 
Accession 
number 
Scan(s) Peptide  Phosphorylation sites 
  R.EFLESQEDY*DPCWS*LQEK.Y Y93 not confirmed 
S98 confirmed by b13, b14 
  R.SS*DSWEVWGSASTNR.N S361  
  K.ASELGHS*LNENVLKPAQEK.V S246 not confirmed 
Q9Y6G9 DC1L1_HUMAN 
Cytoplasmic dynein 1 light 
intermediate chain 1  
   
  R.DFQEYVEPGEDFPAS*PQR.R S207 confirmed by y3, y5 
  K.KTGSPGGPGVSGGS*PAGGAGGG
SS*GLPPSTKK.S 
S468 confirmed by b11, b15 
  K.PVT*VS*PTTPTSPTEGEAS* T508 confirmed by b3 
S510 confirmed by y13, y14 
Q9Y2U5 M3K2_HUMAN Mitogen-
activated protein kinase 
kinase kinase 2  
   
  R.DRSS*PPPGYIPDELHQVAR.N S164 confirmed by b3, b4 
  R.AQS*YPDNHQEFSDYDNPIFEK.F S239 confirmed by b3, b4  
  K.RLS*IIGPTSR.D S153 confirmed by y7, y8 
  R.GS*DIDNPT*LTVM#DISPPSR.S S331 confirmed by  b3 
T337 not confirmed 
O00193 SMAP_HUMAN Small 
acidic protein 
   
  R.S*ASPDDDLGSSNWEAADLGNEE
R.K 
S15 not confirmed 
O95218 ZRAB2_HUMAN Zinc 
finger Ran-binding domain-
containing protein 2  
   
  R.ENVEYIEREES*DGEYDEFGR.K S120 
  R.EES*DGEYDEFGR.K S120 confirmed by y9, y10 
  K.YNLDAS*EEEDSNK.K S188 confirmed by y7, y8 
  K.EVEDKES*EGEEEDEDEDLSK.Y S153 confirmed by b7 
  R.S*SSRS*S*SPSSSRSR.S S213 & S217 & S218 not 
confirmed 
Q8N5F7 NKAP_HUMAN NF-
kappa-B-activating protein 
   
  R.IGELGAPEVWGLS*PK.N S149 confirmed by b12, b13 
  K.Y*S*EDS*DSDSDSETDSSDEDNK.
R 
Y209  &S 210 & S213 not 
confirmed 
Q9NSK0 KLC4_HUMAN Kinesin 
light chain 4  
   
  R.AAS*LNYLNQPSAAPLQVSR.G S590 confirmed by b3 
Y593 not phosphorylated by y12, 
y14 
Q9H1E3 NUCKS_HUMAN Nuclear 
ubiquitous casein and 
cyclin-dependent kinases 
substrate 
   
  K.VVDYSQFQES*DDADEDYGR.D S19 confirmed by y8, y10 
Q92625 ANKS1_HUMAN Ankyrin 
repeat and SAM domain-
containing protein 1A 
(Odin) 
  
  K.SPS*FASEWDEIEK.I S663 confirmed by y10, y11 
O00192 ARVC_HUMAN Armadillo 
repeat protein deleted in 
velo-cardio-facial syndrome 
   
  R.S*LAADDEGGPELEPDYGTATR.R S267 confirmed by b3 
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Table A-2 (continued). 
 
Accession 
number 
Scan(s) Peptide  Phosphorylation sites 
  R.NFDT*LDLPK.R T642 confirmed by y5, y6 
O15027 K0310_HUMAN 
Uncharacterized protein 
KIAA0310 
   
  R.FTGS*FDDDPDPHRDPYGEE
VDR.R 
S1149 confirmed by b2, b5 
Y1161 not phosphorylated by y4, y7 
Q14247 SRC8_HUMAN Src 
substrate cortactin  
   
  R.LPSS*PVYEDAASFK.A S418 confirmed by y10, y11 
  K.TQT*PPVS*PAPQPTEER.L T401 confirmed by y13, y14 
S405 confirmed by y9, y10 
  R.VDKSAVGFDY*QGKT*EK.H Y178 confirmed by b6, b10 
T182 confirmed by b13, b14 
  K.GRY*GLFPANY*VELR.Q Y538 confirmed by  b3 
Y545 confirmed by y2, y5 
  K.LS*KHCS*QVDSVRGFGGK.F S109 confirmed by b3 
S113 confirmed by  y11, y13 
  R.LPSS*PVY*EDAASFK.A S418 confirmed by y10, y11 
Y421 not confirmed 
Q14498 RBM39_HUMAN RNA-
binding protein 39  
   
  K.DKS*PVREPIDNLTPEER.D S136 confirmed by b3 
T146 not phosphorylated by y4, y5 
  R.YRS*PYSGPK.F S97 confirmed by y6, y7 
Q6ICG6 CV009_HUMAN 
Uncharacterized protein 
C22orf9 
   
  K.SHS*ANDSEEFFR.E S324 confirmed by y9, y10 
Q9NYF8 BCLF1_HUMAN Bcl-2-
associated transcription 
factor 1  
   
  K.FNDS*EGDDTEETEDYR.Q S397 confirmed by y11, y13 
  R.AEGEWEDQEALDYFS*DKES
GK.Q 
S385 not confirmed 
  K.KAEGEPQEES*PLK.S S177 confirmed by b9, b10 
  K.DLFDYS*PPLHK.N S512 confirmed by y5, y6 
  K.LKDLFDYS*PPLHK.N  
  R.IDIS*PSTLR.K S658 confirmed by y5, y6 
  R.YSPS*QNS*PIHHIPSR.R S287 not confirmed 
S 290 confirmed by y8, y9 
  R.AEGEWEDQEALDYFS*DK.E S385 confirmed by b14, b15 
  R.RIDIS*PSTLR.K S658 
  R.SSSSS*AS*PSSPSS*REEK.E S755 confirmed by b4, b5 
S757 confirmed by b6, b7 S763 not 
confirmed 
  R.S*SSSRSSSPYSKSPVS*K.R S141 not confirmed 
S156 confirmed by y3 
  R.YSPS*QNS*PIHHIPSR.R  
P42167 LAP2B_HUMAN Lamina-
associated polypeptide 2, 
isoforms beta/gamma  
   
  K.GPPDFS*SDEEREPTPVLGSG
AAAAGR.S 
S66 not confirmed 
  R.SST*PLPTISSSAENTR.Q T160 confirmed by y13, y14 
  K.GPPDFSSDEEREPT*PVLGSG
AAAAGR.S 
T174 confirmed by b12, b14 
  R.EQGTES*RSST*PLPTISSSAE
NTR.Q 
S156 not confirmed 
T160 confirmed by y13, y14 
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Table A-2 (continued). 
 
Accession 
number 
Scan(s) Peptide  Phosphorylation sites 
P54578 UBP14_HUMAN Ubiquitin 
carboxyl-terminal hydrolase 
14  
   
  R.AS*GEMASAQYITAALR.D S143 confirmed by b5, b6 
  R.AS*GEM#ASAQYITAALR.D see line 118 
  K.S*S*KISRLPAYLTIQMVR.F S314  & S315 not confirmed 
Q8NDX5 PHC3_HUMAN 
Polyhomeotic-like protein 3  
   
  R.MDRT*PPPPTLS*PAAITVGR.G T609 confirmed by  b4, b5 
S616 confirmed by y8, y9 
Q8IYB3 SRRM1_HUMAN 
Serine/arginine repetitive 
matrix protein 1  
   
  K.KETES*EAEDNLDDLEK.H S874 confirmed by y11, y12 
  K.KPPAPPS*PVQSQS*PSTNWSP
AVPVK.K 
S769 confirmed by  b5, b7 
S775 confirmed by y12, y13 
  K.KPPAPPS*PVQSQS*PSTNWS*
PAVPVK.K 
S 781 confirmed by y6, y7 
  K.EKT*PELPEPSVK.V T220 confirmed by y9, y10 
  K.SRVS*VS*PGR.T S429 confirmed by y5, y6 
S431 confirmed by y3, y4 
  R.RYS*PPIQR.R S597 confirmed y5, y6 
  R.RLS*PSAS*PPR.R S389 confirmed by b2, b3 
S393 confirmed by b6, b7 
  R.HRPS*PPAT*PPPK.T S402 confirmed by b5  
T406 confirmed by  y5 
P10644 KAP0_HUMAN cAMP-
dependent protein kinase type 
I-alpha regulatory subunit  
   
  R.EDEIS*PPPPNPVVK.G S83 confirmed by y9, y10 
  R.TDSREDEIS*PPPPNPVVK.G  
P06748 NPM_HUMAN 
Nucleophosmin 
   
  K.DELHIVEAEAMNYEGS*PIK.V S70 confirmed by y3, y4 
  K.DELHIVEAEAMNYEGS*PIKV
TLATLK.M 
 
P31943 HNRH1_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein H  
   
  R.PSGEAFVELES*EDEVK.L S63 confirmed by y5, y6 
P16949 STMN1_HUMAN Stathmin    
  K.ESVPEFPLS*PPK.K S38 confirmed by y3, y4 
S31 not phosphorylated by b2, b3 
  R.ASGQAFELILS*PR.S S25 confirmed by y3, y4 
Q14694 UBP10_HUMAN Ubiquitin 
carboxyl-terminal hydrolase 
10  
   
  K.NHSVNEEEQEEQGEGS*EDEW
EQVGPR.N 
S576 confirmed by y8, y11 
Q9UK76 HN1_HUMAN 
Hematological and 
neurological expressed 1 
protein  
   
  R.RNS*SEASSGDFLDLK.G S87 confirmed by y12, y13 
S88 not phosphorylated by y11, 
y12 
S91 not phosphorylated by y8, y9 
  R.NS*SEASSGDFLDLK.G  
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Table A-2 (continued). 
 
Accession 
number 
Scan(s) Peptide  Phosphorylation sites 
Q13263 TIF1B_HUMAN 
Transcription intermediary 
factor 1-beta  
   
  R.STAPSAAASASASAAASS*PAGGGAE
ALELLEHCGVCR.E 
S50 confirmed by b17, b18 
  R.SRS*GEGEVSGLMR.K S473 confirmed by b2, b3 
  R.S*GEGEVSGLMR.K  
Q53SF7 CBLL1_HUMAN Cordon-
bleu protein-like 1 
   
  R.AGS*LQLSSMSAGNSSLR.R S382 confirmed by y14, y15 
  R.QS*SLTFQSSDPEQMR.Q S1146 confirmed by y14 
O75821 IF34_HUMAN Eukaryotic 
translation initiation factor 3 
subunit 4 (eIF-3 delta) 
   
  K.GIPLATGDT*SPEPELLPGAPLPPPK.E T41 not confirmed 
Q9UKL0 RCOR1_HUMAN REST 
corepressor 1  
   
  R.EREES*EDELEEANGNNPIDIEVDQN
K.E 
S257 confirmed by b4, b6 
Q6PKG0 LARP1_HUMAN La-related 
protein 1  
   
  K.GLSAS*LPDLDSENWIEVK.K S548 confirmed by y13, y14 
  R.S*LPTTVPESPNY*R.N S766 confirmed by b2 
Y777 confirmed by b11,b12 
  R.SLPTTVPES*PNYR.N S774 confirmed by y4, y6 
  K.ILIVTQT*PHYMR.R T649 not confirmed 
  R.EHRPRTASISSS*PSEGTPT*VGSYGC
TPQSLPK.F 
S851 not confirmed  
S858 not confirmed 
  K.QEVENFKKVNM#IS*R.E S716 not confirmed 
O43741 AAKB2_HUMAN 5'-AMP-
activated protein kinase 
subunit beta-2  
   
  R.DLSSS*PPGPYGQEMYAFR.S S184 confirmed by y13, y14 
Q9Y2V2 CHSP1_HUMAN Calcium-
regulated heat stable protein 1 
   
  R.GNVVPS*PLPTR.R S41 confirmed by y5, y6 
P12694 ODBA_HUMAN 2-
oxoisovalerate dehydrogenase 
subunit alpha, mitochondrial 
precursor 
  
  R.S*VDEVNYWDK.Q S347 confirmed by b2, b3 
  R.IGHHS*TSDDSSAYR.S S337 not confirmed 
Q8NEY8 PPHLN_HUMAN Periphilin-
1  
   
  R.DNTFFRES*PVGR.K S133 confirmed by y4, y5 
Q96JM3 K1802_HUMAN Zinc finger 
protein KIAA1802 
   
  R.KPSPSES*PEPWKPFPAVS*PEPR.R S286 confirmed by b6, b9 
S 297 confirmed by y4, y7 
  R.KPSGS*PDLWK.L S445 confirmed by y5, y7 
  R.KPS*PS*ESPEPWKPFPAVSPEPR.R S282 not confirmed 
 S284 not confirmed 
  K.TAPTLS*PEHWK.A S405 confirmed by y5, y6 
  R.RPAPAVS*PGSWK.P S308 confirmed by y5, y6 
  R.GGS*PDLWK.S S476 confirmed by y5, y6 
  R.KPGPPLS*PEIR.S S427 confirmed by y4, y5 
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Table A-2 (continued). 
 
Accession 
number 
Scan(s) Peptide  Phosphorylation sites 
  R.KTS*PASLDFPESQK.S S459 not confirmed  
  R.KT*SPASLDFPES*QKS*SR.G S458  & S468  & S471 not 
confirmed 
Q15459 SF3A1_HUMAN Splicing 
factor 3 subunit 1  
   
  K.FGESEEVEMEVES*DEEDDKQEK.A S329 confirmed by y9, y10 
Q9UL54 TAOK2_HUMAN 
Serine/threonine-protein 
kinase TAO2  
   
  K.MLLARHS*LDQDLLR.E S656 confirmed by y7, y9 
  R.HS*LDQDLLR.E S656 confirmed by b5, b6 
Q15139 KPCD1_HUMAN 
Serine/threonine-protein 
kinase D1 
   
  R.RLS*NVS*LTGVSTIR.T S205 confirmed by y11. y12 
S208 confirmed by y7, y9 
  R.RLS*NVSLTGVSTIR.T S205 confirmed by y11, y12 
  R.T*SS*AELST*SAPDEPLLQKSPSESFI
GREK.R 
T217 & S219  & T224 not 
confirmed 
Q9UEW8 STK39_HUMAN 
STE20/SPS1-related proline-
alanine-rich protein kinase  
   
  K.TEDGDWEWS*DDEMDEK.S S387 confirmed by y6, y9 
  K.ADMWSFGITAIELATGAAPY*HKY*
PPMK.V 
Y275 & Y278 not 
confirmed 
Q9H0B6 KLC2_HUMAN Kinesin 
light chain 2 (KLC 2) 
   
  R.RDS*APYGEYGSWYK.A S428 confirmed by y11, y12 
  R.ASS*LNFLNK.S S528 confirmed by y6, y7 
  R.TLSSS*SMDLSR.R S610 confirmed by y6, y7 
Q32MZ4 LRRF1_HUMAN Leucine-
rich repeat flightless-
interacting protein 1  
   
  R.RGS*GDTSISIDTEASIR.E S120 confirmed by y14, y15 
Q15052 ARHG6_HUMAN Rho 
guanine nucleotide exchange 
factor 6  
   
  R.MS*GFIYQGK.I S488 confirmed by y7, y8, 
P21127 CD2L1_HUMAN PITSLRE 
serine/threonine-protein 
kinase CDC2L1  
   
  K.AYT*PVVVTLWYR.A T595 confirmed by y9, y10 
P17812 PYRG1_HUMAN CTP 
synthase 1  
   
  R.SGSSS*PDSEITELK.F S575 confirmed by y9, y10 
  K.YIDSADLEPITS*QEEPVR.Y S347 confirmed by y5, y7 
P25490 TYY1_HUMAN 
Transcriptional repressor 
protein YY1  
   
  K.DIDHETVVEEQIIGENS*PPDYSEYM
TGK.K 
S247 confirmed by y11, y12 
  R.EEVVGGDDS*DGLR.A S118 confirmed by y4, y7 
Q16637 SMN_HUMAN Survival 
motor neuron protein  
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Table A-2 (continued). 
 
Accession 
number 
Scan(s) Peptide  Phosphorylation sites 
  R.GTGQS*DDSDIWDDTALIK.A S28 confirmed by y13, y14 
Q13177 PAK2_HUMAN 
Serine/threonine-protein 
kinase PAK 2  
   
  K.YLS*FTPPEK.D S141 confirmed by y5, y7 
Q08945 SSRP1_HUMAN FACT 
complex subunit SSRP1  
   
  K.EGMNPSYDEYADS*DEDQHDAYL
ER.M 
S444 confirmed by b12, b14 
P35221 CTNA1_HUMAN Catenin 
alpha-1  
   
  R.S*RTS*VQTEDDQLIAGQSAR.A S652 no confirmed 
S 655 confirmed by y14, y16 
  R.T*SVQTEDDQLIAGQSAR.A T654 no confirmed 
Q13242 SFRS9_HUMAN Splicing 
factor, arginine/serine-rich 9  
   
  R.GSPHYFS*PFRPY S216 confirmed by y5, y6 
  R.GS*PHYFS*PFRPY S211 confirmed by b2 
S216 confirmed by y5, y6 
  R.STS*YGYSR.S S189 confirmed by y5, y6 
  R.GRDS*PYQSR.G S204 not confirmed 
O93594 AGM1_HUMAN 
Phosphoacetylglucosamine 
mutase (PAGM)  
   
  K.STIGVMVTAS*HNPEEDNGVK.L S64 confirmed by y10, y12 
Q9Y6X9 MORC2_HUMAN MORC 
family CW-type zinc finger 
protein 2  
   
  R.SVAVS*DEEEVEEEAER.R S743 confirmed by y9, y12 
Q92934 BAD_HUMAN Bcl2 
antagonist of cell death  
   
  R.RMS*DEFVDSFK.K S118 confirmed by b2, b4 
  R.HSS*YPAGTEDDEGMGEEPSPFR.G S75 no confirmed 
  R.S*APPNLWAAQR.Y S99 confirmed by b2, b7 
Q9C0C2 TB182_HUMAN 182 kDa 
tankyrase 1-binding protein 
   
  R.RFS*EGVLQSPSQDQEK.L S429 confirmed by b2, b4 
S435 not phosphorylated  by 
y7, y8 
S437 not phosphorylated by 
y4, y7 
  R.S*QEADVQDWEFR.K S836 not confirmed 
  K.VST*LRES*SAMAS*PLPR.E T5 & S 9 & S14 not 
confirmed 
Q96B36 AKTS1_HUMAN Proline-
rich AKT1 substrate  
   
  R.AATAARPPAPPPAPQPPS*PTPS*PP
RPTLAR.E 
S88 confirmed by  y12, y13 
S92 confirmed by y8, y9 
  K.S*LPVSVPVWGFK.E S183 not confirmed  
  R.LNT*SDFQK.L T246 not confirmed  
  R.AAT*AARPPAPPPAPQPPS*PT*PSP
PR.P 
T73 & S88 &T 90 not 
confirmed 
Q14671 PUM1_HUMAN Pumilio 
homolog 1 (Pumilio-1)  
   
  R.RDS*LTGSSDLYK.R S709 confirmed by y9, y10 
  R.S*ASSASSLFSPSSTLFSS*SR.L S797 not confirmed 
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Accession 
number 
Scan(s) Peptide  Phosphorylation sites 
P08559 ODPA_HUMAN Pyruvate 
dehydrogenase E1 
component alpha subunit 
   
  R.YHGHS*MSDPGVS*YR.T S293 confirmed by y9, y10 
S300 confirmed by b11,b12 
  R.YGMGTS*VER.A S232 confirmed by y3, y4 
  R.YHGHSMS*DPGVSYR.T S295 not confirmed 
Q9UQ35 SRRM2_HUMAN 
Serine/arginine repetitive 
matrix protein 2  
   
  R.HGGS*PQPLATTPLSQEPVNPPSEA
S*PTR.D 
S377 no confirmed 
S398 confirmed by y3, y4 
  K.SST*PPGESYFGVSSLQLK.G T1043 no confirmed 
  R.S*RT*PLLPR.K S2032 no confirmed 
T2034 confirmed by y5, y6 
  R.GPS*PEGSS*ST*ESSPEHPPK.S S1648 confirmed by b4 
S1653 & T1655 not confirmed 
  R.AHRSTSADS*ASSS*DTS*R.S S268  &S 272 &T275 not 
confirmed 
  R.QS*PSRS*SSPQPK.V S908 & S912 not confirmed 
P98175 RBM10_HUMAN RNA-
binding protein 10  
   
  R.HRHS*PTGPPGFPR.D S189 confirmed by b2, b4 
  R.Y*GATDRSQDDGGENRS*R.D Y16 confirmed by b3 
Q9BW71 HIRP3_HUMAN HIRA-
interacting protein 3 
   
  K.SLKES*EQES*EEEILAQK.K S223 confirmed by y12, y14 
S227 confirmed by b8, b9 
Q9BSJ8 FA62A_HUMAN Protein 
FAM62A  
   
  R.KLDVSVKSNS*SFMS*R.E S1063 no confirmed 
S1067 confirmed by y2, y4 
Q9UKS6 PACN3_HUMAN Protein 
kinase C and casein kinase 
substrate in neurons protein 3 
   
  R.DGTAPPPQSPGSPGTGQDEEWS*D
EESPR.K 
S354 confirmed by y6, y7 
P24844 MLRN_HUMAN Myosin 
regulatory light chain 2, 
smooth muscle isoform  
   
  R.ATS*NVFAMFDQSQIQEFK.E S20 no confirmed 
P04792 HSPB1_HUMAN Heat-
shock protein beta-1 (HspB1) 
(Heat shock 27 kDa protein)  
   
  R.QLS*SGVSEIR.H S82 confirmed by y7, y8 
S83 not phosphorylated by y6, 
y7 
  R.GPS*WDPFR.D S15 confirmed by b2, b3 
P05455 LA_HUMAN Lupus La 
protein (Sjoegren syndrome 
type B antigen) 
   
  K.FAS*DDEHDEHDENGATGPVK.R S366 confirmed by b2, b3 
  R.SPS*KPLPEVTDEYK.N S94 confirmed by y11, y13 
O60841 IF2P_HUMAN Eukaryotic 
translation initiation factor 
5B  
   
  K.NKPGPNIES*GNEDDDASFK.I S214 confirmed by y10, y11 
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Accession 
number 
Scan(s) Peptide  Phosphorylation sites 
P51114 FXR1_HUMAN Fragile X 
mental retardation syndrome-
related protein 1 (hFXR1p) 
   
  R.RGPNYTSGYGTNSELSNPS*ETES
ER.K 
S409 confirmed by y5, y7 
  R.RGPNYTSGYGTNSELS*NPS*ETE
SER.K 
S406 confirmed by y9, y10 
P08238 HS90B_HUMAN Heat shock 
protein HSP 90-beta (HSP 84) 
(HSP 90) 
   
  K.IEDVGS*DEEDDSGKDK.K S255 confirmed by b4, b6 
S261 not phosphorylated by 
b11, b12 
  K.IEDVGS*DEEDDSGK.D S255 confirmed by y7, y10 
  K.IEDVGS*DEEDDSGKDKK.K  
  R.EKEIS*DDEAEEEK.G S226 confirmed by y8, y9 
Q9UEE9 CFDP1_HUMAN Craniofacial 
development protein 1  
   
  K.LDWES*FKEEEGIGEELAIHNR.G S250 confirmed by b4, b9 
Q9Y383 LC7L2_HUMAN Putative 
RNA-binding protein Luc7-like 
2 
   
  R.AMLDQLMGTS*R.D S18 confirmed by y2, y3 
T17 not phosphorylated by 
y3, y4 
Q99613 IF38_HUMAN Eukaryotic 
translation initiation factor 3 
subunit 8 (eIF3 p110)  
   
  K.QPLLLS*EDEEDTKR.V S39 confirmed by y8, y9 
O14974 MYPT1_HUMAN Protein 
phosphatase 1 regulatory 
subunit 12A  
   
  K.TGS*YGALAEITASK.E S445 confirmed by y11,y12 
  K.SPLIES*TANMDNNQSQKTFKNK.
E 
S304 confirmed by b5, b6 
  R.RST*QGVTLTDLQEAEK.T T696 not confirmed 
  R.KTGS*YGALAEITASK.E S445 
Q9Y3S2 ZN330_HUMAN Zinc finger 
protein 330  
   
  R.KDS*DTESSDLFTNLNLGR.T S291 confirmed by y15, y16 
P61978 HNRPK_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein K  
   
  R.GSY*GDLGGPIITTQVTIPK.D Y380 confirmed by y14, y17 
  R.RDYDDMS*PR.R S284 confirmed by y2, y3 
  R.GSY*GDLGGPIITT*QVTIPK.D  
  R.DYDDMS*PR.R S284 
P51858 HDGF_HUMAN Hepatoma-
derived growth factor (HDGF)  
   
  R.AGDLLEDS*PK.R S165 confirmed by y3, y4 
  R.RAGDLLEDS*PK.R  
  R.AGDLLEDS*PKRPK.E  
  K.GNAEGS*S*DEEGKLVIDEPAK.E S132 not confirmed 
S133 not confirmed 
  K.KGNAEGS*S*DEEGKLVIDEPAK.
E 
 
  K.GNAEGS*SDEEGKLVIDEPAK.E S132 confirmed by b5, b6 
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Accession 
number 
Scan(s) Peptide  Phosphorylation sites 
P22059 OSBP1_HUMAN Oxysterol-
binding protein 1 
  
  R.TGS*NISGASSDISLDEQYK.H S379 confirmed by y16, y17 
  K.GDMS*DEDDENEFFDAPEIITMPE
NLGHK.R 
S351 not confirmed 
Q8NE71 ABCF1_HUMAN ATP-binding 
cassette sub-family F member 1  
   
  K.LSVPTS*DEEDEVPAPK.P S109 confirmed by y9, y11 
  K.LSVPTS*DEEDEVPAPKPR.G S109 confirmed by y12, y13 
P55795 HNRH2_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein H'  
   
  K.HTGPNS*PDTANDGFVR.L S104 confirmed by y10, y11 
Q9BYG3 MK67I_HUMAN MKI67 FHA 
domain-interacting nucleolar 
phosphoprotein  
   
  K.S*QVAELNDDDKDDEIVFK.Q S247 confirmed by b3 
P02545 LMNA_HUMAN Lamin-A/C 
(70 kDa lamin)  
   
  R.NKS*NEDQSMGNWQIK.R S458 confirmed by b4 
  R.LRLS*PSPTSQR.S S390 confirmed by y7, y8 
  R.KLEST*ES*RSSFSQHAR.T T424 confirmed by y11, y12 
S426 no confirmed 
  R.LRLS*PS*PTSQR.S S390 confirmed by y7, y8 
S392 confirmed by y5, y6 
  R.SVGGS*GGGSFGDNLVTR.S S632 not confirmed 
P06493 CDC2_HUMAN Cell division 
control protein 2 homolog (p34 
protein kinase) 
   
  R.VYT*HEVVTLWYR.S T161 confirmed by y9, y10 
P49585 PCY1A_HUMAN Choline-
phosphate cytidylyltransferase A  
   
  R.MLQAIS*PK.Q S315 confirmed by b5,b6 
  K.T*SPPCS*PANLSR.H T342 not confirmed 
S347 confirmed by y6, y7 
Q16204 CCDC6_HUMAN Coiled-coil 
domain-containing protein 6 (H4 
protein) 
   
  R.PIS*PGLSYASHTVGFTPPTSLTR.
A 
S367 confirmed by b3 
  R.T*VSSPIPYTPSPSSSR.P T349 no confirmed 
  R.PIS*PGLSYASHTVGFT*PPTSLTR.
A 
S367 confirmed by  b3 T380 
not confirmed 
  R.QLSESES*SLEMDDER.Y S327 no confirmed 
  K.LDQPVS*APPS*PR.D S240 confirmed by b5, b7 
S244 confirmed by y2, y3 
Q9NTJ3 SMC4_HUMAN Structural 
maintenance of chromosomes 
protein 4  
   
  R.T*ESPATAAETASEELDNR.S T39 no confirmed 
  K.S*S*LAMNRS*R.G S588 & S589 not confirmed 
S595 confirmed by y3 
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Accession 
number 
Scan(s) Peptide  Phosphorylation sites 
Q8TAQ2 SMRC2_HUMAN SWI/SNF-
related matrix-associated actin-
dependent regulator of 
chromatin subfamily C member 
2 
  
  R.KRS*PSPSPT*PEAK.K S302 confirmed by b2, b3 
T308 confirmed by y4, y6 
  K.DMDEPS*PVPNVEEVTLPK.T S347 confirmed by y12, y14 
Q14676 MDC1_HUMAN Mediator of 
DNA damage checkpoint 
protein 1  
   
  R.LLLAEDS*EEEVDFLSER.R S168 confirmed by y9, y11 
Q8WUA2 PPIL4_HUMAN Peptidyl-
prolyl cis-trans isomerase-like 
4 (PPIase) 
   
  R.INHTVILDDPFDDPPDLLIPDRSPE
PT*R.E 
T182 not confirmed 
  R.INHTVILDDPFDDPPDLLIPDRS*P
EPTR.E 
S178 confirmed by y5, y7 
P18887 XRCC1_HUMAN DNA-repair 
protein XRCC1  
   
  K.TKPTQAAGPSS*PQKPPT*PEETK.
A 
S447 no confirmed 
T453 confirmed by y5, y7 
P07814 SYEP_HUMAN Bifunctional 
aminoacyl-tRNA synthetase  
   
  K.EYIPGQPPLSQSSDSS*PTR.N S886 confirmed by y3, y4 
  R.AKIDM#SS*NNGCMRDPTLY*R.C S346 not confirmed 
  K.HPKNPEVGLKPVWY*S*PK.V Y546 & S547 not confirmed 
P27824 CALX_HUMAN Calnexin 
precursor  
   
  K.AEEDEILNRS*PR.N S583 confirmed by b9, b10 
O75494 FUSIP_HUMAN FUS-
interacting serine-arginine-rich 
protein 1  
   
  R.S*FDYNYR.R S133 confirmed by b2 
  R.S*RS*FDYNYR.R S131 confirmed by b2 
S133 confirmed by b2, b4 
Q15773 MLF2_HUMAN Myeloid 
leukemia factor 2  
   
  R.QHMS*RMLSGGFGY*SPFLSIT*D
GNMPGTR.P 
S29 & Y37 & T44 not 
confirmed 
  R.LAIQGPEDS*PSR.Q S238 confirmed by y3, y4 
Q15366 PCBP2_HUMAN Poly(rC)-
binding protein 2 (Alpha-CP2)  
   
  K.PSSS*PVIFAGGQDR.Y S189 confirmed by b3, b4 
P30622 CLIP1_HUMAN Restin     
  K.LT*NLQENLSEVSQVKETLEK.E T822 confirmed by b4 
  K.TISSEKAS*S*TPSS*ETQEEFVDD
FRVGER.V 
S43 & S44 & S48 not 
confirmed 
  R.VM#ATTSASLKRSPSASSLSSMS*
SVASS*VSSR.P 
S320 & S325 not confirmed 
  R.SPSASSLS*SMS*SVASSVSSRPSR.
T 
S317 confirmed by y15, y16  
S320 not confirmed 
  K.RS*PSASS*LSSM#SSVASSVSSR.P S310 confirmed by b2 
S315 not confirmed  
  K.EPSATPPIS*NLTKTAS*ESISNLSE
AGS*IK.K 
S186 & S193 not confirmed 
 S204 confirmed by y3, y4 
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Accession 
number 
Scan(s) Peptide  Phosphorylation sites 
P11717 MPRI_HUMAN Cation-
independent mannose-6-
phosphate receptor precursor  
   
  K.LVSFHDDS*DEDLLHI S2484 confirmed by y6, y8 
O00567 NOP56_HUMAN Nucleolar 
protein Nop56  
   
  K.EELMSS*DLEETAGSTSIPK.R S520 confirmed by y13, y14 
P52756 RBM5_HUMAN RNA-binding 
protein 5  
   
  R.GLVAAYSGDS*DNEEELVER.L S624 confirmed by y9, y12 
Q8ND30 LIPB2_HUMAN Liprin-beta-2     
  R.T*QSGNFYTDTLGMAEFR.R T510 not confirmed 
P40222 TXLNA_HUMAN Alpha-
taxilin 
   
  R.RPEGPGAQAPSS*PR.V S515 confirmed by y2, y3 
Q8IWS0 PHF6_HUMAN PHD finger 
protein 6 (PHD-like zinc finger 
protein) 
   
  K.TAHNSEADLEESFNEHELEPSS*P
K.S 
S155 confirmed by y3 
Q13595 TRA2A_HUMAN 
Transformer-2 protein homolog 
(TRA-2 alpha) 
   
  R.PTHS*GGGGGGGGGGGGGGGG
RRR.D 
S215 not confirmed 
  R.AHT*PTPGIYMGR.P T202 confirmed by y9, y10 
  R.RS*PS*PYYSR.Y S260 confirmed by b2 
S262 confirmed by b3, b4 
  R.S*PS*PYYSR.Y  
  R.RRDSY*YDR.G Y237 not confirmed 
  R.RRS*PSPYY*SR.Y S260 confirmed by b2, b3 
Y265 confirmed by y2, y3 
Q13489 BIRC3_HUMAN Baculoviral 
IAP repeat-containing protein 3  
   
  -.M#NIVENS*IFLS*NLMK.S S7 confirmed by y7, y10 
S11 confirmed by y4, y7 
P49736 MCM2_HUMAN DNA 
replication licensing factor 
MCM2  
   
  R.GLLYDS*DEEDEERPAR.K S139 confirmed by y9, y11 
  R.VM#LES*FIDTQK.F S801 confirmed by b3, b5 
Q12968 NFAC3_HUMAN Nuclear 
factor of activated T-cells, 
cytoplasmic 3 (NF-ATc3)  
   
  R.PS*S*DSGCSHDSVLS*GQR.S S730 not confirmed 
S731 not confirmed 
S742 confirmed by y3, y5 
Q9H410 CT172_HUMAN 
Uncharacterized protein 
C20orf172 
   
  K.SLHLS*PQEQSASYQDR.R S81 confirmed by y11, y12 
Q9ULU4 PKCB1_HUMAN Protein 
kinase C-binding protein 1  
   
  R.RIS*LSDMPR.S S425 confirmed by y6, y8 
S427 not phosphorylated by 
y3, y5 
  K.S*DSSDSEYISDDEQK.S S595 not confirmed 
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Accession 
number 
Scan(s) Peptide  Phosphorylation sites 
P31321 KAP1_HUMAN cAMP-
dependent protein kinase type I-
beta regulatory subunit 
   
  -.M#ASPPACPS*EEDESLK.G S9 confirmed by b8, b11 
Q7L7X3 TAOK1_HUMAN 
Serine/threonine-protein kinase 
TAO1 
   
  R.AS*DPQSPPQVS*R.H S417 confirmed by b3 
S426 confirmed by b9, b11 
P51587 BRCA2_HUMAN Breast cancer 
type 2 susceptibility protein  
  
  K.VFADIQS*EEILQHNQNMSGLE
KVS*K.I 
S1926 not confirmed 
Q8TF66 LRC15_HUMAN Leucine-rich 
repeat-containing protein 15 
precursor (hLib) 
  
  R.M#LANLQNIS*LQNNRLR.Q S371 confirmed by y6, y9 
Q5VT25 MRCKA_HUMAN 
Serine/threonine-protein kinase 
MRCK alpha  
  
  R.HSTAS*NSS*NLSSPPS*PASPR.
K 
S1700  & S1703  & S1710 not 
confirmed 
  R.TVFSGS*VSIPS*ITK.S 1611 NEW & 1616 NEW 
Q9UMY1 NOL7_HUMAN Nucleolar 
protein 7  
  
  K.VQSVS*QNKSY*LAVRLK.D S167 confirmed by y11, y12 
Y172 confirmed by y4, y7 
P28161 GSTM2_HUMAN Glutathione 
S-transferase Mu 2 (GSTM2-2)  
  
  K.S*S*RFLPRPVFTK.M S200 & S201 not confirmed 
Q9UKX3 MYH13_HUMAN Myosin-13 
(Myosin heavy chain 13) 
  
  R.VEEKES*LISQLT*K.S S1300 confirmed by b4, b6 
T1306 confirmed by b11, b12 
P55199 ELL_HUMAN RNA polymerase 
II elongation factor ELL  
  
  R.KSGAS*AVSGGS*GVS*QR.P S194 not confirmed 
S200 confirmed by b10, b12 
S203 confirmed by y2, y3 
Q9BXT6 M10L1_HUMAN Putative 
helicase Mov10l1  
  
  K.WEDDSRNHGSPS*DCGPR.V S113 confirmed by b11, b12 
  K.SSQALT*S*AKTTVVVTAQK.R T472 & S473 not confirmed 
Q14181 DPOA2_HUMAN DNA 
polymerase subunit alpha B  
  
  R.GGAGNIS*LKVLGCPEALTGSY
KSMFQK.L 
S192 confirmed by b5, b7 
Q12824 SNF5_HUMAN SWI/SNF-
related matrix-associated actin-
dependent regulator of chromatin 
subfamily B member 1 
  
  R.YPS*LWRRLATVEER.K S49 confirmed by b2,b6 
Q8IWV8 UBR2_HUMAN E3 ubiquitin-
protein ligase UBR2  
  
  K.M#RES*SPTSPVAET*EGTIMEE
SSRDK.D 
S1005 not confirmed 
T1014 confirmed by y12, y13 
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number 
Scan(s) Peptide  Phosphorylation sites 
  K.MRESS*PT*SPVAETEGTIMEES*S
RDK.D 
S1006 confirmed by b4, b5 
T1008 confirmed by b6, b7 
S1022 confirmed by y4, y5 
P49006 MRP_HUMAN MARCKS-
related protein  
  
  R.GDVTAEEAAGAS*PAK.A S22 confirmed by y3, y4 
  K.LSGLS*FK.R S104 confirmed by y2, y3 
  K.LSGLS*FKR.N S104 confirmed by y3, y4 
Q99733 NP1L4_HUMAN Nucleosome 
assembly protein 1-like 4  
  
  R.REFITGDVEPTDAESEWHS*ENEE
EEK.L 
S125 confirmed by y7, y9 
Q13541 4EBP1_HUMAN Eukaryotic 
translation initiation factor 4E-
binding protein 1  
  
  R.VVLGDGVQLPPGDYSTT*PGGTL
FSTT*PGGTR.I 
T37 confirmed by b16, b17 
T46 confirmed by y5, y6 
  R.RVVLGDGVQLPPGDYSTT*PGGT
LFSTT*PGGTR.I 
T37 confirmed by b17, b18 
T46 confirmed by y5, y6 
Q9H6Z4 RANB3_HUMAN Ran-binding 
protein 3 (RanBP3) 
  
  R.TSS*LTQFPPSQSEER.S S126 confirmed by y12, y13 
P42566 EP15_HUMAN Epidermal 
growth factor receptor substrate 
15 (Protein Eps15)  
  
  R.S*SPELLPSGVTDENEVTTAVTEK.
V 
S562 not confirmed  
P62258 1433E_HUMAN 14-3-3 
protein epsilon (14-3-3E) 
  
  K.AAFDDAIAELDTLS*EESYK.D S210 confirmed by y5, y6 
O46021 RL1D1_HUMAN Ribosomal 
L1 domain-containing protein 1 
  
  K.ATNES*EDEIPQLVPIGK.K S361 confirmed by b4, b6 
P29966 MARCS_HUMAN 
Myristoylated alanine-rich C-
kinase substrate (MARCKS)  
  
  K.LSGFS*FK.K S170 confirmed by y2, y3 
  K.LSGFS*FKK.N  
O95400 CD2B2_HUMAN CD2 antigen 
cytoplasmic tail-binding protein 
2  
  
  K.HSLDS*DEEEDDDDGGSSK.Y S49 confirmed by y13, y15 
P05783 K1C18_HUMAN Keratin, type 
I cytoskeletal 18  
  
  R.PVSSAAS*VYAGAGGSGSR.I S34 confirmed by y11, y12 
  R.LLEDGEDFNLGDALDSSNS*MQTI
QK.T 
S401 confirmed by y6, y7 
  R.STS*FRGGM#GSGGLATGIAGGL
AGMGGIQNEK.E 
S53 not confirmed 
  R.ST*FSTNYR.S T8 not confirmed 
  R.S*LGSVQAPSYGAR.P S15 confirmed by b2 
Q96QR8 PURB_HUMAN 
Transcriptional activator 
protein Pur-beta  
  
  R.DSLGDFIEHYAQLGPSS*PEQLAA
GAEEGGGPR.R 
S101 confirmed by y15, y16 
  R.RGGGS*GGGEES*EGEEVDED S298 confirmed by  b4, b8 
S304 confirmed by b10, b11 
 182
Table A-2 (continued). 
 
Accession 
number 
Scan(s) Peptide  Phosphorylation sites 
  R.RGGGSGGGEES*EGEEVDED S304 confirmed by b10, b12 
Q5BKZ1 ZN326_HUMAN Zinc finger 
protein 326 
  
  R.SMDSYLNQS*YGMDNHSGGGGG
SR.F 
S56 not confirmed 
    
P29692 EF1D_HUMAN Elongation 
factor 1-delta (EF-1-delta)  
  
  R.ATAPQTQHVS*PMR.Q S133 confirmed by b9, b10 
Q9UGV2 NDRG3_HUMAN Protein 
NDRG3 
  
  R.THS*TSSSLGSGESPFSR.S S331 confirmed by y14, y15 
Q05519 SFR11_HUMAN Splicing 
factor arginine/serine-rich 11  
  
  K.LNHVAAGLVS*PSLK.S S207 confirmed by y4, y5 
  R.DYDEEEQGYDS*EKEK.K S434 confirmed by y4, y5 
P25788 PSA3_HUMAN Proteasome 
subunit alpha type 3  
  
  K.ESLKEEDES*DDDNM S250 confirmed by y5, y6 
Q6UN15 FIP1_HUMAN Pre-mRNA 3'-
end-processing factor FIP1  
  
  R.DHS*PTPSVFNSDEER.Y S492 confirmed by b2, b3 
Q9NYB0 TE2IP_HUMAN Telomeric 
repeat-binding factor 2-
interacting protein 1  
  
  K.YLLGDAPVS*PSSQK.L S203 confirmed by y5, y6 
P27816 MAP4_HUMAN Microtubule-
associated protein 4 (MAP 4) 
  
  K.DMES*PTKLDVTLAK.D S280 confirmed by b2, b4 
  K.VGS*LDNVGHLPAGGAVK.T S1073 not confirmed 
  K.DMS*PLSETEMALGK.D S507 confirmed by b2, b3 
  K.T*STSKAKTQPTSLPK.Q T712 not confirmed 
  K.VGS*TENIK.H S941 not confirmed 
P08729 K2C7_HUMAN Keratin, type 
II cytoskeletal 7 (Cytokeratin-
7) 
  
  R.T*LNETELTELQS*QISDTSVVLSM
DNSR.S 
T227 not confirmed 
S238 confirmed by y15, y17 
  R.T*LNETELT*ELQSQISDTSVVLSM
#DNSR.S 
T227 not confirmed 
T234 confirmed by b7, b11 
Q9H307 PININ_HUMAN Pinin (140 
kDa nuclear and cell adhesion-
related phosphoprotein) 
  
  K.S*LSPGKENVSALDMEK.E S441 confirmed by b2 
Q9BQE3 TBA6_HUMAN Tubulin 
alpha-6 chain (Alpha-tubulin 6) 
  
  K.TIGGGDDS*FNTFFSETGAGK.H S48 confirmed by y12, y13 
Q93009 UBP7_HUMAN Ubiquitin 
carboxyl-terminal hydrolase 7  
  
  K.AGEQQLS*EPEDMEMEAGDTDDP
PR.I 
S18 confirmed by b6, b8 
P52597 HNRPF_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein F (hnRNP F)  
  
  K.ATENDIYNFFS*PLNPVR.V S310 confirmed by y6, y7 
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Q13185 CBX3_HUMAN Chromobox 
protein homolog 3  
  
  K.SLS*DSESDDSK.S S95 confirmed by y8, y9 
Q8TE77 SSH3_HUMAN Protein 
phosphatase Slingshot homolog 
3 (SSH-3L) (hSSH-3L) 
  
  R.S*PPGSGASTPVGPWDQAVQR.R S4 not confirmed 
  R.RQS*FAVLR.G S37 confirmed by b2, b5 
Q9NR30 DDX21_HUMAN Nucleolar 
RNA helicase 2  
  
  K.NEEPS*EEEIDAPKPK.K S121 confirmed by b4, b6 
O95359 TACC2_HUMAN 
Transforming acidic coiled-
coil-containing protein 2  
  
  K.LDNTPAS*PPRS*PAEPNDIPIAK.
G 
S2317 not confirmed 
S2321 confirmed by y11, y12 
Q86W92 LIPB1_HUMAN Liprin-beta-1    
  R.SQS*TTFNPDDMSEPEFK.R S601 confirmed by y14, y15 
P23588 IF4B_HUMAN Eukaryotic 
translation initiation factor 4B  
  
  K.SPPY*TAFLGNLPYDVTEESIK.E Y96 not confirmed 
  R.RES*EKS*LENETLNK.E S442 confirmed by b2, b4 
S445 confirmed by y8, y9 
  R.ARPATDS*FDDYPPR.R S207 confirmed by y7, y8 
  R.HPS*WRS*EETQER.E S406 confirmed by y9, y10 
S409 confirmed by b5, b7 
  K.PRST*PEEDDSS*AS*TSQSTR.A T341 confirmed by b3, b5 
S348 & S350 not confirmed 
  K.YAALS*VDGEDENEGEDYAE S597 confirmed by y14, y15 
O15164 TIF1A_HUMAN Transcription 
intermediary factor 1-alpha  
  
  K.SEWLDPSQKS*PLHVGETR.K S811 confirmed by b9, b10 
  R.SILTSLLLNSS*QSS*T*SEETVLR.
S 
S768 confirmed by y11, y12 
S771 & T772 not confirmed 
P46821 MAP1B_HUMAN 
Microtubule-associated protein 
1B (MAP 1B)  
  
  K.LGDVS*PTQIDVSQFGSFK.E S1501 confirmed by y13, y14 
  K.TTSPPEVS*GYS*Y*EK.T S1970 & S1973  
& Y1974  not confirmed  
Q06265 EXOS9_HUMAN Exosome 
complex exonuclease RRP45 
(Exosome component 9)  
  
  K.APIDTS*DVEEK.A S306 confirmed by y4, y6 
Q8WUZ0 BCL7C_HUMAN B-cell 
CLL/lymphoma 7 protein 
family member C 
  
  K.GTEPS*PGGTPQPSRPVS*PAGPP
EGVPEEAQPPR.L 
S114 not confirmed 
S126 confirmed by b16, b19 
  K.GTEPS*PGGT*PQPSRPVSPAGPP
EGVPEEAQPPR.L 
T118 not confirmed  
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Table A-2 (continued). 
 
Accession 
number 
Scan(s) Peptide  Phosphorylation sites 
O43290 SNUT1_HUMAN U4/U6.U5 
tri-snRNP-associated protein 1  
  
  R.RVS*EVEEEKEPVPQPLPSDDTR.
V 
S448 confirmed by b2, b4 
  R.DLQGLT*VEHAIDSFREGETMILT
*LKDK.G 
T258 not confirmed 
  K.KMSSS*DT*PLGT*VALLQEK.Q S762  & T764  & T768 not 
confirmed 
  K.KMS*S*S*DTPLGTVALLQEKQK.
A 
S760 & S761 & S762 not 
confirmed 
  K.M#SS*SDT*PLGTVALLQEK.Q S761&T764 not confirmed 
    
P30291 WEE1_HUMAN Wee1-like 
protein kinase (Wee1A kinase)  
  
  K.S*PAAPY*FLGSSFS*PVRCGGPG
DASPR.G 
S127 & Y132 not confirmed 
S139 confirmed by y13, y14 
  K.S*RYTTEFHELEKIGS*GEFGSVFK
.C 
S293 not confirmed 
S307 confirmed by y5, y9 
P16333 NCK1_HUMAN Cytoplasmic 
protein NCK1  
  
  K.RKPS*VPDSASPADDSFVDPGER.
L 
S85 confirmed by b3, b4 
Q9UNE7 STUB1_HUMAN STIP1 
homology and U box-
containing protein 1  
  
  R.LGAGGGS*PEKS*PSAQELK.E S19 confirmed by b5, b7 
S23 confirmed by y7, y9 
Q9BTC0 DIDO1_HUMAN Death-
inducer obliterator 1 (DIO-1)  
  
  R.RNS*VERPAEPVAGAATPSLVEQ
QK.M 
S1456 confirmed by b2, b5 
Q96I25 SPF45_HUMAN Splicing 
factor 45  
  
  R.S*MGGAAIAPPTSLVEK.D S169 confirmed by b2 
  R.SPT*GPSNSFLANMGGTVAHK.I T224 not confirmed 
Q53EL6 PDCD4_HUMAN 
Programmed cell death protein 
4 (Nuclear antigen H731-like)  
  
  R.KDS*VWGSGGGQQSVNHLVK.E S313 confirmed by b2,b3 
  R.SGLTVPTS*PK.G S94 confirmed by y2, y3 
  K.NSSRDS*GRGDS*VS*DSGSDALR
.S 
S71 & S76 not confirmed 
Q9H2U2 IPYR2_HUMAN Inorganic 
pyrophosphatase 2, 
mitochondrial precursor  
  
  R.SLVESVSSS*PNKESNEEEQVWHF
LGK 
S317 not confirmed 
  K.FKPGYLEATLNWFRLY*K.V Y241 not confirmed 
Q8ND56 LS14A_HUMAN LSM14 
protein homolog A  
  
  K.S*PTMEQAVQTASAHLPAPAAVG
R.R 
S192 confirmed by b2 
  R.SS*PQLDPLR.K S183 not confirmed 
Q13247 SFRS6_HUMAN Splicing 
factor, arginine/serine-rich 6  
  
  R.SNS*PLPVPPSK.A S303 confirmed by b2, b3 
  R.LIVENLSS*R.C S119 confirmed by y1, y2 
S118 not phosphorylated by 
y2, y3 
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Table A-2 (continued). 
 
Accession 
number 
Scan(s) Peptide  Phosphorylation sites 
Q9H7L9 SDS3_HUMAN Sin3 histone 
deacetylase corepressor 
complex component SDS3  
  
  K.RPAS*PSS*PEHLPATPAESPAQR.F S234 & S237 not confirmed 
Q9BXP5 ARS2_HUMAN Arsenite-
resistance protein 2 
  
  R.TQLWASEPGT*PPLPTSLPSQNPILK
.N 
T544 confirmed by b9, b10 
  R.HELS*PPQK.R S74 confirmed by y4, y5 
P68366 TBA1_HUMAN Tubulin 
alpha-1 chain   
  
  R.EDM#AALEKDY*EEVGIDSYEDED
EGEE 
Y432 confirmed by b9, b12 
Q96D71 REPS1_HUMAN RalBP1-
associated Eps domain-
containing protein 1 
  
  R.TSADAQEPASPVVSPQQS*PPTS*P
HTWR.K 
S118 confirmed by y9, y10 
S122 not confirmed 
  R.RQS*SSYDDPWK.I S220 confirmed by y8, y9 
  R.HAAS*YS*SDSENQGSY*SGVIPPPP
GRGQVKK.G 
S63 & S65 & Y74 not 
confirmed 
O94888 UBXD7_HUMAN UBX 
domain-containing protein 7 
  
  R.SESLIDASEDS*QLEAAIR.A S288 confirmed by y5, y8 
  R.SES*LIDASEDSQLEAAIR.A S280 not confirmed 
  R.DFQT*ET*IRQEQELR.N T116 confirmed by b3, b4 
T118 confirmed by y8, y10 
P67809 YBOX1_HUMAN Nuclease 
sensitive element-binding 
protein 1  
  
  R.NYQQNYQNS*ESGEKNEGSESAPE
GQAQQR.R 
S165 not confirmed 
  K.NEGSES*APEGQAQQR.R S176 confirmed by y9, y10 
Q9UN36 NDRG2_HUMAN Protein 
NDRG2 (Protein Syld709613) 
  
  R.SRT*AS*LTSAASVDGNR.S T330 confirmed by y13, 
y14 
S332 confirmed by y11, y12 
O00264 PGRC1_HUMAN Membrane-
associated progesterone 
receptor component 1 (mPR) 
  
  K.EGEEPTVYS*DEEEPKDESAR.K S181 confirmed by y11, y12 
Q9UBC2 EP15R_HUMAN Epidermal 
growth factor receptor 
substrate 15-like 1  
  
  K.FHDTS*SPLMVTPPSAEAHWAVR.V S107 confirmed by b4, b5 
  K.DS*LRSTPS*HGSVSSLNSTGSLSPK
HS*LK.Q 
S235 confirmed by b4 
S241 confirmed by b7, b8 
O00499 BIN1_HUMAN Myc box-
dependent-interacting protein 1 
  
  K.S*PSPPDGS*PAATPEIR.V S296 confirmed by b2 
S303 confirmed by y8, y9 
  K.S*PSPPDGSPAATPEIR.V S296 confirmed by b2 
Q9BQI5 SGIP1_HUMAN SH3-
containing GRB2-like protein 
3-interacting protein 1 
  
  K.WVHFSDTSPEHVTPELT*PR.E T328 confirmed by y4 
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Accession 
number 
Scan(s) Peptide  Phosphorylation sites 
Q9ULM3 YETS2_HUMAN YEATS 
domain-containing protein 2 
  
  K.T*EES*S*ELGNYVIK.I T1131 confirmed by b3 
S1134 & S1135 not 
confirmed 
Q9Y233 PDE10_HUMAN cAMP and 
cAMP-inhibited cGMP 3',5'-
cyclic phosphodiesterase 10A 
  
  K.S*QHLTGLTDEKVK.A S8 confirmed by b3 
Q15054 DPOD3_HUMAN DNA 
polymerase subunit delta 3 
(DNA polymerase subunit delta 
p66) 
  
  K.TEPEPPSVKS*S*SGENK.R S374 & S375 not confirmed 
  K.S*KLAVT*ASIHVY*SIQK.A S90 confirmed by b3 
T95 confirmed by b3, b6 
Y101 not confirmed 
  R.VALS*DDETKETENMR.K S307 confirmed by b3, b5 
Q9UNZ2 NSF1C_HUMAN NSFL1 
cofactor p47 (p97 cofactor p47) 
  
  R.KKS*PNELVDDLFK.G S114 confirmed by y10, y11 
Q9Y6W5 WASF2_HUMAN Wiskott-
Aldrich syndrome protein 
family member 2  
  
  K.RS*SVVSPSHPPPAPPLGSPPGPK.P S292 not confirmed 
  R.S*S*VVS*PSHPPPAPPLGSPPGPK.P S292  & S293  & S296 not 
confirmed 
Q9BQA1 MEP50_HUMAN 
Methylosome protein 50 
(MEP50 protein) (WD repeat 
protein 77) 
  
  R.KET*PPPLVPPAAR.E T5 confirmed by y10, y11 
P49407 ARRB1_HUMAN Beta-
arrestin-1 (Arrestin beta 1) 
  
  R.KDLFVANVQS*FPPAPEDK.K S86 confirmed by y8, y10 
    
Q9P2B4 CT2NL_HUMAN CTTNBP2 
N-terminal-like protein 
  
 7470 K.EQKKLS*SQLEEER.S S165 confirmed by b4, b6 
Q5JTD0 TJAP1_HUMAN Tight 
junction-associated protein 1 
(Tight junction protein 4)  
  
  R.KDS*LTQAQEQGNLLN S545 confirmed by b3 
P24043 LAMA2_HUMAN Laminin 
subunit alpha-2 precursor 
(Laminin M chain) 
  
  R.NS*HIAIAFDDT*KVKNR.L S2772 confirmed by b4 
T2781 confirmed by y5, y6 
Q6Y7W6 PERQ2_HUMAN PERQ 
amino acid-rich with GYF 
domain-containing protein 2  
  
  R.PGT*PSDHQSQEASQFER.K T382 confirmed by b3 
Q86WB0 NIPA_HUMAN Nuclear-
interacting partner of ALK  
  
  K.QSSQPAETDS*MSLSEKS*RK.V S479 & S486 not confirmed 
  R.SMGTGDT*PGLEVPSS*PLR.K T387 & S395 not confirmed 
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Accession 
number 
Scan(s) Peptide  Phosphorylation sites 
Q12955 ANK3_HUMAN Ankyrin-3 
(ANK-3) (Ankyrin-G) 
  
  R.RQS*FASLALR.K S1459 confirmed by y7, y8 
Q15642 CIP4_HUMAN Cdc42-
interacting protein 4  
  
  R.APSDS*SLGTPSDGRPELR.G S298 not confirmed 
O15173 PGRC2_HUMAN Membrane-
associated progesterone 
receptor component 2  
  
  R.LLKPGEEPSEY*TDEEDTK.D Y210 not confirmed 
Q8N5S9 KKCC1_HUMAN 
Calcium/calmodulin-dependent 
protein kinase kinase 1  
  
  R.KLS*LQER.P S74 confirmed by y4, y5 
  R.LIPS*WTT*VILVKS*MLRK.R S443 not confirmed 
T446 confirmed by b6, b7 
S452 confirmed by b10, b13 
P30086 PEBP1_HUMAN 
Phosphatidylethanolamine-
binding protein 1 (PEBP-1)  
  
  K.NRPTS*ISWDGLDSGK.L S52 confirmed by y10, y11 
Q9UQB8 BAIP2_HUMAN Brain-
specific angiogenesis inhibitor 
1-associated protein 2  
  
  K.LSDSYSNT*LPVR.K T340 confirmed by y4, y6 
O15530 PDPK1_HUMAN 3-
phosphoinositide-dependent 
protein kinase 1 (hPDK1) 
  
  R.ANS*FVGTAQYVSPELLTEK.S S241 confirmed by b4, b5 
Q9H788 SH24A_HUMAN SH2 
domain-containing protein 4A 
(Protein SH(2)A) 
  
  R.TLS*SSAQEDIIR.W S315 confirmed by y9, y10 
P18615 NELFE_HUMAN Negative 
elongation factor E (NELF-E) 
(RD protein) 
  
  R.SIS*ADDDLQESSR.R S115 confirmed by y9, y11 
  K.QPMLDAAT*GKSVWGS*LAVQNS*
PKGCHR.D 
T340 & S347 & S353 not 
confirmed 
  R.S*LSEQPVMDTATATEQAK.Q S49 not confirmed 
Q9H1B7 CN004_HUMAN Protein 
C14orf4 
  
  R.KAS*PEPPDSAEGALK.L S547 confirmed by b3 
  R.RNS*SS*PVSPASVPGQR.R S657 confirmed by  b2, b3 
S659 confirmed by y11, y12 
  R.QSPNSSSAAAS*VAS*RR.G S224 confirmed by y5, y7 
S227 confirmed by b13, b15 
Q12857 NFIA_HUMAN Nuclear factor 
1 A-type (Nuclear factor 1/A)  
  
  R.S*PGSGSQSSGWHEVEPGMPSPTTL
K.K 
S300 confirmed by b3 
  R.RSLPSTS*ST*SSTKR.L S273 & T275 not confirmed 
UE93 PI3R6_HUMAN 
Phosphoinositide 3-kinase 
regulatory subunit 6  
  
  R.PS*GDGEM#LPGVSRLHTAR.V S401 confirmed by b3, y17 
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Accession 
number 
Scan(s) Peptide  Phosphorylation sites 
P21675 TAF1_HUMAN Transcription 
initiation factor TFIID subunit 
1  
  
  R.M#LLAAGS*AASGNNHRDDDTAS
VTSLNS*SATGR.C 
S1138 confirmed by b5, b9 
S1158 not confirmed 
  R.TDPMVTLSSILES*IINDM#R.D S1391 confirmed by b12, 
b14 
  R.VGT*TVHCDYLNR.P T1360 not confirmed 
  R.VGTTVHCDY*LNRPHK.S Y1366 not confirmed 
Q8N1N0 CLC4F_HUMAN C-type lectin 
domain family 4 member F  
  
  K.SSFDNT*S*AEIQFLR.G T313 & S314 not confirmed 
Q04726 TLE3_HUMAN Transducin-
like enhancer protein 3 (ESG3) 
  
  R.ESSANNSVS*PSESLR.A S203 confirmed by y6, y7 
  K.DLGHNDKS*STPGLKSNTPT*PR.N S310 confirmed by b7, b8 
  K.SDDLVVDVSNEDPAT*PRVSPAHS*
PPENGLDK.A 
T259 confirmed by y15, 
y17 
S267 not confirmed 
  R.VS*PAHS*PPENGLDK.A S263 not confirmed 
S267 not confirmed 
Q5VV41 ARHGG_HUMAN Rho 
guanine nucleotide exchange 
factor 16 
  
  R.HQS*FGAAVLSR.E S107 confirmed by y8, y9 
Q12906 ILF3_HUMAN Interleukin 
enhancer-binding factor 3  
  
  K.RPMEEDGEEKS*PSK.K S382 confirmed by y3, y5 
Q96IT1 ZN496_HUMAN Zinc finger 
protein 496 
  
  R.PPS*QLS*GDPVLQDAFLLQEENVR
.D 
S185 confirmed by  b4 
S188 not confirmed 
Q9UN86 G3BP2_HUMAN Ras GTPase-
activating protein-binding 
protein 2 (G3BP-2)  
  
  K.STT*PPPAEPVSLPQEPPK.A T227 not confirmed  
P55317 HNF3A_HUMAN Hepatocyte 
nuclear factor 3-alpha  
  
  K.TGQLEGAPAPGPAAS*PQTLDHSG
ATATGGASELK.T 
S332 confirmed by b10, b16 
    
P35579 MYH9_HUMAN Myosin-9 
(Myosin heavy chain 9)  
  
  K.KMEDS*VGCLET*AEEVK.R S1376 confirmed by  y11, 
y14 
T1382 confirmed by b9, 
b12 
P08621 RU17_HUMAN U1 small 
nuclear ribonucleoprotein 70 
kDa (U1 snRNP 70 kDa)  
  
  R.YDERPGPS*PLPHR.D S226 confirmed by y5, y7 
  R.GGGGGQDNGLEGLGNDS*R.D S410 confirmed by y2, y4 
Q13315 ATM_HUMAN Serine-protein 
kinase ATM (Ataxia 
telangiectasia mutated)  
  
  K.RSLES*VYS*LYPTLSR.L S2165 confirmed by b3, b5 
S2168 confirmed by b7, b8 
  K.M#LQPIT*R.L T2031 confirmed by b5, b6 
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Accession 
number 
Scan(s) Peptide  Phosphorylation sites 
Q9UKM9 RALY_HUMAN RNA-binding 
protein Raly  
  
  R.GRLS*PVPVPR.A S135 confirmed by y6, y7 
  R.AAS*AIYSGYIFDYDYYR.D S206 confirmed by b4 
Q9BSG1 ZNF2_HUMAN Zinc finger 
protein 2 (Zinc finger 2.2) 
(Zinc finger protein 661) 
  
  K.VFSSKS*SVIQHQR.R S410 not confirmed  
Q6ZMT1 STAC2_HUMAN SH3 and 
cysteine-rich domain-
containing protein 2  
  
  R.SSFSS*T*SESPTRSLSER.D S224 & T225 not confirmed 
P85037 FOXK1_HUMAN Forkhead 
box protein K1 (Myocyte 
nuclear factor)  
  
  R.S*APAS*PTHPGLMSPR.S S416 confirmed by  b4 
S420 confirmed by y10, y11 
  R.EGS*PIPHDPEFGSK.L S445 confirmed by b3 
O15062 ZBTB5_HUMAN Zinc finger 
and BTB domain-containing 
protein 5 
  
  K.HYLTTRTLPMS*PPSER.V S127 confirmed by b9, b11 
Q9H2M9 RBGPR_HUMAN Rab3 
GTPase-activating protein non-
catalytic subunit  
  
  K.QDFS*PEVLKLANEER.D S952 confirmed by b3, b6 
P22626 ROA2_HUMAN 
Heterogeneous nuclear 
ribonucleoproteins A2/B1  
 
  R.GFGDGYNGYGGGPGGGNFGGS*P
GYGGGR.G 
S259 confirmed by y7, y8 
  R.NMGGPYGGGNYGPGGSGGS*GGY
GGR.S 
S259 confirmed by y6, y7 
  R.GGNFGFGDS*R.G S212 confirmed by b8, b9 
  R.NMGGPYGGGNYGPGGS*GGSGGY
GGR.S 
S341 confirmed by y9, y10 
Q9UHD8 SEPT9_HUMAN Septin-9 
(MLL septin-like fusion 
protein)  
  
  R.S*FEVEEVETPNSTPPR.R S30 confirmed by b3 
  K.RS*FEVEEVETPNSTPPR.R  
  R.S*FEVEEVET*PNSTPPR.R S38 confirmed by b6 
T30 confirmed by y7, y8 
Q8TEA8 DTD1_HUMAN Probable D-
tyrosyl-tRNA(Tyr) deacylase 1 
  
  R.S*ASSGAEGDVSSEREP S194 confirmed by b2 
  K.EDRS*ASSGAEGDVS*S*EREP S 194 confirmed by b3, b4 
S204 & S205 not confirmed 
  K.EDRSAS*SGAEGDVS*S*ER.E S196 not confirmed 
S204 confirmed by b13, b14 
S205 confirmed by b14, b16 
Q5JSZ5 K0515_HUMAN 
Uncharacterized protein 
KIAA0515 
  
  K.LKFS*DDEEEEEVVK.D S388 confirmed by y10, y11 
O95460 MATN4_HUMAN Matrilin-4 
precursor 
  
  R.VGVIQYS*SQVQSVFPLR.A S79 not confirmed 
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Accession 
number 
Scan(s) Peptide  Phosphorylation sites 
P25205 MCM3_HUMAN DNA 
replication licensing factor 
MCM3  
  
  K.DGDSYDPYDFS*DTEEEMPQVHTP
K.T 
S711 confirmed by y13, y14 
O95248 MTMR5_HUMAN SET-
binding factor 1 (Sbf1) 
(Myotubularin-related protein 
5) 
  
  R.RTTVPSGPPMT*AILER.C T546 confirmed by y5, y6 
Q6P6C2 ALKB5_HUMAN Alkylated 
repair protein alkB homolog 5 
  
  R.RGS*FSSENYWR.K S361 confirmed by y8, y9 
  K.YQEDS*DPERSDYEEQQLQK.E S64 not confirmed 
  R.GS*FSSENYWR.K S361 
  R.LET*KS*LSSSVLPPSYASDRLSGN
NR.D 
T294 & S296 not confirmed 
Q9NX63 CHCH3_HUMAN Coiled-coil-
helix-coiled-coil-helix domain-
containing protein 3 
  
  R.YS*GAYGASVSDEELK.R S50 confirmed by y14, b2 
P21796 VDAC1_HUMAN Voltage-
dependent anion-selective 
channel protein 1 (VDAC-1) 
  
  K.LTFDSSFS*PNTGK.K S104 confirmed by y5, y6 
Q76KP1 B4GN4_HUMAN N-acetyl-
beta-glucosaminyl-glycoprotein 
4-beta-N-acetylgalactosam 
  
  R.TLGPAAPTVDS*NLS*SEAR.P S616 confirmed by b10, b12 
S619 not confirmed 
Q13573 SNW1_HUMAN SNW 
domain-containing protein 1 
(Nuclear protein SkiP)  
  
  R.GPPS*PPAPVMHS*PSR.K S224 confirmed by  y11, 
y12 
S232 confirmed by y3, y4 
Q9NPH0 PPA6_HUMAN 
Lysophosphatidic acid 
phosphatase type 6 precursor  
  
  R.GRRQTAS*LQPGIS*EDLK.K S223 confirmed by y10, y11 
S229 confirmed by b12, b14 
Q6WKZ4 RFIP1_HUMAN Rab11 
family-interacting protein 1 
(Rab11-FIP1) 
  
  K.HLFSS*TENLAAGSWK.E S357 confirmed by y10, y11 
P23193 TCEA1_HUMAN 
Transcription elongation factor 
A protein 1  
  
  K.EPAITSQNS*PEAR.E S100 confirmed by y4, y5 
  K.KKEPAITSQNS*PEAR.E  
O75446 SAP30_HUMAN Histone 
deacetylase complex subunit 
SAP30  
  
  K.DTLTYFIY*SVKNDK.N Y202 confirmed by b7, b8 
Q07666 SAM68_HUMAN KH domain-containing, RNA-binding, signal 
transduction-associated protein 1 
 
  R.SGS*MDPSGAHPSVR.Q S20 not confirmed 
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Accession 
number 
Scan(s) Peptide  Phosphorylation sites 
Q9UHR4 BI2L1_HUMAN Brain-specific 
angiogenesis inhibitor 1-
associated protein 2-like 
protein 1 
  
  K.TPASTPVSGT*PQAS*PMIER.S T257 confirmed by  y9, y11 
S261 confirmed by y5, y6 
P09651 ROA1_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein A1  
  
  K.S*ESPKEPEQLR.K S4 confirmed by b2 
  R.SS*GPYGGGGQYFAK.P S338 not confirmed 
Q9Y446 PKP3_HUMAN Plakophilin-3   
  R.LS*SGFDDIDLPSAVK.Y S313 confirmed by b2, y14 
  R.ADYDTLS*LR.S S180 confirmed by y2, y3 
Q96T21 SEBP2_HUMAN SECIS-
binding protein 2  
  
  K.S*ARGSHHLSIYAENSLK.S S174 confirmed by b4 
P52948 NUP98_HUMAN Nuclear pore 
complex protein Nup98-Nup96 
precursor  
  
  R.DSENLAS*PSEYPENGER.F S623 confirmed by y10, y11 
P35527 K1C9_HUMAN Keratin, type I 
cytoskeletal 9 (Cytokeratin-9)  
  
  R.GSRGGSGGSY*GGGGS*GGGYGG
GSGS*R.G 
Y497 & S502 & S512 not 
confirmed 
  R.GSRGGSGGS*Y*GGGGSGGGYGG
GS*GSR.G 
S496 & Y497 & S510 not 
confirmed 
P51991 ROA3_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein A3  
  
  R.SSGS*PYGGGYGSGGGSGGYGSR.R S358 confirmed by y18, y20 
  R.SSGSPY*GGGYGS*GGGS*GGYGS
R.R 
Y360 & S366 & S370 not 
confirmed 
  R.SS*GSPY*GGGYGSGGGS*GGYGS
RRF 
S356 & Y360 not 
confirmed 
S370 confirmed by b13, b16 
Q6P5R6 RL22L_HUMAN Ribosomal 
protein L22-like 1 
  
  R.YFQISQDEDES*ESED S118 confirmed by b10, b12 
Q96T37 RBM15_HUMAN Putative 
RNA-binding protein 15  
  
  R.SLS*PGGAALGYR.D S294 confirmed by y9, y10 
  K.NS*S*GGGESRSSSRGGGGES*R.S S134 & S135 not confirmed 
S151 confirmed by b18, b19 
  R.SRS*PLDKDTY*PPSASVVGASVGG
HR.H 
S259 & Y266 not 
confirmed 
Q9UQF2 JIP1_HUMAN C-jun-amino-
terminal kinase-interacting 
protein 1  
  
  K.QFVEYT*CPTEDIYLE T702 confirmed by y9, y10 
O96013 PAK4_HUMAN 
Serine/threonine-protein kinase 
PAK 4 (p21-activated kinase 4)  
  
  R.PFNT*YPR.A T207 confirmed by y3, y5 
Q15233 NONO_HUMAN Non-POU 
domain-containing octamer-
binding protein  
  
  R.FGQAATMEGIGAIGGT*PPAFNR.A T450 confirmed by y6, y8 
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Accession 
number 
Scan(s) Peptide  Phosphorylation sites 
Q96PK6 RBM14_HUMAN RNA-
binding protein 14  
  
  R.RLS*ESQLSFR.R S618 confirmed by y7, y8 
P21291 CSRP1_HUMAN Cysteine and 
glycine-rich protein 1  
  
  K.GFGFGQGAGALVHS*E S192 confirmed by y3 
Q9P2K5 MYEF2_HUMAN Myelin 
expression factor 2 (MyEF-2) 
(MST156) 
  
  K.AEVPGATGGDS*PHLQPAEPPGEP
R.R 
S17 confirmed by y13, y14 
Q96J84 KIRR1_HUMAN Kin of 
IRRE-like protein 1 precursor  
  
  R.FSQEPADQT*VVAGQR.A T31 confirmed by b7, b11 
Q9UHL0 DDX25_HUMAN ATP-
dependent RNA helicase 
DDX25 (DEAD box protein 
25)  
  
  K.WLTVEMIQDGHQVS*LLS*GELTV
EQR.A 
S366 & S369 not confirmed 
Q5T8P6 RBM26_HUMAN RNA-
binding protein 26  
  
  K.T*QMQKELLDT*ELDLYKK.M T808 & T817 not confirmed 
Q9Y3Q4 HCN4_HUMAN 
Potassium/sodium 
hyperpolarization-activated 
cyclic nucleotide-gated channel 
4 
  
  R.RGTPPLT*PGR.L T1075 confirmed by y2, y6 
Q8TEW8 PAR3L_HUMAN Partitioning-
defective 3 homolog B (PAR3-
beta)  
  
  R.T*QEELVAMLRST*K.Q T445 confirmed by b3 
TT456 not confirmed 
O60825 F262_HUMAN 6-
phosphofructo-2-
kinase/fructose-2,6-
biphosphatase 2  
  
  R.RNS*FTPLSSSNTIR.R S446 confirmed by b2, b3 
Q96JC9 EAF1_HUMAN ELL-
associated factor 1 
  
  K.T*SPLKDNPS*PEPQLDDIKR.E T158 not confirmed 
S165 confirmed by y8, y11 
O43583 DENR_HUMAN Density-
regulated protein (DRP)  
  
  K.LTVENS*PKQEAGISEGQGTAGEE
EEK.K 
S73 confirmed by b5, b6 
Q9C0C2 TB182_HUMAN 182 kDa 
tankyrase 1-binding protein 
  
  R.SPS*QDFSFIEDTEILDSAMYR.S S1554 confirmed by b3 
O14745 NHERF_HUMAN Ezrin-
radixin-moesin-binding 
phosphoprotein 50 (EBP50)  
  
  R.S*ASSDTSEELNSQDSPPK.Q S288 not confirmed 
  R.SAS*SDTSEELNSQDSPPK.Q S290 not confirmed 
  R.EALAEAALES*PRPALVR.S S280 confirmed by y7, y8 
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Table A-2 (continued). 
 
Accession 
number 
Scan(s) Peptide  Phosphorylation sites 
P42858 HD_HUMAN Huntingtin 
(Huntington disease protein) (HD 
protein) 
  
  R.VNHCLTICENIVAQS*VR.N S116 confirmed by b13, b15 
Q9Y266 NUDC_HUMAN Nuclear 
migration protein nudC  
  
  K.NGSLDS*PGKQDTEEDEEEDEKD
K.G 
S139 confirmed by b4, b9 
O00264 PGRC1_HUMAN Membrane-
associated progesterone receptor 
component 1 (mPR) 
  
  K.EGEEPTVYS*DEEEPK.D S181 not confirmed 
Q9BVG4 CX026_HUMAN UPF0368 
protein Cxorf26 
  
  K.GADS*GEEKEEGINR.E S197 confirmed by b3, b5 
Q13286 CLN3_HUMAN Battenin 
(Protein CLN3)  
  
  R.RFS*DS*EGEET*VPEPR.L S12 confirmed by  y13 
S14 confirmed by  y10, y11 
T19 confirmed by y5, y9 
Q5JTV8 TOIP1_HUMAN Torsin-1A-
interacting protein 1 
  
  R.LQQQHSEQPPLQPS*PVMTR.R S143 not confirmed 
  K.VNFSEEGET*EEDDQDSSHSSVTT
VK.A 
T220 confirmed by b7, b9 
Q13501 SQSTM_HUMAN 
Sequestosome-1  
  
  R.LTPVS*PESSSTEEK.S S272 confirmed by y9, y10 
P20700 LMNB1_HUMAN Lamin-B1   
  R.LKLS*PS*PSSR.V S391 confirmed by b3, b4 
S393 confirmed by y4, y6 
  R.LKLS*PSPSSR.V S391 confirmed by y6, y7 
Q8IXT5 RB12B_HUMAN RNA-binding 
protein 12B  
  
  R.FPPEDFRHS*PEDFR.R S575 confirmed by y5, y6 
O14578 CTRO_HUMAN Citron Rho-
interacting kinase (CRIK)  
  
  R.TPLSQVNKVWDQS*S*V S2025 not confirmed 
S2026 confirmed by y2 
Q8WWM
7 
ATX2L_HUMAN Ataxin-2-like 
protein (Ataxin-2 domain 
protein)  
  
  K.EVDGLLTSEPMGS*PVSSK.T S594 confirmed by y5, y7 
P62995 TRA2B_HUMAN 
Arginine/serine-rich-splicing 
factor 10 (Transformer-2-beta)  
  
  K.RPHT*PTPGIYMGR.P T201 confirmed by b2, b4 
Q14157 UBP2L_HUMAN Ubiquitin-
associated protein 2-like (Protein 
NICE-4) 
  
  R.RYPSSISSS*PQK.D S609 confirmed by y3, y4 
  K.NPS*DSAVHSPFTK.R S410 confirmed by  b3 
P31749 AKT1_HUMAN RAC-alpha 
serine/threonine-protein kinase  
  
  R.RPHFPQFS*YSASGTA S473 confirmed by b7, b8 
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Table A-2 (continued). 
 
Accession 
number 
Scan(s) Peptide  Phosphorylation sites 
O14646 CHD1_HUMAN 
Chromodomain-helicase-DNA-
binding protein 1  
  
  K.S*DSSPLPSEKSDEDDDK.L S1353 not confirmed 
  K.SDS*SPLPSEKSDEDDDK.L S1355 confirmed by b3 
O00257 CBX4_HUMAN E3 SUMO-
protein ligase CBX4 
(Chromobox protein homolog 4)  
  
  R.EEEVSGVS*DPQPQDAGSR.K S334 not confirmed 
O14874 BCKD_HUMAN [3-methyl-2-
oxobutanoate dehydrogenase 
[lipoamide]] kinase 
  
  R.ARS*TSAT*DTHHVEMAR.E S31 not confirmed 
T35 confirmed by y9, y10 
Q15056 IF4H_HUMAN Eukaryotic 
translation initiation factor 4H 
(eIF-4H)  
  
  R.AY*SS*FGGGR.G Y12 confirmed by b2 
S14 not confirmed 
Q8NC51 PAIRB_HUMAN Plasminogen 
activator inhibitor 1 RNA-
binding protein  
  
  K.SKS*EEAHAEDSVMDHHFR.K S330 confirmed by b2, b3 
Q9Y478 AAKB1_HUMAN 5'-AMP-
activated protein kinase subunit 
beta-1  
  
  R.S*HNNFVAILDLPEGEHQYK.F S108 confirmed by b2 
P43243 MATR3_HUMAN Matrin-3   
  R.RDS*FDDR.G S188 confirmed by b2, b3 
P18669 PGAM1_HUMAN 
Phosphoglycerate mutase 1  
  
  R.HGES*AWNLENR.F S11 confirmed by y7, y8 
Q96AT1 K1143_HUMAN 
Uncharacterized protein 
KIAA1143 
  
  R.IQPQPPDEDGDHS*DKEDEQPQV
VVLK.K 
S50 confirmed by y13, y14 
P47736 RGP2_HUMAN Rap1 GTPase-
activating protein 1 (Rap1GAP) 
  
  R.RSS*AIGIENIQEVQEK.R S499 confirmed by  y13, 
y14 
Q9BUZ4 TRAF4_HUMAN TNF receptor-
associated factor 4  
  
  R.GS*LDESSLGFGYPK.F S426 confirmed by b2 
Q96T58 MINT_HUMAN Msx2-
interacting  
  
  K.FGKVTSVQIHGTS*EER.Y S374 confirmed by b12, 
b13 
Q5HYJ3 FA76B_HUMAN Protein 
FAM76B 
  
  K.ISNLS*PEEEQGLWK.Q S193 confirmed by y9, y10 
Q13427 PPIG_HUMAN Peptidyl-prolyl 
cis-trans isomerase G  
  
  R.RS*ET*PPHWR.Q S356 confirmed by  b2 
T358 confirmed by y5, y6 
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Table A-2 (continued). 
 
Accession 
number 
Scan(s) Peptide  Phosphorylation sites 
Q9UDY2 ZO2_HUMAN Tight junction 
protein ZO-2 (Zonula occludens 
2 protein)  
  
  R.DNS*PPPAFKPEPPK.A S986 confirmed by b3, b4 
Q9HC52 CBX8_HUMAN Chromobox 
protein homolog 8  
  
  R.HGS*GPPSSGGGLYR.D S311 confirmed by b3, b5 
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Table A-3 Subcellular locations and functional categories of the characterized phosphoproteins. 
 
Swissprot 
code 
 Protein name Subcellular 
localization 
Functional category 
HS90A HUMAN Heat shock protein HSP 
90-alpha (HSP 86) 
Cytoplasm Molecular chaperone 
SEPT2  HUMAN Septin-2 (Protein 
NEDD5) 
 
unknown Involved in cytokinesis 
TEBP HUMAN Prostaglandin E 
synthase 3 (Cytosolic 
prostaglandin E2 synthase) 
 
Cytoplasm 
 
RNA processing and Transcription 
regulation 
CTND1 HUMAN Catenin delta-1 (p120 
catenin)  
 
Cytoplasm. 
Nucleus 
Transcription regulation 
TR150  HUMAN Thyroid hormone 
receptor-associated protein 3 
 
Nucleus RNA processing and Transcription 
regulation 
NFIC  HUMAN Nuclear factor 1 C-type 
(Nuclear factor 1/C) (NF1-C)  
 
Unknown RNA processing and Transcription 
regulation 
G3BP1 HUMAN Ras GTPase-activating 
protein-binding protein 1 (G3BP-
1) 
 
Cytoplasm. 
Cytoplasm; 
cytosol. Cell 
membrane. 
Nucleus. 
DNA processing 
LRRF2  HUMAN Leucine-rich repeat 
flightless-interacting protein 2  
 
Unknown Signal Transduction 
BRE1A  HUMAN Ubiquitin-protein ligase 
BRE1A (BRE1-A) (hBRE1) 
 
Nucleus RNA processing and Transcription 
regulation 
ARFG1  HUMAN ADP-ribosylation 
factor GTPase-activating protein 
1 
 
 
Cytoplasm Unknown 
DC1L1 HUMAN Cytoplasmic dynein 1 
light intermediate chain 1 
 
Unknown May play a role in binding dynein to 
membranous organelles or 
chromosomes. May associate with 
the heavy chains in the dynein head 
where they might regulate enzyme 
activity 
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Table A-3 (continued). 
    
Swissprot 
code 
 Protein name Subcellular 
localization 
Functional category 
M3K2  HUMAN Mitogen-activated 
protein kinase kinase kinase 2 
 
Cytoplasm Signal transduction 
SMAP  HUMAN Small acidic protein 
 
Unknown Unknown 
ZRAB2 HUMAN Zinc finger Ran-
binding domain-containing 
protein 2  
 
Nucleus Translation  
NKAP HUMAN NF-kappa-B-activating 
protein 
 
Nucleus  Regulator of TNF and IL-1 induced 
NF-kappa-B activation 
KLC4 HUMAN Kinesin light chain 4 
(KLC 4) (Kinesin-like protein 8) 
 
Unknown  Kinesin is a microtubule-associated 
force-producing protein that may 
play a role in organelle transport. The 
light chain may function in coupling 
of cargo to the heavy chain or in the 
modulation of its ATPase activity 
NUCKS HUMAN Nuclear ubiquitous 
casein and cyclin-dependent 
kinases substrate 
 
Nucleus Unknown 
ANKS1  HUMAN Ankyrin repeat and 
SAM domain-containing protein 
1A (Odin) 
 
Cytoplasm Signal transduction 
ARVC HUMAN Armadillo repeat 
protein deleted in velo-cardio-
facial syndrome 
 
Unknown  Involved in protein-protein 
interactions at adherent junctions 
K0310  HUMAN Uncharacterized 
protein KIAA0310 
 
Unknown Unknown 
SRC8 HUMAN Src substrate cortactin 
(Amplaxin) (Oncogene EMS1) 
 
Cytoplasm Cell cycle 
RBM39  HUMAN RNA-binding protein 
39 (RNA-binding motif protein 
39)  
 
Nucleus RNA processing and Transcription 
regulation 
CV009  HUMAN Uncharacterized 
protein C22orf9 
Unknown Unknown 
BCLF1 HUMAN Bcl-2-associated 
transcription factor 1 (Btf) 
 
Cytoplasm. 
Nucleus 
Death-promoting transcriptional 
repressor 
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Table A-3 (continued). 
 
Swissprot 
code 
 Protein name Subcellular 
localization 
Functional category 
LAP2B HUMAN Lamina-associated 
polypeptide 2, isoforms 
beta/gamma  
 
Nucleus  DNA processing  
UBP14  HUMAN Ubiquitin carboxyl-
terminal hydrolase 14  
 
Unknown Unknown 
PHC3  HUMAN Polyhomeotic-like 
protein 3 (hPH3) (Homolog of 
polyhomeotic 3)  
 
Nucleus RNA processing and Transcription 
regulation 
SRRM1 HUMAN Serine/arginine 
repetitive matrix protein 1  
 
Nucleus Translation 
KAP0  HUMAN cAMP-dependent 
protein kinase type I-alpha 
regulatory subunit  
 
Unknown Unknown 
NPM HUMAN Nucleophosmin (NPM) 
(Nucleolar phosphoprotein B23)  
 
Nucleus Associated with nucleolar 
ribonucleoprotein structures and bind 
single-stranded nucleic acids. It may 
function in the assembly and/or 
transport of ribosome 
HNRH1  HUMAN Heterogeneous nuclear 
ribonucleoprotein H (hnRNP H) 
 
Nucleus; 
nucleoplasm. 
 
RNA processing and Transcription 
regulation 
STMN1  HUMAN Stathmin 
(Phosphoprotein p19) (pp19) 
(Oncoprotein 18)  
 
Cytoplasm 
 
Involved in the regulation of the 
microtubule (MT) 
 
UBP10  HUMAN Ubiquitin carboxyl-
terminal hydrolase 10 
 
Unknown Ubiquitin specific protease  
 
HN1  HUMAN Hematological and 
neurological expressed 1 protein  
 
Nucleus Unknown 
TIF1B HUMAN Transcription 
intermediary factor 1-beta (TIF1-
beta)  
Nucleus  Transcription factor 
CBLL1 HUMAN Cordon-bleu protein-
like 1 
 
Unknown  Unknown  
IF34 HUMAN Eukaryotic translation 
initiation factor 3 subunit 4 (eIF-
3 delta) 
Unknown  Translation  
RCOR1  HUMAN REST corepressor 1  
 
Nucleus 
 
RNA processing and Transcription 
regulation 
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Table A-3 (continued). 
 
Swissprot 
code 
 Protein name Subcellular 
localization 
Functional category 
LARP1 HUMAN La-related protein 1  
 
Unknown  Unknown  
AAKB2 HUMAN 5'-AMP-activated 
protein kinase subunit beta-2 
(AMPK beta-2 chain) 
 
Unknown  AMPK is responsible for the 
regulation of fatty acid synthesis by 
phosphorylation of acetyl-CoA 
carboxylase 
CHSP1 HUMAN Calcium-regulated heat 
stable protein 1 
 
Cytoplasm  May play a role in acinar cell 
metabolism 
ODBA  HUMAN 2-oxoisovalerate 
dehydrogenase subunit alpha, 
mitochondrial precursor 
 
Mitochondrio
n; 
mitochondria
l matrix 
 
The branched-chain alpha-keto 
dehydrogenase complex 
 
PPHLN  HUMAN Periphilin-1 (Gastric 
cancer antigen Ga50) 
 
Nucleus. 
Cytoplasm 
 
Involved in epithelial differentiation 
and contributes 
 
K1802 HUMAN Zinc finger protein 
KIAA1802 
 
Unknown  Unknown  
SF3A1  HUMAN Splicing factor 3 
subunit 1 (Spliceosome-
associated protein 114)  
 
Nucleus Unknown 
TAOK2 HUMAN Serine/threonine-
protein kinase TAO2 
 
Cytoplasm   Activates the JNK MAP kinase 
pathway through the specific 
activation of the upstream MKK3 
and MKK6 kinases. 
KPCD1  HUMAN Serine/threonine-
protein kinase D1 (nPKC-D1) 
(Protein kinase D) 
 
Unknown Unknown 
STK39  HUMAN STE20/SPS1-related 
proline-alanine-rich protein 
kinase 
Cytoplasm 
(Probable). 
Nucleus 
(Probable). 
Signal transduction 
KLC2 HUMAN Kinesin light chain 2 
(KLC 2) 
 
Unknown  Kinesin is a microtubule-associated 
force-producing protein that may 
play a role in organelle transport. The 
light chain may function in coupling 
of cargo to the heavy chain or in the 
modulation of its ATPase activity 
LRRF1  HUMAN Leucine-rich repeat 
flightless-interacting protein 1 
 
Nucleus. 
Cytoplasm. 
 
RNA processing and Transcription 
regulation 
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Table A-3 (continued). 
 
Swissprot 
code 
 Protein name Subcellular 
localization 
Functional category 
ARHG6 HUMAN Rho guanine nucleotide 
exchange factor 6  
 
Unknown  Acts as a RAC1 guanine nucleotide 
exchange factor 
CD2L1 HUMAN PITSLRE 
serine/threonine-protein kinase 
CDC2L1  
 
Cytoplasm. 
Nucleus 
Appears to play multiple roles in cell 
cycle progression, cytokinesis and 
apoptosis 
PYRG1 HUMAN CTP synthase 1 (UTP--
ammonia ligase 1) 
 
Unknown  Catalyzes the ATP-dependent 
amination of UTP to CTP with either 
L-glutamine or ammonia as the 
source of nitrogen. 
TYY1_ HUMAN Transcriptional 
repressor protein YY1 (Yin and 
yang 1) (YY-1)  
 
Nucleus  Transcription factor 
SMN HUMAN Survival motor neuron 
protein (Component of gems 1) 
(Gemin-1) 
 
Cytoplasm. 
Nucleus 
The SMN complex plays an essential 
role in spliceosomal snRNP assembly 
in the cytoplasm and is required for 
pre-mRNA splicing in the nucleus. It 
may also play a role in the 
metabolism of snoRNPs. 
 
PAK2 HUMAN Serine/threonine-
protein kinase PAK 2 (p21-
activated kinase 2)  
 
Unknown  The activated kinase acts on a variety 
of targets. Phosphorylates ribosomal 
protein S6, histone H4 and myelin 
basic protein. 
SSRP1  HUMAN FACT complex subunit 
SSRP1 
 
Nucleus 
 
Component of the FACT complex, a 
general chromatin factor that acts to 
reorganize nucleosomes. 
CTNA1  HUMAN Catenin alpha-1 
(Cadherin-associated protein)  
 
Cell junction 
 
May play a crucial role in cell 
differentiation 
 
SFRS9  HUMAN Splicing factor, 
arginine/serine-rich 9  
 
Nucleus 
 
Translation  
AGM1  HUMAN 
Phosphoacetylglucosamine 
mutase (PAGM)  
Unknown  Interconvert GlcNAc-6-P and 
GlcNAc-1-P 
 
MORC2  HUMAN MORC family CW-type 
zinc finger protein 2  
 
Unknown Unknown 
BAD  HUMAN Bcl2 antagonist of cell 
death (BAD)  
 
Mitochondrio
n; 
mitochondria
l outer 
membrane 
Cell cycle 
TB182  HUMAN 182 kDa tankyrase 1-
binding protein 
 
Nucleus. 
Cytoplasm 
 
Binds to the ANK repeat domain of 
TNKS1 and TNKS2 
AKTS1  HUMAN Proline-rich AKT1 
substrate 1 (40 kDa proline-rich 
AKT substrate) 
Cytoplasm; 
cytosol  
 
Signal transduction 
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Table A-3 (continued). 
 
Swissprot 
code 
 Protein name Subcellular 
localization 
Functional category 
PUM1  HUMAN Pumilio homolog 1 
(Pumilio-1) (HsPUM) 
 
Cytoplasm   
 
RNA processing and Transcription 
regulation 
ODPA  HUMAN Pyruvate dehydrogenase 
E1 component alpha subunit  
 
Mitochondrio
n; 
mitochondria
l matrix. 
 
Metabolic pathway 
SRRM2 HUMAN Serine/arginine 
repetitive matrix protein 2  
 
Nucleus  Translation  
RBM10 HUMAN RNA-binding protein 10 
(RNA-binding motif protein 10) 
 
Nucleus  Unknown  
HIRP3  HUMAN HIRA-interacting 
protein 3 
 
Nucleus  
 
May play a role in chromatin 
function and histone metabolism via 
its interaction with HIRA and 
histones. 
 
FA62A HUMAN Protein FAM62A 
(Membrane-bound C2 domain-
containing protein) 
 
Membrane  Unknown  
PACN3  HUMAN Protein kinase C and 
casein kinase substrate in neurons 
protein 3 
 
Cytoplasm. 
Cell 
membrane; 
peripheral 
membrane 
protein; 
cytoplasmic 
side. 
 
May play a role in vesicle formation 
and transport. 
 
MLRN HUMAN Myosin regulatory light 
chain 2, smooth muscle isoform  
 
Unknown  Plays an important role in regulation 
of both smooth muscle and 
nonmuscle cell contractile activity 
HSPB1 HUMAN Heat-shock protein beta-
1 (HspB1) (Heat shock 27 kDa 
protein) 
 
Cytoplasm, 
Nucleus  
Involved in stress resistance and 
actin organization. 
LA  HUMAN Lupus La protein 
(Sjoegren syndrome type B 
antigen)  
 
Nucleus  
 
RNA processing and Transcription 
regulation 
IF2P HUMAN Eukaryotic translation 
initiation factor 5B (eIF-5B)  
 
Unknown  Translation  
FXR1  HUMAN Fragile X mental 
retardation syndrome-related 
protein 1 (hFXR1p) 
 
Cytoplasm. 
 
RNA processing and Transcription 
regulation 
HS90B  HUMAN Heat shock protein HSP 
90-beta (HSP 84)  
Cytoplasm Molecular chaperone 
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Table A-3 (continued). 
 
Swissprot 
code 
 Protein name Subcellular 
localization 
Functional category 
CFDP1  HUMAN Craniofacial 
development protein 1 
(Bucentaur) 
 
Unknown  May play a role during 
embryogenesis (By similarity). 
 
LC7L2 HUMAN Putative RNA-binding 
protein Luc7-like 2 
 
Unknown  May bind to RNA via its Arg/Ser-
rich domain 
IF38 HUMAN Eukaryotic translation 
initiation factor 3 subunit 8 (eIF3 
p110)  
 
Unknown  Translation  
MYPT1  HUMAN Protein phosphatase 1 
regulatory subunit 12A  
 
Cytoplasm 
 
Regulates myosin phosphatase 
activity 
 
ZN330  HUMAN Zinc finger protein 330 
(Nucleolar cysteine-rich protein)  
 
Nucleus  Unknown  
HNRPK HUMAN Heterogeneous nuclear 
ribonucleoprotein K  
Cytoplasm. 
Nucleus; 
nucleoplasm. 
One of the major pre-mRNA-binding 
proteins. 
HDGF  HUMAN Hepatoma-derived 
growth factor (HDGF)  
 
Cytoplasm 
 
Heparin-binding protein, with 
mitogenic activity for fibroblasts. 
 
OSBP1 HUMAN Oxysterol-binding 
protein 1 
 
Cytoplasm  May play a role in the regulation of 
sterol metabolism 
ABCF1  HUMAN ATP-binding cassette 
sub-family F member 1 
 
Unknown  Translation  
HNRH2 HUMAN Heterogeneous nuclear 
ribonucleoprotein H' (hnRNP H') 
(FTP-3) 
 
Nucleus; 
nucleoplasm 
Translation 
MK67I  HUMAN MKI67 FHA domain-
interacting nucleolar 
phosphoprotein 
 
Nucleus; 
nucleolus 
 
Unknown  
LMNA  HUMAN Lamin-A/C (70 kDa 
lamin) 
 
Nucleus. 
 
Unknown 
CDC2  HUMAN Cell division control 
protein 2 homolog (p34 protein 
kinase)  
 
Nucleus  Cell cycle  
PCY1A  HUMAN Choline-phosphate 
cytidylyltransferase A  
 
Cytoplasm; 
cytosol. 
Membrane; 
peripheral 
membrane 
protein.  
Controls phosphatidylcholine 
synthesis 
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Table A-3 (continued). 
 
Swissprot 
code 
 Protein name Subcellular 
localization 
Functional category 
CCDC6  HUMAN Coiled-coil domain-
containing protein 6 (H4 protein)  
 
Cytoplasm. 
Cytoplasm; 
cytoskeleto
n 
 
Unknown  
SMC4 HUMAN Structural maintenance 
of chromosomes protein 4  
Nucleus. 
Cytoplasm 
DNA processing  
SMRC2 HUMAN SWI/SNF-related 
matrix-associated actin-
dependent regulator of chromatin 
subfamily C member 2 
Nucleus  transcriptional activation and 
repression 
MDC1 HUMAN Mediator of DNA 
damage checkpoint protein 1  
 
nucleus Cell cycle  
PPIL4 HUMAN Peptidyl-prolyl cis-
trans isomerase-like 4  
 
Nucleus  PPIases accelerate the folding of 
proteins 
XRCC1  HUMAN DNA-repair protein 
XRCC1  
 
Nucleus  Unknown 
SYEP HUMAN Bifunctional 
aminoacyl-tRNA synthetase 
 
Unknown  Unknown  
CALX  HUMAN Calnexin precursor 
 
Endoplasmi
c reticulum 
Translation  
FUSIP  HUMAN FUS-interacting serine-
arginine-rich protein 1 
 
Nucleus; 
cytoplasm 
Translation  
MLF2  HUMAN Myeloid leukemia 
factor 2  
 
Cytoplasm; 
nucleus 
Unknown  
PCBP2 HUMAN Poly(rC)-binding 
protein 2 (Alpha-CP2)  
 
Nucleus; 
cytoplasm 
Major cellular poly(rC)-binding 
protein 
CLIP1  HUMAN Restin  cytoplasm Unknown 
MPRI HUMAN Cation-independent 
mannose-6-phosphate receptor 
precursor  
 
Lysosome; 
lysosomal 
membrane 
Signal transduction 
NOP56 HUMAN Nucleolar protein 
Nop56  
Nucleus  Translation  
RBM5 HUMAN RNA-binding protein 5 Nucleus  Tumor suppressor protein that reduces 
cell proliferation and promotes 
apoptosis and cell cycle arrest 
LIPB2 HUMAN Liprin-beta-2  
 
Unknown  May regulate the disassembly of focal 
adhesions. Did not bind receptor-like 
tyrosine phosphatases type 2A 
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Table A-3 (continued). 
 
Swissprot 
code 
 Protein name Subcellular 
localization 
Functional category 
TXLNA  HUMAN Alpha-taxilin 
 
Unknown  Unknown 
PHF6 HUMAN PHD finger protein 6 
(PHD-like zinc finger protein) 
 
Nucleus  Transcription regulation  
TRA2A HUMAN Transformer-2 protein 
homolog  
 
Nucleus  Translation  
BIRC3  HUMAN Baculoviral IAP 
repeat-containing protein 3 
 
Unknown  Unknown 
MCM2  HUMAN DNA replication 
licensing factor MCM2 
 
Nucleus  Cell cycle  
NFAC3 HUMAN Nuclear factor of 
activated T-cells, cytoplasmic 3 
(NF-ATc3)  
 
Cytoplasm, 
nucleus 
Plays a role in the inducible expression 
of cytokine genes in T-cells, especially 
in the induction of the IL-2. 
CT172  HUMAN Uncharacterized 
protein C20orf172 
 
Nucleus Cell cycle  
PKCB1 HUMAN Protein kinase C-
binding protein 1 (Rack7)  
 
Unknown  Unknown  
KAP1  HUMAN cAMP-dependent 
protein kinase type I-beta 
regulatory subunit 
 
Unknown  Unknown  
TAOK1 HUMAN Serine/threonine-
protein kinase TAO1  
 
Cytoplasm  Signal transduction  
BRCA2 HUMAN Breast cancer type 2 
susceptibility protein  
 
Unknown  Cell cycle  
LRC15  HUMAN Leucine-rich repeat-
containing protein 15 precursor 
(hLib) 
 
Membrane  Unknown  
MRCKA HUMAN Serine/threonine-
protein kinase MRCK alpha  
 
Cytoplasm  Cell cycle  
NOL7  HUMAN Nucleolar protein 7  
 
Nucleus  Unknown  
GSTM2  HUMAN Glutathione S-
transferase Mu 2  
 
Cytoplasm  Unknown 
MYH13  HUMAN Myosin-13 (Myosin 
heavy chain 13)  
Unknown  Muscle contraction 
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Table A-3 (continued). 
 
Swissprot 
code 
 Protein name Subcellular 
localization 
Functional category 
ELL HUMAN RNA polymerase II 
elongation factor ELL  
 
Nucleus  Elongation factor 
M10L1 HUMAN Putative helicase 
Mov10l1  
 
Unknown  Putative RNA helicase. Isoform 1 may 
play a role in male germ cell 
development. 
DPOA2  HUMAN DNA polymerase 
subunit alpha B  
 
Nucleus. 
 
RNA processing and transcription 
regulation 
SNF5 HUMAN SWI/SNF-related 
matrix-associated actin-dependent 
regulator of chromatin subfamily 
B member 1 
 
Nucleus  Cell cycle  
UBR2 HUMAN E3 ubiquitin-protein 
ligase UBR2 (N-recognin-2)  
 
nucleus Signal transduction 
MRP  HUMAN MARCKS-related 
protein (MARCKS-like protein 1) 
Unknown Signal transduction 
NP1L4  HUMAN Nucleosome assembly 
protein 1-like 4  
 
Nucleus Unknown 
4EBP1 HUMAN Eukaryotic translation 
initiation factor 4E-binding 
protein 1  
 
Unknown  Translation  
RANB3  HUMAN Ran-binding protein 3 
(RanBP3) 
 
Cytoplasm. 
Nucleus. 
 
Acts as a cofactor for XPO1/CRM1-
mediated nuclear export, perhaps as 
export complex scaffolding protein.  
EP15 HUMAN Epidermal growth 
factor receptor substrate 15 
(Protein Eps15)  
 
Cytoplasm, 
cell 
membrane 
Cell growth  
1433E HUMAN 14-3-3 protein epsilon 
(14-3-3E) 
 
Cytoplasm  Signal transduction 
RL1D1 HUMAN Ribosomal L1 domain-
containing protein 1  
 
Nucleus  Unknown  
MARCS HUMAN Myristoylated alanine-
rich C-kinase substrate 
(MARCKS)  
Unknown  MARCKS is the most prominent 
cellular substrate for protein kinase C 
CD2B2 HUMAN CD2 antigen 
cytoplasmic tail-binding protein 2 
Cytoplasm  Unknown  
K1C18 HUMAN Keratin, type I 
cytoskeletal 18 (Cytokeratin-18) 
(CK-18)  
Unknown  Unknown  
PURB HUMAN Transcriptional 
activator protein Pur-beta  
 
Nucleus  Has capacity to bind repeated elements 
in single-stranded DNA such as the 
purine-rich single strand of the PUR 
element located upstream of the MYC 
gene.  
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ZN326 HUMAN Zinc finger protein 326 
 
Nucleus  transcriptional activator 
EF1D  HUMAN Elongation factor 1-
delta (EF-1-delta) (Antigen NY-
CO-4) 
 
Unknown  Translation 
NDRG3 HUMAN Protein NDRG3 
 
Unknown  Unknown  
SFR11  HUMAN Splicing factor 
arginine/serine-rich 11  
Nucleus RNA processing and Transcription 
regulation 
PSA3 HUMAN Proteasome subunit 
alpha type 3 (Proteasome 
component C8)  
Cytoplasm, 
nucleus  
proteasome 
FIP1  HUMAN Pre-mRNA 3'-end-
processing factor FIP1 (FIP1-like 
1) 
 
Unknown RNA processing and Transcription 
regulation 
TE2IP HUMAN Telomeric repeat-
binding factor 2-interacting 
protein 1 
 
Nucleus  May play a role in telomere length 
regulation. 
MAP4  HUMAN Microtubule-associated 
protein 4 (MAP 4) 
 
Unknown  Non-neuronal microtubule-associated 
protein. Promotes 
 
K2C7 HUMAN Keratin, type II 
cytoskeletal 7  
 
Unknown  Unknown  
PININ  HUMAN Pinin (140 kDa nuclear 
and cell adhesion-related 
phosphoprotein) 
 
Nucleus; 
nuclear 
speckle. 
Cell 
junction; 
 
RNA processing and Transcription 
regulation 
TBA6 HUMAN Tubulin alpha-6 chain 
(Alpha-tubulin 6) 
 
Unknown  Tubulin is the major constituent of 
microtubules. It binds two moles of 
GTP, one at an exchangeable site on 
the beta chain and one at a non-
exchangeable site on the alpha-chain. 
UBP7 HUMAN Ubiquitin carboxyl-
terminal hydrolase 7 (Ubiquitin 
thioesterase 7) 
 
Nucleus  Cell cycle  
HNRPF HUMAN Heterogeneous nuclear 
ribonucleoprotein F (hnRNP F)  
 
Nucleus; 
nucleoplasm 
Component of the heterogeneous 
nuclear ribonucleoprotein (hnRNP) 
complexes which provide the substrate 
for the processing events that pre-
mRNAs undergo before becoming 
functional, translatable mRNAs in the 
cytoplasm. Probably binds G-rich 
sequences in pre-mRNAs 
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localization 
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CBX3  HUMAN Chromobox protein 
homolog 3  
 
Nucleus 
(Probable).  
 
RNA processing and Transcription 
regulation 
SSH3 HUMAN Protein phosphatase 
Slingshot homolog 3 (SSH-3L)  
 
Cytoplasm, 
nucleus  
Protein phosphatase which may play a 
role in the regulation of actin filament 
dynamics 
DDX21  HUMAN Nucleolar RNA 
helicase 2 (Nucleolar RNA 
helicase II) 
 
Nucleus; 
nucleolus. 
 
RNA processing and Transcription 
regulation 
TACC2 HUMAN Transforming acidic 
coiled-coil-containing protein 2  
 
Cytoplasm. 
Nucleus. 
Centrosome. 
May play a role in organizing 
centrosomal microtubules. May act as 
a tumor suppressor protein. May 
represent a tumor progression marker 
LIPB1  HUMAN Liprin-beta-1 
 
Unknown  May regulate the disassembly of focal 
adhesions. Did not bind receptor-like 
tyrosine phosphatases type 2A. 
 
IF4B  HUMAN Eukaryotic translation 
initiation factor 4B (eIF-4B) 
 
Unknown RNA processing and Transcription 
regulation 
TIF1A HUMAN Transcription 
intermediary factor 1-alpha 
(TIF1-alpha) 
 
Nucleus  Interacts selectively in vitro with the 
AF2-activating domain of the estrogen 
receptors. Association with DNA-
bound estrogen receptors requires the 
presence of estradiol. 
MAP1B HUMAN Microtubule-associated 
protein 1B (MAP 1B)  
 
Unknown  The function of brain MAPS is 
essentially unknown. Phosphorylated 
MAP1B may play a role in the 
cytoskeletal changes that accompany 
neurite extension 
EXOS9  HUMAN Exosome complex 
exonuclease RRP45 (Exosome 
component 9)  
 
Cytoplasm. 
Nucleus; 
nucleolus. 
 
RNA processing and Transcription 
regulation 
BCL7C HUMAN B-cell CLL/lymphoma 
7 protein family member C 
 
Unknown  May play an anti-apoptotic role 
SNUT1 HUMAN U4/U6.U5 tri-snRNP-
associated protein 1  
 
Nucleus  Translation  
WEE1 HUMAN Wee1-like protein 
kinase (Wee1A kinase) 
(WEE1hu) 
 
Nucleus  Cell cycle  
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NCK1 HUMAN Cytoplasmic protein 
NCK1 (NCK adaptor protein 1) 
 
Cytoplasm  Adapter protein which associates with 
tyrosine-phosphorylated growth factor 
receptors or their cellular substrates. 
STUB1  HUMAN STIP1 homology and U 
box-containing protein 1  
 
Cytoplasm 
 
Unknown 
DIDO1  HUMAN Death-inducer 
obliterator 1 (DIO-1)  
Cytoplasm. 
Nucleus 
RNA processing and Transcription 
regulation 
SPF45  HUMAN Splicing factor 45 (45 
kDa-splicing factor) 
 
Nucleus. 
 
RNA processing  
PDCD4  HUMAN Programmed cell death 
protein 4 (Nuclear antigen H731-
like)  
 
Nucleus. 
Cytoplasm 
 
Tumor suppressor. Inhibits tumor 
promoter-induced 
 
IPYR2 HUMAN Inorganic 
pyrophosphatase 2, mitochondrial 
precursor (PPase 2)  
 
Mitochondr
ion  
Unknown  
LS14A  HUMAN LSM14 protein 
homolog A (Protein SCD6 
homolog)  
 
Unknown Unknown 
SFRS6 HUMAN Splicing factor, 
arginine/serine-rich 6  
 
Nucleus  Plays a role in constitutive splicing and 
can modulate the selection of 
alternative splice sites 
SDS3 HUMAN Sin3 histone 
deacetylase corepressor complex 
component SDS3  
 
Unknown  Regulatory protein which represses 
transcription and augments histone 
deacetylase activity of HDAC1. May 
have a potential role in tumor 
suppressor pathways. May function in 
the assembly and/or enzymatic activity 
of the mSin3A corepressor complex or 
in mediating interactions between the 
complex and other regulatory 
complexes 
ARS2 HUMAN Arsenite-resistance 
protein 2 
 
Unknown  Confers arsenite resistance 
TBA1 HUMAN Tubulin alpha-1 chain 
(Alpha-tubulin 1)  
 
Unknown  Tubulin is the major constituent of 
microtubules. It binds two moles of 
GTP, one at an exchangeable site on 
the beta chain and one at a non-
exchangeable site on the alpha-chain 
REPS1  HUMAN RalBP1-associated Eps 
domain-containing protein 1  
 
Unknown  Unknown 
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UBXD7 HUMAN UBX domain-
containing protein 7 
 
Unknown  Unknown  
YBOX1  HUMAN Nuclease sensitive 
element-binding protein 1  
 
Cytoplasm. 
Nucleus 
 
Translation  
NDRG2  HUMAN Protein NDRG2 
(Protein Syld709613) 
Cytoplasm. 
Cytoplasm; 
perinuclear 
region 
May be involved in dendritic cell and 
neuron differentiation. May have anti-
tumor activity. 
PGRC1  HUMAN Membrane-associated 
progesterone receptor component 
1 (mPR) 
 
Microsome; 
microsomal 
membrane;  
 Receptor for progesterone  
 
EP15R HUMAN Epidermal growth 
factor receptor substrate 15-like 1 
 
Cell 
membrane  
Seems to be a constitutive component 
of clathrin-coated pits that is required 
for receptor-mediated endocytosis 
BIN1  HUMAN Myc box-dependent-
interacting protein 1 (Bridging 
integrator 1) 
 
Nucleus ; 
cytoplasm 
Unknown 
SGIP1 HUMAN SH3-containing GRB2-
like protein 3-interacting protein 
1 
 
Unknown  Possible role in the regulation of 
energy homeostasis 
MATN4  HUMAN Matrilin-4 precursor 
 
Secreted 
protein 
Unknown 
YETS2 HUMAN YEATS domain-
containing protein 2 
 
Nucleus  Unknown  
PDE10  HUMAN cAMP and cAMP-
inhibited cGMP 3',5'-cyclic 
phosphodiesterase 10A 
 
Soluble 
cellular 
fractions 
Signal transduction 
DPOD3  HUMAN DNA polymerase 
subunit delta 3 (DNA polymerase 
subunit delta p66) 
 
Nucleus. 
 
Unknown  
NSF1C  HUMAN NSFL1 cofactor p47 
(p97 cofactor p47) 
 
 Nucleus. 
Golgi 
apparatus; 
 
Translation  
WASF2  HUMAN Wiskott-Aldrich 
syndrome protein family member 
2  
 
Cytoplasm  Signal transduction  
MEP50 HUMAN Methylosome protein 
50 (MEP50 protein) (WD repeat 
protein 77) 
 
Unknown  The methylosome may regulate an 
early step in the assembly of U 
snRNPs, possibly the transfer of Sm 
proteins to the SMN-complex 
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ARRB1 HUMAN Beta-arrestin-1 
(Arrestin beta 1) 
 
Unknown  Regulates beta-adrenergic receptor 
function. Beta-arrestins seem to bind 
phosphorylated beta-adrenergic 
receptors, thereby causing a significant 
impairment of their capacity to 
activate G(S) protein 
CT2NL HUMAN CTTNBP2 N-terminal-
like protein 
 
Unknown  Unknown  
TJAP1  HUMAN Tight junction-
associated protein 1 (Tight 
junction protein 4)  
 
Golgi 
apparatus 
Unknown  
LAMA2 HUMAN Laminin subunit alpha-
2 precursor (Laminin M chain)  
 
Secreted 
protein; 
extracellular 
space; 
extracellular 
Binding to cells via a high affinity 
receptor, laminin is thought to mediate 
the attachment, migration and 
organization of cells into tissues 
during embryonic development by 
interacting with other extracellular 
matrix components 
PERQ2  HUMAN PERQ amino acid-rich 
with GYF domain-containing 
protein 2  
 
Unknown  Signal transduction  
NIPA HUMAN Nuclear-interacting 
partner of ALK 
 
Nucleus  Signal transduction  
ANK3  HUMAN Ankyrin-3 (ANK-3) 
(Ankyrin-G) 
 
Unknown  Unknown 
CIP4  HUMAN Cdc42-interacting 
protein 4  
 
Cytoplasm; 
lysosome; 
Golgi 
apparatus. 
Cell 
membrane 
Signal transduction 
PGRC2  HUMAN Membrane-associated 
progesterone receptor component 
2  
 
Unknown  Receptor for steroids 
KKCC1 HUMAN Calcium/calmodulin-
dependent protein kinase kinase 1 
Cytoplasm, 
nucleus  
Signal transduction 
Calcium/calmodulin-dependent 
protein kinase that belongs to a 
proposed calcium-triggered signaling 
cascade involved in a number of 
cellular processes 
PEBP1  HUMAN 
Phosphatidylethanolamine-
binding protein 1 (PEBP-1)  
 
Cytoplasm  
 
Unknown 
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BAIP2 HUMAN Brain-specific 
angiogenesis inhibitor 1-
associated protein 2  
 
Cytoplasm, 
membrane  
Adapter protein that links membrane-
bound small G-proteins to cytoplasmic 
effector proteins. Necessary for 
CDC42-mediated reorganization of the 
actin cytoskeleton and for RAC1-
mediated membrane ruffling.  
PDPK1  HUMAN 3-phosphoinositide-
dependent protein kinase 1 
(hPDK1) 
Cytoplasm. 
membrane; 
peripheral 
membrane  
Signal transduction 
SH24A  HUMAN SH2 domain-containing 
protein 4A 
 
Unknown  Unknown  
NELFE HUMAN Negative elongation 
factor E (NELF-E)  
 
Nucleus  Transcription regulation  
CN004 HUMAN Protein C14orf4 
 
Nucleus  Unknown  
NFIA  HUMAN Nuclear factor 1 A-type 
(Nuclear factor 1/A) 
 
Nucleus 
 
RNA processing and Transcription 
regulation 
PI3R6  HUMAN Phosphoinositide 3-
kinase regulatory subunit 6  
 
Cytoplasm 
 
Unknown 
TAF1  HUMAN Transcription initiation 
factor TFIID subunit 1  
 
Nucleus  Transcription regulation 
CLC4F HUMAN C-type lectin domain 
family 4 member F 
 
Membrane  Receptor with an affinity for galactose 
and fucose. Could be involved in 
endocytosis 
TLE3  HUMAN Transducin-like 
enhancer protein 3 (ESG3) 
 
Unknown  Transcription regulation 
ARHGG  HUMAN Rho guanine nucleotide 
exchange factor 16 
 
Unknown  Unknown  
ILF3 HUMAN Interleukin enhancer-
binding factor 3  
 
Nucleus  DNA processing  
ZN496 HUMAN Zinc finger protein 496 
 
Nucleus  Transcription regulation 
G3BP2  HUMAN Ras GTPase-activating 
protein-binding protein 2 (G3BP-
2)  
 
Unknown  Scaffold protein 
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HNF3A HUMAN Hepatocyte nuclear 
factor 3-alpha  
 
Nucleus  Transcription activator  
MYH9  HUMAN Myosin-9 (Myosin 
heavy chain 9)  
 
Unknown  Cell cycle  
RU17  HUMAN U1 small nuclear 
ribonucleoprotein 70 kDa (U1 
snRNP 70 kDa)  
 
Unknown  Unknown 
ATM  HUMAN Serine-protein kinase 
ATM (Ataxia telangiectasia 
mutated)  
 
Nucleus. 
Cytoplasmic 
vesicle 
 
Signal transduction 
RALY HUMAN RNA-binding protein 
Raly  
 
Nucleus  Translation  
ZNF2 HUMAN Zinc finger protein 2 
(Zinc finger 2.2) (Zinc finger 
protein 661) 
 
Nucleus  Transcription regulation  
STAC2  HUMAN SH3 and cysteine-rich 
domain-containing protein 2  
 
Unknown  Unknown  
FOXK1  HUMAN Forkhead box protein 
K1 (Myocyte nuclear factor) 
(MNF) 
 
Unknown  Transcription regulation  
ZBTB5  HUMAN Zinc finger and BTB 
domain-containing protein 5 
 
Nucleus  Transcription regulation  
RBGPR HUMAN Rab3 GTPase-activating 
protein non-catalytic subunit 
 
Cytoplasm  Regulatory subunit of a GTPase 
activating protein that has specificity 
for Rab3 subfamily (RAB3A, 
RAB3B, RAB3C and RAB3D). Rab3 
proteins are involved in regulated 
exocytosis of neurotransmitters and 
hormones. Rab3 GTPase-activating 
complex specifically converts active 
Rab3-GTP to the inactive form Rab3-
GDP. Required for normal eye and 
brain development.  
ROA2  HUMAN Heterogeneous nuclear 
ribonucleoproteins A2/B1 
(hnRNP A2 / hnRNP B1) 
 
Nucleus RNA processing and Transcription 
regulation 
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SEPT9 HUMAN Septin-9 (MLL septin-
like fusion protein)  
 
Cell 
membrane  
Involved in cytokinesis. May 
function as an ovarian tumor 
suppressor 
DTD1 HUMAN Probable D-tyrosyl-
tRNA(Tyr) deacylase 1 
 
Cytoplasm  Hydrolyzes D-tyrosyl-tRNA(Tyr) 
into D-tyrosine and free 
tRNA(Tyr). Could be a defense 
mechanism against a harmful effect 
of D-tyrosine 
K0515  HUMAN Uncharacterized protein 
KIAA0515 
 
Unknown Unknown 
MCM3 HUMAN DNA replication 
licensing factor MCM3 
 
Nucleus  DNA processing  
MTMR5 HUMAN SET-binding factor 1 
(Sbf1) (Myotubularin-related 
protein 5) 
 
Nucleus  Probable pseudophosphatase. Lacks 
several amino acids in the catalytic 
pocket which renders it catalytically 
inactive as a phosphatase. The 
pocket is however sufficiently 
preserved to bind phosphorylated 
substrates, and maybe protect them 
from phosphatases. Inhibits 
myoblast differentiation in vitro and 
induces oncogenic transformation 
in fibroblasts 
ALKB5  HUMAN Alkylated repair protein 
alkB homolog 5 
 
Unknown  Unknown  
CHCH3 HUMAN Coiled-coil-helix-coiled-
coil-helix domain-containing 
protein 3 
 
Unknown  Unknown  
VDAC1  HUMAN Voltage-dependent 
anion-selective channel protein 1 
(VDAC-1)  
 
Mitochondrio
n; 
mitochondrial 
outer 
membrane. 
 
Unknown 
B4GN4 HUMAN N-acetyl-beta-
glucosaminyl-glycoprotein 4-beta-
N-acetylgalactosaminyltransferase 
1 
 
Golgi 
apparatus 
Transfers N-acetylgalactosamine 
(GalNAc) from UDP-GalNAc to N-
acetylglucosamine-beta-benzyl with 
a beta-1,4-linkage to form N,N'-
diacetyllactosediamine, GalNAc-
beta-1,4-GlcNAc structures in N-
linked glycans and probably O-
linked glycans. 
SNW1  HUMAN SNW domain-containing 
protein 1 (Nuclear protein SkiP)  
 
Nucleus RNA processing and Transcription 
regulation 
PPA6 HUMAN Lysophosphatidic acid 
phosphatase type 6 precursor  
 
Secreted 
protein  
Hydrolyzes lysophosphatidic acid 
to monoacylglycerol 
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RFIP1  HUMAN Rab11 family-
interacting protein 1 (Rab11-
FIP1)  
Endosome; 
recycling 
endosome. 
Isoform 2: 
 
A Rab11 effector protein involved in 
the endosomal recycling process. Also 
involved in controlling membrane 
trafficking along the phagocytic 
pathway and in phagocytosis  
TCEA1 HUMAN Transcription 
elongation factor A protein 1  
 
Nucleus  Transcription regulation  
SAP30 HUMAN Histone deacetylase 
complex subunit SAP30 
 
Nucleus  Transcription regulation  
SAM68  HUMAN KH domain-containing, 
RNA-binding, signal 
transduction-associated protein1 
 
Nucleus. 
Membrane. 
 
Signal transduction, transcription 
regulation and cell cycle 
BI2L1 HUMAN Brain-specific 
angiogenesis inhibitor 1-
associated protein 2-like protein1 
 
Unknown  May function as adapter protein 
ROA1 HUMAN Heterogeneous nuclear 
ribonucleoprotein A1  
 
Nucleus, 
cytoplasm  
Involved in the packaging of pre-
mRNA into hnRNP particles, transport 
of poly(A) mRNA from the nucleus to 
the cytoplasm and may modulate 
splice site selection 
PKP3  HUMAN Plakophilin-3 
 
Nucleus. 
Cell 
junction; 
desmosome. 
May play a role in junctional plaques. 
SEBP2 HUMAN SECIS-binding protein 
2  
 
Nucleus  Binds to the SECIS element in the 3' 
UTR of some mRNAs encoding 
selenoproteins. Binding is stimulated 
by SELB. 
NUP98 HUMAN Nuclear pore complex 
protein Nup98-Nup96 precursor  
 
Nucleus  Nup98 and Nup96 play a role in the 
bidirectional transport across the 
nucleoporin complex (NPC). The 
repeat domain in Nup98 has a direct 
role in the transport 
K1C9 HUMAN Keratin, type I 
cytoskeletal 9 (Cytokeratin-9) 
 
Unknown  May serve an important special 
function either in the mature palmar 
and plantar skin tissue or in the 
morphogenic program of the formation 
of these tissues 
ROA3  HUMAN Heterogeneous nuclear 
ribonucleoprotein A3 (hnRNP 
A3) 
 
Nucleus RNA processing and Transcription 
regulation 
RL22L  HUMAN Ribosomal protein L22-
like 1 
 
Unknown Unknown 
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RBM15  HUMAN Putative RNA-binding 
protein 15 (RNA-binding motif 
protein 15)  
 
Nucleus  May be implicated in HOX gene 
regulation 
 
JIP1  HUMAN C-jun-amino-terminal 
kinase-interacting protein 1  
 
Cytoplasm; 
nucleus  
Signal transduction 
PAK4 HUMAN Serine/threonine-
protein kinase PAK 4 (p21-
activated kinase 4)  
 
Unknown  Signal transduction  
NONO  HUMAN Non-POU domain-
containing octamer-binding 
protein (NonO protein) 
 
Nucleus RNA processing and Transcription 
regulation 
RBM14  HUMAN RNA-binding protein 
14 (RNA-binding motif protein 
14) 
 
Unknown  Transcription regulation 
CSRP1 HUMAN Cysteine and glycine-
rich protein 1 (Cysteine-rich 
protein 1)  
 
Nucleus  Could play a role in neuronal 
development 
MYEF2 HUMAN Myelin expression 
factor 2 (MyEF-2) (MST156) 
 
Nucleus  Transcription repressor 
KIRR1 HUMAN Kin of IRRE-like 
protein 1 precursor  
 
Membrane  Signal transduction 
DDX25 HUMAN ATP-dependent RNA 
helicase DDX25 (DEAD box 
protein 25)  
 
Cytoplasm  ATP-dependent RNA helicase 
RBM26 HUMAN RNA-binding protein 
26 (RNA-binding motif protein 
26)  
 
Unknown  Unknown  
HCN4 HUMAN Potassium/sodium 
hyperpolarization-activated cyclic 
nucleotide-gated channel 4 
 
 
Membrane  Hyperpolarization-activated ion 
channel with very slow activation and 
inactivation exhibiting weak 
selectivity for potassium over sodium 
ions. May contribute to the native 
pacemaker currents in heart (If) and in 
neurons (Ih). Activated by cAMP. 
May mediate responses to sour stimuli. 
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PAR3L HUMAN Partitioning-defective 3 
homolog B (PAR3-beta)  
Intracytopla
smic 
membrane. 
Cell 
junction 
Putative adapter protein involved in 
asymmetrical cell division and cell 
polarization processes. May play a role 
in the formation of epithelial tight 
junctions 
F262 HUMAN 6-phosphofructo-2-
kinase/fructose-2,6-biphosphatase 
2  
 
Unknown  Synthesis and degradation of fructose 
2,6-bisphosphate 
EAF1 HUMAN ELL-associated factor 1 
 
Nucleus  Transcription regulation 
DENR  HUMAN Density-regulated 
protein (DRP) (Protein DRP1) 
 
Unknown Unknown 
TB182 HUMAN 182 kDa tankyrase 1-
binding protein 
 
Nucleus, 
cytoplasm 
Binds to the ANK repeat domain of 
TNKS1 and TNKS2 
NHERF  HUMAN Ezrin-radixin-moesin-
binding phosphoprotein 50 
(EBP50)  
 
Intracytopla
smic 
membrane; 
peripheral 
 
 Scaffold protein  
 
HD HUMAN Huntingtin (Huntington 
disease protein) (HD protein) 
 
Cytoplasm, 
nucleus  
May play a role in microtubule-
mediated transport or vesicle function 
NUDC  HUMAN Nuclear migration 
protein nudC 
 
Cytoplasm. 
Nucleus 
 
Plays a role in neurogenesis and 
neuronal migration  
 
PGRC1 HUMAN Membrane-associated 
progesterone receptor component 
1 (mPR) 
 
Microsome; 
microsomal 
membrane; 
single-pass 
membrane 
protein 
Receptor for progesterone 
CX026  HUMAN UPF0368 protein 
Cxorf26 
 
Unknown  Unknown  
CLN3  HUMAN Battenin (Protein 
CLN3) (Batten disease protein) 
 
Lysosome; 
lysosomal 
membrane 
Unknown  
TOIP1  HUMAN Torsin-1A-interacting 
protein 1 
 
Nucleus  Unknown 
SQSTM  HUMAN Sequestosome-1  
 
Cytoplasm. 
Endosome; 
late 
endosome. 
Nucleus 
Signal trasduction 
LMNB1  HUMAN Lamin-B1 Nucleus  Unknown 
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RB12B  HUMAN RNA-binding protein 
12B (RNA-binding motif protein 
12B) 
 
Unknown  Unknown  
CTRO  HUMAN Citron Rho-interacting 
kinase (CRIK) 
 
cytoplasm Unknown 
ATX2L HUMAN Ataxin-2-like protein  
 
Membrane  Unknown  
TRA2B  HUMAN Arginine/serine-rich-
splicing factor 10 (Transformer-2-
beta)  
 
Nucleus  Translation  
UBP2L  HUMAN Ubiquitin-associated 
protein 2-like (Protein NICE-4) 
 
Unknown  Unknown  
AKT1  HUMAN RAC-alpha 
serine/threonine-protein kinase  
 
Cytoplasm. 
Nucleus 
 
Signal transduction 
CHD1  HUMAN Chromodomain-
helicase-DNA-binding protein 1  
 
Nucleus 
 
Gene Regulation 
CBX4  HUMAN E3 SUMO-protein 
ligase CBX4  
 
Nucleus. 
 
Transcription regulation 
BCKD  HUMAN [3-methyl-2-
oxobutanoate dehydrogenase 
[lipoamide]] kinase 
 
Mitochondr
ion; 
mitochondri
al matrix. 
 
Metabolic pathways 
IF4H  HUMAN Eukaryotic translation 
initiation factor 4H (eIF-4H)  
 
Cytoplasm  
 
Translation regulation 
PAIRB  HUMAN Plasminogen activator 
inhibitor 1 RNA-binding protein  
 
Cytoplasm. 
Nucleus 
RNA processing and transcription 
regulation 
AAKB1  HUMAN 5'-AMP-activated 
protein kinase subunit beta-1  
Cytoplasm Metabolic pathways 
MATR3  HUMAN Matrin-3 
 
 
Nucleus 
 
RNA processing and transcription 
regulation 
PGAM1  HUMAN Phosphoglycerate 
mutase 1  
 
Unknown Unknown 
K1143  HUMAN Uncharacterized protein 
KIAA1143 
 
Unknown Unknown 
RGP2  HUMAN Rap1 GTPase-activating 
protein 1 (Rap1GAP) 
 
Golgi 
apparatus; 
Golgi 
apparatus 
membrane 
Signaling transduction 
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TRAF4  HUMAN TNF receptor-associated 
factor 4  
 
Cytoplasm. 
Nucleus 
 
Signal transduction 
MINT  HUMAN Msx2-interacting 
protein (SPEN homolog) 
 
Nucleus 
 
Signal transduction 
FA76B  HUMAN Protein FAM76B 
 
Unknown Unknown 
PPIG  HUMAN Peptidyl-prolyl cis-trans 
isomerase G  
 
Nucleus RNA processing and transcription 
regulation 
ZO2  HUMAN Tight junction protein 
ZO-2 (Zonula occludens 2 
protein) 
 
Cell 
junction 
 
Cell structure 
CBX8  HUMAN Chromobox protein 
homolog 8 (Polycomb 3 homolog) 
 
Nucleus 
 
RNA processing and transcription 
regulation 
The information was compiled from Swiss-Prot annotations. 
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Table A-4 Details of characterized phosphoproteins. 
 
Accession 
number 
Protein Peptide Site Phosphory-
lation site 
99-
029 
98-
065 
99-
045 
99-
067 
99-
010 
Phosphoproteins found in all 5 specimens 
Q05682 Caldesmon  K.RGS*IGENQVEVMVEEK.T S202 (b6） Y Y Y Y Y Y 
  K.RGS*IGENQVEVM#VEEK.T S202 Y N Y N N N 
P17661 Desmin R.TFGGAPGFPLGSPLSS*PVFPR.A S32 (y5, y6) Y N Y Y N N 
  R.TFGGAPGFPLGS*PLSSPVFPR.A S28 (y9,y10) N Y Y Y Y Y 
  R.TFGGAPGFPLGS*PLSS*PVFPR.A S32 (y5, y6) Y Y N Y Y N 
P04792 Heat-shock protein 
beta-1 (Heat shock 27 
kDa protein)  
R.QLS*SGVSEIR.H S82 (y7, y8) Y Y Y Y Y Y 
  R.GPS*WDPFR.D S15 (b2, b3) Y Y Y Y N N 
  R.GPS*WDPFRDWYPHSR.L S15 Y N N N Y N 
Q9UMS6 Synaptopodin-2  R.AQS*PTPSLPASWK.Y S902 (y10, y11) Y Y Y Y Y Y 
  R.AQS*PTPS*LPASWK.Y S906 (y5, y7) Y Y N Y N N 
  R.TAKPFPGSVNQPATPFS*PTR.N S604 (y3, y6) Y N Y N Y N 
  K.PFPGSVNQPATPFS*PTR.N S604 Y N Y N Y N 
  R.GVSS*PIAGPAQPPPWPQPAPWSQPAFYD
SSER.I 
S638 (not) Y N Y N N N 
  K.SKS*PDPDPNLSHDR.I S226 (not) N N N N Y N 
          
Phosphoproteins found in 4 out of 5 specimens 
O14558 Heat-shock protein 
beta-6 (Heat-shock 20 
kDa-like protein) 
R.RAS*APLPGLSAPGR.L S16 (y11, y12) N Y Y N Y Y 
Q14315 Filamin-C  R.LGS*FGSITR.Q S2233 (b2, b3) N Y N Y Y Y 
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Table A-4 (continued). 
 
Accession 
number 
Protein Peptide Site Phosphory-
lation site 
99-
029 
98-
065 
99-
045 
99-
067 
99-
010 
Q9H3Z4 DnaJ homolog 
subfamily C member 5  
R.S*LSTSGESLYHVLGLDK.N S8 (not) Y Y N Y Y N 
  R.SLSTS*GESLYHVLGLDK.N S12 (not) Y N Y N N N 
Q9HBL0 Tensin-1 R.RMS*VGDR.A S1393 (y5, y6) N Y N N Y N 
  R.WDS*YDNFSGHR.D S338 (y8, y9) Y Y N N N N 
  K.EAT*SDPSRTPEEEPLNLEGLVAHR.V T854  (not) N N Y N N N 
  R.T*PTQPLLESGFR.S T1105 (not) N N N Y N N 
  K.EATSDPSRT*PEEEPLNLEGLVAHR.V T860 (not) N N N Y Y N 
  R.SQS*FSEAEPQLPPAPVR.G S621 (not) N N N Y N N 
          
Phosphoproteins found in 2 out of 5 specimens 
Q15019 Septin-2  K.IYHLPDAES*DEDEDFKEQTR.L S218 (y11, y12) Y Y N Y N N 
Q08554 Desmocollin-1 
precursor  
R.MKVQDQDLPNT*PHSK.A T385 (not) N Y N N N Y 
P21291 Cysteine and glycine-
rich protein 1  
K.GFGFGQGAGALVHS*E S192 (y2, y3) Y Y N Y N N 
Q8N283 Ankyrin repeat domain-
containing protein 35 
R.QS*VGLLT*NELAM#EK.E S672; T677 
(b3, b4/ not) 
N,N Y N Y N N 
Q01995 Transgelin  K.HVIGLQMGS*NR.G S181 (y2,y6) Y Y Y N N N 
P08670 Vimentin R.ISLPLPNFS*SLNLR.E S419 (y5, y6) Y N N Y Y N 
Q6P597 Kinesin light chain 3  K.APRTLSAST*QDLS*PH T493; S497 
(not/y2,y3) 
N,N N N Y N Y 
O95425 Supervillin  R.S*LSDFTGPPQLQALK.Y S547 (not) N N N Y Y N 
Q15746 Myosin light chain 
kinase 
R.KSS*TGSPTSPLNAEK.L S1773 (y12, y13) Y N N Y Y N 
Q63ZY3 Ankyrin repeat domain-
containing protein 25  
R.ALAMPGRPES*PPVFR.S S375 (y5,y6) Y N N Y Y N 
  K.KIS*ITER.S S406 (not) N N N Y N N 
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Table A-4 (continued). 
 
Accession 
number 
Protein Peptide Site Phosphory-
lation site 
99-
029 
98-
065 
99-
045 
99-
067 
99-
010 
Phosphoproteins found in 1 out of 5 specimens 
Q92736 Ryanodine receptor 2  R.SSSENAKVTS*LDS*SSHR.I S4546; S4549 
(not/not) 
N,N Y N N N N 
P13796 Plastin-2  R.GS*VSDEEMMELR.E S5 (y10, y11) Y Y N N N N 
Q15283 Ras GTPase-activating 
protein 2  
K.S*SFKETFMCEFFK.M S559 (not) N Y N N N N 
P43353 Aldehyde dehydrogenase 
3B1  
R.FDY*IFFTGS*PR.V Y183; S189 
(b3/y2, y4) 
N,N Y N N N N 
P17252 Protein kinase C alpha 
type 
R.STLNPQWNES*FTFK.L S226 (y4, y5) Y N Y N N N 
Q8IYX7 Protein FAM154A R.EY*QKGPIPMEGLTTSR.R Y59 (not) N N Y N N N 
O75069 Transmembrane and 
coiled-coil domains 
protein 2  
R.GAS*LHS*SSGGGSS*GSSSRRTK.S S166; S169 
(not/not) 
N,N N Y N N N 
P27216 Annexin A13  K.YQKS*LSDMVRSDTSGDFR.K S294 (not) N N Y N N N 
Q6PCE3 Phosphoglucomutase-2-
like 1  
K.AVAGVMITAS*HNR.K S175 (y3, y4) Y N Y N N N 
P01854 Ig epsilon chain C region R.VAHTPS*STDWVDNK.T S92 (y8, y9) N N Y N N N 
Q8TCU4 Alstrom syndrome protein 
1 
R.SPLQEAES*KVSMALEETLR.Q S2367 (y11, 
y14) 
N N Y N N N 
P80421 Ig heavy chain V-I region 
DOT 
R.DRLVMSSDTSANTVS*MQLR.N S79 (b14, b15) N N Y N N N 
Q8TAP8 Putative uncharacterized 
protein C7orf47 
K.S*SLALGLELR.A S108 (not) N N Y N N N 
P36871 Phosphoglucomutase-1  K.AIGGIILTAS*HNPGGPNGDFGIK.F S117 (b9, b12) Y N Y N N N 
P60174 Triosephosphate 
isomerase  
R.KQS*LGELIGTLNAAK.V S21 (y12, y13) Y N N Y N N 
Q9NZN4 EH domain-containing 
protein 2 
R.GPDEAMEDGEEGS*DDEAEWVVTK.D S438 (not) Y N N Y N N 
P22059 Oxysterol-binding protein 
1 
K.GDMS*DEDDENEFFDAPEIITMPENLGHK.R S351 (b4) Y N N Y N N 
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Table A-4 (continued). 
 
Accession 
number 
Protein Peptide Site Phosphory-
lation site 
99-
029 
98-
065 
99-
045 
99-
067 
99-
010 
Q32MZ4 Leucine-rich repeat flightless-
interacting protein 1 
R.RGS*GDTSISIDTEASIR.E S120 (b3) N N N Y N N 
Q9UBT6 DNA polymerase kappa  K.CDS*YKDDLLLR.M S10 (b3) N N N Y N N 
Q86SQ6 Probable G-protein coupled 
receptor 123 
K.QVT*KKAPLCLDTDQPPYPR.Q T833 (b4,b5) N N N Y N N 
Q9Y618 Nuclear receptor corepressor 2  K.REGTPPPPPPS*R.D S1390 (y2,y3) N N N Y N N 
Q9H2J4 Phosducin-like protein 3  K.LS*ES*GAIMTDLEENPK.K S199; S201 
(not/y12, y14) 
N,N N N Y N N 
P09496 Clathrin light chain A  R.LQS*EPESIR.K S105 (b3,b4) N N N Y N N 
O43237 Cytoplasmic dynein 1 light 
intermediate chain 2 
K.SGQKT*VLSNVQEELDR.M T463 (y10, y12) N N N Y N N 
P35558 Phosphoenolpyruvate 
carboxykinase  
R.WM#S*EEDFEK.A S118 (y6, y7) Y N N Y N N 
P05386 60S acidic ribosomal protein P1 K.KEES*EES*DDDMGFGLFD S101; S104 
(b5, b6/y10, 
y11) 
Y,Y N N Y N N 
P13861 cAMP-dependent protein kinase 
type II-alpha regulatory subunit 
K.GDS*ES*EEDEDLEVPVPSR.F S77; S79 
(not/not) 
Y,Y N N Y N N 
Q6P9B9 Integrator complex subunit 5 R.FQAPSPS*TLLR.Q S1012 (not) N N N Y N N 
Q14195 Dihydropyrimidinase-related 
protein 3  
R.GSPT*RPNPPVR.N T524 (y6, y9) N N N Y N N 
Q13618 Cullin-3  R.FLLES*FNNDRLFK.Q S359 (not) N N N Y N N 
P48681 Nestin R.S*LGEQDQMTLRPPEK.V S767 (not) Y N N N Y N 
Q9NSE4 Isoleucyl-tRNA synthetase K.GLVYRS*Y*KPVFWSPSSR.T S239; Y240 
(b5, b6/b6, b7) 
N,N N N N Y N 
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Table A-4 (continued). 
 
Accession 
number 
Protein Peptide Site Phosphory-
lation site 
99-
029 
98-
065 
99-
045 
99-
067 
99-
010 
O43432 Eukaryotic translation 
initiation factor 4 gamma 3 
R.SS*ASSLNR.F S1194 (not) N N N N Y N 
P27824 Calnexin precursor K.AEEDEILNRS*PR.N S583 (y2, y3) Y N N N Y N 
P20711 Aromatic-L-amino-acid 
decarboxylase  
K.GLQAY*IR.K Y377 (y2, y3) N N N N Y N 
O76041 Nebulette  R.SMQHS*PNLR.T S953 (y4, y5) N N N N Y N 
P08238 Heat shock protein HSP 
90-beta (HSP 90) 
K.IEDVGS*DEEDDSGKDKK.K S254 (b5, b8) Y N N N Y N 
O75385 Serine/threonine-protein 
kinase ULK1  
R.KM#S*LGGGR.P S495 (y4, y6) N N N N Y N 
Q9Y5C1 Angiopoietin-related 
protein 3 precursor  
K.NMSLELNS*K.L S122 (y2, y3) N N N N Y N 
Q6KC79 Nipped-B-like protein  K.QNEST*IVEPK.Q T667 (y3, y6) N N N N Y N 
P58107 Epiplakin R.QPLQAT*FRGLRKQVS*AR.D T1495, S1504 
(b5, b6/b14, b15) 
N,N N N N N Y 
P02545 Lamin A/C  R.LRLS*PSPTSQR.S S390 (y7, y8) Y N N N N Y 
Q13242 Splicing factor, 
arginine/serine-rich 9  
R.GS*PHYFSPFRPY S211 (b2) Y N N N N Y 
Q13263 Transcription intermediary 
factor 1-beta 
R.SRS*GEGEVSGLMR.K S473 (b2, b3) Y N N N N Y 
P07197 Neurofilament triplet M 
protein 
K.GKSPVPKS*PVEEK.G S617 (y5, y6) Y N N N N Y 
P15924 Desmoplakin  K.GLPSPYNMSSAPGS*R.S S2825 (y2) Y N N N N Y 
O00264 Membrane associated 
progesterone receptor 
component 1  
K.LLKEGEEPTVYS*DEEEPKDESAR.K S180 (b11, b12) Y N N N N Y 
The assignments of exact sites of phosphorylation were validated manually through inspection of the corresponding product ions.
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Table A-5 Scansite results for the characterized phosphorylation sites. 
 
Accession 
number 
Protein  
Site 
Scansite result 
Kinase/binding 
 
Type 
O14558 Heat-shock protein beta-6 
(Heat-shock 20 kDa-like 
protein) 
S16 14-3-3 Mode 1 pS/T binding 
group 
Q14315 Filamin-C  S2233 Akt Kinase Basophilic S/T 
kinase group 
Q9H3Z4 DnaJ homolog subfamily C 
member 5  
S8 Calmodulin dependent 
Kinase 2 
Basophilic S/T 
kinase group 
Q9HBL0 Tensin-1 S1393 Protein Kinase A Basophilic S/T 
kinase group 
  T1105 Erk1 Kinase Kinase binding 
site group 
  S621 Calmodulin dependent 
Kinase 2 
Basophilic S/T 
kinase group 
Q15019 Septin-2  S218 Casein Kinase 2 Acidophilic S/T 
kinase group 
Q9NZN4 EH domain-containing protein 
2 
S438 Casein Kinase 2 Acidophilic S/T 
kinase group 
Q9Y618 Nuclear receptor corepressor 2 S1390 GSK3 Kinase Acidophilic S/T 
kinase group 
P09496 Clathrin light chain A  S105 14-3-3 Mode 1 pS/T binding 
group 
P05386 60S acidic ribosomal protein 
P1 
 S104 Casein Kinase 2 Acidophilic S/T 
kinase group 
P13861 cAMP-dependent protein 
kinase type II-alpha regulatory 
subunit 
S77 Casein Kinase 2  Acidophilic S/T 
kinase group 
  S79 Casein Kinase 2 Acidophilic S/T 
kinase group 
P48681 Nestin S767 14-3-3 Mode 1; Protein 
Kinase A 
pS/T binding 
group; Basophilic 
S/T kinase group 
P08238 Heat shock protein HSP 90-
beta (HSP 90) 
S254 Casein Kinase 2 Acidophilic S/T 
kinase group 
P58107 Epiplakin  S1504 PKC zeta Basophilic S/T 
kinase group 
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